i
ISBN: 0-8247-8121-X This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc. 270 Madison Avenue, N...
161 downloads
2785 Views
3MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
i
ISBN: 0-8247-8121-X This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc. 270 Madison Avenue, New York, NY 10016 tel: 212-696-9000; fax: 212-685-4540 Eastern Hemisphere Distribution Marcel Dekker AG Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland tel: 41-61-261-8482; fax: 41-61-261-8896 World Wide Web http://www.dekker.com The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above. Copyright © 2000 by Marcel Dekker, Inc. All Rights Reserved. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher. Current printing (last digit): 10 9 8 7 6 5 4 3 2 1 PRINTED IN THE UNITED STATES OF AMERICA
DEDICATION
This book is dedicated to four individuals who were giants in our field and have passed away in the last few years. Their contributions to the scientific literature, program management, and global tuberculosis control are without parallel. Stefan Grzybowski, a native of Poland, graduated from the University of Edinburgh and did postgraduate work at Brompton Hospital. He came to Canada in 1954, first working in Ontario and then moving to the University of British Columbia in 1964, ultimately as Professor and Director of Pulmonary Disease. The size and body of his work would have been enough to earn him an honored place among his peers, but it will be as a unique person that this vital, remarkable man will be remembered. He approached his life’s work with unquenchable energy, human concern, and infectious humor. His passing leaves a large void in the field of tuberculosis and he will be greatly missed by his many friends and colleagues. Among the numerous qualities that made Karel Styblo an exceptional person were his passion for truth and integrity, his care for human beings, and his indefatigable courage. His passion for truth meant that he spared no effort to obtain proof. Once he obtained that proof, nothing would make him depart from it. He strove very hard to obtain the means and monies to provide proper short-course chemotherapy for patients in developing countries and is considered the father of the now pervasive directly observed therapy short course (DOTS) strategy of the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease (IUATLD). The IUALD and the Royal Netherlands Tuberculosis Association (KNCV) were extremely important to him as they supported him in the demonstration, implementation, and propagation of his concept of tuberculosis control throughout the world. Guan-qing Kan was well known in the tuberculosis community especially as Honorary Director of the Beijing Research Institute for Tuberculosis Control, Honorary President of the Chinese Anti-Tuberculosis Association, and Chief Editor of the Bulletin of the Chinese Anti-Tuberculosis Association. Based on his international experience and China’s situation, he put forward China’s guidelines on tuberculosis control. In 1978, Kan promoted finding the source of TB infection as a top priority and began fully utilizing the powerful weapon of DOTS. These strategies opened a new page in tuberculosis control in China and gave Beijing the lowest prevalence of smear-positive cases in all of China. This
iii
iv
Dedication
success attracted the attention of the WHO and the antituberculosis societies of many countries and paved the way for the successful World Bank loan to China. His death is a great loss to China’s medical community and tuberculosis physicians worldwide. Alexander G. Khomenko, who died in 1999 after a long illness, was a member of the Russian Academy of Medical Sciences, an honored scientist of the Russian Federation, and Director of the Central Tuberculosis Research Institute of the Russian Academy of Medical Sciences. A long-time member of the Executive Committee of the IUATLD, he was the leader in bringing new Western ideas, such as DOTS and evidence-based medicine, into the former Soviet Union and getting them widely accepted. It would be fair to state that he almost single-handedly prevented Russian Tuberculosis Care and Control from falling out of the mainstream of the world’s medical science. L. B. R. E. S. H. To the memory of my father, Dr. C. Sheppy Hershfield (1904–1989), whose concepts of social justice for all had a profound influence on my life. E. S. H.
INTRODUCTION
In her book A History of Medicine (1992), Lois N. Magner comments on the impact of Robert Koch’s announcement in 1882 that he had discovered the tubercle bacillus: “To understand the profound effect of Koch’s announcement requires an appreciation of the way in which this disease (tuberculosis) permeated the fabric of life in the nineteenth century.” In fact, in the 17th century, it was already “difficult to believe that anyone could reach adulthood without at least a touch of consumption.” Since 1950, biomedical research and public health concepts have considerably modified our perspective on tuberculosis. Indeed, no one should fail to recognize the remarkable progress that has benefited generations of people all over the world. However, as we enter a new millennium, it would appear that we are now complacent about tuberculosis, perhaps in great part because of our past successes. We are told that the prevalence of tuberculosis is increasing because, on the one hand, its incidence is going up, and, on the other hand, its treatments are not as effective as they were in the past. Indeed, regarding the latter, the theory and reality of drug resistance are now clearly established. In the United States, the government is responding by stimulating a renewed research focus on understanding drug resistance and also on developing new, effective therapeutic agents. With the tools and approaches in hand to address these research questions, we can be optimistic that answers will soon be found. The issue of complacency is greatly different because to successfully address it requires a “will” that is difficult to create. It is a sad state of affairs that public health matters have not improved as much as they could because the will, or the interest to do what could and should be done, is often lacking. This is not a problem specific to tuberculosis and to other communicable diseases. Indeed, the same problem exists in the control of chronic diseases. This book addresses a wide range of biological and clinical questions; it also discusses worldwide public health issues and what must be accomplished to address them. At the very least, we should make full use of what we know works. v
vi
Introduction
The editors, Lee B. Reichman and Earl S. Hershfield, are well-recognized experts in the study and control of tuberculosis. They, and a remarkable array of contributors, bring the reader up-to-date on the extent of the tuberculosis problem worldwide, and they propose solutions to combat its resurgence. The first edition, published in 1993, had a wide audience. This second edition is a tool for those who are concerned about tuberculosis and want to do something about it. The Lung Biology in Health and Disease series has included many unique volumes. This one is added to the list with the conviction that it will contribute to solving a problem that affects us all. As the executive editor of the series, I am grateful to Drs. Reichman and Hershfield for the opportunity to present this timely and most important contribution. Claude Lenfant, M.D. Bethesda, Maryland
PREFACE TO THE SECOND EDITION
This second edition of Tuberculosis: A Comprehensive International Approach appears only seven years after the debut of the first edition, which was the first textbook exclusively devoted to tuberculosis in over twenty years. In response, it exhausted three printings—unprecedented for a book devoted solely to tuberculosis. Because, since the publication of the first edition in 1993, so much more information has been forthcoming, the editors, executive editor, and publishers felt a revised and expanded edition was required. In 1993, concurrent with publication of the first edition, the World Health Organization publicly recognized, for the first time, that tuberculosis was a “global health emergency.” The year 1993 also marked the beginning of the reversal of the resurgence of tuberculosis in the United States, which was one of the greatest public health successes of the twentieth century. This reversal underscored the observation that political will is the most critical ingredient in tuberculosis control. Unfortunately, events since 1993 have demonstrated that without political will, tuberculosis will get worse and potentially become incurable. As we enter the new millennium, tuberculosis remains the leading killer among the infectious diseases. As this edition goes to press, one-third of the world’s population remains infected. A very ominous new problem is the vast increase in documented multiple drug resistant tuberculosis (MDRTB), which is always a man-made phenomenon. This book presents evidence that the inexpensive but effective directly observed therapy short course (DOTS), the World Health Organization/International Union Against Tuberculosis and Lung Disease standard of care, is not being utilized enough to prevent multidrug resistance. Furthermore, the increasing levels of MDRTB may jeopardize the worldwide use of DOTS, as DOTS may be ineffective in the presence of MDRTB and can actually compound drug resistance. This ominous scenario will increasingly require the use of expensive and more toxic drugs tailored to a patient’s individual drug susceptibility profile— known as DOTS-Plus—to control the epidemic. vii
viii
Preface to the Second Edition
This new edition is unique in that it is responsive to tuberculosis programs in both low- and high-prevalence countries. With the resurgence of tuberculosis and the recent huge amount of attention paid to this disease, this remains the only textbook that presents a comprehensive international approach. Once again we are proud to include contributions from many of the world’s leading authorities on tuberculosis. We are especially honored that the table of contents includes chapters from our mentors and teachers as well as our students. We would like to thank the contributors and their secretarial staffs for meeting our deadline. Jean Norwood and Janet Hayward were invaluable in organizing and coordinating the work. Our production editor, Moraima Suarez, was of great assistance in helping put the work together and carrying it through production. To Claude Lenfant, Executive Editor of the Lung Biology in Health and Disease series, we express our heartfelt thanks for his counsel, support, and encouragement. Finally, we acknowledge the support and patience of our wives, Rose Reichman and Betty Ann Hershfield, and our children, Daniel and Deborah Gar Reichman and Jeffrey, David, and Bryan Hershfield. Lee B. Reichman Earl S. Hershfield
PREFACE TO THE FIRST EDITION
Tuberculosis is an ancient disease. In the past it has been both feared and respected. Despite being glamorized in literature, drama, and opera, its effects have led to death, disfigurement, and disability. It has wiped out young people in the prime of their lives; it has devastated families. The history of tuberculosis parallels the socioeconomic ills of humankind. Endemic in many populations, it rose to epidemic proportions with the advent of overcrowding, undernutrition, lack of fresh water, and poor sewage disposal. When susceptible populations were exposed for the first time, the epidemic flourished. In the long fight against this disease, treatments often evolved from fear and ignorance. Individuals with tuberculosis were isolated, treated with various potions, and subjected to a variety of surgical interventions. The advent of the mass radiograph for early diagnosis and the development of potent antituberculous medications and highly effective treatment regimens raised the hope that eradication of this disease was possible. However, the inability of governments to develop appropriate national tuberculosis control programs has hindered the fight against this disease. The lack of patient adherence to prescribed regimens has led to the development of relapses, often with drug-resistant organisms. Finally, the appearance on the world scene of widespread human immunodeficiency virus infection has increased tuberculosis rates worldwide, in both developing and developed countries. It is against this background that we offer Tuberculosis: A Comprehensive International Approach. This book represents a complete consideration of this disease from the historical, theoretical, practical, and operational points of view. Hopefully the various chapters will provide the reader with valuable information so that appropriate treatment regimens and control programs can be developed to ensure that those infected fully benefit from the most recent advances. We are proud to include contributions from many of the world’s leading authorities on tuberculosis. Their combined knowledge forms the basis of the current principles and practices embodied in this volume. We are especially honored ix
x
Preface to the First Edition
that the List of Contributors includes many of our mentors and teachers as well as our colleagues. We would like to thank the contributors and their secretarial staffs for their assistance in meeting our deadline. Ms. Jean Norwood and Ms. Janet Haywood were invaluable in organizing and coordinating the work. Our Production Editor, Elaine Grohman, was of great assistance in helping us put the work together and carry it to production. To Dr. Claude Lenfant, Executive Editor of the Lung Biology in Health and Disease series, we wish to express our heartfelt thanks for his most cheerful counsel and encouragement. We acknowledge the support and patience of our wives, Rose Reichman and Betty Anne Hershfield, and our children, Daniel and Deborah Gar Reichman, and Jeffrey, David, and Bryan Hershfield. Lee B. Reichman Earl S. Hershfield
CONTRIBUTORS
Nils Eric Billo, M.D., M.P.H. Executive Director, International Union Against Tuberculosis and Lung Disease, Paris, France Nancy J. Binkin, M.D., M.P.H. Associate Director, International Activities, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia Henry M. Blumberg, M.D. Associate Professor, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, and Hospital Epidemiologist, Grady Memorial Hospital, Atlanta, Georgia Naomi N. Bock, M.D., M.S. Medical Officer, Research and Evaluation Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia W. Henry Boom, M.D. Associate Professor, Division of Infectious Diseases, Department of Medicine, Case Western Reserve University School of Medicine, and University Hospitals of Cleveland, Cleveland, Ohio Jaap F. Broekmans, M.D., M.P.H. Director, Royal Netherlands Tuberculosis Association (KNCV), The Hague, The Netherlands Emmanuelle Cambau, M.D. Assistant, Department of Bacteriology and Hygiene, Faculté de Médecine Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France Antonino Catanzaro, M.D. Professor, Department of Medicine, University of California, San Diego, San Diego, California Richard E. Chaisson, M.D. Professor, Department of Medicine, Johns Hopkins University, Baltimore, Maryland xi
xii Pierre Chaulet, M.D.* Algiers, Algiers, Algeria
Contributors Professor, Faculty of Medicine, University of
Cynthia Bin-Eng Chee, M.D., F.R.C.P.(Edin) Consultant, Tuberculosis Control Unit, Department of Respiratory Medicine, Tan Tock Seng Hospital, Singapore Daniel Chemtob, M.D., M.P.H., D.E.A. Director, National Tuberculosis and AIDS Unit, Ministry of Health, Jerusalem, Israel David L. Cohn, M.D. Professor, Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, and Associate Director, Denver Public Health, Denver, Colorado George W. Comstock, M.D., Dr.P.H. Professor, Department of Epidemiology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland Nancy D. Connell, Ph.D. Assistant Professor, Department of Microbiology and Molecular Genetics, New Jersey Medical School National Tuberculosis Center, UMDMJ–New Jersey Medical School, and International Center for Public Health, Newark, New Jersey Thomas M. Daniel, M.D. Professor Emeritus, Department of Medicine, Center for International Health, Case Western Reserve University School of Medicine, and University Hospitals of Cleveland, Cleveland, Ohio Anne L. Davis, M.D. Associate Professor, Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University Medical School and Bellevue Hospital Chest Service, New York, New York Jerrold J. Ellner, M.D. Hunterdon Professor of Emerging and Reemerging Pathogens, and Director, Infectious Diseases Division, Department of Medicine, UMDNJ–New Jersey Medical School, Newark, New Jersey Wafaa M. El-Sadr, M.D., M.P.H. Professor, Department of Medicine, Columbia University College of Physicians and Surgeons, and Chief, Division of Infections Diseases, Harlem Hospital Center, New York, New York Donald A. Enarson, M.D., F.R.C.P.(C), F.R.C.P.(Edin) Professor, Department of Medicine, University of Alberta, Alberta, Canada, and Director of Scien* Retired.
Contributors
xiii
tific Activities, International Union Against Tuberculosis and Lung Disease, Paris, France Sue C. Etkind, R.N., M.S. Director, Division of Tuberculosis Prevention and Control, Massachusetts Department of Public Health, Boston, Massachusetts Paul E. Farmer, M.D., Ph.D. Director, Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts Paul E. M. Fine, V.M.D., Ph.D. Professor, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, England Paula I. Fujiwara, M.D., M.P.H. Director and Assistant Commissioner of Health, Tuberculosis Control Program, New York City Department of Health, and Supervisory Medical Officer, Centers for Disease Control and Prevention, Atlanta, Georgia Karen E. Galanowsky, R.N., B.S.N., M.P.H. Nursing Consultant, Department of Tuberculosis Control, New Jersey Department of Health and Senior Services, Trenton, New Jersey Jacques Grosset, M.D. Professor, Department of Bacteriology and Hygiene, Faculté de Médicine Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France Earl S. Hershfield, M.D., B.Sc., F.R.C.P.(C) Professor, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada Philip C. Hopewell, M.D. Professor, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, San Francisco, and Associate Dean, San Francisco General Hospital, San Francisco, California Jim Yong Kim, M.D., Ph.D. Director, Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts Kraig Klaudt Advocacy Campaign Coordinator, Program on Communicable Diseases, World Health Organization, Geneva, Switzerland
xiv
Contributors
Barry N. Kreiswirth, Ph.D. Director, Tuberculosis Center, Public Health Research Institute, New York, New York, and International Center for Public Health, Newark, New Jersey Adalbert Laszlo, Ph.D. Director, WHO Collaborating Center for Tuberculosis Bacteriology Research, Health Canada, Ottawa, and Consultant Tuberculosis Bacteriology, International Union Against Tuberculosis and Lung Disease, Nepean, Ontario, Canada Philip A. LoBue, M.D. Medical Epidemiologist, Division of Tuberculosis Elimination, Field Services Branch, Centers for Disease Control and Prevention, San Diego, California Bonita T. Mangura, M.D. Associate Professor, Department of Medicine, New Jersey Medical School National Tuberculosis Center and International Center for Public Health, UMDNJ–New Jersey Medical School, Newark, New Jersey Richard I. Menzies, M.D., M.Sc., F.R.C.P.(C) Associate Professor, Department of Medicine and Department of Epidemiology and Biostatistics, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada Bess Miller, M.D., M.Sc. Associate Director for Science, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia Carole D. Mitnick, Sc.M. Research Fellow, Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts Flor M. Muñoz, M.D. Assistant Professor, Department of Microbiology and Immunology and Department of Pediatrics, Baylor College of Medicine, Houston, Texas Sonal S. Munsiff, M.D. Director, Epidemiology and Surveillance, Tuberculosis Control Program, New York City Department of Health, New York, New York Eileen C. Napolitano, B.A. Deputy Director, New Jersey Medical School National Tuberculosis Center and International Center for Public Health, UMDNJ–New Jersey Medical School, Newark, New Jersey Edward A. Nardell, M.D. Associate Professor, Department of Medicine, Harvard Medical School, Chief, Department of Pulmonary Medicine, Cambridge
Contributors
xv
Hospital, and Tuberculosis Control Officer, Massachusetts Department of Public Health, Boston and Cambridge, Massachusetts Richard J. O’Brien, M.D. Chief, Research and Evaluation Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia Frances R. Ogasawara, M.S., C.H.E.S.† Associate Managing Director, American Lung Association, New York, New York Sharon Perry, Ph.D. Staff Research Associate, Department of Medicine, University of California, San Diego, San Diego, California Willy F. Piessens, M.D. Professor, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Harvard Medical School, Boston, Massachusetts Mario C. Raviglione, M.D. Coordinator, Strategy Development and Monitoring of Endemic Bacterial and Viral Diseases, Communicable Disease Control, Prevention and Eradication, World Health Organization, Geneva, Switzerland Hans L. Rieder, M.D., M.P.H. Chief, Tuberculosis Division, International Union Against Tuberculosis and Lung Disease, Paris, France Camilo C. Roa, Jr., M.D. Professor, Department of Medicine, University of the Philippines College of Medicine, Manila, Philippines Rodrigo L. C. Romulo, M.D. Assistant Professor, Section of Infectious and Tropical Diseases, Department of Medicine, Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines Sara Rosenbaum, J.D. Harold and Jane Hirsh Professor, School of Public Health and Health Services, The George Washington University, Washington, D.C. Annik Rouillon, M.D., M.P.H. Honorary Executive Director, International Union Against Tuberculosis and Lung Disease, Paris, France Mona Saraiya, M.D., M.P.H. Medical Epidemiologist, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia
† Retired.
xvi
Contributors
Holger Sawert, M.D., M.P.H. Medical Officer, Ministry of Public Health, World Health Organization, Bangkok, Thailand Patricia M. Simone, M.D. Chief, Field Services Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia Jeffrey R. Starke, M.D. Associate Professor, Department of Pediatric Infectious Disease, Baylor College of Medicine, Houston, Texas Elizabeth J. Stoller, M.P.H.‡ Director, Francis J. Curry National Tuberculosis Center, San Francisco, California Elizabeth Tayler, M.B.B.S., M.R.C.P.(UK), M.F.P.H.M. Health Coordinator, Department of Health, Department for International Development (DFID), British High Commission, Abuja, Nigeria Ralph Timperi, M.P.H. Assistant Commissioner, Massachusetts State Laboratory Institute, Massachusetts Department of Public Health, Boston, Massachusetts Chantal Truffot-Pernot, D.Pharm. Assistant, Department of Bacteriology and Hygiene, Faculté de Médecine Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France Jaap Veen, M.D., Ph.D., D.T.P.H. Senior Tuberculosis Consultant, Royal Netherlands Tuberculosis Association (KNCV), The Hague, The Netherlands Yee-Tang Wang, M.D., F.R.C.P.(Edin) Senior Physician and Head, Tuberculosis Control Unit, Department of Respiratory Medicine, Tan Tock Seng Hospital, Singapore Daniel Weiler-Ravell, M.D. Director, Division of Respiratory Physiology and Medicine, Carmel Medical Center, Haifa, Israel Sheri Weiser, M.A. National Tuberculosis and AIDS Unit, Ministry of Health, Jerusalem, Israel Israel Yitzhak, L.V.N. Health Educator, National Tuberculosis and AIDS Unit, Ministry of Health, Jerusalem, Israel
‡
Current affiliation: Institute for Global Health, San Francisco, California.
CONTENTS
Introduction Claude Lenfant Preface to the Second Edition Preface to the First Edition Contributors Part One
PROGRAMMATIC BACKGROUND
1. A Historical Perspective on Tuberculosis and Its Control Anne L. Davis I. Early Perceptions and Practices II. Concepts from the Renaissance Through the Eighteenth Century III. Nineteenth- and Twentieth-Century Developments and Concepts References 2. Tuberculosis Control in Low-Income Countries Donald A. Enarson I. II. III. IV. V. VI. VII. VIII.
v vii ix xi
Introduction Objectives of Tuberculosis Control The Scientific Basis of Intervention Prevention Through Treatment Basic Principles of Tuberculosis Control Adaptations for Low-Income Countries Achieving Success in Low-Income Countries Effective Strategies for the Management of Tuberculosis
3 5 7 10 43 55 55 55 56 57 58 60 62 65 xvii
xviii
Contents IX. Future Challenges References
3. Tuberculosis Control in Low-Prevalence Countries Jaap F. Broekmans I. The Prospect of Elimination II. Framework for Tuberculosis Control in Low-Prevalence Countries III. Surveillance IV. Program Monitoring References 4. Tuberculosis Laboratories: The Centerpiece of National Tuberculosis Control Programs Adalbert Laszlo I. II. III. IV. V. VI.
68 71 75 75 81 86 89 92
95
Introduction National Tuberculosis Programs Tuberculosis Diagnostic Services Tuberculosis Diagnostic Techniques The NTP National Tuberculosis Laboratory Network Structure and Function of the National Tuberculosis Laboratory Network VII. The National Tuberculosis Laboratory Network as a Source of Data VIII. The National Tuberculosis Laboratory Network as a Source of Operational and Epidemiological Information IX. Conclusion References
101
5. Evaluation of Applied Strategies of Tuberculosis Control in the Developing World Pierre Chaulet and Earl S. Hershfield
107
I. Introduction II. Prerequisites for Evaluating a Tuberculosis-Control Strategy III. Evaluation of the Strategies Applied in Tuberculosis Treatment IV. Evaluation of Strategies Applied in the Detection of Tuberculosis Cases V. Conclusion References
95 97 99 100 101
103 104 104 105
107 108 111 119 124 124
Contents Part Two
xix BASIC ASPECTS
6. Epidemiology of Tuberculosis George W. Comstock I. II. III. IV.
Introduction Etiological Epidemiology Administrative Epidemiology Conclusion References
7. Bacteriology of Tuberculosis Jacques Grosset, Chantal Truffot-Pernot, and Emmanuelle Cambau I. II. III. IV. V. VI. VII. VIII.
Introduction Biological Safety General Characteristics of Tubercle Bacilli Bacteriology for Diagnosis and Monitoring Treatment of Tuberculosis Strain Typing of M. tuberculosis Drug Activity Against M. tuberculosis Immunodiagnostic Tests for Tuberculosis Direct Detection of M. tuberculosis by Nucleic Acid Amplification References
8. Immunology of Tuberculosis Thomas M. Daniel, W. Henry Boom, and Jerrold J. Ellner I. Introduction II. Mycobacterial Protein Antigens III. The Mycobacterial Cell Wall: Mycobacterial Adjuvants and Mycobacterial Polysaccharides IV. Granuloma Formation V. Cell-Mediated Immunity VI. Humoral Immunity VII. Immune Spectrum and Immunoregulation VIII. HIV–M. tuberculosis Interactions IX. Conclusions References 9. Transmission of Tuberculosis Edward A. Nardell and Willy F. Piessens I. Aerobiology of Tuberculosis II. Epidemiology of Transmission
129 129 130 141 149 149 157 157 158 158 160 168 169 175 177 178 187 187 188 192 194 194 199 200 202 203 204 215 217 221
xx
Contents III. IV. V. VI. VII.
Infectious Dose for Humans Recent Outbreaks Preventing Transmission Governmental Recommendations: An Overview Preventing Transmission from Unsuspected Cases of Tuberculosis VIII. Engineering Approaches to Preventing Transmission References 10. Pathogenesis of Tuberculosis Willy F. Piessens and Edward A. Nardell I. Introduction II. Stage 1 (Week 1): Invasion III. Stage 2 (Weeks 2 and 3): Logarithmic Bacillary Growth and the Early Tuberculous Lesion IV. Stage 3 (After Week 3): Infection Control V. Stage 4 (Months to Years Later): Endogenous Reactivation and Transmission VI. Clinical Correlates of Immune Events in Human Tuberculosis VII. Conclusion References 11. Mycobacterial Strain Genotyping Nancy D. Connell and Barry N. Kreiswirth I. II. III. IV. V. VI.
Part Three
Introduction Methodologies Interpreting Genotypes International Applications of Molecular Fingerprinting Implications for Basic Research Clinical Applications of Molecular Fingerprinting References
225 227 228 229 230 231 236 241 241 242 248 249 252 254 255 255 261 261 262 265 267 269 270 270
CLINICAL ASPECTS
12. Tuberculin Skin Testing Richard I. Menzies
279
I. Introduction II. Technical Aspects
279 280
Contents
xxi
III. Simple Cognitive Aspects: False-Negative and False-Positive Reactions IV. Complicated Cognitive Aspects: Interpreting Tuberculin Tests V. Conclusions References 13. Case Finding in High- and Low-Prevalence Countries Hans L. Rieder I. II. III. IV. V. VI.
Introduction Sources of Transmission and Other Cases Identification of Sources of Transmission Factors Modifying the Choice of Case-Finding Methods The Role of Case Finding in Tuberculosis Control Conclusions References
14. Diagnosis of Tuberculosis Philip A. LoBue, Sharon Perry, and Antonino Catanzaro I. II. III. IV. V. VI. VII. VIII.
285 296 310 311 323 323 324 325 331 332 333 334 341
Introduction Medical History and Physical Examination Routine Laboratory Tests The Tuberculin Skin Test Diagnostic Tests: Pulmonary Disease Extrapulmonary Tuberculosis Pediatric Tuberculosis Developments in Rapid Diagnosis: Nucleic Acid Amplification Tests X. Summary References
341 341 343 343 343 351 356
15. Contact Follow-Up in High- and Low-Prevalence Countries Sue C. Etkind and Jaap Veen
377
I. II. III. IV. V. VI.
Introduction Definitions Need for Contact Tracing Contact Tracing in Low-Prevalence Countries Contact Tracing in High-Prevalence Countries New Technology: The Role of Restriction Fragment Length Polymorphism Testing
356 363 363
377 378 379 380 389 391
xxii
Contents VII. Challenges and Unanswered Questions VIII. Summary References
16. Treatment of Tuberculosis Paula I. Fujiwara, Patricia M. Simone, and Sonal S. Munsiff I. Introduction II. History of Tuberculosis Treatment in the Chemotherapeutic Era III. Antituberculosis Medications IV. Standard Antituberculosis Treatment Regimens in the United States V. Antituberculosis Treatment Regimens in Resource-Poor Countries VI. Methods Used to Diagnose Tuberculosis and Monitor Treatment VII. Special Clinical Situations VIII. Adherence to Treatment IX. The Future of Treatment References 17. Responding to Outbreaks of Multidrug-Resistant Tuberculosis: Introducing DOTS-Plus Paul E. Farmer, Jim Yong Kim, Carole D. Mitnick, and Ralph Timperi I. II. III. IV.
Introduction: Strengths and Limitations of DOTS What Is DOTS-Plus? Making DOTS-Plus Work: A Case Study Pitfalls in the Planning and Execution of DOTS-Plus Programs V. Conclusions: DOTS-Plus, We Can’t Afford Not to Try It References
18. Treatment of Latent Tuberculosis Infection David L. Cohn and Wafaa M. El-Sadr I. Introduction II. Treatment of Latent Tuberculosis Infection in Immunocompetent Hosts III. New Regimens for Treatment of Latent Tuberculosis Infection
394 395 396 401 401 402 405 415 418 420 423 432 435 436
447
447 453 455 462 466 466 471 471 472 481
Contents
xxiii
IV. Treatment of Latent Tuberculosis Infection in HIV-Infected Persons V. Treatment of Latent Tuberculosis Infection in Special Populations VI. Development of Disease Due to Resistant Organisms VII. Recommendations for Treatment of Latent Tuberculosis Infection VIII. Conclusions and Future Directions References 19. BCG Vaccines and Vaccination Paul E. M. Fine I. II. III. IV. V. VI. VII. VIII. IX. X.
Part Four
Introduction Historical Background BCG Vaccines Current BCG Policies The Protective Efficacy of BCG Protection Against Diseases Other Than Tuberculosis Adverse Reactions The Impact of BCG Vaccination Programs Improving Upon BCG Immediate Prospects for Vaccination Against Tuberculosis References
482 491 492 493 496 497 503 503 503 505 505 508 512 512 513 514 516 518
SPECIAL PROBLEMS
20. Tuberculosis and Human Immunodeficiency Virus Infection Philip C. Hopewell and Richard E. Chaisson
525
I. Risk of Tuberculosis in Persons with HIV Infection II. Prevalence of HIV Infection Among Patients with Tuberculosis III. Influence of HIV Infection on the Pathogenesis of Tuberculosis IV. Diagnosis of Tuberculosis Infection and Tuberculosis V. Treatment VI. Tuberculosis Caused by Multidrug-Resistant Organisms VII. Prevention VIII. Infection Control IX. Influence of Tuberculosis on the Course of HIV Infection
525 528 529 531 535 539 541 544 545
xxiv
Contents X. Necessary Changes in Approaches to Tuberculosis Control References
21. Tuberculosis in Children Flor M. Muñoz and Jeffrey R. Starke I. II. III. IV. V. VI.
Introduction Epidemiology Pathogenesis Clinical Forms of Tuberculosis Diagnosis of Tuberculosis in Children Treatment References
22. Case Management: The Key to a Successful Tuberculosis-Control Program Bonita T. Mangura and Karen E. Galanowsky I. II. III. IV. V. VI. VII. VIII. IX.
Part Five
Introduction Directly Observed Therapy Clinical Care and Public Health The Newark Experience The Nurse Case-Management Model Tuberculosis Therapy by Directly Observed Therapy Incremental Service Delivery Change and DOT The Interaction: Patient and Health Care Provider Impact on TB Control References
545 547 553 553 555 560 563 574 578 586
597 597 598 598 599 600 601 602 604 604 605
UNIQUE ASPECTS OF TUBERCULOSIS CONTROL
23. Tuberculosis Infection Control Henry M. Blumberg I. Introduction and Historical Overview II. Trends in Nosocomial Transmission of Tuberculosis III. Institutional Controls in the United States and Other Developed Countries IV. Hospital Discharge Planning and Standards V. OSHA Requirements for a Tuberculosis-Control Program VI. Institutional Controls in Developing Countries and Areas with Very Limited Resources References
609 609 610 617 630 631 631 636
Contents
xxv
24. Tuberculosis in Correctional Facilities Naomi N. Bock
645
I. II. III. IV.
Introduction Epidemiology of Tuberculosis in Correctional Facilities Transmission of Tuberculosis in Correctional Facilities Risk Factors for Tuberculosis Among Inmates in Correctional Facilities V. Correctional Facility Tuberculosis and the Community at Large VI. Controlling Tuberculosis in Correctional Facilities References 25. Tuberculosis Among Immigrants Mona Saraiya and Nancy J. Binkin I. II. III. IV. V. VI.
Introduction History of Migration of TB Definitions Epidemiology of TB Among Foreign-Born Persons Drug Resistance Contribution of Immigration to Transmission of TB in Low-Prevalence Countries VII. Approaches to TB in the Foreign-Born References 26. Coalition Building for Tuberculosis Control: The Philippine Experience Camilo C. Roa, Jr., and Rodrigo L. C. Romulo I. Coordinating Tuberculosis-Control Efforts: The Need for Coalitions II. TB Interest Groups III. Rallying Around a Common Goal IV. The Philippine Coalition Against Tuberculosis V. Formalizing and Expanding VI. Generating Resources VII. The Birth of PHILCAT VIII. Pushing Onwards IX. Developing a Unified Strategy: Identifying More Stakeholders X. National Consensus on Tuberculosis XI. Coalition Activities: Achieve Objectives and Maintain Member Enthusiasm
645 646 648 648 649 651 654 661 661 661 662 664 675 677 678 687
693
693 694 696 696 697 697 698 698 700 702 702
xxvi
Contents XII.
Summary References
27. Tuberculosis Education Eileen C. Napolitano and Elizabeth J. Stoller I. Introduction II. Evidence of the Need for Training and Education for Providers III. Current Training Initiatives IV. Health-Care Providers in Need of Education and Training V. Methods VI. Future Directions for Training VII. Topics for Further Discussion References 28. Political Will: The Singapore Tuberculosis Elimination Program Cynthia Bin-Eng Chee and Yee-Tang Wang I. Singapore: An Island City-State II. Tuberculosis in Singapore III. Rationale for the Singapore Tuberculosis Elimination Program IV. Organizational Structure of STEP V. Key Factors for the Success of STEP VI. Conclusion References 29. Medical Anthropology: An Important Adjunct to International TB Control Daniel Chemtob, Sheri Weiser, Israel Yitzhak, and Daniel Weiler-Ravell I. II. III. IV.
Introduction The Relevance of Social Science to Public Health Some Basic Concepts in Social Science Some Key Perspectives in the Social Science Literature on TB V. An Anthropological Study of TB Among Ethiopian Immigrants in Israel VI. The Contribution of Social Science to the New National Program for the Elimination of TB in Israel VII. Conclusion References
703 703 705 705 707 711 713 714 717 718 720
727 727 729 734 735 736 739 740
745
745 746 750 754 757 762 765 766
Contents
xxvii
30. The Role of Nongovernmental Organizations Annik Rouillon, Nils Eric Billo, and Frances R. Ogasawara I. Introduction II. National Tuberculosis Associations III. The International Union Against Tuberculosis and Lung Disease IV. Present Trends: Irreplaceable Partners V. Summary References 31. Economic Considerations for Tuberculosis Control Holger Sawert I. Political Commitment and Economic Arguments II. Economic Analysis: Basic Concepts III. Specific Points for the Analysis of Tuberculosis Control Interventions IV. Example: Improving Tuberculosis Control in Thailand References 32. The Impact of Managed Care on Tuberculosis Control in the United States Bess Miller and Sara Rosenbaum I. Introduction II. Tuberculosis Control in the United States: Current Organizational Structure III. The Advent of Managed Care and Its Impact on TB Control IV. Concerns of TB Health Officials About Managed Care V. Response of TB Health Officials to the Advent of Managed Care VI. Role of Contracts and Memoranda of Agreement VII. Conclusion References 33. The Impact of Health Sector Reform on Tuberculosis Control in Developing Nations Elizabeth Tayler I. II. III. IV.
Introduction Why Health Sector Reform Is Needed Impact of Health Sector Reform Upon TB Services Political Commitment
771 771 775 787 793 795 795 799 799 802 804 807 814
817 817 818 819 820 821 823 825 825
829 829 831 832 833
xxviii
Contents V. Case Finding and Diagnosis VI. Standardized Short-Course Regimen and Supervision of Therapy VII. Drug Supply VIII. Recording and Reporting IX. Conclusions References
34. Mobilizing Society Against Tuberculosis: Creating and Sustaining Demand for DOTS in High-Burden Countries Kraig Klaudt I. Assessment of the Current Response to the Global TB Epidemic II. The Role of Information, Education, and Communication, Advocacy, and Social Mobilization III. The C.A.U.S.E. Strategy for Mobilizing Society IV. The Main Components of Advocacy V. Potential Initiatives to Help Mobilize Society to Control TB VI. Conclusion References Part Six
Index
835 837 837 838 840
843
843 846 850 854 858 863 863
THE FUTURE
35. Tuberculosis in the Future Richard J. O’Brien and Mario C. Raviglione I. II. III. IV. V.
834
Tuberculosis in the 1990s: Reasons to Be Hopeful Problems Looming at the End of the Twentieth Century TB in the New Millennium: Clues from Modelers The Promise of New Technologies Tuberculosis Elimination: An Impossible Dream? References
867 867 871 874 877 878 881 885
Part One PROGRAMMATIC BACKGROUND
1 A Historical Perspective on Tuberculosis and Its Control
ANNE L. DAVIS New York University Medical School and Bellevue Hospital Chest Service New York, New York
Since the first appearance of tuberculosis in humans probably some 8000 years ago (1–3), its control has continued to elude the brightest minds and to challenge both the human and economic resources of countries around the world. One third of the world’s population is estimated to be infected. If the trends of the 1990s continue, the annual number of new cases could exceed 8 million, and 30 million deaths will have resulted from the disease between 1990 and 2000 (4). As an indolent wasting, debilitating condition, “the Captain of the Men of Death” (5), or a highly lethal epidemic, “The Great White Plague” (6,7), it is different from most infectious diseases in the worldwide magnitude of its effects. From a constellation of elusive illnesses of hypothetical etiologies to its final recognition as a single disease caused by a specific microorganism, it has challenged the imagination and intellect of people from prehistory to the present. It has stimulated as well as snuffed out the creative and intellectual endeavors of those who have encountered it. It has enchanted the imaginations of writers, artists, musicians, philosophers, scientists, and most recently news reporters. It has spawned a global public health movement, called attention to the deplorable effects of poverty, overcrowding, and ignorance and raised awareness of the vital role of the nursing and other health professions, as well as veterinary medicine, in its control. The continuing ability of the disease to elude control has prompted re3
4
Davis
strictive laws (8–11) and raised legal ethical issues as recently as the 1990s (12–16). Not only when but also how and where tuberculosis originated and spread is still the subject of debate. Some believe that it existed in animals long before it affected humans (1–3,17,18). When primitive agricultural practices permitted permanent settlements, cattle, swine, and sheep became domesticated and often shared the family’s dwelling space, making the spread between animals and humans possible but initially sporadic and endemic. Whether Mycobacterium tuberculosis evolved from Mycobacterium bovis is still unclear, but some believe that biological and historic evidence support such an evolution (1). The strong degree of DNA homology (19) and the immunological properties suggest that they are subspecies (20) and that M. tuberculosis evolved through genetic mutations from M. bovis in humans after the domestication of cattle (1). Concepts about where on the globe tuberculosis began and how it spread are also changing as new archeological discoveries and molecular technologies emerge (21–25). The distribution of infection and severity of the disease have varied with the time period and geographic location (3,26–31). The epidemiology has been imperfectly hypothesized from the spotty data available before the development of modern tools for more accurate identification of the disease and required reporting of cases. Even if one accepts that tuberculosis was endemically present in areas of Eurasia, Africa, India, China, Japan, and the Americas for perhaps several thousand or more years, the chronology of its devastating impact in the different populations of the world has yielded differing theories explaining the observed phenomena (1,32–34). In addition to exposure to infected cattle, their milk, and milk products (1,17,18,34–37), human “herd immunity” (38) and migration and immigration patterns, industrialization, poverty, poor nutrition, overcrowding, unhealthy lifestyle changes, and concomitant disease [e.g., human immunodeficiency virus (HIV) infection] have played a role. During the lengthy history of the disease there have been brief glimpses of enlightenment, but progress primarily had to await additional observations and discoveries beginning during the Renaissance but continuing with increasing acceleration to the present. The discovery and isolation of the etiological agent by Robert Koch in 1882 and subsequent developments in the first part of the twentieth century provided more accurate ways of detecting the disease, generated vigorous public health campaigns, introduced new treatment and prevention strategies, and renewed hope that tuberculosis could be prevented and even cured. Clinical and laboratory investigations burgeoned and have provided the background for the present application of sophisticated new tools to the persistent challenges retarding the conquest of tuberculosis into the next century. This chapter can only hint at the rich history of this ancient disease and highlight a few of the events and trends—particularly in the nineteenth and twentieth
History of Tuberculosis
5
centuries—that have led to current concepts of tuberculosis and strategies for its potential control.
I. Early Perceptions and Practices Prehistoric humans thought that supernatural powers were responsible for all that they did not understand, including sickness. Diagnosis was unimportant because the treatment was the same: appeasing the supernatural spirit or scaring away the evil demons, evoked by magic. Herbs and animal parts, their secretions and excretions, were used therapeutically. Sometimes certain stones or colors (red, especially) were considered beneficial. The sun, moon, and stars were also believed to influence health. Transference of disease to another object or animal was practiced (18). A child with scrofula was passed through the hole of a tree or a rock with the belief that the disease would thus be transferred (39). Some of these superstitions regarding disease and health, that existed when Egyptian, Babylonian, Greek, Roman, Hindu, Chinese, and Japanese civilizations began, still exist among some populations in parts of the world where traditional healers still practice (26,40–42). Awareness of such customs is important for the development of successful control programs (40,41). The observations of ancient societies, as detailed in their skeletons, artefacts, drawings and paintings, and later in writings are remarkably recognizable as the clinical features of tuberculosis as we know it today. The bony deformities found in skeletons, drawings, and sculptures in Egypt, Peru, and other countries are very suggestive of Pott’s disease (39,44–47). Data from written sources, although scarce, also tend to support the hypothesis that tuberculosis has existed for a very long time (18,39,48), but some scholars are skeptical because perceptions of the symptoms and course of what we now call tuberculosis varied widely until the last decades of the nineteenth century when the unity of the disease was established. It was known as phthisis (“wasting disease”) or consumption as well as scrofula (the cervical swellings resembling cow’s udders), lupus vulgaris, lung hemorrhage, chronic diarrhea, and hectic fever. The Hindus alluded to consumption. Some historians believe that descriptions of consumption passed orally from generation to generation long before the Vedas were written (26,39). Hindu drugs were known to the Egyptians, who derived cotton from India, long before Hippocrates. Many Greek drugs had Sanskrit names. Hindu remedies were also mentioned in the Old Testament. Antedating by centuries many of the remedies still believed to be beneficial for consumption as late as the nineteenth and first half of the twentieth centuries, the Hindus recommended milk, especially from a lactating woman, many meats and vegetables, and avoidance of fatigue. The Yajur Vedas advised that “to mount and be carried on
6
Davis
gentle horses makes an exercise which increases the flesh and blood and helps sleep. . . . A consumptive should go and live in high altitudes” (39). The Greeks apparently saw most forms of the disease and contributed detailed descriptions of the cardinal symptoms—age, incidence, and prognosis (18,43,49). The careful observations and interest in scientific inquiry by Hippocrates and his followers removed medicine from the realms of religion and philosophy and began to replace superstition with common sense. At the end of this era, Rome and subsequently Byzantium assumed importance, but little medical progress was made. When the Roman Empire eventually disintegrated about 600 A.D. and the Dark Ages ensued, the writings and teachings of Galen (130–200 A.D.), a Greek emigré to Rome, became authoritative in medicine for about the next 1400 years (43,50). The prior interest in keen observation and scientific inquiry exemplified by Hippocrates and others of the Greek Golden Age faded. Mystical explanations for natural phenomena again prevailed, and authority reigned as the source of knowledge. In summary, as these early civilizations developed, little progress was made in the understanding and control of phthisis. Diagnosis, at its best, was based almost solely on careful observations of the patient. Limited attempts at physical examination were made. References to râles and to succussion have been found in the Hippocratic Collection (18,43,49). Human dissection was not permitted, except transiently, in Alexandria around 332 B.C. (39). Sputum as a diagnostic or prognostic tool was barely mentioned, but Aretaeus did suggest that inspection of the sputum was of greater diagnostic value than testing it with fire or water (43). One Hippocratic aphorism stated that “in persons affected with phthisis, if the sputa which they cough up have a heavy smell when poured upon coals, and if the hairs of the head fall off, the case will prove fatal” (49). Without the benefit of pathological or microbiological studies, the causes and pathogenesis of these afflictions were highly speculative. An imbalance of the four humors, heredity, defluxions proceeding from the head, something exhaled in the patient’s breath. ulceration of the lung, which might be due to inflammation extending from the nose or throat, or even chilling of the lung or trauma were a few of the theories (43). The contagious nature of phthisis was not recognized (18). Although long before mycobacteria were identified, Aristotle had hinted at the possibility (39), and Galen (50) and Avicenna, the Arab physician, had suggested (43,51), it was not until the seventeenth century that measures were briefly put in place in Italy to quell the spread. Treatment continued to include many of the superstitious practices of earlier times as well as the old Hindu remedies. Bloodletting and cupping were also employed. Pliny the Elder (23–79 A.D.) commented that sea voyages were desirable especially for hemoptysis (39), and some specific therapeutic concoctions such as wolf’s liver boiled in wine or boiled crocodile for chronic cough were
History of Tuberculosis
7
mentioned. Later “the King’s Touch” for scrofula instituted by King Clovis in 494 A.D. was considered beneficial (39,43), although the idea of healing by royal touch may have originated with Pyrrhus (318–272 B.C.), who cured disease of the spleen by the touch of his right toe. The Christian practice of “laying on of hands” to heal derives from this early belief in the royal healing power. During the Dark Ages, the Christian church and Arab physicians (Syrians, Persians, and Spaniards by virtue of their common language) determined the course of medicine, primarily by collecting and preserving the texts of the Greek physicians. II. Concepts from the Renaissance Through the Eighteenth Century After the invention of printing and the translation of the great Greek texts into Latin and their publication by the middle of the sixteenth century, discussions about possible causes for tuberculosis and controversies over contagion were revived. At last anatomical and pathological studies began to provide a basis for understanding the clinical features and pathogenesis of tuberculosis as we know it today. A. Contagiousness and Early Attempts to Control
A notable achievement in this period was the advancement, at least temporarily, of the notion of contagiousness of tuberculosis. Heironymous D. Fracastorius’s description in his book, De Contagione, in 1546 of three methods of infection— direct contact, fomites, and air—and his postulation of the existence of “seminaria,” imperceptible particles which he believed could exist outside the body for several years and still infect, were the most articulate and original enunciations up to this time of the modern germ theory of contagion (1). In phthisis he postulated that the “seminaria” could come not only from outside, but could arise within the body as well, from “putrefaction of the humors” (39). He believed that “the original germs generate and propagate other germs precisely like themselves and these in turn propagate others until the whole mass and bulk of humors is infected by them” (1,52). He also suggested that contagion was selective: some organs are affected while others may be spared, and “some bodies catch infections very easily, others either not at all or with difficulty” (52). He even suggested the idea of sterilization, which went unheeded for the next 300 years. In the initial stage of treatment, “pay attention to the germs only, for if these could be destroyed, by caustic means no more effective remedy could be employed” (52). Similar conclusions regarding control of tuberculosis with emphasis on detection, isolation, and prompt treatment of infectious tuberculosis followed in the twentieth century, but experience both before (53) and since the chemotherapy era has shown that tu-
8
Davis
berculosis is more than a simple infectious disease and that its effective control requires combat on many fronts (27,54–57). During the seventeenth century the contagious nature of tuberculosis was accepted and dreaded throughout much of Europe, but by the latter half of the century those north of the Alps began touting hereditary or constitutional factors. In southern Europe the contagion notion persisted and resulted in strict measures to safeguard the public. In 1699 the The General Sanitary Council of the Republic of Lucca ordered that “the health of the human body shall not be harmed or imperiled by objects remaining after death of a person infected with the disease of phthisis” (58). Disinfection measures were promptly instituted, including replastering the entire house by the authorities, decontamination or burning of household goods, and removal of the poor sick to a hospital (59). Furthermore physicians had to report persons treated for or suspected of tuberculosis or they faced fines of 300 ducats or banishment for 10 years for a second offense (59). Although systematic recording of cases was not yet practiced, it is generally agreed that there was a sharp increase in cases of consumption in Britain and then throughout western Europe during the 1600s, especially in the overcrowded cities. Following Lucca’s attempts at record-keeping, compulsory notification was introduced by Ferdinand VI in Spain and in Naples. Parish registers from England quoted by Thomas Beddoes in his 1799 essay (60) indicate that over a 7- to 10-year period one in four deaths was ascribed to tuberculosis. Similar mortality statistics were available from New England in the United States (37). Both Florence (1754) and Naples (1782) subsequently passed edicts to control contagion, and for a while the latter’s rules were strictly enforced in Spain and tubercular patients were forbidden to emigrate (52). However, opposition finally prevailed, and the laws were removed or forgotten. Fears that the laws would evoke prejudice against the tubercular poor and create financial burden contributed to the demise of these early public health efforts (52,58,59). These arguments are reminisicent of those expressed against the pioneering public health laws in New York City at the turn of the twentieth century. B. Concepts of Etiology and Pathogenesis
Once Andreas Vesalius (1514–1564) had established the principal of dissecton and corrected Galen’s errors, correlation of post-mortem examination with clinical aspects began to demystify the puzzling constellation of symptoms and signs that we now call tuberculosis. It took more than 100 more years before the results of autopsies during the sixteenth and seventeenth centuries were published by Theophile Bonet in his Sepuchretum in 1679. Cavities (vomicae) were described in some of the lungs of cases from the leading Parisian physician, Jean Fernel
History of Tuberculosis
9
(1497–1558), who had stated that these occurred frequently in consumptive patients (39). Symptoms of consumption were connected with pathological findings by Richard Morton in 1689 in his systematic treatise, Phthisiologica (39). Francis de le Boe (Sylvius) (1614–1672), a professor at Leyden, observed that tubercles were identified with the symptoms of phthisis. He noted their tendency to grow and gradually to suppurate and even to lead to cavities (61), but he misinterpreted their origin as being tiny lymph nodes (39,43,61). Thomas Willis (1621–1675) of Oxford first proposed the heretical idea that phthisis was possible without ulceration (43,51,61). He also noted the variations in the pathology and clinical course in different individuals, which up to this time had not been fully appreciated (51). William Stark (1741–1770), a meticulous Scotland-trained pathologist, observed structural changes in phthisis, which led him to believe, unlike his predecessors, that observed changes reflected variations in the speed and evolution of the pathologic process rather than different diseases (43,51). Of particular note is Benjamin Martin’s amazing book A New Theory of Consumption, More Especially of Phthisis or Consumption of the Lungs, written in 1719, 26 years after Leeuwenhoek’s opening of a new world of microscopical vistas. It was remarkable in its anticipation of the germ theory proposed and validated more than 100 years later. He believed that consumption was not only contagious, but that this infection was possibly due to “some certain Species of Animacula or wonderful minute living creatures that, by their peculiar shape or disagreeable parts are inimicable to our nature” (43,62). He goes on to suggest “the possibility of very minute animals being not only the original and essential cause of many distempers hitherto inexplicable; but that they are, perhaps, the very malignity so much complained of in many distempers but so little understood” (51,52,62). Marten also commented on the liklihood of tuberculosis contagion: “by habitual lying in the same bed with a consumptive patient, consistently eating and drinking with him or by frequently conversing so nearly as to draw in part of the breath he emits from the lung, consumption may be caught by a sound person. . . . I imagine that slightly conversing with consumptive patients is seldom or never sufficient to catch the disease.” (51,52,62). Marten predicted that his ideas would be scorned, and indeed they were for two centuries, until Villeman and Koch appeared. By the end of the eighteenth century, tuberculosis was rampant: early attempts at control had failed, the cause(s) was still speculative, and the treatments ineffective. Although the gross pathology had been described and the tubercles were believed to be associated with the disease, their origin was unknown, as was the relationship of their occurrence in different parts of the body.
10
Davis III. Nineteenth- and Twentieth-Century Developments and Concepts
The observations and investigations of the next hundred years would establish the fact that the diverse clinical and pathological manifestations were indeed one disease, tuberculosis. They would revolutionize understanding of the cause, improve diagnostic accuracy, and lead to more rational attempts at therapy and control. The correlations of clinical symptoms and signs with specific pathology led to new interest in expanding techniques for eliciting physical signs of anatomical pathological changes. A. Percussion and Auscultation in Diagnosis
The use of percussion and of a new tool, the stethoscope, augmented information gained from symptoms alone, and this could be correlated with the history and pathological observations. Leopold Auenbrugger, an innkeeper’s son, had watched his father tapping wine casks to determine their full or empty state. He decided to apply the technique to his patients and to cadavers on which he experimented (43,51,52). Students of physical diagnosis today would be impressed with the scope of his work, as illustrated by his categorization of his observations in the book Inventum Novum ex Percussione Thoracis Humani, ut Sigmo Abstrusos Interni Pectoris Morvos Detegendi, published in 1761. It took another half century for medical clinicians to recognize the value of Auenbrugger’s approach to diagnosis. Only when Jean Nicholas Corvisart, Professor of Medicine at the College of France, discovered the work in 1797, translated and published the original text, and practiced the method did percussion begin to achieve acclaim (51). Laennec ( b. 1781) devised an indirect method of listening to the sounds generated in the chest. Direct auscultation and succussion, practiced by the ancient Greeks, was not practical in obese patients or women or when hospital vermin were common (39). He constructed a simple instrument to obviate these obstacles and first published his observations in 1819 in his Traite de l’Auscultation Mediate. The stethoscope was at first ridiculed as a mere mechanical toy, and critics considered it ludicrous that a “physician would proudly listen through a long tube applied to the patient’s thorax, as if the disease were a living being that could communicate its condition to the sense without” (39,63). Despite initial skepticism, auscultation and percussion remained the only methods of examination of the chest until Roentgen’s discovery of x-rays later in the century. Even with today’s more sophisticated tools, percussion and ausculation have not yet been discarded.
History of Tuberculosis
11
B. Tuberculosis as One Disease
Bayle had dispelled some of the prevalent misconceptions in his Recherches sur la Phthisie Pulmonaire, published in 1810. On the basis of 900 autopsies—many of them on patients he had known at the bedside—he described phthisis on the basis of pathological injury rather than differences in symptoms or possible causes or complications. He described miliary and extrapulmonary lesions, but he was unable to recognize the etiological unity of his findings or to differentiate cases of bronchiectasis or lung abscess (43). His work attracted Laennec, and they were good friends until Bayle’s death in 1816 at the age of 42 (43). Laennec, in a second edition of his book in 1826, noted that “whatever be the form under which the tuberculous matter is developed, it presents, at first, the appearance of a grey semitransparent substance, which gradually becomes yellow, opaque and very dense. Afterwards it softens, and gradually acquires a fluidity nearly equal to that of pus: it being then expelled through the bronchi, cavities are left, vulgarly known by the name of ulcers of the lungs, but which I shall designate tuberculous excavations” (43,51). Although Stark and Bayle had imperfect glimpses of tuberculosis as possibly a single disease, Laennec noticed that tubercles found in various organs and in various varieties and stages of development seemed uniformly to characterize the disease. He traced its evolution from the tiny gray tubercle through successive eruptions and all its pathological manifestations, thus claiming for the first time the unity of the disease. Laennec’s accomplishments were not without their toll. His work was cut short, when he died from tuberculosis in 1826 at age 45 (43). The concept of the unity of tuberculosis which Laennec had so meticulously expounded was disputed until the bacteriological era confirmed it. Such eminent professors as Broussais and Virchow led the dissension. In the meantime, Johann Lukas Schonlein, Professor of Medicine in Zurich, embraced the idea of the tubercle being the fundamental anatomical lesion and suggested in 1839 that the word “tuberculosis” be used for all manifestations of phthisis (58,61). Clinical pathological studies continued throughout the nineteenth and into the twentieth century, with radiological correlations being added. The work of Parrot, Kuss, and Ghon (64) elucidated the characteristic changes of primary infection in children (and subsequently recognized at any age) and supported the theory that most tuberculosis is acquired by inhalation. The pathogenesis of generalized tuberculosis was demonstrated by Carl Weigert in 1882, and the mechanisms of such complications as laryngeal and intestinal tuberculosis, so common before chemotherapy, and of bronchogenic spread were also demonstrated (65). Ranke in 1917 attempted further clarification of the relationship of the primary complex and the later manifestations of tuberculosis. He proposed three stages of the disease and provoked much discussion about “endogenous” exacerbation ver-
12
Davis
sus “exogenous” reinfection as the source of the third stage (43). In 1935 Opie summarized the then current views by noting that “there is no agreement concerning the relative frequency of endogenous and exogenous infection of adults” or whether or not first infection makes one more or less susceptible to a new infection (66). Discussion continues today as molecular techniques suggest that exogenous reinfection occurs more frequently than was previously believed (67–69), especially when prevalence in the community is high. C. Cause and Transmissibility in Animals and Humans
That tuberculosis is a specific infectious disease was not recognized until Jean Antoine Villeman’s astute observations. Working with military horses, he had observed that healthy young rural horses brought into crowded military depots often died of fulminating glanders (52,61). He also noted that military men stationed in barracks, not out in the field, and prisoners, industrial workers, and members of cloistered religious orders were more likely to have tuberculosis than the general population (52). Inocculation experiments had been performed by Kortum in 1789 and later by Cruveilhier, who considered tuberculosis not to be specific but to result from inoculation of a number of substances (39). In 1865 Villemin began his signal series of experiments. He inocculated products of the disease, such as sputum and gray and soft tubercles from the lung and other organs from humans to lower animals and from animal to animal and found that the disease developed in the inoculated animals (51,65). He concluded that tuberculosis is a specific disease the cause of which resides in an inoculable agent. He also went on to show that all forms of scrofula are really tuberculosis (70). Despite Villeman’s significant contribution, many in France and England continued to challenge it, claiming that he was just producing a foreign body reaction. His work, however, stimulated tuberculosis research elsewhere, especially in Italy and Germany, and by 1880 his conclusion was known and accepted (51,52). It was not until Robert Koch isolated the tubercle bacillus in 1882, however, that the unity and transmissibility of tuberculosis were finally confirmed. Experimenting within the new science of bacteriology, Koch developed a method of plate cultivation, which by permitting separation of colonies made possible isolation of individual strains (71). Koch demonstrated that the bacillus he had isolated inoculated into animals could reproduce the disease in them and that the organism could be recovered from those tissues and, when reinoculated into other animals, could again produce the disease (72). Koch’s postulates and his precise experiments to prove them have served as a model for infectious disease investigators ever since. Even though Koch’s demonstrations seem indisputable now, there were at the time still skeptics who clung to their preconceived notions or unproven hy-
History of Tuberculosis
13
potheses. At Koch’s momentous presentation before the Physiological Society in Berlin, the audience looked to Virchow for comment. His silence was cutting. Virchow persisted to the end of his life in claiming that scrofula and pulmonary phthisis were not the same disease. He lectured that certain aspects of the disease in cattle known as “pearl disease” (so named because of the appearance of the lesions on the serous membranes) looked like lymphosarcomas. The peculiar distribution of these grape-like or potato-like lesions in the peritoneum or internal genitalia led to speculation that they must be related to nymphomania and satyriasis (65). Koch himself did not appreciate that there was a distinction between human and bovine tuberculosis. Between 1896 and 1898 Theobold Smith in the United States demonstrated that these were separate strains (73), but even as late as 1908 at the International Conference on Tuberculosis in Washington, D.C., there was still controversy over whether the disease in humans and that in cattle were caused by two different tubercle bacilli (65,74). Ravenel (75) of the United States, however, presented incontrovertible evidence that the bovine bacillus is responsible for most tuberculosis in cattle, a vital step in the subsequent eradication of tuberculosis from bovine herds and consequently preventing many cases of tuberculosis in humans as well. Proving which species of the organism was responsible for bovine tuberculosis took ingenuity. Because cattle can develop cavitary pulmonary lesions, the organism could be recovered from pulmonary secretions. Nocard, a French veterinarian, did this by grasping a cow’s tongue and swabbing the throat—when the cow coughed, he tried to catch the secretions. Ravenel more cleverly constructed a hood, which he put over the cow’s nose and mouth. At the bottom was a wooden platform upon which the cow’s coughed-up secretions would fall. He then collected and examined them for the tubercle bacillus (65). Although contagiousness of tuberculosis had long been suspected, considerable skepticism remained as to whether tubercle bacilli were the cause or merely a by-product of tuberculosis (76). Even those accepting the fact of its transmissibility did not agree about how the infection was transmitted. D. Modes of Transmission: Implications for Control
It was still hypothesized that tuberculosis might be transmitted through the ovum even after Koch’s announcement. Osler temporarily perpetuated the idea using silkworm infestation as an example, saying that even the silkworm egg can be invaded by a parasite, thus providing hereditary transmission. This notion was gradually eroded and finally discounted in Cornet’s statement that the tubercle bacillus would have to be straddling a spermatozoa as it enters the ovum, a situation thought to be too absurd to be believed (65). Theories of how tuberculosis might be transmitted helped to determine certain control measures (Fig. 1). Cornet, among others, was a proponent of the dust
14
Davis
History of Tuberculosis
15
theory, namely that dust arising from expectorated sputum, which has dried and become pulverized, floats in the air and is inhaled (77). The belief that tuberculosis might also be transmitted by soiling hands or mouth helped to foster the idea that most tuberculosis started in childhood. That surfaces could be contaminated was demonstrated by strategically placing pans of water around to collect material emanating from the patient’s cough or by swabbing the floor. Inoculation of animals with such collected material produced tuberculosis (65). It was later confirmed that particles carrying M. tuberculosis can be transiently resuspended by an air current and become a possible reservoir for infectious respirable particles (78). This concept as a major mode of transmission was disputed by Flugge (77), who instead postulated that moist droplets produced by cough and sprayed into the air were the means. Considerable controversy prevailed during the 1880s and 1890s, but Cornet’s work was so persuasive that the environment was contaminated and the disease still so lethal that disinfection pervaded all of the early laws for tuberculosis prevention and control in the United States in the early 1890s and the first part of the twentieth century. Sulfur candles might be used, or, once a patient had died, the walls might be swept down with soft bread if they were whitewashed or papered or washed with carbolic acid or formalin solution if painted (65). It was not until the 1930s, extending into the 1960s, that the current understanding of transmission by droplet nuclei was demonstrated by Wells (79,80) and further elucidated by Richard Riley (81). Wells exposed animals to various concentrations of droplet particles and demonstrated that it is not the moist droplet particle that is the usual immediate means of transmission, but the particle that loses its content of moisture, leaving a single bacillus or small clump of bacilli to float freely in the air for considerable periods of time. Wells termed these lighter particles “droplet nuclei.” He noted that the heavier droplets, greater than several micrometers in diameter, generally fell to the floor and dried out and their organisms usually died off. Droplet nuclei produced by a single cough in Loudon’s and Robert’s experiments remained suspended in the air after 30 minutes (82). Such droplets could be readily inhaled and if they reached an alveolus could initiate primary infection (80,81). Riley and coworkers in Baltimore subsequently demonstrated how the dried nuclei may be airborne for some distances and still be capable of infecting animals (83). Such transmission was demonstrated in humans in the well-documented Figure 1. Antituberculosis campaign educational poster circa 1915. For some time transmission of tuberculosis was believed to be by fomites and dust particles. Disinfection was widely used until the work of Wells and Riley in the mid-twentieth century showed that airborne droplet nuclei were the means of transmission. (Courtesy of the American Lung Association, New York.)
16
Davis
Navy submarine epidemic reported during the 1960s (84) and more recently in hospital outbreaks of multidrug-resistant tuberculosis (85). The work of Wells, Riley, and their colleagues, as reflected in a National Tuberculosis Association Committee Report in 1967 (86), has been crucial to the modern strategies of environmental tuberculosis control aimed at preventing infected droplet nuclei from entering the air, diluting their numbers by adequate number of air exchanges, preventing dissemination by maintaining negative pressure in the contaminated space relative to the adjoining areas, using devices to filter or “sterilize” the air leaving the room, and preventing persons entering the infectious patient’s room from inhaling infected particles by using particulate respirators (87–89).
E. Evolution of Public Health Campaign
Other events important to the history of tuberculosis were occurring during the nineteenth century. The first international medical congress, held in 1867 in Paris, included presentations on tuberculosis, including Villeman’s work. Subsequent international congresses devoted specifically to tuberculosis were held regularly until the end of the century and still meet periodically even today. Toward the end of the nineteenth century, national organizations composed of medical, lay, and government persons evolved to combat tuberculosis in Austria, Denmark, and France, with other countries in Europe and Canada rapidly joining the movement (43). Lawrence Flick in Philadelphia in 1892 organized the first voluntary society in the United States to combat a specific disease, the Pennsylvania Society for Prevention of Tuberculosis (90). He wanted to disseminate the idea of the communicability of tuberculosis and to stop its spread using education, legislation, research, and better patient care. Other voluntary associations began to arise and competed for the honor of representing the United States at the International Tuberculosis Congress in Paris in 1904. Adolphus Knopf urged the organization of a strong national scientific and popular organization against the disease. The National Association for the Study and Prevention of Tuberculosis, later called the National Tuberculosis Association and now known as the American Lung Association, was thus born in 1904 (90,91). By 1914, with the collaboration of its many grass-root affiliates, it had become a powerful force in the crusade against the disease (90). Through the innovative idea of a Danish postal worker, Einar Holboell, and the philanthropic efforts of Emily Bissell, a Delaware Red Cross volunteer, the sale of Christmas seals provided remarkable financial support for an expanding antituberculosis campaign (92). In 1902 an International Central Bureau for the campaign against tuberculosis under the emblem of the double-barred cross was established, with an office in Berlin and then Geneva. After World War I, it became the International Union
History of Tuberculosis
17
Against Tuberculosis, now the International Union Against Tuberculosis and Lung Disease (IUATLD) (43). The antituberculosis campaign extended to other parts of the industrializing world: Asia, Africa, the Near East, and Latin America. In 1898 in Japan, Goto Shinpei petitioned the government to establish an office of sanitary police. Attention to epidemic control and water supplies would keep the population healthy and benefit Japanese imperialism (42). In China the YMCA organized city-wide health campaigns between 1915 and 1921, enlisting the cooperation of city officials, educators, churches, newspapermen, students, boy scouts, and the Chamber of Commerce, but tuberculosis was a low priority of the government despite the dismal statistics available in the early twentieth century. It was 1933 before the Chinese Medical Association held its first tuberculosis conference and an antituberculosis association was formed in Shanghai (42). In Korea the first tuberculosis sanatorium opened in 1928, the School of Hygiene was organized, and in 1932 the sanatorium became the seat of the new Korean Christmas Seal organization. Some historians feel that the campaign against tuberculosis has been driven primarily by “the need to protect the investment and profits of the owning class” (93). When labor was initially unskilled, cheap, and easily replaceable, employers had little concern for the health of individual workers. Only as the labor pool shrank and increased skills were required did employers realize the financial importance of not losing employees. Such motives may have hastened the institution of preventive measures in South Africa in the early twentieth century as the alarming rates of pneumococcal disease and tuberculosis in mine workers became known (94). The other catalyst in the campaign was the recognition by physicians that untreated, unsupervised poor people were a threat not only to themselves but to the larger public’s health as they came in contact with middle and upper class persons as their servants, repairmen, or in other capacities. During the recent resurgence of tuberculosis in New York City this threat resurfaced, caught the media’s attention and thus the public’s, and undoubtedly stimulated the rapid action of legislators and public health departments even beyond the United States. The time was also ripe for social activism. The belief in the importance of constitutional and hereditary factors in tuberculosis persisted throughout the nineteenth and even the twentieth century in North America and England, despite Koch’s isolation of the infectious agent. Toward the end of the nineteenth century vulnerability to tuberculosis was linked to immorality and lower social class. Adolphus Knopf in his 1907 prize-winning essay, “Tuberculosis as a Disease of the Masses and How to Combat It” (95), identified those most susceptible as the unfortunate poor, the ignorant or depraved, or the alcoholic. As large numbers of people moved from rural to urban areas and immigants flooded the larger cities, greedy landlords offered the worst of housing conditions: dark cramped quarters with inadequate water, sewage, or ventilation (Fig. 2).
18
Davis
Figure 2. Tenement visit by visiting nurse in 1924. The nurse/social worker was an essential link in the antituberculosis campaign, educating families about tuberculosis, expectoration, disinfectation, importance of ventilation, good hygiene, and nutrition. She was a liaison between the community, medical facilities, and the health department, identifying those at risk or ill, referring to appropriate medical facilities, and monitoring their subsequent follow-up. The poverty and inadequate housing reflected here, believed to contribute to prevalence of the disease, are still with us. (Photograph Courtesy of the Bellevue Hospital Chest Service Archives, New York.)
Death rates from tuberculosis in the 1890s soared to more than 776 per 100,000 (93) in some districts. Xenophobia augmented the difficulties of controlling the disease. Many Americans feared being overwhelmed by aliens with different cultures and beliefs. New waves of immigrants and refugees in the latter part of the twentieth century stimulated similar sentiments in some areas, and many immigrants do not seek health care for sociocultural, economic, or other reasons, including fear of the consequences if they are undocumented (96,97). As Koch had predicted at the conclusion of his scholarly thesis in 1882, “when the conviction that tuberculosis is an exquisite infectious disease has become firmly established among physicians, the question of an adequate campaign
History of Tuberculosis
19
against tuberculosis will certainly come under discussion, and it will develop by itself” (72). He was correct in predicting that such a campaign would evolve. In Edinburgh Sir Robert W. Phillip was a prime mover in establishing an organized system for the control of tuberculosis. In 1887, just 5 years after Koch’s announcement, Phillip opened the first tuberculosis dispensary in the world. It became the nucleus of the Edinburgh Anti-tuberculosis Scheme (37,43). Phillip’s dispensary was unique in its organization not only for the treatment of tuberculosis, but also in its prevention, case finding, record filing, sputum examinations, home visits by physicians, and specially trained nurses. Social service in the home, classification, triage, and aftercare of discharged patients was practiced, and education was freely dispensed (98). In the United States, Canada, and Germany the sanatorium movement preceded any generally organized antituberculosis effort (98). Phillip’s pioneering efforts led to the development of city chest clinics throughout the world, often integrating case finding and referral within a sanatorium or hospital system in collaboration with developing municipal antituberculosis structures (99,100) (Fig. 3). In the United States state health departments began to broaden their mandates from primarily sanitary water supplies, safe sewage, and garbage disposal to the control of transmissible diseases. Public health physicians began to replace sanitary engineers. In 1888 Commissioner of Health in New York City, Joseph D. Bryant, asked a group of consultants, including Herman Biggs, an 1883 graduate of the Bellevue Medical College, to issue a position paper on tuberculosis for the Board. The document asserted the validity of Koch’s findings and recommended the inspection of cattle to prevent consumption of infected meat and milk, public education regarding the dangers of pulmonary discharges from tuberculous individuals, and disinfection of rooms occupied or previously occupied by tubercular individuals. Since the report was not embraced by most of the medical community, a political campaign to educate the public was launched, with flyers distributed in several languages (93). By 1893 the Board of Health requested updated recommendations and accepted the first six of the following measures recommended by Biggs (101): 1. Educate the public via circulars and publications. 2. Require public institutions to notify the Department within 7 days of all persons suffering from pulmonary tuberculosis. 3. Appoint inspectors to ensure effective disinfection of contaminated premises. 4. In hospitals, separate tuberculosis patients from other patients. 5. Establish a hospital exclusively for tuberculosis patients. 6. Require the Board of Health to do diagnostic bacteriological sputum examination in every case of pulmonary disease of doubtful character, at the physician’s request.
20
Davis
Figure 3. Tuberculosis clinic, Bellevue Hospital, early 1900s. The dispensary or TB clinic became an increasingly integral part of the tuberculosis-control effort. Because case rates were not declining as rapidly as mortality, more attention was directed to earlier identification of cases and prevention of transmission. The dispensary served as a diagnostic and triage center and provided social services, case management, and follow-up after hospital or sanatorium care in cooperation with the health department. James Alexander Miller established in New York this model organization, similar to that initiated by Dr. Phillip of Edinburg in 1888. Note the “No Spitting on the Floor” sign on the wall. (Photograph Courtesy of the Bellevue Hospital Chest Service Archives, New York.)
7. Insist that all physicians practicing in New York City notify the Board of all patients with pulmonary tuberculosis coming under their care. Just as in Naples in the 1700s, physicians resisted the “punitive” reporting laws. Physicians in New York and as far away as Philadelphia fought this suggestion on the basis that it would stigmatize such patients and make them outcasts of society and physicians would lose both medical control and a source of their income. Gradual enforcement of compulsory notification finally succeeded because of the political astuteness and sensitivity of the Board of Health and its advisors.
History of Tuberculosis
21
Between 1898 and 1910 the numbers of reported cases increased from 8,559 to 32,065 and sputum examinations from 1,920 to 40,000 (93). In Britain, although Sir Robert Phillip advocated compulsory notification as early as 1890, 20 more years elapsed before it was finally enacted into law (43). In 1901 Robert Koch commended Biggs for the willingness of the American people to accept the limitation of their liberties in the interest of public health, and he recommended the New York model for the “study and imitation of all municipal sanitary authorities” (102). Biggs, writing on administrative measures for the control of tuberculosis in New York City, noted that Edinburgh and New York had more comprehensive plans than any other cities, and he gave great credit to Sir Robert Phillip for his innovative initiative in addressing tuberculosis control (98). The New York City Health Department became a model in the United States in the 1890s. A century later, in the recent upsurge of the disease, it again reacted aggressively to squelch the epidemic and serve as a resource for others, including a delegation from the World Health Organization, in anticipation of similar increases in cases and problems with drug resistance in other parts of the world. The reasons for the upsurge even in developed countries are multiple (12,55,56, 96,97,103,104), but complacency and diversion of resources to other priorities contributed (27,56,103,104). The sudden need to relearn and reinstitute the lessons of the past has been painful and costly. The importance of continuous monitoring of control strategies and provision of adequate resources to implement necessary measures has been illustrated repeatedly by the necessity for task forces and conferences to address the continuing problem of control (37,56,105,106). F. Treatment and Control: The Sanatorium Era from the Mid-1800s to the Mid-1900s
The increasing emphasis on fresh air, diet, rest, and exercise as a means of preventing miasmas, the rise of the Public Health Movement stimulated by the atrocious sanitary conditions related to increasing urbanization, and the socioeconomic effects of the Industrial Revolution all intertwined with the development of the sanatorium era of treatment beginning around the mid-1800s and reaching its prime during the first half of the twentieth century (107). Diseased people may have been segregated in ancient times, but the “modern” sanatorium movement began slowly with the efforts of a few widely separated pioneers, then spread at an accelerating pace throughout the world. The originator of the movement was George Bodington, a Warwickshire physician, who in 1840 rebelled against the popular “antiphlogistic” therapy and advocated fresh air, sensible diet, and gradually increasing exercise. He felt that a structured program under close supervision was superior to the benefits of just go-
22
Davis
ing to a boarding house for the climate or change of scene. He instituted such a program in a house near his own (43). The Brompton Hospital in London in 1841 and the Channing Home in Boston in 1857 (43,108) took in consumptive patients out of humane concern, but it was Hermann Brehmer, his ex-patient Peter Dettweiler, and then Otto Walther who led the “more therapeutic” European sanatorium movement, which spread to the riverside and coastal areas of Great Britain, to the mountains of Switzerland, and after 1882 to America and other continents as well. Brehmer was aware of Rokitansky’s finding that 90% of those who died from other causes had healed tuberculous lesions within normal lung tissue, and he was curious about the reasons for such spontaneous cures. He thought that the pulmonary disease was due to deficient circulation of the blood to the lung, as manifested by the disproportion between the size of the phthisic lung and the small heart and aorta, and he strongly believed that tuberculosis was curable with exercise at high altitude and abundant food to stimulate the circulation and metabolism. Having experienced good results in his own case by application of his theory, by 1859 he managed to build a 40-room Kurhaus with entertainment rooms and a kitchen in Gobersdorf, a mountain valley 1715 feet above sea level in Silesia. By 1869 he had treated 958 patients (109). The later recognition that tuberculosis was infectious almost closed this first real sanatorium as patients were reluctant to congregate in an institution where they would be continuously exposed, but Brehmer developed a successful disinfection system to allay their fears. In addition he added chemistry and bacteriology laboratories and an observatory to monitor the meteorological conditions believed so important to the patients. The sanatorium flourished. By the time of Brehmer’s death in 1899 there were more than 300 sanatoria in Germany alone (110). In 1904 it was the largest in the world, able to accommodate about 300 patients (112). Brehmer’s ex-patient and assistant, Peter Dettweiler, later established his own sanatorium in Falkenstein, which became a mecca for visitors interested in sanatorium treatment. He advocated much closer medical supervision, patient education, rest with graduated exercise only as tolerated without fatigue, and openair treatment in all seasons. He introduced the reclining chair (Liegekur), which subsequently became a hallmark of “taking the cure,” and invented an “ingenious little cuspidor” to prevent spread of the disease. It was made of blue glass and could be hidden in the folds of a handkerchief and manipulated with one hand (111). Walther similarly opened a successful sanatorium in the Black Forest at Nordrach. His strict discipline and therapeutic regimen became popular in Britain and a prototype for many sanatoria that included Nordrach in their name (113). Carl Spengler’s establishment of a sanatorium in Davos (114) initiated a multiplicity of institutions—including Rollier’s for heliotherapy—hotels, and
History of Tuberculosis
23
boarding houses, which transformed Switzerland into a major health resort and inspired Thomas Mann’s novel The Magic Mountain (107). In the United States the perception of beneficial effects of altitude and climate were evident in the mid- to late 1800s, but it was Edward L. Trudeau who led the American sanatorium movement with the establishment of the Adirondack Cottage Sanitarium in 1885 near the village of Saranac Lake, New York. Having tirelessly cared for his brother during his rapidly fatal tuberculosis, Trudeau himself developed a cold abscess during medical school, but the true nature of his illness was recognized only shortly after he entered practice in New York City. The diagnosis was essentially a death sentence to him. As his health deteriorated, friends urged him to go to the mountains. He reluctantly left his wife and two young children for an exhausting trip to Paul Smith’s hunting lodge in the Adirondack Mountains. He wrote that “the change, the stimulus of renewed hope, and the constant open air life had a wonderful effect on my health” (115). The value of rest in the treatment of tuberculosis was not yet appreciated in the United States, but Trudeau noticed that his health improved as he was reclining on balsam boughs and blankets much of the day while he was being rowed by a guide from place to place on one of the beautiful Saranac lakes looking for fish or wildlife. When Trudeau first went to the Adirondacks in 1873, tuberculosis was still considered largely hereditary. Only the seriously symptomatic wealthy had access to climatic treatment. Trudeau’s awareness of the European sanatoriums and his own personal experience stimulated him, with the financial help of his influential friends and donations from devoted guides, to purchase some land and begin construction of first one and then a number of cottages in order to test the principles of a structured supervised regimen. A cottage system would permit expansion as monies became available, and after Koch’s work became known separate cottages seemed plausible as a strategy to minimize transmission. When Trudeau first obtained an English translation of Koch’s remarkable findings, he was inspired to set up his own little laboratory in a room of his house to study the tubercle bacillus and other aspects of the disease. With the guidance of Koch’s paper, a few lessons from Dr. Prudden in New York, and his own ingenuity, Trudeau managed to grow the tubercle bacillus despite the inclemently cold Saranac nights (107). He was only the second person in America to grow pure cultures, and throughout his life he supplied cultures without charge to other scientists (115). He repeated Koch’s experiments and was then able to test for the bacillus in patient’s secretions and perform his own experiments to determine factors related to progression of the disease and the effects of different treatments. Trudeau spent parts of almost every day in the laboratory, hoping to find some “magic bullet” against tuberculosis. The Saranac laboratory was the first in the United States devoted to original investigations into tuberculosis. When the sanatorium finally closed almost 40 years after Trudeau’s death from tuberculosis, the new Trudeau Institute for Re-
24
Davis
search was created in 1964 with financial help from the sale of the property, the fund-raising efforts of his only remaining son, Francis P. Trudeau, and his grandson, Francis B. Trudeau, Jr., and many devoted friends. Its contributions to the understanding of immunology and the interaction of dust diseases and tuberculosis and more recently the immune system in relation to other infectious diseases and cancer have extended far beyond the little village of Saranac Lake (107). Trudeau’s sanatorium treatment gained momentum only slowly, but when he reported the results of his first 165 patients at the opening of the Henry Phipps Institute in Philadelphia in 1903 (116) and noted that he had succeeded in educating the public as to the safety and value of sanatorium treatment (“phthisiophobia” was prevalent in some communities) (117), his influence began to spread. He participated in the medical and public health activities going on and evolving around him in 1904, became the first president of the newly organized National Association for the Study and Prevention of Tuberculosis (now the American Lung Association), and later president of the Congress of American Physicians and Surgeons (107). His protegés included Dr. Edward Baldwin, who was awarded the Trudeau Medal (the highest award of the National Tuberculosis Association) in 1927 for his research into immunological mechanisms; Dr. Lawrason Brown, who devised a system that set standards so that different centers could compare success rates and who founded the Journal of Outdoor Life in 1903 to disseminate information about the prevention and cure of tuberculosis to those seeking health through an outdoor life; Allen K. Krausse, a pathologist who went to Johns Hopkins as the first full-time teacher in the field of tuberculosis and subsequently was the first managing editor of the American Review of Tuberculosis (now the American Journal of Respiratory and Critical Care Medicine), first published in 1917 for promotion of clinical investigation, laboratory research, and discussion of scientific and philosophical issues; Esmond R. Long, a pathologist who later headed the Henry Phipps Institute in Philadelphia and contributed in collaboration with Florence Siebert to the additional understanding of immunological aspects of tuberculin; and James Alexander Miller, founder of the prestigious Bellevue Hospital Tuberculosis Service in New York City (now the Chest Service) (107). Trudeau’s epitaph—Guerir quelquefois, soulanger souvent, consoler toujours—is not only a tribute to the man, but exemplifies the caring spirit of Trudeau’s treatment center. From its simple beginning, it developed into a “tuberculosis university” (118), which included not only the Saranac laboratory for the study of tuberculosis, but a nurses’s training school, which opened in 1912 for ex-patient nursing students, and the internationally renowned Trudeau School for Tuberculosis, established in 1916 to provide postgraduate education in tuberculosis (107). Sanatoria proliferated throughout the United States and Canada. By 1904 there were 115 sanatoria in the United States with less than 8000 beds for tuber-
History of Tuberculosis
25
culosis. By 1923 there were 656 such facilities with 66,000 beds, about half being under state, county, or municipal auspices (119). The number of institutions and beds continued to increase steadily, despite declining mortality (with morbidity only slowly following suit), so that by 1953 there were 839 facilities in the United States and its territories with 130,322 beds set aside for tuberculosis patients. Federal hospital and mental institutions as well as state penal institutions accounted for some of these (120). As sanatoria sprouted around the world, so did controversies about the components of good sanatorium treatment, the benefits of treatment in a sanatorium versus alternative care at home, and finally whether the era of sanatorium care contributed positively or negatively to overall progress against the recalcitrant disease tuberculosis (107). The structured, sheltered environment provided by sanatoria represented to some patients a haven from the stigma and realities of their previous situations. It provided a structure for education and psychological support. To others, it represented a time of imprisonment, isolation, and diversion from their responsibilities and achievement of their ambitions. The sanatorium system enabled physicians to observe closely the effects of tuberculosis at different stages and with different manifestations in vast numbers of demographically diverse individuals. During this era the natural history of the disease, its pathogenesis, and its pathology were further elucidated. The closed environment permitted a valuable reference base and population for the study of emerging diagnostic and therapeutic technologies. From the public health standpoint, the effect of sequestering thousands of infectious persons for several months to whole lifetimes is still uncertain. Mortality had already been declining (37,121,122), and improved living conditions, nutrition, and economics may have played a role (121,122). The lagging decline in new case rates, however, despite growing availability of sanatorium beds and declining mortality, implies that isolation was not sufficient to eradicate the disease (53). Alternatives to sanatorium care during this period were often innovative and ranged from tents on tenement roof tops (Fig. 4), or window tents within a room, to old streetcars and even ferry boats (Fig. 5). Provisions for children included a unique foster care system in France (123) and preventoria in the United States [the first opened in 1909 and became the only one in the country to have cribs for the isolation of infants from tuberculous parents (124)]. Special camps and fresh air schools were organized for children with tuberculosis believed to be at risk because of anemia and malnutrition. Although the prevalence of tuberculosis was particularly devastating to blacks and American Indians, it was not until the 1930s that the enormity of the problem was recognized by the Tuberculosis Movement in America and facilities became more available to such patients (90,124).
26
Davis
Figure 4. Roof-top “cure” of tuberculosis, an alternative to sanatorium care. Beginning in the mid-1800s, before effective chemotherapy for tuberculosis, a structured, often strict regimen of fresh air, rest with specifically prescribed exercise, and abundant nourishment were the sole mainstays of treatment until adjunctive collapse therapies were introduced in the early twentieth century. (Photograph circa 1920. Courtesy of the Bellevue Hospital Chest Service Archives, New York.)
Initial enthusiasm during the period of sanatoria was supplanted by reality as statistics began to be examined around 1914–1920. Among nine sanatoria from which statistics were available for periods of up to 15 years, 51% of the discharged patients were dead at 5 years (125). Early data from Saranac Lake indicated that among those discharged as “cured” the death rate was still triple that of the general population (90,110). Relapse and reentry rates to sanatoria were as high as 50% in some cases (126), but not all (127,128). These discouraging results caused more attention to be paid to after-care and rehabilitation (129) (Fig. 6). Some sanatoria provided opportunities for learning new skills or for regaining lost ones, and abroad, model colonies were developed
History of Tuberculosis
27
where patients could live and work with supervision and encouragement (130). In the United States state vocational rehabilitation services increased 176% between 1936 and 1940 (131). Clinic practice was surveyed and standards recommended (99). More organized efforts at case finding, isolation of active cases, and emphasis on follow-up were initiated, and collapse therapies and surgical procedures were added to sanatorium regimens in the 1920s and 1930s. Mortality, which had steadily declined in Western Europe and the United States during the nineteenth century, decreased even further (37,122).
Figure 5. Children receiving eggs and milk on Southfield ferry boat in New York City. Children at risk of tuberculosis because of poor nutrition, living in crowded tenements, or household exposure to tuberculosis often received nutritional supplements and attended fresh air schools, or day camps. Children might be sent to “preventoria,” or in France they were placed in foster care in the countryside to remove them from exposure and to improve their resistance. (Photograph 1909, Courtesy of Bellevue Hospital Chest Service Archives, New York.)
28
Davis
Figure 6. Men enjoying occupational therapy or vocational rehabilitation. These activities, an integral part of improving compliance and better treatment outcomes before chemotherapy, helped break the monotony of “the cure,” which often lasted for months or even years. Retraining for physically less demanding work or providing work in a medically supervised sheltered environment might reduce relapses. Also, unfortunately, even after effective drugs many patients were left with crippling respiratory insufficiency from the extensive lung damage already sustained or from the collapse therapy and its sequellae. (Photograph circa 1930, Courtesy of the Bellevue Hospital Chest Service Archives, New York.)
G. Developments in Diagnosis: Laboratory Tests and X-Rays
After the causative agent of tuberculosis was known, more precise diagnosis was an early interest. Prudden and Trudeau applied examination of the sputum to clinical problems before the turn of the century, but Grancher and Gerhardt in 1890 each cautioned about the late appearance of the bacilli in the sputum in comparison to the physical signs (132). Relevant even today in the AIDS era is Riviere’s comment: “Disastrous is it to wait for the advent of tubercle bacilli to establish a diagnosis; still more disastrous to regard a negative sputum examination as evi-
History of Tuberculosis
29
dence that the patients’ disease is not tuberculous.” Riviere advocated repeated deep cough specimens (132). Other mycobacteria were known to exist before 1900, and with continuing advances in microbiological and molecular techniques and clinical experience it is now known that some are pathogenic and others not and that tuberculosis disease can be caused by M. tuberculosis complex, which presently includes not only M. tuberculosis and M. bovis, but also M. microti and M. africanum. By the early 1900s culture techniques and biochemical tests began to permit separation of these mycobacterial species by their growth rate, colonial and microscopic morphology, biochemical characteristics and behavior in experimental animals (73,75,133). By the 1940s and 1950s nontuberculous mycobacteria were being increasingly identified around the world (134). Rosenberger in 1908 was the first to describe acid-fast rods in blood, but their significance was disputed because animal tests did not confirm their pathogenicity. Riviere wrote: “So far as the early diagnosis of tubercle is concerned, the detection of bacilli in the blood offers as yet no practical assistance; we await with interest the appearance of further developments in this direction” (132). Riviere’s conclusion is of interest in view of the current availability of the peripheral blood-based PCR assay (135) and recovery of mycobacteria from blood with the use of the isolator tube (Wampole) (136). Experiments with other diagnostic tests such as the tuberculo-opsonic index initiated by Wright in 1905 and complement fixation methods in the early 1900s were abandoned. Throughout the twentieth century other immunological assays using various antigens from the tubercle bacillus were attempted (137,138). The recent upsurge of tuberculosis begining in the late 1980s has hastened the development of modifications and innovative culture techniques to improve the rapidity of diagnosis and detection of resistant organisms, such as the Bactec system, the Septi-chek AFB (BBL), and the Mycobacteria Growth Indicator Tube (MGIT,BBL), which are described elsewhere (136). Most exciting and promising, however, has been the recent application of nucleic acid probes to the earlier identification of mycobacterial species (139,140), and DNA fingerprinting, which has helped to identify clusters of disease and outbreak patterns and aided in the understanding of transmission and spread of resistant organisms in the community (21,68) and laboratory cross-contamination (141). Their usefulness and validity in the management of patients, however, is still being debated and evaluated (141–143). New technologies such as fiberoptic bronchoscopy and bronchoalveolar lavage have, in the last quarter of the twentieth century, enhanced diagnosis and improved understanding of pathogenesis and host immunological responses at different stages of tuberculosis (143a). They are discussed elsewhere. Even after Koch’s discovery, detection of disease continued to depend primarily on symptoms or physical findings and only seldom on radiographic tech-
30
Davis
niques. When Konrad Roentgen discovered x-rays in 1895, their value in diagnosis was, like many previous innovations, received with caution or ridicule. A London firm allegedly advertised the sale of x-ray–proof underclothing (43). The use of x-rays in the diagnosis and management of tuberculosis was apparently ignored except for a brief note in 1896 in Lancet (43). In Boston, Francis H. Williams, without knowledge of their physical findings, performed fluoroscopic examinations on more than 100 patients with pulmonary tuberculosis and reported correspondence between physical signs and xray examination in a considerable number, but in some the disease was more extensive than the physical examination indicated. In others, x-ray detected increased density before it could be discerned clinically (43). Valuable investigations were also going on in France and Britain. The Trudeau and Loomis Sanatoria were the first in the United States to apply this technique routinely (43). Even in the 1930s some senior and influential physicians, for fear of jeopardizing their reputations, which had been built on their physical diagnostic prowess, were reluctant to admit the value of the tool. By the 1930s x-ray examination of patients with pulmonary tuberculosis was routine, and in the middle of the twentieth century mass x-ray screening became a major thrust in the control of tuberculosis (Fig. 7). Agreement on the meaning of findings discovered on x-ray was certainly not uniform, just as it is not today. Additional pathological investigations were necessary to clarify the pathogenesis of the disease and facilitate roentgenological interpretation. Around the 1920s there was interest in the “early pulmonary infiltrate,” frequently recognized by roentgenological examination in adults who presented with tuberculosis but with few or no symptoms or typical apical “crackles” (65). Worldwide interest in the significance of this early infitrate stimulated many investigations through the 1940s. Medlar (144) and other eminent pathologists studied postmortem material from accident victims and those dying unexpectedly of unknown causes. The early lesions were shown to be small areas of exudative bronchopneumonic tuberculosis. They were typically found in the upper posterior part of the lung near the pleural surface. By the time they were visible radiologically, they were usually necrotic at the center, and with repeated culturing of gastric contents they were found frequently to be discharging tubercle bacilli. Communication with a small bronchus was usually demonstrated, but discharge of tubercle bacilli could be intermittent if the bronchiole became plugged with the semisolid caseous material. Hope of discovering this early infiltrate in order to detect the disease at its earliest stages to prevent spread prompted the mass x-ray surveys so popular in the mid–twentieth century (65). Even when x-ray screening was abandoned in the 1970s as case rates dropped, radiological examination of patients admitted to hospitals or clinics or doctors’ offices was considered productive (145). Developments in computed tomography and magnetic resonance imaging and the use of contrast material and nuclear medicine techniques have improved differential diagnosis and detection and helped guide management. With the re-
History of Tuberculosis
31
Figure 7. Mass x-ray screening mid-twentieth century. Once x-ray was accepted as a valuable diagnostic tool and more was learned about pathogenesis of tuberculosis from clinical, pathological, and radiological studies, mass screening was instituted in the 1940s in hope of detecting and treating cases earlier but was later abandoned as the drop in new cases made it less cost-effective. In many developing countries such surveys were not feasible. In such cases sputum smear has been used to detect disease, and when possible tuberculin testing has been used to detect distribution and prevalence of infection and to identify candidates for BCG vaccination. (Photograph Courtesy of the American Lung Association, New York.)
cent changes in the epidemiology of tuberculosis, the prevalence of impaired immune response, and more widespread mycobacterial drug resistance, the role of radiological tools has expanded rather than diminished. H. Adjunctive Therapies: Collapse Procedures and Surgical Resection
Better understanding of the pathology of tuberculosis and the ability through Roentgen’s discovery to see cavities during life spurred interest in mechanical methods of treating tuberculosis. Traction on the walls of cavities from elastic re-
32
Davis
coil augmented with respiration, and reduced blood and lymph flow to the upper zones from upright posture were thought to impair healing. The idea of collapsing the lung to “rest” the lung and promote healing was first suggested by Edmund Bourru in Paris as early as 1770. The history of collapse therapy has been described elsewhere (43,146,147). Carlo Forlanini of Pavia in 1894 was the first to induce pneumothorax successfully through the chest wall. John B. Murphy in Chicago independently applied pneumothorax in tuberculosis in 1897; he was the first to do it under x-ray control (146,147). Trudeau was treated with therapeutic pneumothorax before he died in 1915 (107). It became a major adjunct to bedrest during the latter part of the sanatorium era, sometimes used in conjunction with other surgical procedures (148). Hans Christian Jacobeus’s invention of the thorascope in 1911 and his thorascopic cauterization of adhesions (intrapleural pneumonolysis), which often prevented effective collapse, enhanced the usefulness of therapeutic pneumothorax (149). Experience after 1912 and particularly in the 1920s and 1930s indicated that artificial pneumothorax was effective in about one third of patients in whom it was attempted (150–152) and was best in patients with unilateral disease not responding to rest alone, although there were heated debates about the indications. Complications included mild serofibrinous pleurisy in about 80–90% of patients, chronic pleural changes leading to “trapped lung” in some, empyema occasionally, bronchopleural fistula rarely, and air embolism very rarely (152). Other procedures to aid cavity closure included avulsion or crushing of the phrenic nerve to induce hemidiaphragmatic paralysis. Pneumoperitoneum was occasionally used in intestinal and peritoneal tuberculosis, and in 1933 Vadja reported possible benefit in patients with pulmonary tuberculosis. About 50% of patients showed radiological cavity closure, and sputum conversion occurred in slightly fewer. It was used in patients with bilateral, far-advanced cavitary disease to elevate the diaphragm (107). Thoracic surgery began to flourish during this period. In Europe during the 1880s ribs were removed to bring the chest wall down to the lung. Estandler first used the term “thoracoplasty” in 1879, and de Cerenville in 1885 first applied the procedure to collapse a tuberculous cavity. John Alexander refined the technique and wrote the first of his famous textbooks at Trudeau’s sanatorium while curing his own vertebral tuberculosis (148,153). A number of variations on the procedure subsequently were developed, and collapse of the lung was occasionally achieved by introduction of oil, paraffin, or plastic spheres into an extraperiosteal pocket (plombage thoracoplasy) in an attempt to minimize deformity and pulmonary function impairment. Thoracoplasy could achieve cavity closure and sputum conversion in as many as 80% of selected patients. With collapse therapy mortality rates ranged from 14 to 27% after 1–20 years, but without collapse therapy patients with cavitary disease had an average survival time of less than 2 years. On the other hand, such therapy sometimes led to longer
History of Tuberculosis
33
sanatorium stays, serious impairment of pulmonary function, and increased mortality (107). Resection of diseased lung was first performed by Block in 1883 with fatal consequences (148). Even though Tuffier in 1891 successfully resected an apical tuberculous nodule, resection was considered so dangerous that it was not until 1934 that the first lobectomy and pneumonectomy were accomplished successfully for tuberculosis. However, before effective drugs against the disease and the technological developments that have markedly improved surgical outcomes, spread of disease, fistula formation, and empyema were common. In 1943 morbidity from such procedures was 50% or more and mortality 20–40% (153). In the 1950s with chemotherapy, resection for localized disease was rather common until the results of drug therapy proved it to be unnecessary in most cases. However, in selected multidrug-resistant patients resection is still occasionally performed. I. Tuberculin as Therapy, Method of Detection of Infection and Window to Understanding Immunity and Host Defenses
Koch followed many leads from the immunological studies of Jenner and Pasteur before him. He observed in guinea pigs that prior experience with tubercle bacilli, living or dead, altered the animal’s response to the new innoculation of tubercle bacilli and allowed the animal to survive. Much of what has become the science of cellular immunology has derived from Koch’s work (71,154). Koch later prepared a sterile filtrate of cultured organisms, subsequently termed “old tuberculin” (OT), and found that the same “Koch phenomenon” occurred. Koch’s great mistake was that he prematurely reported the use of this preparation as a remedy. It became widely used until it was soon recognized that it killed more patients than it helped (154,155). Koch’s observation of the delayed reaction to this material, however, spawned the term “delayed hypersensitivity,” and his observations of the difference in the effects of OT in patients infected with the tubercle bacillus versus noninfected patients formed the basis for the use of tuberculin as a diagnostic agent (156). Veterinarians were the first to recognize and demonstrate the potential diagnostic use of tuberculin. Tuberculosis was common in cattle, but symptoms, physical examination, and recovery of tubercle bacilli usually detected advanced disease. Professor Eber of Berlin and Leonard Pearson, an American who had worked in Koch’s laboratory in 1890, tested tuberculin in cattle as early as 1891 (157,158). It became evident early from clinical pathological correlations that the test could identify clinically inapparent infections. To control the spread of disease to other cattle and to humans, tuberculin-positive animals were slaughtered in large numbers (17,18). In the United States in 1917 the economic loss to the cattle industry and the serious threat of bovine tuberculosis to the public’s health prompted establishment of a national program to eliminate tuberculosis in cattle.
34
Davis
The positive tuberculin reaction rate in cattle approached 5% in 1918. Systematic testing was instituted, along with prompt disposal of infected cattle, adequate disinfection, and regulations governing movement of animals. Pasturization of milk assured further protection for humans (17,36,37). By 1974 tuberculin reactor rates were 0–0.03% in the United States (18). Various control measures have been used in other countries, where infection rates have been as high as 70–90%, with 30–40% having disease on slaughter (18). Eradication of bovine tuberculosis worldwide requires continued vigilence, public and legislative support, and adequate availability of veterinarians. Von Pirquet first demonstrated that reactions to OT in humans could be induced by cutaneous injection and that a response was indicative of prior tuberculous infection (156). His observations were published in 1907 and 1908. In the early 1900s a patch test, percutaneous test, conjunctival test, and subcutaneous test had been tried, but the intracutaneous test of Charles Mantoux introduced in 1908 persisted as the preferred method because the dose could be most precisely controlled and the reaction, measured in millimeters of induration, could be more readily quantitated (158). Tuberculin is still used as a major method of detecting tuberculosis infection, but experience during much of this century has prompted a variety of changes in its preparation, its method of administration, and its interpretation. As testing was extended beyond herds suspected of the disease, doubts began to occur regarding the specificity of the test because some cattle reacted to tuberculin but had no signs of tuberculosis infection at post-mortem examination. Although variations in administering or reading the test or overlooking a small lesion might have accounted for the reactions, E. G. Hastings believed by 1924 that sensitization by some other organism or organisms was the cause of these false-positive reactions (158). By the mid-1920s nontuberculous mycobacteria were recognized to be widespread, and by the 1930s veterinarians had concluded that false-positive tuberculin reactions were due to nontuberculous mycobacteria (158). As tuberculin testing was extended to apparently healthy humans, the need for a standardized tuberculin more reliable than Koch’s OT became apparent. The development of a purified protein derivative (PPD), which was a potent stable tuberculin without sensitizing properties, was prepared by Florence Siebert of the Henry Phipps Institute in Philadelphia in 1934, and in 1941 Siebert and Glenn made a single large lot of ammonium sulfate–precipitated PPD (lot 349608) from a single strain of human tubercle bacilli, which was deposited as the International Standard of mammalian tuberculin (PPD-S) (159). Even with PPD-S, problems with specificity and sensitivity have continued. Pulmonary calcification had been considered diagnostic of tuberculosis, but the presence of calcification in tuberculin nonresponders noted in the 1930s raised questions about its specificity. Studies by Carol Palmer beginning in 1943 (160) and subsequent studies confirmed the likelihood of a fungal (histoplasmosis) origin (161,162).
History of Tuberculosis
35
Concerns then arose about the sensitivity of the test. Quantitative studies showed that if sufficiently high doses of tuberculin were used, almost everyone would respond, while most patients with tuberculosis and known contacts reacted to a relatively low dose. Without a history of tuberculosis or known contact, only higher doses would elicit a response, so the author concluded that reactions to higher doses were probably not due to M. tuberculosis (163). Palmer, using what appeared to be the ideal dose of 0.0001 mg (5 TU), based on Furcolow’s studies, and 0.005 mg (250 TU) in student nurses found that with 5 TU the percentage of reactors correlated with the degree of exposure to tuberculosis and not place of residence, while with 250 TU the frequency of reactions correlated with geographical area of residence and not contact history. He concluded, like the veterinarians, that tuberculin sensitivity was not dependent on a single source but that antigenically related organisms prevalent in certain geographic environments could elicit a response to higher doses (158). Further Mantoux testing of general populations around the world indicated that sensitivity to 5 TU of PPD is quite uniform among tuberculous individuals, but in certain areas a bimodal distribution of reactions was apparent, with positive reactors having 6–26 mm induration (peak 14–15 mm), and those with reactions 5 mm were considered to be uninfected (164). In still other areas no clear-cut separation existed. The probability that these small reactions represented cross-reactions to tuberculin because of sensitization to other microorganisms was considered in the 1940s and 1950s (164,165). Between 1958 and 1970 further studies with some tuberculous mycobacterial antigens in Navy recruits demonstrated that reactions of 4–12 mm of induration and false-positive reactions to PPD-S appear to be related to prevalence of certain nontuberculous mycobacteria in the environment (166–169). In the 1960s false-negative results in bacteriologically proven cases of tuberculosis began to be reported (170,171). Adsorption of tuberculo-protein onto glass and plastic surfaces was believed to be a factor, and Tween R 80 detergent was subsequently added to help stabilize the material. Other recommendations coming from the advisory panel called by the NIH in 1972 related to timing of preparation in relation to infection and demonstration of bioequavalency of PPD tuberculin to 5 TU of PPD-S in phosphate buffer without polysorbate (158). Another problem affecting tuberculin test diagnostic reliability and interpretation was the “booster phenomenon,” an increase in the size of the reaction to a second tuberculin test compared to the reaction to the first test, first described by Steele and Willis (172). Two-step testing was then recommended for those undergoing serial testing to minimize errors in interpretation (173,174). Von Pirquet in 1908 had observed that the tuberculin test was almost always positive in patients moderately sick with tuberculosis but often negative in those with more severe or rapidly progressive disease (154). He used the terms “allergy” and “anergy” to describe the type of response elicited. For many years tuberculin reactivity was considered an indicator of protective immunity until Rich and Mc-
36
Davis
Cordick in 1929 (175) challenged this view and Wilson later showed that animals could be made tuberculin negative without losing their immunity (176). Koch’s initial investigations of tuberculin have spawned numerous questions and further studies. Tuberculin testing has enhanced knowledge about distribution and other epidemiological aspects of mycobacterial, nonmycobacterial, and fungal diseases and the role of environmental antigens, but more specific tests for tuberculosis based on more specific mycobacterial components are still being pursued. Demonstration of cellular transfer of cutaneous hypersensitivity to tuberculin by Merrill Chase in 1945 (177) and others led to the recognition of the pivotal role of the lymphocyte in cellular hypersensitivity, and Mackaness’s work at the Saranac Laboratory began to elucidate the interaction between cellmediated immune response and macrophage activation (178). Host and mycobacterial factors in delayed hypersensitivity and protective immunity and their relationship are still the subject of ongoing research, as is the meaning of skin test anergy. Several editorials in the 1970s addressed these issues and reflect the understanding at that time (179,180,181). Since the AIDS epidemic the meaning of a negative tuberculin skin test and its relationship to protective immunity and to anergy are still disputed (182,183) as the complex interplay of many factors in tuberculin skin test sensitivity and host immune responses continues to be explored (184). J. Vaccine Development
Ever since Koch’s discovery of the microbial etiology, there has been interest in developing an effective vaccine to prevent tuberculosis. After 1882 many attempts using killed or chemically treated tubercle bacilli generally failed. In 1891 Trudeau found that a strain of M. tuberculosis became attenuated for the guinea pig after repeated subcultures on a serum glycol medium. The RI strain elicited protective immune responses in the animal, but it was not tried in humans. His studies established that living attenuated tubercle bacilli gave greater protection than killed bacill. A live vaccine appeared then to be needed (59). Albert Calmette, a scientist at the Pasteur Institute in Lille, and Camille Guérin, a veterinary school graduate and associate of Calmette, were working with a virulent bovine type tubercle bacillus previously isolated from a heifer’s udder by Nocard in 1902. Serendipitously they found that adding ox bile to the medium to prevent clumping, and subculturing of the microorganism lowered its virulence. Between 1906 and 1919 after 231 3-weekly transfers, they had a microorganism that failed to produce progressive tuberculosis when injected into guinea pigs, rabbits, cattle, or horses. In 1921 it was first given to a human, a newborn child whose mother had died of tuberculosis a few hours after the birth (185). In 1924 oral vaccinations had been given to 664 infants and an additional 114,000 were vaccinated by 1928 without serious consequences. It began to be used in
History of Tuberculosis
37
Spain, Germany, and Scandinavia, but some British and U.S. authorities were skeptical about it. In 1928 the League of Nations announced the safety of the bacille CalmetteGuérin (BCG) for vaccination of humans and animals, but the deaths of 72 and infection of 135 of 250 children orally vaccinated in Lübeck, Germany, in 1929–1930 halted general acceptance of the vaccine until after World War II. It turned out that the children had inadvertently received a virulent strain. After 20 months of criminal proceedings the Lübeck doctors were imprisoned and BCG was exonerated (185). Even after most countries embraced the use of the vaccine, the United States and the Netherlands were not proponents of its use, and only in the late 1940s did England and Australia begin widespread use (186). In 1948 the first International BCG Congress in Paris stated that BCG was effective in preventing tuberculosis and that the BCG strain stably maintained its residual virulence (187). The Danish Red Cross had begun vaccination campaigns in war-ravaged Europe because of the serious tuberculosis situation, and in 1948 a joint enterprise with three Scandanavian voluntary organizations and UNICEF was initiated (188). In 3 years this International Tuberculosis Campaign had effected testing of almost 30 million persons and vaccination of 14 million. After mid-1951 this work was continued and expanded under joint WHO/UNICEF auspices. By the end of 1956 an additional 160 million people had been tuberculin tested and 60 million had been vaccinated (188). The preparation of the vaccines, the details of the animal experiments, the immunological aspects, the variable results from 0 to 80% effectiveness, and possible reasons for the differences have been discussed by others (189–193). The methodological aspects have also been evaluated (188,194–196). BCG vaccine trials have provided some of the best and most complete information on tuberculosis in human populations and have been invaluable in the development of vaccine trial methodology. The past failures of BCG in terms of variable and unpredictable efficacy and yet its remarkable success in terms of the magnitude of its worldwide use can point the way to future success with new vaccines. The 1949 international campaign was the first large-scale centralized public health campaign conducted with the WHO structure and was a forerunner and model for subsequent campaigns, including the eradication of smallpox (188). BCG has evoked endless discussions about the relationship between cellmediated immunity and delayed hypersensitivity. It has stimulated research into host immune mechanisms in mycobacterial infection. It has served as a vehicle for the introduction of other antigens in the hope of creating a single multiantigenic vaccine for use in developing countries (197). It has also led to a number of investigations of immunostimulation in neoplasia, especially in the therapy of bladder cancer. Attempts to develop better vaccines with novel molecular genetic approaches are accelerating and will be discussed elsewhere.
38
Davis K. Drug-Therapy Trials
A search for an effective therapy began almost immediately after the causative bacillus was identified. Koch’s tuberculin had failed, but Ehrlich’s magic bullet for syphilis stimulated interest in other chemical agents for tuberculosis. A number of these had been tried in animals and some in selected human patients. Amberson’s clinical trial of gold in 1931 is historically important in that randomization was utilized for the first time. Randomization was between a group of patients and a group of controls matched “as close as possible” (198). The study represents a transition from the matched to modern randomized clinical trials. The paper is also notable for Amberson’s meticulously detailed critique of previously reported clinical studies. A number of trials of sulfanilamide and other related compounds were performed in the late 1930s and early 1940s in experimental animals and humans with some favorable results, but often with significant associated toxicity (199). Waksman’s Nobel Prize–winning isolation of streptomycin in 1944 together with Schatz’s crucial astute laboratory observations (200) and Feldman’s and Hinshaw’s first clinical application ushered in the momentous era of modern chemotherapy of tuberculosis (43,201). Within 12 months of its announced isolation, William Feldman, professor of comparative pathology at the Mayo Foundation of Experimental Medicine, and H. Corwin Hinshaw, a bacteriologist and subsequent consultant physician at the Mayo Clinic, together demonstrated unequivocably streptomycin’s antituberculosis action in vitro and in vivo (43,201). A number of clinical trials ensued, including cooperative investigations by the Army and Navy and U.S. Veterans Administration (202–204) with liasons with the American Trudeau Society, the Mayo Clinic group, and Walsh McDermott’s group studying toxicity at Cornell University Medical College. Details are summarized elsewhere (199). It was apparent by 1947 not only that streptomycin was the most effective therapeutic agent so far against experimental tuberculosis in guinea pigs, but also that it produced promising results in certain types of pulmonary and extrapulmonary tuberculosis in humans. Rapid development of drug resistance and some toxicity became early concerns, however. Although Max Pinner had commented, in relation to evaluation of chemotherapy that “the therapeutic effects of a truly efficacious chemotherapeutic agent are not likely to depend for proof on elaborate control series” (205), the British Medical Research Council decided that studies using their precious allocation of streptomycin should be rigorously planned and use concurrent controls. Their trial, begun in 1947 (206), was a model for subsequent trials not only in the United Kingdom, but overseas as well, and was the first to incorporate all of the elements of the modern, randomized clinical trial (207). Many attempts to prevent or delay bacterial resistance by varying dosage, duration, or frequency of medication were, however, to no avail.
History of Tuberculosis
39
The second important landmark in understanding chemotherapy of tuberculosis was the recognition that a two-drug regimen could prevent the emergence of resistance. Jorgen Lehman, following up on earlier studies indicating that benzoic acid and salicylic acids stimulated oxygen uptake by pathogenic strains of M. tuberculosis, was searching for competitive inhibitors of these acids. He discovered that para-aminosalicylic acid (PAS) had demonstrable bacteriostatic activity in vitro against M. tuberculosis. Animal experiments and a small clinical trial were begun in 1944. His favorable report in 1946 (208) paved the way for subsequent trials. The Medical Research Council study of three concurrent regimens—PAS alone, streptomycin alone, and the combination of streptomycin and PAS—reported in 1949 and 1950 (209) demonstrated unequivocably the reduction in risk of developing streptomycin resistance when both were used and broadened the potential application of such treatment. Nevertheless, chemotherapy was not yet accepted as definitive therapy except in tuberculous meningitis and miliary tuberculosis. The drugs at first tended to be used adjunctively with bedrest, collapse therapy, or surgical resection (210). Until the appearance of isonicotinic acid hydrazide (isoniazid) in 1951 and subsequent laboratory and clinical experience with this new “miracle drug” (211), it was not appreciated that chemotherapy alone might cure tuberculosis. Many additional clinical trials were carried out with various combinations, dosages, frequencies of administration, and durations of these initial three drugs and others as they became available in the 1950s and 1960s. By the 1970’s experience had dictated that ethambutol, rifampin, and pyrazinamide be added to the list of first-line drugs against tuberculosis (201). The large clinical trials conducted by the U.S. Public Health Service and by the VA–Armed Forces Study Units in the United States, the collaborative studies in East Africa, Hong Kong, Singapore, and Madras under the joint auspices of the British Medical Research Council and WHO (199), together with others such as the International Union Against Tuberculosis (IUAT) (212), have provided invaluable information to guide therapy today. Information gained from these trials revolutionized the treatment of tuberculosis around the world. It led to abandonment of sanatoriums and emphasis on ambulatory therapy, discontinuation of collapse therapy, and sparing use of surgery for very selected patients. It changed the careers of sanatorium doctors and led to an emphasis on other aspects of pulmonary medicine and the neglect of tuberculosis in the medical curriculum. The trials taught that relapse rates tend to be a better endpoint in evaluating therapy than radiological findings and that failure of cavities to close did not always mean drug failure (199). Bed rest and sanatorium care did not add to the benefits produced by chemotherapy (203,213,214,). The eradication of tuberculosis was now deemed possible if drug therapy was applied vigorously to persons with disease and preventive therapy was given to those who were already infected but
40
Davis
without disease, as recommended by an expert group convened at Arden House by the American Lung Association (105). Ambulatory domiciliary care was feasible, as shown in Hong Kong and Madras (213,214) (Fig. 8). Short-course and intermittent regimens (204), stimulated by the problems of noncompliance with older standard regimens, drug costs, and availability of medical services in their countries of origin, were also effective elsewhere (199). Nine-month regimens were effective with inclusion of rifampin, and pyrazinamide permitted further shortening to 6 months. The importance of supervised and especially directly observed therapy (DOT) had long been appreciated from trials in other countries (215) but except for isolated instances was slow to be widely promoted in the United States until the problems of high noncompletion rates and multidrug resistance became alarmingly apparent in the late 1980s and early 1990s. L. Chemoprophylaxis
Once isoniazid, an effective, inexpensive oral medication with relatively low toxicity, was available, its usefulness in preventing tuberculosis was considered, especially in preventing the sequellae of infection (i.e., tuberculosis disease, which fosters transmission and stalls eradication). Controlled trials of chemoprophylaxis were carried out in a number of groups with various risk factors for developing disease; these are reviewed by Ferebee (216). In the United States isoniazid was shown to be effective, inexpensive, and relatively non-toxic in appropriately selected populations and was therefore preferred over BCG vaccination as a preventive strategy. BCG was not consistently shown to be effective except in preventing serious complications such as miliary tuberculosis and meningitis in children, and it has not been widely embraced in the United States, to the consternation of some (57). Because of the relatively low risk of acquiring infection in the United States, the diagnostic value of the tuberculin test has been considered important, and BCG would negate its reliability. Farer has also reviewed some of the personal and public health issues and the epidemiological and scientific background related to the use of chemoprophylaxis (217). In view of the competing risks of tuberculosis and isoniazid-associated hepatitis (218), lack of recent data from controlled trials, the possibility of drug-resistant infection, and the problems of distinguishing initial infection, exogenous superinfection, long-standing infection, and in some cases latent versus active disease, the recommendations regarding indications and choice of prophylactic therapeutic regimen continually change (219–223). While during the sanatorium era and beyond much attention was focused on practical therapies for tuberculosis, fortunately basic research was carried out simultaneously in a number of institutions around the world. In 1954 investigators from research institutes and medical school departments from the United States, the United Kingdom, France, Switzerland, and Denmark participated in a sympo-
History of Tuberculosis
41
Figure 8. Patient in Madras receiving ambulatory directly observed therapy. The British Medical Research Council clinical trials of antituberculosis chemotherapeutic agents proved that sanatorium or hospital care was not necessary and that domiciliary or ambulatory treatment could be successful. This finding had important implications for TB control not only for the developing world, but for all countries. Directly observed therapy in an outpatient setting is now a major control strategy of WHO. (Photograph Courtesy of the American Lung Association, New York.)
42
Davis
sium on the nature of the tubercle bacillus and the reactions of the host tissues. Arnold Rich’s prophetic remarks regarding the importance of fundamental research for long-range victory are as relevant now as they were almost 50 years ago (224): “In other spheres we know that superior weapons do not guarantee a permanent end of hostilities, and that for the surest preservation of security it is, in addition, essential to understand thoroughly the nature, designs and potentialities of the enemy and our own reaction toward, and human capacity to resist that type of nature; for new and superior defensive weapons can alone rarely if ever be relied upon to ensure enduring safety. Too often they are neutralized or surpassed by the development of new countermeasures by the enemy.” M. The Latter Half of the Twentieth Century
New tools and major technological developments have greatly accelerated knowledge about many aspects of tuberculosis. Max Lurie developed strains of animals that were genetically resistant or susceptible to M. tuberculosis and then studied the role of hereditary factors in the immunological responses in tuberculosis. Since then other animal models, including “knockout” mice and transgenic animals, improved cell culture techniques, development of specific monoclonal antibodies, and methods of isolating and identifying genes and gene products are among many tools facilitating research into the fundamental aspects of tuberculosis. The recent elucidation of the M. tuberculosis genome (225) opens up a whole array of prophylactic and therapeutic possibilities and may at last be another strategic milestone in humanity’s long struggle against this “captain of the men of death.” Despite the many advances in our understanding and ability to detect, diagnose, treat, and prevent tuberculosis and despite repeated admonitions of tuberculosis experts and lung association and other task forces, external societal factors persisting or resurfacing from the past, such as poverty, inadequate housing, poor nutrition, and ignorance, together with overpopulation, new waves of immigrants from countries of high prevalence of tuberculosis, drug abuse, emergence of the HIV epidemic, and increased problems with drug resistance have all combined to obstruct or delay tuberculosis control in the twentieth century. The unexpected (apparently transient in the United States) increase in tuberculosis in the late 1980s and early 1990s led to a revamping of the public health infrastructure so carefully constructed in the past. Case finding, isolation of infectious persons, and prompt appropriate treatment to completion under directly observed therapy—even in locked facilities, if necessary—became important issues. Education of a whole new generation of medical students, faculty, hospital and public health staff, and governmental officials as well as the public became imperative. Screening of high-risk populations and new guidelines for prophylactic treatment were issued. The race for faster methods of diagnosis, a more reliable
History of Tuberculosis
43
method of detecting infection, and for new effective therapies and vaccines based on new knowledge of host and mycobacterial responses became more compelling. After thousands of years the twenty-first century may bring eradication closer to fruition. References 1. Haas F, Haas SS. The origins of Mycobacterium tuberculosis and the notion of its contagiousness. In: Rom WR, Garay S, eds. Tuberculosis. Boston: Little, Brown and Company, 1996:3–19. 2. Ayvazian LF. History of tuberculosis. In: Reichman LB, Hershfield E, eds. Tuberculosis. A Comprehensive International Approach, 1st ed. New York: Marcel Dekker, 1993:1–20. 3. Bates JH, Stead WW. The history of tuberculosis as a global epidemic. Med Clin North Am 1993; 77:1205–1217. 4. Report on the tuberculosis epidemic, 1997. Global TB Programme. Geneva: World Health Organization, 1997. 5. Dubos R, Dubos J. The White Plague: Tuberculosis, Man and Society. Boston: Little, Brown, 1952:8. 6. Weisse AB. Tuberculosis: why “the white plague”? Perspect Biol Med 1995; 39:132–138. 7. Holmes OW. Medical Essays, 1842–1882. 2d ed. Boston: Random House, 1892:353. 8. Lerner BH. Public health then and now. Temporarily detained: tuberculous alcoholics in Seattle, 1949–1960. Am J Pub Health 1996; 86:257–265. 9. Gostin LO. Controlling the resurgent tuberculosis epidemic: a 50-state survey of TB status and proposals for reform. JAMA 1993; 269:255–261. 10. Centers for Disease Control and Prevention. Tuberculosis control laws—United States, 1993. MMWR 1993; 42(suppl RR-15):1–28. 11. Oscherwitz T, Tulsky JP, Roger S, Sciortino S, Alpers A, Royce S, Lo B. Detention of persistently non-adherent patients with tuberculosis. JAMA 1997; 278(10): 843–846. 12. Singleton L, Turner M, Haskal R, Etkind S, Tricarico M, Nardell E. Long-term hospitalization for tuberculosis control. Experience with a medical-psychosocial inpatient unit. JAMA 1997; 278:838–842. 13. Dubler NN, Bayer R, Landesman S, White A. The Tuberculosis Revival: Individual Rights and Societal Obligations in a Time of AIDS. A Special Report. New York: United Hospital Fund of New York, 1992. 14. The dual epidemics of tuberculosis and AIDS: health care policy, professional practice, law and ethics. A Conference for World AIDS Day, New York, American Society of Law, Medicine and Ethics, Columbia University School of Public Health, Albert Einstein School of Medicine and Montefiore Medical Center, New York City Department of Health, and United Hospital Fund, Dec. 4–5, 1992. 15. Annas GJ. Control of tuberculosis—the law and the public’s health. N Engl J Med 1993; 328:585–588.
44
Davis
16. Bayer R, Dupuis L. Tuberculosis, public health, and civil liberties. Annu Rev Pub Health 1995; 16:307–326. 17. Steele JH, Ranney AF. Animal tuberculosis. Am Rev Tuberc Pulm Dis 1958; 77:908–922. 18. Myers JA. Captain of All These Men of Death. St. Louis: Warren H. Green, Inc., 1977. 19. Baes I. Deoxyribonucleic acid relatedness among species of slowly-growing mycobacteria. Acta Pathol Microbiol Scand Sec B 1979; 87:221–226. 20. Wayne LG, Diaz GA. Reciprocal immunological distances of catalase derived from strains of mycobacterium avium, mycobacterium tuberculosis, and closely related species. Int J Syst Bacteriol 1979; 29:19–24. 21. Small PM, van Embden JDA. Molecular epidemiology of tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection and Control. Washington, DC: American Society for Microbiology, 1994. 22. Salo WL, Aufderheide AC, Buikstra J, Holcomb TA. Identification of Mycobacterium tuberculosis DNA in a pre-Columbian Peruvian mummy. Proc Natl Acad Sci USA 1994; 91:2091–2094. 23. Hermans PWM, Messadi F, Guebrexabber H, van Soolingen D, de Haas PEW, de Neeling H, Ayoub A, Portaels F, Frommel D, Zribi M, van Embden JDA. Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia, and the Netherlands: usefulness of DNA typing for global tuberculosis epidemiology. J Infect Dis 1995; 171:1504–1513. 24. Rigout SL, Maregeya B, Travore H, Collart JP, Fisette K, Portaels F. Use of DNA restriction fragment typing in the differentiation of Mycobacterium tuberculosis complex isolates from animals and humans in Burundi. Tubercle and Lung Dis 1996; 77:264–268. 25. Cohn DL, O’Brien RJ. The use of restriction fragment length polymorphisim (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 1998; 2(1):16–26. 26. Kiple KF, ed. The Cambridge World History of Human Disease. Cambridge: Cambridge University Press, 1993. 27. Kochi A. Tuberculosis: distribution, risk factors, mortality. Symposium to Commemorate the 150th birthday of Robert Koch, Berlin, June 20, 1994. Immunobiology 1994; 191:325–336. 28. Williams HE, Phelan PD. The epidemiology, mortality and morbidity of tuberculosis in Australia: 1850–94. J Paediatr Child Health 1995; 31:495–498. 29. Gryzybowski S, Styblo K, Dorken E. Tuberculosis in Eskimos. Tubercle 1976; 57(suppl):S1–S44. 30. Wartski SA. Epidemiology and control of tuberculosis in Israel. Public Health Rev 1995; 23:297–341. 31. Daniel TM, Bates JH, Downes KA. History of Tuberculosis. In: BR Bloom, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: American Society for Microbiology, 1994:13–24. 32. Paulsen HJ. Tuberculosis in the Native American: indigenous or introduced? Rev Infect Dis 1987; 9:1180–1186. 33. Clark GA, Kelley MA, Grange JM, Hill CM. The evolution of mycobacterial disease in human populations: a reevaluation. Curr Anthropol 1987; 28:45–62.
History of Tuberculosis
45
34. Manchester K. Tuberculosis and leprosy in antiquity: an interpretation. Med Hist 1984; 28:162–173. 35. Sigurdsson J. Studies on the risk of infection with bovine tuberculosis to the rural population. In: ACTA Tuberculosea Scand. Copenhagen: Einar Munksgaard, 1945; suppl 15. 36. Sjogren I, Sutherland I. Studies of tuberculosis in man in relation to infection in cattle. Tubercle 1974; 56:113–127. 37. Lowell AM, Edwards LB, Palmer CE. Tuberculosis. Cambridge, MA: Harvard University Press, 1969. 38. Stead WW. Genetics and resistance to tuberculosis. Ann Intern Med 1992; 116:937–994. 39. Webb GB. Tuberculosis. Clio Medica. New York: Paul B. Hoeber Inc., Medical Book Department of Harper & Brothers, 1936. 40. Brouwer JA, Boeree, Kager P, Varkevisser CM, Harries AD. Traditional healers and pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis 1998; 2:231–234. 41. Hewson MG. Traditional healers in Southern Africa. Ann Intern Med 1998; 128:1029–1034. 42. Andrews BJ. Tuberculosis and the Assimilation of Germ Theory in China 1895–1937. Vol. 52. Oxford: Oxford University Press, 1997:114–157. 43. Keers RY. Pulmonary Tuberculosis: A Journey Down the Centuries. London: Bailliere-Tindall, 1978. 44. Morse D, Brothwell D, Ucko PJ. Tuberculosis in ancient Egypt. Am Rev Respir Dis 1964; 90:524–541. 45. Perzigan AJ, Widmer J. Evidence for tuberculosis in a prehistoric population. JAMA 1979; 242:2643–2646. 46. Allison MJ, Mendoza D, Pezzia A. Documentation of a case of tuberculosis in preColumbian America. Am Rev Respir Dis 1973; 107:985–991. 47. Zimmerman MR. Pulmonary and osseous tuberculosis in an Egyptian mummy. Bull NY Acad Med 1979; 55:604–608. 48. Kinnier JV, Wilson MA. Diseases of Babylon: an examination of selected texts. J R Soc Med 1996; 89:135–140. 49. Adams LB. The Genuine Works of Hippocrates (English translation). Birmingham, AL: Classics of Medicine Library, Division of Gryphon Editions Ltd., 1985:739. 50. Walsh J. Galen’s treatment of pulmonary tuberculosis. Am Rev Tuberc 1931; 24: 1–41. 51. Cummins SL Tuberculosis in History from the 17th Century to Our Times. London: Bailliere, Tindall and Cox, 1949. 52. Haas F, Haas SS. The history of pulmonary medicine: tuberculosis from the Renaissance to 1900. In: Baum G, Wolinsky J, eds. Textbook of Pulmonary Diseases. 5th ed. Boston: Little, Brown, 1993:xix–xliii. 53. Frost WH. The outlook for the eradication of tuberculosis. Am Rev Tuberc 1935; 32:644–650. 54. Styblo, K, Salomao MA. National tuberculosis control programs. In: Reichman LB, Hershfield EH, eds. Tuberculosis: A Comprehensive International Approach, 1st ed. New York: Marcel Dekker, Inc., 1993:573–600.
46
Davis
55. Cantwell, MF, McKenna MT, McCray E, Onorato IM. Tuberculosis and race /ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1997; 157:1016–1020. 56. The American Lung Association Conference on Re-establishing Control of Tuberculosis in the United States. March 11–13, 1994, Washington D.C. Am J Respir Crit Care Med 1996; 154:251–262. 57. Feldberg GD. Disease and Class. Tuberculosis and the Shaping of Modern North American Society. New Brunswick, NJ: Rutgers University Press, 1995. 58. Castiglione A. History of Tuberculosis. New York: Medical Life Press, 1933. 59. Dubos R, Dubos J. The White Plague. New Brunswick, NJ: Rutgers University Press, 1992. 60. Beddoes T. Essay on the Causes, Early Signs and Prevention of Pulmonary Consumption. London: Longman & Rees, 1799:4. 61. Burke RM. An Historical Chronology of Tuberculosis. 2d ed. Springfield, IL: Charles C Thomas, 1955. 62. Marten B. A New Theory of Consumption, More Especially of a Phthisis or Consumption of the Lungs. London: Knaplock, 1720:50–51. 63. Laennec RTH. A Treatise on Diseases of the Chest and on Mediate Auscultation. New York Academy of Medicine History of Medicine Series No. 17. New York: Hafner Publishing Company, 1962:5. 64. Ghon A. The Primary Lung Focus of Tuberculosis in Children (English translation by D. B. King). New York: Paul B. Hoeber, 1916. 65. Amberson JB. A retrospect of tuberculosis: 1865–1965. Am Rev Respir Dis 1966; 93:343–351. 66. Opie EL. Present concepts of tuberculosis infection and disease. Am Rev Tuberc 1935; 32:617–630. 67. Small PM, Shafer RW, Hopewell PC, Singh BP, Murphy MJ, Desmond E, Sierra MF, Schoolnick GK. Exogenous reinfection with multidrug resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328:1137–1144. 68. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemioloogic methods. N Engl J Med 1994; 330:1710–1716. 69. Shafer RW, Singh SP, Larkin C, Small PM. Exogenous reinfection with multidrugresistant Mycobacterium tuberculosis in an immunocompetent patient. Tubercle and Lung Dis 1995; 76:575–577. 70. Villeman JA. Etudes sur la Tuberculose: Preuves Rationales et Experimentales de la Specifite et de son Inoculabilite. Paris: Baillieres, 1868. 71. Daniel TM. Robert Koch. Tuberculosis and the subsquent history of medicine (editorial). Am Rev Respir Dis 1982 (Part 2); 125(3):1–3. 72. Koch R. The etiology of tuberculosis. Am Rev Tuberc 1932; 25:284–323. 73. Smith T. A comparative study of bovine tubercle bacilli and of human bacilli from sputum. J Exp Med 1898; 3:451–511. 74. Smith T. The relation between human and animal tuberculosis with special reference to the transformation of human and other types of the tubercle bacillus. Boston Med Surg J 1908; 159:707–711.
History of Tuberculosis 75. 76. 77. 78.
79. 80. 81. 82. 83. 84. 85.
86.
87.
88. 89. 90. 91.
92. 93.
47
Ravenel MP. The intercommunicability of human and bovine tuberculosis. Medicine 1902; 8:529–546. The bacillus tuberculosis and the contagiousness of phthisis. Boston Med Surg J 1883; 108:235–236. Chapin CV. Sources and Modes of Infection. New York: John Wiley and Sons, 1910:252–255. Smith PG, Moss AR. Epidemiology of tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: American Society for Microbiology, 1994:47–59. Wells WF. On air-borne infection: II. Droplets and droplet nuclei. Am J Hyg 1934; 20:611–618. Wells WF. Airborne Contagion and Air Hygiene. Cambridge, MA: Harvard University Press, 1955. Riley RL, O’Grady F. Airborne Infection: Transmission and Control. New York: Macmillan, 1961. Loudon RG, Roberts RM. Droplet expulsion from the respiratory tract. Am Rev Respir Dis 1967; 95:435–442. Riley RL, Mills CC, O’Grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. Am Rev Respir Dis 1962; 85:511–525. Houk VN, Baker JH, Sorensen K, and Kent DC. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 1968; 16:26–35. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992; 326:1514–1521. Infectiousness of tuberculosis: a report of the National Tuberculosis Association ad hoc Committee on Treatment of Tuberculosis in general hospitals. Am Rev Respir Dis 1967; 96:836–837. Nardell E, Keegan J, Cheney SA, Etkind SC. Airborne infection. Theoretical limits of protection achievable by building ventilation. Am Rev Respir Dis 1991; 144:302–306. Riley RL, Nardell EA. State of the art. Clearing the air. The theory and application of ultraviolet air disinfection. Am Rev Respir Dis 1989; 139:1286–1294. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR 1990; 39:RR-17. Shyrock RH. The National Tuberculosis Association 1904–1954. New York: National Tuberculosis Association, 1957. Knopf SA. A History of the National Tuberculosis Association. The Anti-Tuberculosis Movement in the United States. New York: National Tuberculosis Association, 1922. Hodges LM. The People Against Tuberculosis: The Story of the Christmas Seal. New York: National Tuberculosis Association, 1942. Haas F, Haas. S. The sociopolitical response to the discovery of mycobacterium tuberculosis. In: Baum GL, Crapo JD, Celli BR, Karlinsky JB, eds. Textbook of Pulmonary Diseases. 6th ed. Philadelphia: Lippincott-Raven Publishers, 1998: 3–21.
48 94.
95. 96. 97. 98. 99. 100. 101. 102. 103. 104.
105. 106.
107. 108.
109. 110. 111. 112.
113.
Davis Tuberculosis in South African Natives with Special Reference to the Disease Amongst the Mine Labourers on the Witwatersrand. Report of the Tuberculosis Research Committee. Johannesburg: South African Institute for Medical Research, 1932. Knopf SA. Tuberculosis as a Disease of the Masses and How to Combat It. New York: Fred P. Flori, 1907. Asch S, Leake B, Anderson R, Gelberg L. Why do symptomatic patients delay obtaining care for tuberculosis? Am J Respir Crit Care Med 1998; 157:1244–1248. Rubel AJ, Garro LC. Social and cultural factors in the control of tuberculosis. Public Health Rep 1992; 107:626–636. Elliott J. The evolution of dispensary control of tuberculosis. Am Rev Tuberc 1937; 36:577–591. Edwards H. Clinic standards and clinic practice. Am Rev Tuberc 1937; 36:592–601. Long ER. A half century of medical progress in the control of tuberculosis. Am Rev Tuberc 1954; 70:383–390. Winslow CEA. The Life of Hermann M. Biggs. Philadelphia: Lea and Febiger, 1929:132–133. Fox DM Social policy and city politics: tuberculosis reporting in New York, 1889–1900. Bull Hist Med 1974; 49:169–195. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Am Rev Respir Dis 1991; 144:745–749. Raviglione MC, Dye C, Schmidt S, Kochi A, for the WHO Global Surveillance and Monitoring Project. Assessment of worldwide tuberculosis control. Lancet 1997; 350:624–629. Long ER. Recommendations of the Arden House Conference on Tuberculosis. Am Rev Respir Dis 1960; 81:481–484. Centers for Disease Control. National action plan to combat multidrug-resistant tuberculosis: meeting the challenge of multidrug-resistant tuberculosis. MMWR 1992; 41(No. RR-11):1–57. Davis AL. History of the sanatorium movement. In: Rom W, Garay S, eds. Tuberculosis. Boston: Little, Brown, 1996:35–54. Knopf SA. The anti tuberculosis movement in the United States prior to and since the formation of the National Tuberculosis Association. Med Rec 1920; 97: 1071–1074. Kinghorn HM. Brehmer and Dettweiler. A review of their methods of treatment of pulmonary tuberculosis. Am Rev Tuberc 1922; V(12):950–972. Huber JB. Consumption. Its Relation to Man and His Civilization. Its Prevention and Cure. Philadelphia: Lippincott, 1906. Knopf SA. Geheimrath Dr. Dettweiler. Med Rec 1905; LXVII:136–137. Knopf SA. Herman Brehmer and the semi-centennial celebration of Brehmer’s sanatorium for the treatment of consumptives: the first institution of its kind. NY Med J Phila Med J 1904; LXXX(1):3–6. Bowditch VY. The English sanatorium. Three leading institutions as seen through American eyes—the newly completed King’s sanatorium in Sussex. J Outdoor Life 1906; III:461–464.
History of Tuberculosis 114. 115. 116. 117. 118. 119. 120. 121. 122. 123.
124. 125. 126. 127.
128. 129.
130. 131. 132. 133.
134. 135.
49
Long ER. A History of the Therapy of Tuberculosis and the Case of Frederic Chopin. Lawrence: University of Kansas Press, 1956:54. Trudeau EL. An Autobiography. National Tuberculosis Association. New York: Doubleday, 1944. Trudeau EL, The history of the tuberculosis work at Saranac Lake, New York. Med News NY 1903; October 24:1–12. Knoph SA. Are sanatoriums for consumptives a danger to the neighborhood? Med Rec 1896; 1(4):82–83. Skavlem JH. The closing of the Trudeau sanatorium (editorial). Am Rev Tuberc Pulm Dis 1955; 71:163–164. Growth of the sanatorium movement. J Outdoor Life 1923; 20:255. Tuberculosis Hospital and Sanatorium Directory. New York: National Tuberculosis Association, 1954:184–185, 188–189. Frost WH. The age selection of mortality from tuberculosis in successive decades. Am J Epidemiol 1995; 141:4–9. McKeown T. The Role of Medicine: Dream, Mirage or Nemesis? London: The Nuffield Provincial Hospitals Trust, 1976. Armand Delille P. The campaign against infantile tuberculosis in France and the preservation of childhood against its ravages by the system of the “Oeuvre Grancher.” Am Rev Tuberc 1918–1819; II(7):435–448. Teller ME. The Tuberculosis Movement: A Public Health Campaign in the Progressive Era. Westport, CT: Greenwood Press, 1988. Weisner DE. Sanatorium follow up studies. Am Rev Tuberc 1922; VI:320–326. Goldstein SE. After the sanatorium what? J Outdoor Life 1914; 11:266–268. Mitchell RS. Mortality and relapse of uncomplicated advanced pulmonary tuberculosis before chemotherapy: 1,504 consecutive admissions followed for fifteen to twenty five years (parts I and II). Am Rev Tuberc 1955; 72:487–501, 502–512. Stephens MG. Follow-up of 1,041 tuberculosis patients. Am Rev Tuberc 1941; 44: 451–462. Siltzbach LE. Medical aspects of the rehabilitation of the tuberculous. The experience of a quarter century with 964 patients at Altro Work Shops. Am Rev Tuberc 1942; 46:489–504. Woodhead GS, Varrier-Jones PC. Experiences in colony treatment and after-care. Lancet 1917; 2:779–785. Willis S. Perspectives and treatment in tuberculosis. Am Rev Tuberc 1944; 50: 251–256. Riviere C. The Early Diagnosis of Tubercle. 3rd ed. London: Oxford Medical Publications, 1921:197, 222. Grange JM. The mycobacteria. In: Topley & Wilson’s Principles of Bacteriology, Virology and Immunity. Parker MT, Duerden BI, eds. 8th ed. Vol. 2. Philadelphia: BC Decker, Inc., 1990:73–101. Runyon EH. Anonymous Mycobacteria in pulmonary disease. Med Clin North Am 1959; 43:273–290. Condos R, McCune A, Rom WN, Schluger NW. Identification of patients with active tuberculosis using a peripheral blood-based polymerase chain reaction assay. Lancet 1996; 347:1082–1085.
50 136. 137.
138. 139.
140.
141. 142. 143.
143a.
144. 145. 146. 147. 148. 149. 150. 151.
152.
Davis Hanna BA. Diagnosis of tuberculosis by microbiologic techniques. In: Rom W, Garay S, eds. Tuberculosis. Boston: Little, Brown, 1996:149–159. Daniel TM, Debanne SM. The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay. State of the art. Am Rev Respir Dis 1987; 135:1137–1151. Daniel TM. Rapid diagnosis of tuberculosis: laboratory techniques applicable in developing countries. Rev Infect Dis 1989; 11(suppl. 2):S471–S478. Dalovisio JR, Montenegro-James S, Kemmerly SA, Genre CF, Chambers R, Greer D, Pankey GA, Failla DM, Haydel KG, Hutchinson L, Lindley MF, Nunez BM, Praba A, Eisenach KD, Cooper ES. Comparison of the amplified mycobacterium tuberculosis (MTB) direct test, amplicor MTB PCR, and IS6110-PCR for detection of MTB in respiratory specimens. Clin Infect Dis 1996; 23: 1099–1106. Editorial response: comparison of the amplified mycobacterium tuberculosis (MTB) direct test, amplicor MTB PCR, and IS6110-PCR for detection of MTB in respiratory specimens. Clin Infect Dis 1996; 23:1107–1108. Roth A, Schaberg T, Mauch H. Molecular diagnosis of tuberculosis: current clinical validity and future perspectives. Eur Respir J 1997; 10:1877–1891. ATS Workshop Report. Rapid diagnostic tests for tuberculosis. Am J Respir Crit Care Med 1997; 155:1804–1814. Goldberger MJ, Matthews WC, Rose DN, Fujiwara PI, Sbabaro J, Bozzette SA, Chaisson RE, Davidson BL, Geiter LJ, Jordan TJ, Moser KS, Reichman LB. Rapid diagnostic tests for tuberculosis: What is the appropriate use? Am J Respir Crit Care Med 1997; 155:1804–1814. Condos R, Rom WN, Liu YM, Schluger NW. Local immune responses correlate with presentation and outcome in tuberculosis. Am J Respir Crit Care Med 1998; 157:729–735. Medlar EM. The behavior of pulmonary tuberculous lesions. A pathological study. Am Rev Tuberc Pulm Dis 1955; 71(pt 2 of 2):1–244. Steinberg I, Barnard MW. Tuberculosis case-finding in a consultation chest service for private physicians. Am Rev Tuberc 1937; 36:602–612. Sakula A. Caarlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis. Thorax 1983; 38:326–332. Brown L. The Story of Clinical Pulmonary Tuberculosis. Baltimore: Williams & Wilkins, 1941. Gaensler EA. The surgery for pulmonary tuberculosis. Am Rev Respir Dis 1982; 125(pt II):73–84. Thompson SA, Greenberg M. Jacobaeus operation. Am Rev Tuberc 1941; 44: 183–190. Peters A. Artificial pneumothorax at the Loomis sanatorium over fourteen years. Am Rev Tuberc 1928; 18:348–374. Mitchell RS. Artificial pneumothorax: a statistical analysis of 557 cases initiated in 1930–39 and followed in 1949 (parts I-VI). Am Rev Tuberc 1951; 64:1–40, 127–158. Amberson JB, Jr. Tuberculosis. In: Cecil RL, ed. A Textbook of Medicine. 5th ed. Philadelphia: Saunders, 1940:313–370.
History of Tuberculosis 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163.
164. 165. 166. 167. 168.
169.
170. 171.
172.
173.
51
Gibbon JH, Jr, Sabiston DC, Jr, Spencer FC, eds. Surgery of the Chest. 2d ed. Philadelphia: Saunders, 1969:420–439. Bothamley GH. The Koch phenomenon and delayed hypersensitivity: 1891–1991. Tubercle 1991; 72:7–11. Burke DS. Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis. Vaccine 1993; 8(11):795–804. Pottenger FM. Clinical Tuberculosis. Vol. 1. Pathological Physiology, Diagnosis and Prognosis. 2d ed. St. Louis: CV Mosby Co. 1922:502–515. Pearson L. Tuberculosis in cattle. Tuberculin as a diagnostic agent. Med News 1892; 60:358–359. Snider DE. The tuberculin skin test. Am Rev Respir Dis 1982 (Part 2); 125(3): 108–118. Seibert FB, Glenn JT. Tuberculin purified protein derivative: preparation and analyses of a large quantity for standard. Am Rev Tuberc 1941; 44:9–25. Palmer CE. Nontuberculosis pulmonary calification and sensitivity to histoplasmin. Public Health Rep 1945; 60:513–520. Christie A, Petersen JC. Pulmonary calification in negative reactors to tuberculin. Am J Public Health 1945; 35:1131–1147. Furcolow M.L. Development of calification in pulmonary diseases associated with sensitivity to histoplasmis. Public Health Rep 1949; 64:1363–1365. Furcolow ML, Hewell B, Nelson we, Palmer CE. Quantitative studies of the tuberculin reaction: I. Titration of tuberculin sensitivity and its relation to tuberculous infection. Public Health Rep 1941; 56:1082–1100. WHO Tuberculosis Research Office. Further studies of geographic variation in naturally acquired tuberculin sensitivity. Bull WHO 1955; 12:63–83. Edwards PQ, Edwards LB. Story of the tuberculin test. Am Rev Respir Dis (Part 2) 1960; 81:1–47. Palmer CE, Edwards LB. Tuberculin test in retrospect and prospect. Arch Environ Health 1967; 15:792–808. Edwards LB, Acquaviva FA, Livesay VT. Identification of tuberculous infected. Am Rev Respir Dis 1973; 108:1334–1339. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969; 99:1–132. Falkinham JO, Parker BC, Gruft H. Epidemiology of infection by non-tuberculosis mycobacteria. I. Geographical distribution in the United States. Am Rev Respir Dis 1980; 121:931–937. Kent DC, Schwartz R. Active pulmonary tuberculosis with negative tuberculin skin reaction. Am Rev Respir Dis 1967; 95:411–418. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med. 1971; 285:1506–1509. Steele AH, Willis HS. A study of the increase in sensitiveness in normal children produced by repeated injections of tuberculin. Transactions of the 30th Annual Meeting of the National Tuberculosis Association, New York, 1934 p. 1. Atkinson ML, Farer LS. TB testing for hospital employees: new recommendations. Hosp Med Staff 1979:16–20.
52
Davis
174. Thompson NJ, Glassroth JL, Snider DE, Jr, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119:587–597. 175. Rich AR, McCordock HA. An enquiry concerning the role of allergy, immunity, and other factors of importance in the pathogenesis of human tuberculosis. Bull Johns Hopkins Hosp 1929; 44:273–422. 176. Wilson GS, Schwabacher H, Maier I. The effect of desensitization of tuberculous guinea pigs. J Path Bact 1940; 50:89–109. 177. Chase MW. The cellular transfer of cutaneous hypersensitivity to tuberculin. Proc Soc Exp Biol Med 1945; 59:134–135. 178. Mackaness GB. The immunology of antituberculous immunity. Am Rev Respir Dis 1967; 97:337–344. 179. Youmans GP. Relation between delayed hypersensitivity and immunity in tuberculosis. Am Rev Respir Dis 1975; 11:109–118. 180. Lefford MJ. Delayed hypersensitivity and immunity in tuberculosis. Am Rev Respir Dis 1975; 111:243–246. 181. Salvin SB, Neta R. A possible relationship between delayed hypersensitivity and cell-mediated immunity. Am Rev Respir Dis 1975; 111:373–377. 182. Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA, Mangura BT, Osmond D, Wallace JM, Rosen MJ, Reichman LB. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119:185–193. 183. Tuberculin reactions in apparently healthy HIV-seropositive and HIV sero-negative women—Uganda. MMWR 1990; 39(37):638–639, 645–646. 184. Schluger NW, Rom WN. The host response to tuberculosis. State of the Art. Am J Respir Crit Care Med 1998; 157:679–691. 185. Sakula A. BCG: Who were Calmette and Guérin? Thorax 1983; 38:806–812. 186. Smith FB. Tuberculosis and bureaucracy—Bacille Calmette et Guérin: its troubled path to acceptance in Britain and Australia. Med J Aust 1993; 159:408–411. 187. Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review. Tubercle and Lung Dis 1992; 73:252–261. 188. Comstock GW. The international tuberculosis campaign: a pioneering venture in mass vaccination and research. Clin Infect Dis 1994; 19:528–540. 189. Ten Dam HG, Toman K, Hitze KL, Guld J. Present knowledge of immunization against tuberculosis. Bull WHO 1976; 54:255–269. 190. Fine PEM. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989; 11(suppl 2):S353–S359. 191. Houston S, Fanning A, Soskolne CL, Fraser N. The effectiveness of bacillus Calmette-Guérin (BCG) vaccination against tuberculosis: a case-control study in Treaty Indians, Alberta, Canada. Am J Epidemiol 1990; 131:340–348. 192. ten Dam HG. Research on BCG vaccination. Adv Tuberc Res 1984; 21:79–106. 193. Rodrigues LC, Smith PG. Tuberculosis in developing countries and methods for its control. Trans R Soc Trop Med Hyg 1990; 84:739–744. 194. Clemens JD, Chuong JJH, Feinstein AR. The BCG controversy: a methodological and statistical reappraisal. JAMA 1983; 249:2362–2369.
History of Tuberculosis 195. 196. 197.
198. 199. 200.
201. 202. 203. 204. 205. 206. 207. 208. 209. 210.
211.
212.
213.
53
Smith PG. Epidemiological methods to evaluate vaccine efficacy. Br Med Bull 1988; 44(3):679–690. Comstock GW. Vaccine evaluation by case-control or prospective studies (editorial). Am J Epidemiol 1990; 131:205–207. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, Snapper SB, Barletta RG, Jacobs WR, Jr., Bloom BR. New use of BCG for recombinant vaccines. Nature 1991; 351: 456–460. Amberson Jr. JB, McMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuberc 1931; 24:401–435. D’Esopo ND. Clinical trials in pulmonary tuberculosis. Am Rev Respir Dis 1982 (Part 2); 125(3):85–93. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram positive and gram negative bacteria. Proc Soc Exp Biol 1944; 55:66–99. Ryan F. The Forgotten Plague: How the Battle Against Tuberculosis Was Won and Lost. Boston: Little, Brown, 1992. Barnwell JB. Veterans Administration Tuberculosis Division 1945–1947. Progress Report. Am Rev Tuberc 1948; 58:64–76. Snider GL. Tuberculosis then and now: a personal perspective on the last 50 years. Ann Intern Med 1997; 126:237–243. Fox W, Mitchison DA. State of the art: a short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1975; 111:325–353. Pinner M. Evaluation of chemotherapy. Editorial. Am Rev Tuberc 1944; 50: 257–259. Medical Research Council Investigation. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2:769–782. Lillenfeld AH. The Fielding H. Garrison Lecture. Ceterus paribus: the evolution of the clinical trial. Bull Hist Med 1982; 56:1–18. Lehman J. Para-amino salicylic acid in the treatment of tuberculosis. Lancet 1946; 1: 15–16. Medical Research Council Investigation. Treatment of pulmonary tuberculosis with streptomycin and para-amino salicylic acid. Br Med J 1950; 2:1073–1085. Yeager RL, Goodwin RA, Parker EF, Muschenheim C, Chapman PT, Thomas MC, Mitchell R, Corpe RF, Ebert RH. Bed rest in the treatment of tuberculosis: a statement by the Committee on Therapy. Am Rev Tuberc 1954; 69:1069–1070. Robitzek EH, Selikoff IJ. Hydrazine derivatives of isonicotinic acid (Rimifon, Marsalid) in the treatment of progressive caseous-pneumonic tuberculosis. A preliminary report. Am Rev Tuberc 1952; 65:402–428. Bignall JR, Rist N. An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis. A trial directed by the Committee on Treatment and the Committee on Bacteriology and Immunology of the International Union Against Tuberculosis. Bull Int Un Tuberc 1964; 34:79–191. Moodie AS. Ambulatory treatment of tuberculosis in Hong Kong. Tubercle 1956; 37:451–454.
54
Davis
214. Tuberculosis Chemotherapy Center Madras. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull WHO 1959; 21:51–144. 215. Bayers R, Wilkensin D. Directly observed therapy: history of an idea. Lancet 1995; 345(8964):1545–1548. 216. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970; 17:28–106. 217. Farer L. Chemoprophylaxis. Am Rev Respir Dis 1982; 125(Part 2 of 2):102–107. 218. Comstock GW, Edwards PQ. The competing risks of tuberculosis and hepatitis for adult tuberculin reactors (editorial). Am Rev Respir Dis 1975; 111:573–577. 219. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982; 60:555–564. 220. Snider DE, Cares GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255:1579–1583. 221. Screening for tuberculosis and tuberculosis infection in high-risk populations, and the use of preventive therapy for tuberculosis infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1990; 39(RR-8):1–12. 222. Mc Anulty JM, Fleming DW, Hawley MA, Baron RC. Missed opportunities for tuberculosis prevention. Arch Intern Med 1995; 155:713–716. 223. Villarino ME, Dooley SW, Geiter LT, Castro KG, Snider DE, Jr. Management of persons exposed to multidrug-resistant tuberculosis. MMWR 1992; 41(RR11):59–71. 224. Ciba Foundation Symposium on Experimental Tuberculosis. Wolstenholme GEW, Cameron MP, eds. Boston: Little, Brown and Co., 1955:2. 225. Williams N. Genome of TB culprit deciphered. Science 1998; 279:25.
2 Tuberculosis Control in Low-Income Countries
DONALD A. ENARSON University of Alberta Alberta, Canada, and International Union Against Tuberculosis and Lung Disease Paris, France
I. Introduction The importance of tuberculosis to public health can hardly be questioned. In the first meeting of specialists in internal medicine held in Paris in 1867, it was noted that tuberculosis was the most frequent condition with which the specialists had to deal, and for this reason a series of scientific meetings was initiated that led to the establishment of the International Union Against Tuberculosis and Lung Disease. More than a century later, in 1993, tuberculosis was reported as the most frequent cause of death from a single agent among persons aged 15–49 years (1) and has been declared a global emergency. Anyone today may become infected with tuberculosis simply by breathing the air in a space through which a tuberculosis patient has passed. Because of its frequency, its potential effects, and the fact that it can be spread to the general public, tuberculosis has a significance to public health greater than most other disease conditions. II. Objectives of Tuberculosis Control Because tuberculosis is caused by a microorganism whose principal reservoir is the human population and because it represents such a danger to public health, the 55
56
Enarson
objective of activities directed against this disease should be nothing short of its elimination from the human population. Some would argue that this is an unrealistic objective. Nevertheless, it may be a reasonable one because of the inefficiency of the dynamics of tuberculosis (2). Beyond this are the strategic implications of aiming at elimination; this objective clarifies the obstacles in the way of achieving it and an agenda for action. The folly of thinking that tuberculosis can be reduced to a level beyond which it is no longer a concern to the public without eliminating it has been dramatically illustrated by the resurgence of this contagious disease where it was previously thought to be controlled (3). III. The Scientific Basis of Intervention A. The Dynamics of Transmission
Tuberculosis involves a dynamic process (4). Understanding this process is essential to interventions for its control; transmission of the causative microorganism from one person to another is the key component. To become infected with tuberculosis, a biologically effective dose of the microorganism is required; this is achieved primarily by inhalation. The microorganism enters the environment as an aerosol, a susceptible individual is exposed, becomes infected, and may subsequently develop disease, which may be contagious, thus passing the organism to others. The individual remains contagious for a limited period of time, during which transmission may occur. This period is limited either by the death of the individual or the suppression of growth of the microorganism in the body (as when the patient is cured). The key transitions in maintaining the cycle are (1) from exposure to infection, (2) from infection to disease, (3) from disease to exposure. B. Determinants
Key determinants in the transition from exposure to infection are the concentration of microorganisms in the environment, the degree of susceptibility of the exposed, and the duration of exposure (5). The key determinant in the transition from infection to disease is the state of the immune system of the individual infected. Key determinants in the transition from disease to being contagious are the numbers of bacteria in the lung and their access to the airways. The stages in the transmission cycle increase its inefficiency. C. Probabilities
In enhancing or retarding transmission, the probability of transition from one state to another must be modified. An understanding of the “base” probabilities (the
Tuberculosis Control in Low-Income Countries
57
probabilities of transition in the absence of the intervention) is essential to evaluate the impact of any intervention. Base probabilities can be derived from studies of individuals in contact with those with active tuberculosis (5). The probability of transition from exposure to infection varies, on average, from slightly more than 25% in a person living in the same household as a case with sputum smear positive tuberculosis to about 12% for someone who is a friend or colleague of such a case. The probability of transition from infection to disease in this setting is less than 15%. Finally, the probability of a case of tuberculosis being highly contagious, if the case is an adult, is approximately 50%. Thus, the combined probability (if a susceptible person lives in the same household with a highly contagious case of tuberculosis) is 0.25 times 0.12 times 0.50, which is 1.5%. This is clearly an inefficient cycle of transmission, which makes it theoretically possible to consider elimination a reasonable objective. A strategy for elimination needs to take account of the fact that Mycobacterium tuberculosis remains dormant in a high proportion of those infected; the low probability and long latent period between infection and disease means that most of those infected do not have the disease but retain the possibility of developing the disease throughout their lifetime. Thus, an elimination strategy focused on the sources of infection must be sustained over a long period of time. IV. Prevention Through Treatment A. Failure of a Vaccine Strategy
The most promising strategy for elimination of a disease is vaccination, as with smallpox. A vaccine was one of the earliest tools developed for the control of tuberculosis following the identification of the causative organism (6). This vaccine is capable only of limiting the dissemination of the microorganism within the body after infection (7) and does not prevent infection. In addition, the most frequent schedule of administration (shortly after birth) prevents those forms of tuberculosis that are not highly contagious (8) and so has limited impact on the transmission cycle. B. Preventive Therapy as a Secondary Prevention Strategy
Shortly after the development of effective chemotherapy for treatment, it was used to treat latent bacteria in those who had been infected but who had not yet developed disease (9). It was clearly effective in reducing the probability of developing subsequent tuberculosis. However, the number of persons who needed treatment to prevent a contagious case, and the duration of such treatment made this strategy cumbersome to apply at a population level.
58
Enarson C. Evidence for Case Management as an Effective Preventive Tool
The possibility that chemotherapy could permanently cure a patient with tuberculosis was convincingly demonstrated in the early 1960s in Edinburgh (10). Prior to that time, many did not believe that tuberculosis could be cured, only that it could be suppressed, to reactivate at a later time in life. Evidence that chemotherapy could curtail infectiousness of a patient was provided by a study in India of the contacts of patients whose treatment was domiciliary as compared with those who received wholly ambulatory treatment (11); the proportion infected by exposure to the case was not different in the two groups. The ability of chemotherapy of tuberculosis cases to arrest infection of succeeding generations of children in the community has been more difficult to demonstrate. The evidence for its impact has been summarized (12). Supportive evidence includes the demonstration that the rate of decline in prevalence of infection in military recruits in the Netherlands was hastened after the introduction of chemotherapy (13), but it had been declining for some time prior to this period and was already at a relatively low level prior to the initiation of this treatment. More compelling evidence has been provided from intensive intervention in Inuit communities where the rate of tuberculosis was extremely high (14). The rates were very rapidly reduced primarily through the rapid identification and treatment of cases of tuberculosis in the community, but this was accompanied by an extensive application of preventive chemotherapy. V. Basic Principles of Tuberculosis Control A. Results of Chemotherapy
Chemotherapy of tuberculosis was associated with an immediate and dramatic effect on fatality: patients who would have clearly died of their disease remained alive. The trend in tuberculosis mortality after introduction of chemotherapy was illustrated in Norway (Fig. 1); the greatest reduction occurred immediately following the introduction of drugs before modern, multidrug chemotherapy was used. Subsequently it was conclusively shown that patients did not relapse if they had diligently completed the multidrug treatment prescribed (15). Chemotherapy, while saving the lives of patients, reduced the period of time of being contagious and prevented patients from again becoming contagious, removing them from the cycle of transmission. B. Effective Means of Case-Finding
Following the second world war, periodic radiographic examination of large proportions of the general population was performed in the belief that such active
Tuberculosis Control in Low-Income Countries
59
Figure 1. Trend in mortality from tuberculosis in Norway, 1925–1970, in relation to the introduction of chemotherapy. (Adapted from Ref. 59.)
measures would remove the infectious cases from the community and prevent further spread of tuberculosis. In an extensive field trial evaluating the components of the emerging strategy for tuberculosis control, Styblo and colleagues (16) in the Kolin district of Czechoslovakia showed convincingly that where routine services are regularly provided, periodic examinations are not efficient in identifying further cases of tuberculosis in the community, especially the most contagious cases. Studies in Kenya (17) indicated that patients identified on screening examinations had most likely attended the health service (in many instances on numerous occasions) where they had not been diagnosed. An international, multicenter evaluation of the ability of tuberculosis specialists to correctly identify active cases of tuberculosis using chest radiographs (18) demonstrated a striking degree of nonconcordance in the examination results. The most appropriate means of case detection was bacteriological examination of those presenting with compatible symptoms in routine health services.
C. Impact of Chemotherapy on Tuberculosis Control
In addition to saving the lives of tuberculosis patients, adequate multidrug chemotherapy rapidly reduced the numbers of tuberculosis patients in the community by quickly curing the long-term ( prevalence) cases, leaving primarily new, previously undiagnosed cases as the only patients in the community, and even these could be quickly rendered bacteriologically negative (Fig. 2).
60
Enarson
Figure 2. Impact of chemotherapy on prevalence of infectious cases, incidence of infectious cases, and prevalence of resistant cases of tuberculosis in Edinburgh in relation to the introduction of chemotherapy. (Adapted from Ref. 10.)
D. Rationalization of Tuberculosis Services
From the elements outlined above, a model was proposed for tuberculosis services as a full-scale public health program (19). It included government responsibility for tuberculosis control activities, ambulatory chemotherapy of tuberculosis patients using a standardized multidrug regimen under the supervision of a specialist, case detection based on examination of individuals presenting themselves to the general health services with symptoms compatible with tuberculosis, bacteriological monitoring of the course and outcome of treatment, periodic evaluation of activities, and the use of BCG vaccination. Application of this approach in many industrialized countries was followed by rapid reduction in the number of tuberculosis cases. VI. Adaptations for Low-Income Countries A. Constraints in Providing Tuberculosis Services
Attempts to reproduce the results achieved in industrialized countries using the same methods were successful in a few other countries, such as Cuba, Libya, Al-
Tuberculosis Control in Low-Income Countries
61
geria, Uruguay, and Chile. The poorest countries, where the majority of the cases lived, faced marked constraints. Infrastructure for providing services was in most instances nonexistent, financial resources were inadequate to deal with the disease burden, populations were scattered, and communication was insufficient to ensure accessibility to such services as did exist. Only few of the elements of the model developed in industrialized countries could be implemented promptly in the poorest countries. Vaccination was the easiest and was extensively applied; other elements were incompletely implemented due to the constraints encountered. B. The Need to Focus Interventions
The need to set priorities was evident. In addition to the experimental work supported by the World Health Organization (WHO) undertaken in the Kolin district of Czechoslovakia, a broad program of research was undertaken, primarily in India (20), which provided a scientific basis for discussion. A number of modifications were proposed. One of the earliest modifications was the use of isoniazid alone in the treatment of tuberculosis. This approach had been evaluated at the initiation of chemotherapy (21) and was shown to be effective in increasing the proportion of patients who could be cured, and the long-term outlook for those cured was not different from that for those whose disease was arrested using multidrug chemotherapy. It was clearly cheap and easy to apply and received enthusiastic support from many experts, including Johannes Holm, the executive director of the International Union Against Tuberculosis, an action praised by Halfdan Mahler, Director General of the World Health Organization (22). This policy led to the proliferation of resistance to isoniazid and ultimately to the present problem of multidrug resistance. Another recommendation was based on mathematical models applied to the transmission cycle for tuberculosis (23). The importance of case finding was stressed by the models because it was noted that if one could achieve a relatively modest level of success of treatment in a large number of cases, it would be much more effective in reducing the burden of disease in the community than if a high level of success of treatment was achieved in a limited number of cases. From this came a focus on case finding as the key activity of tuberculosis services. A formal recommendation was developed by WHO in 1964 for the development and implementation of national tuberculosis programs (24) and reiterated in a revision 10 years later (25). The report identified the need for a program that is countrywide, permanent, responsive to the felt needs of the population, integrated within the existing health services, and within the reach of the resources available. As a consequence of these recommendations, most governments instituted a national tuberculosis program.
62
Enarson VII. Achieving Success in Low-Income Countries A. Impact of Applied Interventions
Within a few years of the recommendation of this strategy, millions of cases of tuberculosis were reported to WHO (26). The number of notified cases of tuberculosis declined in successive reports, which was interpreted as indicating success of the strategy. A more critical evaluation of the evidence, however, suggested that the number of cases of tuberculosis reported to WHO seriously underestimated the real number of cases that existed and that, instead of declining, the number of cases may actually have been increasing (27). Far from being successful, the interventions were shown to have been contributing to a worsening of the tuberculosis situation (28), an analysis initially presented to the annual meeting of the International Union Against Tuberculosis in 1973. Subsequent information from the national prevalence surveys periodically carried out in East Asia [particularly in Korea (29) and China (30)] indicated that more than half the sources of transmission of tuberculosis were cases known to the health services that had received treatment but had not been cured. Moreover, the majority of these cases harbored drug-resistant microorganisms. Instead of bringing the problem under some semblance of control, the ineffective treatment of the cases was actually making the epidemiological situation far worse than if the patients had never been treated. The conclusion of this evaluation was that it was far better to do nothing at all than to treat the cases badly! This information had already been available from the first years of chemotherapy in Edinburgh (Fig. 2) as well as from community studies in India (31), but the message had not been heeded. The immediate consequence of the lack of success was a decline in priority given to tuberculosis and an emphasis on improving general health services through a focus on “primary health care” and mobilization of the general population for health following the successful examples of services in China and of specific projects in India and Indonesia. It was felt that, when such services were established, it might be possible to revisit the focused intervention against tuberculosis (32). B. Redefining the Strategy
The failure of attempts to successfully address the tuberculosis problem in low-income countries was very much evident in Beijing in 1978, when Kan and Zhang (33) set out to introduce a revised strategy for management of tuberculosis in that municipality of 10 million inhabitants. Their program emphasized diagnosis based on bacteriological examination, treatment employing direct observation of a regimen of 12 months of chemotherapy including streptomycin, isoniazid, and para-aminosalicylic acid for one month, followed by twice-weekly streptomycin
Tuberculosis Control in Low-Income Countries
63
and isoniazid for 11 months, with an emphasis on the successful treatment of newly diagnosed cases, a separate treatment regimen for patients failing to respond to initial treatment, and BCG vaccination of newborns. Over the subsequent decade, the program was expanded from several model areas, where it had proved successful, to cover the entire population of the municipality. Childhood tuberculous meningitis virtually disappeared, and subsequent evaluation of tuberculin reactivity in a cohort of unvaccinated children showed that transmission of tuberculosis has been dramatically reduced. The reduction in transmission paralleled the decline in prevalence of tuberculosis cases in adults whose numbers were rapidly reduced through the implementation of directly observed chemotherapy, even though rifampicin-containing regimens were not used. The success in the model areas at the outset of the program was sufficient to convince the authorities of the municipality to provide full funding as the program was expanded to the whole population, and this treatment has been provided to the entire population free of charge through the resources of the local government. The constraints on implementing successful tuberculosis services were equally in mind in 1977 when the government of Tanzania invited representatives of the International Union Against Tuberculosis, WHO, and the Tanzania Anti-tuberculosis Association to a Meeting on the National Tuberculosis Control Program, financed by the Swiss Association against Tuberculosis, in an attempt to consolidate the sporadic successes achieved in certain parts of the country over the preceding years (34). After this meeting a process was commenced that included the establishment of a panel of national and international participants and a workshop, from which resulted a plan and the establishment of a national committee. The proposal was approved by the Ministry of Health in May 1977 (35). The principles of this program followed those of the Ninth Report of the WHO Expert Committee. Other key components were: A defined structure, with implementation in district health services, a designated health worker responsible to ensure that policies are followed, with support from both an intermediate and central level in order to ensure a regular supply of necessary materials, liaison with other relevant bodies, planning, monitoring, and evaluating services. Standardization of technical policies, including ambulatory treatment with different treatment regimens for new and previously treated patients, procedures for bacteriological monitoring of the results of treatment, case finding focusing on microscopic examination of sputum specimens from patients presenting with symptoms to the routine health services, and vaccination with BCG as part of the expanded program on immunization.
64
Enarson Routine evaluation, monitoring activities, and their results using standardized instruments for recording and reporting as an integral part of the routine activities of the program. An in-built program of research as an essential component of the activities and included in the routine budget of the program.
This program was introduced after intensive training of existing health service personnel and with a concentrated effort of supportive visits to the district medical officers who had responsibility for its implementation. At the outset, treatment of cases never previously given chemotherapy involved a daily regimen lasting 12 months: 2 months of isoniazid, streptomycin, and thioacetazone, followed by 10 months with isoniazid and thioacetazone. Early results of the program were disappointing: success in treatment, at the outset just over 30% of sputum smear–positive cases, rose to 56% within the first several years but stabilized at that level. The failure to achieve a higher level of success was primarily caused by a high proportion of patients who failed to complete their treatment. By 1982, it was clear that the results achieved by the program would not be satisfactory if the current strategy was not revised. At this point, it was decided to introduce a rifampicin-containing chemotherapy regimen for the treatment of new cases who were sputum smear positive, consisting of 8 months of treatment: 2 months of isoniazid, rifampicin, pyrazinamide, and streptomycin followed by 6 months of isoniazid and thioacetazone daily. This was administered under very careful supervision, requiring patients to be admitted to the hospital for direct observation of swallowing of medications in the initial intensive phase of treatment while rifampicin was being given. Results in the first groups of patients were very encouraging, with 89% the patients successfully treated. With the progressive extension of this policy, the overall success rate for the whole country in the treatment of new sputum smear–positive cases approached 80% within several years and has remained at this level ever since. The most important component of success in treatment was a reduction in the proportion of patients failing to complete the full course of their treatment. The proportion of patients dying while taking treatment was already very low (6%) even when the success rate of treatment was low, and this changed very little as the success of treatment improved. There was a decline in the proportion of patients in whom the sputum remained or became again smear positive while taking treatment, but this proportion was relatively small (5%) even at the outset. The decline in proportion of cases failing to complete the full course of treatment was the determining factor in the improvement in treatment results. No systematic evaluation was made of the reasons for the decline in failing to complete treatment. The decline did not begin immediately but lagged 18–24 months after introduction of the revised strategy (36). Patients treated in the pro-
Tuberculosis Control in Low-Income Countries
65
gram pointed out that the community, at the outset, did not believe that tuberculosis was a curable disease, but that it could be controlled only to a certain extent and the moment of death merely delayed. The interaction of groups of patients at various stages in their treatment course at the time that they were in hospital or came together to the ambulatory clinic for the directly observed treatment demonstrated to the patients, their families, and the community that individuals were improving and being permanently cured. This factor was determinative in the increasing proportion of patients who followed their treatment to completion. The health education provided by patient-to-patient interaction was much more powerful than the same health education given by a health worker. Moreover, the daily interaction of patients for directly observed medications provided the opportunity for this interchange. Periodic evaluation of drug susceptibility in a representative sample of patients was undertaken (37). Among patients never previously treated, the proportion of cases resistant to isoniazid was low (10%) and did not change over the three decades evaluated; resistance to both isoniazid and rifampicin (multidrug resistance) was essentially nonexistent and had not appeared in the community by 1988. The most important factor in preventing the emergence of drug resistance, even while using the medications throughout the country, was undoubtedly the policy to ensure that rifampicin was used only in the initial intensive phase of treatment, along with at least three other medications, and to use thioacetazone, along with isoniazid, in the continuation phase. This minimized the period of directly observed treatment and ensured that rifampicin was never used alone with isoniazid in patients in whom initial resistance to isoniazid was not rare. VIII. Effective Strategies for the Management of Tuberculosis A. Generalization of the Strategy
The success achieved in Tanzania was received with some skepticism; the commitment of the government to health care as a priority, the centralized organization of the health service, and the general accessibility of the health service were thought to be reasons for the success. Clearly, the generalizability of the strategy was not accepted. In consequence, and in collaboration with a number of partners, the strategy was extended during the following 5 years to a number of other lowincome countries: Malawi, Senegal, Mozambique, Benin, Nicaragua, Yemen, Mali, and parts of Kenya (areas with nomadic populations). Similar results were obtained in Malawi (38), Mozambique (39), Kenya (40), Benin (41), and Nicaragua (42). The other countries failed to achieve satisfactory results: in Mali, the failure to extend the services into the periphery compromised accessibility; in Senegal, simple failure to follow the principles (in particular, directly observed
66
Enarson
treatment) compromised the results of treatment; in Yemen, both of these errors resulted in equally inadequate results in spite of strong financial inputs. A critical evaluation of the results, particularly those in Tanzania, as part of a larger project termed the “health sector priorities review” undertaken by the World Bank and published in 1989 (43) demonstrated the success of these programs and pointed out their cost-effectiveness. Based on information obtained from Tanzania for patients commencing treatment in 1986, the estimated costs of this treatment were: per case treated, $123 using the 12-month regimen not containing rifampicin and $168 for the 8-month regimen containing rifampicin; $368 and $314 per case cured; $569 and $514 per death averted. The detailed analysis was extended to include Malawi and Mozambique (44). Average costs per case treated using 8-month chemotherapy were $160–217 with hospitalization and $139–196 for ambulatory treatment. The conclusion of this evaluation was that chemotherapy for sputum smear–positive tuberculosis patients is cheaper than other cost-effective health interventions such as immunization against measles and oral rehydration therapy. Further comparison was made and published in the annual report of the World Bank in 1993 (1). In this report, 47 health interventions were compared for cost and effectiveness: chemotherapy for smear-positive tuberculosis was estimated to cost $1–3 per disability-adjusted life-year saved as compared with a cost of more than $10 for measles vaccination; it was estimated to be among the three most cost-effective of the 47 interventions. B. The “Policy Package”
At the time of the retirement of Dr. Styblo as director of scientific activities, a review of the experience of the International Union Against Tuberculosis and Lung Disease (IUATLD) in the collaborative tuberculosis programs was made (45). Up to that point (1988), a total of 109,691 cases of sputum smear-positive tuberculosis who had never previously received chemotherapy had been evaluated in collaborative programs in Tanzania, Malawi, Mozambique, Nicaragua, and Benin. Among these, 52,840 had been given treatment with the 8-month daily regimen containing streptomycin, isoniazid, rifampicin, and pyrazinamide in the initial 2 months of treatment followed by 6 months of daily isoniazid and thioacetazone. The rifampicin was always directly observed to be swallowed (given combined with isoniazid in the same tablet), and the isoniazid and thioacetazone was also provided as a combined preparation. Of these patients, 80% were successfully treated compared with only 56% of those given the 12-month regimen not containing rifampicin. The conditions necessary for achieving success in these programs were: 1.
Political commitment on the part of government, reflected by the establishment of an adequate structure. This included a designated manager within the district (serving, on average, 100,000 population), an in-
Tuberculosis Control in Low-Income Countries
2.
3.
4.
67
termediate-level manager to support the district manager and a central unit for supervision, materials management and training, consisting of a full-time coordinator, as well as logistical support for administration and transport. A secure supply of drugs and materials, including the amount of medications and diagnostic supplies required for regular use as well as a stock (6 months equivalent at central, 3 months equivalent at region, and 3 months equivalent at district levels) to ensure that the supply was never interrupted. A network of microscopy centers with a system of quality control consisting of a binocular microscope and a trained microscopist who, among other duties, carried out sputum smear examinations. Each center was located at the same site as the district manager. Proper recording and reporting of cases, using a standard set of forms and registers: the numbers of cases newly diagnosed and the results of their treatment were recorded and reported on a quarterly basis, based on the “cohort” of patients registered within the same calendar quarter.
In addition, requirements for the introduction of rifampicin-containing treatment regimens were outlined: 1.
2.
3.
Adequate supervision of drug taking during the initial intensive phase, consisting of observing the swallowing of every dose of medication during the period in which rifampicin was being administered. Proper training and supervision of health workers: initial training in the technical policies of the national tuberculosis program was followed by quarterly supportive visits from officers of the program, focusing on the records of patients and interviews with selected individual patients. Step-wise introduction of rifampicin-containing regimens, not at a single point in time. The sites selected for initial introduction were those most likely to achieve success (showing the best results using the 12-month regimen) and gradually but progressively expanded to other sites are thus the majority of patients in the country. Patients unable to participate in direct observation of the swallowing of medications were not given a rifampicin-containing treatment regimen.
This experience was reviewed once again in 1995 (46). From 55,561 cases in 1990 at a total cost of $3.5 million ($63 per case) of donor support, the collaboration increased to include 129,889 cases in 1994 in 26 low-income countries at a cost of $3.0 million ($23 per case). The reduction in cost was primarily due to a reduction in the price of medications obtained through centralized drug procurement with international tender and competitive bidding.
68
Enarson C. The Importance of Action Beyond Medication
While these results were encouraging, they were not sufficient to stimulate an adequate response to address the global problem. The most important achievement was the recognition of tuberculosis as a priority among decision makers and their commitment to providing resources to address it. Three important developments helped to promote this recognition and commitment. The first, and probably most important, was the recognition in the popular press, particularly in the United States, of the threat posed by tuberculosis (47). This recognition had an impact far beyond the borders of the United States and extended to decision makers in low-income countries. The second important development was the evaluation by the World Bank of tuberculosis as a high priority, the management of which was among the most cost-effective of any health intervention in low-income countries. The third was the designation by WHO of tuberculosis as a “global emergency.” Recognition of the cost-effectiveness of interventions in tuberculosis led the World Bank to provide loans to a number of countries, many of which, such as China, India, and Bangladesh, have large numbers of tuberculosis cases. These loans have set in motion revised programs based on the experience of the IUATLD collaborative programs and have reported a high degree of success (48). The priority given by WHO has led to a series of actions that have been indispensible to the extension of tuberculosis services in low-income countries. The declaration of a global emergency raised the visibility of tuberculosis in the various regions where the disease is particularly frequent. The acceptance of the thesis that a great deal can be achieved using existing technology (49) has stressed immediate action. The adoption of the principles of the IUATLD collaborative programs, first in the form of the framework for effective tuberculosis control (50), prepared under the leadership of Dr. Petra Graf, and subsequently, under the user-friendly brand name DOTS, has advanced the awareness of the strategy. Subsequently, the Global Tuberculosis Program of the World Health Organization has been markedly expanded in personnel, budget, and activities and has provided the credibility and leadership that had previously been lacking and that can only be provided by an official, governmental organization if it is to gain the attention of political leaders and other decision-makers. IX. Future Challenges A. Feasibility of Elimination
The objective of tuberculosis services is the elimination of tuberculosis; this identifies the strategy to be employed and the methods of evaluation to be undertaken. Is there good evidence that the application of the strategy has reduced the problem of tuberculosis in low-income countries?
Tuberculosis Control in Low-Income Countries
69
To date there is no incontrovertible evidence that the strategy has dramatically reduced transmission of M. tuberculosis infection in a low-income country. Indirect evidence of the effectiveness of the strategy comes from the experience previously noted in Beijing Municipality, where periodic surveys have shown that the prevalence of cases of tuberculosis has declined rapidly; one can only assume that this must be associated with a decrease in transmission of infection. As expected, the prevalence has declined more rapidly than the rate of newly diagnosed cases. Other indirect evidence comes from Nicaragua (51), where the case-notification rate has declined steadily over the past decade. What is the situation in sub-Saharan Africa? In the countries that have been involved in the IUATLD collaborative programs, case notification has not declined. Indeed, in a number of countries, case rates have risen alarmingly. This is due in large part to the epidemic of acquired immunodeficiency syndrome (AIDS) in these countries (see Chap. 20) (52). The dire predictions of a mathematical model of the impact of the AIDS epidemic on tuberculosis rates in countries of sub-Saharan Africa (53) have been shown to be disturbingly accurate. The impact of AIDS on the global situation of tuberculosis will be substantial as the epidemic spreads in the countries of the Indian subcontinent and Southeast Asia. The only bright spot is that, in spite of the rapid rise in the numbers of tuberculosis cases, it has been possible to maintain a high rate of success of treatment in smear-positive cases. B. Economic Sustainability
While tuberculosis services have been clearly shown to be cost-effective, the increasing economic crisis in many low-income countries has seriously jeopardized the possibility that these services can be routinely provided and sustained over the long term. This situation is leading to increasing donor dependence at a time of “donor fatigue.” If the strategy is donor-dependant, it will not be sustainable in the long term because it calls for efficient application for the duration of a full generation if it is to be effective. Moreover, the increasing reliance on bank loans will only compound the economic crisis as inflation and currency devaluation follow the decline in productivity over the short term. C. Maintenance of the Health Services
The economic crisis affecting many low-income countries and accompanying health sector reform (see Chap. 33) has reduced the number of health care workers, peripheralized decision making, and encouraged privatization of health services. The usual structure of tuberculosis services in the successful models may require revision. This is particularly true where the numbers of cases of tuberculosis are rapidly rising and accessibility to services is already compromised in consequence. Whether cost-effective tuberculosis services can be provided by the
70
Enarson
private sector in low-income countries is not clear. Moreover, the support required from central and regional levels for quality assurance of services in peripheral health facilities may be increasingly difficult to provide as the health sector reform process proceeds. D. Drug Resistance
The wide distribution of resistance, first to isoniazid (54) and then to both isoniazid and rifampicin (55), in low-income countries will be a threat to continued success of the tuberculosis services because cost-effective alternative treatment strategies are simply not available, nor are they expected in the near future. The importance of rapidly implementing the present strategy as a means of preventing further development and spread of drug resistance cannot be overemphasized (56). The ability of the strategy, and particularly the rigorous observation of administration of medications, to prevent the appearance of multidrug resistance has been shown where the strategy has been followed (57). The strategy incorporates specific measures to protect rifampicin, including never using it alone with isoniazid (unnecessary where thioacetazone is used in the continuation phase) (Fig. 3), always using it combined with isoniazid in preparations of proven bioavailability, and observing the swallowing of every dose of medication where rifampicin is given. This is in contrast with the situation where the strategy has not been followed (58). Where case rates can be expected to rise rather than decline, the least that can be done is to ensure that the development of multidrug resistance is minimized. It is highly unlikely that new medications will become available for use in low-income countries in the near future.
Figure 3. Balance of recommended regimens for treatment of new and retreatment cases of tuberculosis, outlining the medications in retreatment not previously used for new cases. Principles are as follows: Assume H resistance, always a companion to R never previously used alone with H. Assume that the patient is incurable when resistant to both H and R.
Tuberculosis Control in Low-Income Countries
71
References 1. World Development Report 1993: Investing in Health. Oxford: Oxford University Press, 1993. 2. Enarson DA. Why not the elimination of tuberculosis? Mayo Clin Proc 1994; 69: 85–86. 3. Brudney K, Dobkin J. A tale of two cities: tuberculosis control in Nicaragua and New York City. Sem Respir Inf 1991; 6:261–272. 4. Enarson DA, Rouillon A. The epidemiological basis of tuberculosis control. In: Davies PDO, ed. Clinical Tuberculosis London: Chapman Hall Medical, 1993:19–32. 5. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Un Tuberc 1975; 50:90–106. 6. Calmette A, Negre L, Boquet A. Essai de vaccination du lapin et du cobaye contre l’infection tuberculeuse. Ann Inst Pasteur 1922; 36:625–635. 7. Sutherland I, Lindgren I. The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 1979; 60:225–231. 8. Styblo K, Meijer J. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 1976; 57:17–43. 9. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962; 85: 490–510. 10. Crofton J. The contribution of treatment to the prevention of tuberculosis. Bull Int Union Tuberc 1962; 32:643–653. 11. Kamat SR, Dawson JJY, Devadatta S, Fox W, Janardhanam B, Radhakrishna S, Ramakrishnan CV, Somasundaram PR, Stott H, Velu S. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull WHO 1966; 34: 517–532. 12. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976; 57:275–299. 13. Bleiker MA, Griep WA, Beunders BJW. The decreasing tuberculin index in Dutch recruits. KNCV Selected Papers 1964; 8:38–49. 14. Grzybowski S, Styblo K, Dorken E. Tuberculosis in Eskimos. Tubercle 1976; 57 (suppl. 4):S1–S58. 15. Nakielna EM, Cragg R, Grzybowski S. Lifelong follow up of inactive tuberculosis: its value and limitations. Am Rev Respir Dis 1975; 112:765–772. 16. Styblo K, Dankova D, Drapela J, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia. Bull WHO 1967; 37:819–874. 17. Nsanzumuhire H, Lukwago EW, Edwards EA, Stott H, Fox W, Sutherland I. A study of the use of community leaders in case-finding for pulmonary tuberculosis in the Machakos district of Kenya. Tubercle 1977; 58:117–128. 18. Lotte A (rapporteur). Results of the multiple radiophotography reading trial performed in 1963. Bull Int Union Tuberc 1965; 38:61–72.
72
Enarson
19. National Tuberculosis Association. Recommendations of the Arden House Conference on tuberculosis. Am Rev Respir Dis 1960; 81:482–484. 20. International work in tuberculosis 1949–1964. Geneva: World Health Organization, 1965. 21. United States Public Health Service Tuberculosis Therapy Trials. Long-term consequences of isoniazid alone as initial therapy. Am Rev Respir Dis 1960; 81:824–830. 22. Halfdan Mahler. “Posthumous” letter to Dr. Holm. Bull Int Union Tuberc 1990; 65 (4):82. 23. Waaler H, Geser A, Andersen S. The use of mathematical models in the study of the epidemiology of tuberculosis. Am J Public Health 1962; 6:1002–1013. 24. World Health Organization. WHO Expert Committee on Tuberculosis, Eighth Report. Geneva: WHO Technical Report Series 290, 1964. 25. World Health Organization. WHO Expert Committee on Tuberculosis, Ninth Report. Geneva: WHO Technical Report Series 552, 1974. 26. Bulla A. World health statistics report: tuberculosis patients—how many now? WHO Chron 1977; 31:35–40. 27. Styblo K, Rouillon A. Estimated global incidence of smear-positive pulmonary tuberculosis. Unreliability of officially reported figures on tuberculosis. Bull Int Union Tuberc 1981; 56:118–126. 28. Grzybowski S, Enarson DA. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc 1978; 53:70–75. 29. Report on the Third Tuberculosis Prevalence Survey in Korea. Seoul: Korean National Tuberculosis Association, 1975. 30. Nationwide random survey for the epidemiology of pulmonary tuberculosis conducted in 1979. Chin J Respir Dis 1981; 5:67–71. 31. Frimodt-Moller J. Changes in tuberculosis prevalence in a south Indian rural community following a tuberculosis control programme over a seven years’ period. Ind J Tuberc 1962; 9:187–191. 32. International Union Against Tuberculosis/World Health Organization. Tuberculosis Control. Geneva: World Health Organization Technical Report Series 671, 1982. 33. Zhang L-X, Kan G-Q. Tuberculosis control programme in Beijing. Tuber Lung Dis 1992; 73:162–166. 34. L Stirling. Address to the National TB Workshop, Arusha, Tanzania, February 24, 1977. 35. International Union Against Tuberculosis. Tanzania National Tuberculosis Programme. Bull Int Union Tuberc 1977; 52:53–64. 36. Enarson DA, Hopewell PC. Treatment of tuberculosis in low income countries. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria II: Chemotherapy. New York: Chapman and Hall, 1997:161–182. 37. Chonde TM. The role of bacteriological services in the National Tuberculosis and Leprosy Programme in Tanzania. Bull Int Union Tuberc 1989; 64:37–39. 38. Nuyangulu DS, Nkhoma WN, Salaniponi FML. Factors contributing to a successful tuberculosis control programme in Malawi. Bull Int Union Tuberc Lung Dis 1990/1991(suppl); 66:45–46. 39. Salomao MA, Parkkali LM. Case-finding and treatment results of pulmonary tuberculosis in Mozambique, 1985–1988. Bull Int Union Tuberc Lung Dis 1990 /1991 (suppl); 66:47–49.
Tuberculosis Control in Low-Income Countries
73
40. Idukitta GO, Bosman MCJ. The tuberculosis Manyatta Project for Kenyan nomads. Bull Int Union Tuberc Lung Dis 1990/1991(suppl); 66:44–47. 41. Gninafon M. The antituberculosis programme of Benin. Bull Int Union Tuber Lung Dis 1990/1991(suppl); 66:57–58. 42. Arguello L. Results of the tuberculosis control programme in Nicaragua in 19841989. Bull Int Union Tuberc Lung Dis 1990 /1991(suppl); 66:51–52. 43. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65:2–20. 44. Murray CJ, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost-effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338:1305–1308. 45. Enarson DA. Principles of IUATLD Collaborative National Tuberculosis Programmes. Bull Int Union Tuberc Lung Dis 1991; 66:195–200. 46. Enarson DA. The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes. Tuber Lung Dis 1995; 76:95–99. 47. Reichman LB. The U-shaped curve of concern. Am Rev Respir Dis 1991; 144:741– 742. 48. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347:358–362. 49. Styblo K. The epidemiological situation of tuberculosis and the impact of control measures. Bull Int Union Tuberc 1983; 58:179–186. 50. World Health Organization. Framework for effective tuberculosis control. Geneva: WHO / TB/CARG(4)/94.3, 1994. 51. Cruz JR, Heldal E, Amadottir T, Juarez I, Enarson DA. Tuberculosis case finding in Nicaragua: evaluation of routine activities in the control programme. Tuber Lung Dis 1995; 75:417–422. 52. Chum HJ, O’Brien RJ, Chonde TM, Graf P, Rieder HL. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991–1993. AIDS 1996; 10:299–309. 53. Schulzer M, Fitzgerald JM, Enarson DA, Grzybowski S. An estimate of the future size of the tuberculosis problem in sub-Saharan Africa resulting from HIV infection. Tuber Lung Dis 1992; 73:52–58. 54. Kleeberg HH, Olivier MS. A World Atlas of Initial Drug Resistance. 2d ed. Pretoria: Tuberculosis Research Institute of South African Medical Research Council, 1984. 55. World Health Organization. Anti-tuberculosis drug resistance in the world. Geneva: WHO / TB/97.229, 1997. 56. Chonde TM. The role of bacteriological services in the National Tuberculosis and Leprosy Programme in Tanzania. Bull Int Union Tuberc 1989; 64:37–39. 57. Anagonou SY, Gninafon M, Kinde-Gazard D, Tawo L, Trebucq A, Boulahbal F. Etude de resistance primaire des mycobacteries tuberculeuses aux antibacillaires: une enquete nationale au Benin 1995–1997. Int J Tuber Lung Dis 1997; 5(suppl.):S28. 58. Rodier G, Gravier P, Sevre J-P, Binson G, Omar CS. Multidrug-resistant tuberculosis in the horn of Africa. J Infect Dis 1993; 168:523–524. 59. Bjartveit K. The tuberculosis situation in Norway. Scand J Respir Dis 1978, 102:28–35.
3 Tuberculosis Control in Low-Prevalence Countries
JAAP F. BROEKMANS Royal Netherlands Tuberculosis Association (KNCV) The Hague, The Netherlands
I. The Prospect of Elimination A. Elimination in the Indigenous Population
Tuberculosis remains one of the world’s major public health challenges, causing more than 2 million (mostly young) adult deaths per year. The scale of the problem is such that in 1993 the World Health Organization (WHO) was forced to declare tuberculosis a “global emergency.” This somber picture hides the overall success of tuberculosis-control efforts in most of the industrialized countries. After the Second World War, most industrialized countries successfully moved from high to low tuberculosis prevalence in little more than a generation by effectively treating infectious cases in well-established tuberculosis networks. For example, in the Netherlands the decline in the risk of infection was 4–5% per year between the two world wars, and with the introduction of modern chemotherapy this decline further increased to 13% per year after World War II (Fig. 1) (1). Case rates followed suit (Fig. 2) (1b,2). The tremendous impact of these measures on the tuberculosis situation in the Netherlands is best understood by observing the estimated prevalence of Mycobacterium tuberculosis by age in the indigenous population of the Netherlands in 1940, 1970, 2000, and 2030. In 2030 the prevalence of infection in the Dutch 75
Figure 1 1a.)
Annual risk of tuberculous infection: the Netherlands, 1910–1979. (From Ref.
Figure 2 Annual risks of tuberculous infection and incidence of new active tuberculosis in subjects aged 0–14, 15–19, 20–24, and 25–29 years, the Netherlands, 1952–1970. (From Refs. 1b,2.)
Tuberculosis Control in Low-Prevalence Countries
77
Figure 3 Estimated prevalence of tuberculous infection prevalence by age, the Netherlands, 1940, 1970, 2000, 2030. (From Ref. 3.)
population will be less than 1% and the incidence of smear-positive tuberculosis is expected to be below 1 per million, the conventional limit of elimination (Fig. 3) (3). Further evidence as to the prospect of elimination can be derived from the decline in the incidence of new bacillary pulmonary cases in the Netherlands. The rates of such cases (foreigners excluded) from 1973–1976 to 1993–1995 declined from 3.7 per 100,000 to 2.4 per 100,000 (Table 1). Moreover, age-specific rates show a marked shift to higher age group, consistent with the underlying shift to higher age groups of the prevalence of infection (Fig. 4). An emerging international consensus defines a low-prevalence country as a country with a reliable case rate (all cases) of 20 per 100,000 and declining. Most industrialized countries fit in this category, although some countries like Spain and Portugal still have rates higher than 40 per 100,000 (Fig. 5). Thus, countries with case rates of 20 per 100,000 and declining can be considered to be in the elimination phase of the disease. However, elimination in low-
78
Broekmans
Table 1 Average Annual Notification Rates of Bacteriologically Confirmed Pulmonary Tuberculosis (New Cases Only, Foreigners Excluded) per 100,000 Population, The Netherlands, 1973–1996
Male Female All a b
1973–1976a (P/100,000)
1977–1980a (P/100,000)
1981–1984a (P/100,000)
1993–1996b (P/100,000)
4.9 2.6 3.7
3.9 2.4 3.2
3.5 2.0 2.7
2.6 1.6 2.1
Source: Ref. 3a. Source: Ref. 4.
prevalence countries, given the extent of the underlying high prevalence of infection in older age groups, will take at least another 30–50 years, for which period tuberculosis-control activities, preferably in the context of a national program, must be maintained. B. The Impact of Migration on Low-Prevalence Countries
Since 1992 more than half of all tuberculosis cases in the Netherlands have been among foreigners (Fig. 6). DNA fingerprint technology made it possible to study the impact of migration on the native Dutch tuberculosis situation. From a study
Figure 4 Age-specific rates of infectious cases (Dutch), by age, the Netherlands, 1973–1984 and 1993–1996. (From Ref. 4.)
Figure 5
Incidence rate of notified tuberculosis, 1995, WHO European region. (From Ref. 11.)
Tuberculosis Control in Low-Prevalence Countries 79
80
Figure 6 Ref. 4.)
Broekmans
Notified tuberculosis cases (all forms), the Netherlands, 1974–1996. (From
in 1993–1995 involving all infectious pulmonary cases, it has been concluded that (1) 17% of native Dutch cases can be attributed to recent transmission from a foreign source, (2) 15% of native Dutch cases can be attributed to recent transmission from a native Dutch source, and (3) 68% of cases had a unique DNA fingerprint (or were assigned as the source case of a cluster) and could be attributed to exacerbation of latent infection and not from recent transmission (Fig. 7).
Figure 7
Dutch tuberculosis cases by transmission category.
Tuberculosis Control in Low-Prevalence Countries
81
In addition to the excess transmission from foreign sources, native cases in low-prevalence countries occur due to infection acquired during travel in highprevalence countries. For example, it is reported that 61 (2%) of 3070 Dutch cases reported in 1993–1996 most likely were due to infection acquired outside the Netherlands (4). An extremely rare situation occurred in 1993–1997 in the Netherlands, when a single infectious source from outside the country caused at least 400 infections and more than 50 bacteriologically confirmed secondary cases. This ongoing cluster epidemic, which could only be studied with DNA fingerprint technology, is characterized by an unusually long patient’s and doctor’s delay in diagnosing the source case, which was a rather asymptomatic illness (5). The initial patient’s social life was extremely active. From the above it can be concluded that migration from countries with a high disease prevalence influences cases rates in low-prevalence countries and even has a distinct effect on transmission. Given the underlying trend in the prevalence of infection in the indigenous population, however, such migration at current rates is unlikely to delay elimination more than a few years. C. Impact of HIV Transmission
The effect of HIV transmission on the elimination of tuberculosis in low-prevalence countries will depend on the “overlap” between the prevalence of tuberculous and that of HIV infection in the population studied. In the Netherlands, the general population younger than 50 years of age is virtually free of tuberculous infection. The prevalence of tuberculous infection for those aged 15–54 years—the age group most vulnerable for HIV transmission—was only 7.1% in 1985 and 2.7% in 1995 (Fig. 3). Although excess cases of tuberculosis will occur due to HIV transmission, this will not result in a subsequent distinct deterioration of the tuberculosis situation in the Netherlands as a whole. In 1993–1996 116 (4.1%) of 2885 Dutch and 146 (4.3%) of 3411 foreign tuberculosis patients were reported to be HIV positive (4). However, because HIV testing is not encouraged, these data are not representative, and the precise interaction between the HIV epidemic and the tuberculosis situation in the Netherlands is not well documented. II. Framework for Tuberculosis Control in LowPrevalence Countries In 1993 WHO published the “Framework for Effective Tuberculosis Control,” which essentially encapsulates the DOTS (directly observed therapy, short course) strategy for high-prevalence countries. No such framework document exists for low-prevalence countries. The decline in disease incidence, the health sec-
82
Broekmans
tor reforms, and the shift towards outbreak management of tuberculosis control have major consequences for network maintenance and control activities. A. Consequences of the Decline in Disease Incidence
In a low-prevalence country tuberculosis essentially becomes a rare disease. At the level of the health care provider, a decline in practical experience will result in a decline of expertise in both the clinical and public health management of the disease. At programmatic level a categorical tuberculosis network becomes unsustainable and for this reason needs to be integrated with other public health programs (e.g., other infectious disease programs). A multifunctional approach after such an integration has a diluting effect on the expertise, especially in the public health management of the disease (Fig. 8). In the Netherlands 400 chest physicians and 40 tuberculosis control officers take care of 800 infectious cases annually. After integration in the infectious disease departments of the Municipal Health Services in the early 1990s, 80 multifunctional public health nurses (instead of 40 previously assigned to tuberculosis cases only) became responsible for approximately the same number of tuberculosis patients. B. Consequences of the Health Sector Reform
Most industrialized countries experienced health sector reforms resulting in a decentralization of responsibilities and funding of the management of public health programs. Such developments fragment national tuberculosis networks (Fig. 9). In the Netherlands health sector reform carried out in the early 1990s decentralized funding (from an earmarked national subsidy to a nonearmarked, multipurpose municipal grant) and responsibilities for the tuberculosis program management to 45 administratively autonomous Municipal Health Services.
Figure 8
Consequences of the decline of disease incidence.
Tuberculosis Control in Low-Prevalence Countries
Figure 9
83
Consequences of health sector reform.
C. Consequences of the Shift Toward Outbreak Management
Three distinct but very much interrelated developments elucidate a marked shift towards a more focused public health response during the elimination phase of the disease, best described as shifting away from passive case finding and toward outbreak management (Fig. 10). Occurrence of Microepidemics
In the elimination phase, in which the great majority of the younger population is virtually free of tuberculosis infection, the occurrence of microepidemics becomes a discernible epidemiological event. Microepidemics require a highly specialized public health response, based on the “stone in the pond principle.” Such outbreaks are often characterized by a single source of infection with a marked patient and/or doctor’s delay. A specific institutional environment (e.g., discotheque, school, or prison) may facilitate transmission to a multitude of contacts (see Chap. 15).
Figure 10 Consequences of shift towards outbreak management.
84
Broekmans Emergence of High-Risk Groups
During the elimination phase, in which the great majority of the young population is virtually free of infection, specific high-risk groups tend to be characterized by a higher prevalence of infection and/or disease than the general population. Such high-risk groups are often characterized by socially marginalized conditions. In the Netherlands, drug abusers, homeless persons, prisoners, and the foreign-born from high-prevalence countries have been found to have higher rates of tuberculosis. Identifiable high-risk groups thus become accessible for active case finding. In the Netherlands a high-risk group is characterized by a registered tuberculosis incidence (all cases) of 50 per 100,000 or more (6). Active case finding in such groups becomes the policy of choice where the following conditions are met: Passive case finding well organized Favorable treatment results (80%) in patients diagnosed by passive case finding Built-in evaluation of coverage and yield of the target population Treatment outcome monitoring Activities in accordance with ethical and legal regulations The importance of active case finding in high-risk groups is illustrated by the coverage and yield of screening asylum seekers on entry in the Netherlands in 1993–1996 (Table 2) (7). Introduction of DNA Fingerprint Technology
DNA fingerprint technology may revolutionize tuberculosis control in low-prevalence countries because of its ability to detect recent transmission (see Chap. 11). The application of this technology in a control program clarified and elucidated the epidemiological situation in the country as a whole, as well as the emergence Table 2 Tuberculosis Among Asylum Seekers Screened on Entry, The Netherlands, 1993–1996 Asylum seekers Examined Year 1993 1994 1995 1996
N
%
31,578 (90%) 42,939 (95%) 24,424 (97%) 17,919 (90%)
Source: Ref. 7.
Tuberculosis cases on entry
Total
All cases
Infectious PTB
N
N
p/100,000
N
p/100,000
35,000 45,202 25,089 19,868
137 149 94 52
434 347 385 290
46 61 40 26
146 142 164 145
Tuberculosis Control in Low-Prevalence Countries
85
of high-risk groups and so-called cluster epidemics in particular. The specific “added value” of the application of this technology in routine program management is still limited, but its potential in identifying outbreaks in special settings, only suspected to occur in earlier decades, makes it potentially an extremely powerful new tool in tuberculosis control in low-prevalence countries. The great challenge to program management will be to demonstrate the specific role of this technology in the actual control of cluster epidemics. The occurrence of microepidemics, the emergence of high-risk groups, and the ability to substantiate recent transmission by DNA fingerprint technology are characteristic for the shift towards outbreak management that is due to occur in the elimination phase of tuberculosis. Away from but definitively not excluding the emphasis on passive case finding, this shift toward outbreak management constitutes a paradigm shift in control technology. D. Program Support and Coordination
Declining expertise due to declining incidence and integration of services, the danger of fragmentation of the tuberculosis network, and, moreover, the unmistakable shift toward outbreak management require urgent reassessment as to maintain an adequate tuberculosis network during the elimination phase of the disease (Fig. 11). In the Netherlands the national support and coordination functions were reexamined against that background. Key (government) functions and supportive (nongovernmental) functions were delineated (Table 3). Key functions are vital for the support and coordination of the tuberculosis network. Supportive functions add value to the activities of the tuberculosis network. Within the network itself it is of major importance to continue to have identifiable and accountable staff (e.g., tuberculosis control officers, public health nurses) to guide and execute program implementation.
Figure 11 Key issues within the tuberculosis network in the elimination phase.
86
Broekmans Table 3
Key and Supportive Functions for Program Maintenance
Key functions for program maintenance: Consensus-based technical and policy guidelines Consensus-based system of quality assurance Surveillance Program monitoring Technical support by national consultants Supportive functions for program maintenance: Graduate/Postgraduate training Development of health-education material Research Documentation center International collaboration
E. Legal Framework
There exists a growing awareness of the importance of a legal framework to guide program policies. In most industrialized countries such a legal framework underlies most tuberculosis control activities. Surveillance, specific interventions such as screening of foreigners on entry, prisoners, sailors etc., mandatory isolation of noncompliant infectious patients, and even the specific functions of a tuberculosis clinic are often written in special laws or other official government documents. The distinct importance of a transparent and, from the public health point of view, up-to-date legal framework is not very well known. Research in this area is urgently needed for this reason as well as for the benefit of the implementation of WHO DOTS strategy in high-prevalence countries.
III. Surveillance A. Surveillance of Infection
The annual tuberculosis infection rate is the best single indicator for evaluating the tuberculosis problem and its trend in developed and developing countries. It is an index that expresses the attacking force of tuberculosis within a given population and, unlike disease notification rates, is not linked directly to the case-finding and treatment measures of the tuberculosis program. In the Netherlands the decline of the risk of infection was 13% annually in 1956–1965, 10.4% in 1966–1979, and 8.3% in 1979–1991 (Fig. 12). It is estimated that the annual rate of infection in the Netherlands was less than 10 per 100,000 in the mid-1990s.
Tuberculosis Control in Low-Prevalence Countries
87
Figure 12 Prevalence of tuberculous infection and annual risk of tuberculous infection, the Netherlands, 1956–1991. (From ITSC/TSRU, unpublished.) B. Surveillance of Recent Transmission
Introduction of DNA fingerprint technology in control programs in low-prevalence countries enables the identification of cluster epidemics and may open the way to control the size of these clusters (Table 4). The use of DNA fingerprint Table 4
The Four Largest Cluster Outbreaks, The Netherlands, 1991–1997
Number of cases with identical DNA fingerprint from January 1, 1991 66 55 50 41 Source: Ref. 8.
Notification of first source case
Cluster growth in 1997
July 1991 March 1993 July 1993 December 1992
11 10 6 13
Nature of cluster (proportion attributed) Homeless/Drug abusers (77%) Related to foreign source (92%) Homeless/Drug abusers (60%) Asylum seekers (Ethiopia/ Somalia) (95%)
88
Broekmans
technology often validates routine contact examinations and contributes to the identification of epidemiological links previously unsuspected (8). C. Surveillance of Disease
Notification of New and Relapse Cases
The notification rates of new and relapse cases in low-prevalence countries are of greatest value in evaluating the overall epidemological situation. In general, significant intracountry differences exist in the trend and level of notification. Resurgent tuberculosis in central Harlem in New York City was attributed to the effects of HIV transmission, homelessness, and the premature disintegration of the tuberculosis program. Implementation, at great cost, of standard control measures redressed the situation effectively. Even in a small country like the Netherlands, notification rates may differ from 25–35 (all cases) per 100,000 in major metropolitan areas to 5–10 (all cases) per 100,000 in more rural areas. Notification Rates for Infectious Pulmonary Tuberculosis
Notification rates of infectious pulmonary tuberculosis provide a sensitive measure for the occurrence of sources of infections in the population and its trend towards elimination (Table 1 and Fig. 4). Surveillance of Drug Resistance
Systematic surveillance of initial drug resistance in new cases and acquired resistance in retreatment cases may be of importance for both epidemiological surveillance as well as a measure of program performance. A special study concluded that in the Netherlands three quarters of all drugresistant cases occur in foreign-born persons (9). The great majority of these patients were infected or poorly treated in their country of origin. Thus, the rates of drug resistance in tuberculosis cases in the foreign-born in the Netherlands do not reflect the actual program performance in the Netherlands (Table 5). In the same Table 5
Drug-Resistant Pulmonary Tuberculosis, The Netherlands, 1993–1995
Isoniazid Streptomycin Rifampicin Other anti-TB drugs Any drug resistance Source: Ref. 4.
Asylum seekers, N 351 (%)
Other foreigners, N 786 (%)
Dutch N 1089 (%)
14 14 3 4 22
8 9 2 1 15
3 3 1 1 6
Tuberculosis Control in Low-Prevalence Countries
89
study it was observed that in Dutch patients both acquired and primary drug resistance were rare. The high mean age of Dutch patients with drug-resistant tuberculosis suggests that this level of drug resistance mostly reflects program performance of a more distant past (9). D. Surveillance of Mortality
In low-prevalence countries, mortality rates are of only historical value in indicating the extent of the tuberculosis problem and its trend. With the introduction of effective chemotherapy after World War II, mortality rates have been reduced to very low levels. IV. Program Monitoring A. Surveillance of Diagnostic Measures
Patient and Doctor Delay
Patient and doctor delays in the diagnosis of sources of infection, an inevitable phenomenon of a case-finding and treatment program, is of importance because it contributes to transmission and microepidemics. Routine surveillance data from the Netherlands, compared with earlier studies, suggest an increased patient and doctor delay for Dutch patients. This observation may be consistent with the fact that tuberculosis is becoming a rare disease for Dutch patients and Dutch physicians. The comparatively shorter delays for foreign-born patients could be consistent with active case finding among foreigners and/or greater awareness among physicians that tuberculosis is still a problem among foreign-born persons (Table 6). Further studies are necessary to validate these findings. Table 6 Patient and Doctor Delay Bacteriologically Confirmed Pulmonary Tuberculosis Patients, The Netherlands, 1973–1996 1973–1976a Months
N
1–2 1346 3–4 713 5 or more 468 Total 2527 No 78 information a b
Source: Ref. 3a. Source: Ref. 4.
1977–1980a
1981–1984a
1993–1996b Dutch
1993–1996b Foreigners
%
N
%
N
%
N
%
N
%
53 28 19 100 3
1136 601 450 2187 52
52 27 21 100 2
996 469 374 1839 77
54 26 20 100 4
326 203 217 746 142
44 27 29 100 16
455 187 165 807 156
56 23 20 100 16
90
Broekmans Table 7
Mode of Detection, The Netherlands, 1993–1996 1993–1996
Case finding Active case finding (screening) Passive case finding (complaints) Other/Unknown Total
N
%
1671 4482 492 6645
25 67 7 100
Source: Ref. 4.
Mode of Detection
In low-prevalence countries, in addition to passive case finding among self-reporting suspects, active case finding by screening of risk groups and the containment of microepidemics and cluster epidemics has become progressively more important. For example, in the Netherlands in 1993–1996, 25% of cases were detected by active case finding (Table 7). In the Netherlands in 1993–1996, 50% of patients were diagnosed by chest physicians, 21% by other clinical specialists, and 29% by tuberculosis control officers of a Municipal Health Service (Table 8) (4). B. Surveillance of Treatment Measures
Treatment-Outcome Monitoring of Infectious Pulmonary Cases
The first aim of a tuberculosis program is to cure all (or nearly all) sources of infection. To what extent the treatment results achieved in a tuberculosis program approximate the results obtained in controlled clinical trials is the most important issue in the surveillance of treatment measures.
Table 8 Mode of Detection, The Netherlands, 1993–1996 1993–1996 Diagnosing physician Chest physician Other specialist TB control officer Total Source: Ref. 4.
N
%
3294 1448 1903 6645
50 21 29 100
Tuberculosis Control in Low-Prevalence Countries
91
Table 9 Treatment Outcome Monitoring of Infectious Dutch Cases, The Netherlands, 1993–1996
Treatment result Total (N) Cured/Completed Interrupted Died (TB) Died (non-TB) Transferred out
1993 (%)
1994 (%)
1995 (%)
1996 (%)
(329) 74.5 7.9 3.3 12.5 1.2
(410) 81.2 5.9 1.7 11.2
(368) 80.4 4.3 3.0 11.7 0.5
(410) 84.4 2.0 3.7 10.0
Total N
%
1517 1224 74 44 171 4
100 80.3 4.9 2.9 11.2 0.4
Source: Ref. 4.
In the Netherlands the treatment success rate in Dutch infectious pulmonary cases was 80% for the period 1993–1996 (Table 9). The treatment success rate would be substantially higher if it was corrected for the relatively high case fatality due to other diseases than tuberculosis. The treatment success rate in nonDutch infectious pulmonary cases (Table 10) was 83% in the same period, with a markedly higher interrupted rate of 9.1% than in the Dutch cohort 4.9%. The importance of treatment outcome monitoring in specific subgroups is demonstrated by the fact that among asylum seekers 10% interrupted treatment in 1993–1996 (Table 11) (4). Directly Observed Treatment
The great majority of patients in low-prevalence countries are treated by medication self-administration. With an increasing proportion of patients coming from Table 10 Treatment Outcome Monitoring of Infectious Non-Dutch Cases, The Netherlands, 1993–1996 Total
Treatment result
1993 (%)
1994 (%)
1995 (%)
1996 (%)
N
Total (N) Cured/Completed Interrupted Died (TB) Died (non-TB) Transferred out
(429) 79.7 11.2 1.2 3.3 4.4
(453) 78.4 12.4 0.7 2.2 6.4
(401) 85.8 6.5 0.5 1.5 5.7
(420) 86.9 6.0 0.7 1.4 5.0
1703 1411 155 13 36 88
Source: Ref. 4.
% 100 82.6 9.1 0.8 2.1 5.4
92
Broekmans
Table 11 Treatment Outcome Monitoring of Infectious Asylum Seekers Only, The Netherlands, 1993–1996
Treatment result Cured/Completed Interrupted Died (TB) Died (non-TB) Transferred out Total
1993 (N)
1994 (N)
1995 (N)
1996 (N)
90 11 1
116 18 1
128 13
112 10
7 109
6 141
1 2 144
3 125
Total N
%
446 52 2 1 18 519
85.9 10.0 0.4 0.2 3.5 100
Source: Ref. 4.
specific risk groups and proportionally more patients detected by active case finding, direct observed treatment becomes an increasingly important intervention (see Chap. 16). Based on a special survey, it was observed that in 1996 at least 78 (4.6%) of 1678 cases reported in the Netherlands were put on direct observed treatment (10). References 1. Styblo K, Meijer J, Sutherland I. The transmission of tubercle bacilli. Its trend in a human population. Tuberculosis Surveillance Research Unit Report No. 1. Bull Int Un Tuberc 1969; 42:5–104. 1a. Sutherland I, Bleiker MA, Meijer J, Styblo K. The risk of tuberculous infection in The Netherlands from 1967 to 1979. Tubercle 1983; 64:241–253. 1b. Styblo K. Epidemiology of Tuberculosis. In: Selected papers, Vol. 24, KNCV, The Hague, The Netherlands. 2. Styblo K, Meijer J. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 1976; 57:17–43. 3. Styblo K. The elimination of tuberculosis in the Netherlands. Bull Int Un Tuberc 1990; 65:49–55. 3a. van Geuns HA, Hellinga HS, Bleiker MA, Styblo K. Surveillance of diagnostic and treatment measures in The Netherlands. Comparison between the periods 1971–1976, 1977–1980, and 1981–1985. Tuberculosis Surveillance Research Unit of the International Union Against Tuberculosis. Progress Report 1987; 1:60–81. 4. Index Tuberculosis 1993–1996. Netherlands Tuberculosis Register (NTR/KNCV). The Hague, The Netherlands, 16 Feb 1998. 5. Kiers A, Drost AP, Soolingen D van, Veen J. Use of DNA fingerprinting in international source case finding during a large outbreak of tuberculosis in the Netherlands. Int J Tuberc Lung Dis 1997; 1:239–245. 6. Tuberculosis Control in High Risk Groups in The Netherlands. Netherlands Tuberculosis Policy Committee/KNCV, The Hague, The Netherlands, 1997.
Tuberculosis Control in Low-Prevalence Countries
93
7. Annual Reports 1993–1996 Tuberculose-screening asielzoekers in opvangcentra. Regio Noord en Zuid Nederland, Municipal Health Service Tilburg and Municipal Health Service Lelystad. 8. Data from KNCV/RIVM Surveillance Project, The Hague/Bilthoven, The Netherlands. 9. Lambregts-van Weezenbeek CSB. Drug-resistant tuberculosis in the Netherlands: trifle or threat? Thesis, University of Amsterdam, 1998. 10. Verhagen M. DOT in Nederland. Ervaringen met en meningen over directly observed therapy bij door Nederlandse GGD’en georganiseerde tuberculosebestrijding. Venlo, The Netherlands, 1998. 11. Euro TB Surveillance of Tuberculosis in Europe. Report on the feasibility study (1996–1997). Tuberculosis cases notified in 1995. European Centre for the Epidemiological Monitoring of AIDS (CESES) and Royal Netherlands Tuberculosis Association (KNCV), Saint Maurice, 1997.
4 Tuberculosis Laboratories The Centerpiece of National Tuberculosis Control Programs
ADALBERT LASZLO Health Canada, Ottawa, and International Union Against Tuberculosis and Lung Disease Nepean, Ontario, Canada
I. Introduction By March 1882, when Robert Koch reported his momentous discovery to the monthly meeting of the Berlin Physiological Society, tuberculosis in Europe had already been in decline for over a generation. In spite of wars and economic depressions, this decline was further accentuated during the first half of the twentieth century, probably fueled by improving socioeconomic conditions and the isolation of infectious cases in sanatoria. The end of World War II marked a turning point in tuberculosis prevention and control programs. In the late 1940s and early 1950s, mass radiography campaigns and bacille Calmette-Guérin (BCG) vaccination programs were introduced almost concurrently with the beginning of the chemotherapy era in industrialized countries as well as in some developing countries. Because the majority of tuberculosis cases are pulmonary, chest x-rays have, from the beginning, played an important role in tuberculosis case finding and in the assessment of the severity of disease. Despite the fact that no chest radiographic pattern is characteristic of tuberculosis and that a scar is not indicative of active disease, certain configurations are still considered by some as highly suggestive of tuberculosis. These assumptions did not apply to as many as one third of patients diagnosed with pulmonary tuberculosis who, even before the HIV/AIDS 95
96
Laszlo
era, were found to have “atypical” chest x-ray patterns. Furthermore, observer error of interpretation of chest radiography films, extensively studied in the late 1940s and early 1950s, was found to be invariably and unacceptably high, with rates of underreading of up to 43% (1). By the early 1970s, periodic radiographic screening campaigns of entire populations were shown to be an inefficient tool of tuberculosis control because of low yields (only 20% of new cases were being discovered) (2). This was explained by the fact that infectious cases develop faster than repeated screening can logistically and economically follow up (3). Case finding by the detection of acid-fast bacilli in sputum, on the other hand, was less prone to misinterpretation and much less expensive than chest radiography. Although Ziehl-Neelsen (ZN) sputum smear microscopy can detect only about 60% of all adults with pulmonary tuberculosis, its specificity is at least 90%, especially in developing countries. Due to the fact that it provides actual proof of the presence of bacilli, that it can give a measure of the extent of disease, and provide an indication of the progress of chemotherapy, sputum smear microscopy is an important diagnostic tool in developed countries (4) and the diagnostic cornerstone of national tuberculosis programs (NTPs) in developing countries (5). Disparity in the results obtained in BCG controlled trials during the 1950s prompted organization by the Indian Council of Medical Research in cooperation with the World Health Organization (WHO) and the Centers for Disease Control, U.S. Public Health Service, of a large-scale controlled BCG trial in south India. Starting in 1968, it included 260,000 participants, but the first results in 1979 (6) showed that there had been no protective effects. Indiscriminate mass BCG vaccination campaigns had been superseded by mass vaccination of newborns and young children, but by the mid-1970s it became evident that this tuberculosis-prevention measure would not substantially improve the overall epidemiological situation (7). The main reason for this was that more than 95% of reported tuberculosis cases among children are smear negative, and it has been shown that smear-negative patients are much less infectious than smear-positive ones. Furthermore, the protection afforded by BCG vaccination was found to be transient at best. In the late 1950s, in spite of early scepticism, it became evident that adequate chemotherapy was the best available tool to achieve high cure rates (8) and to control tuberculosis in the community. Adequate chemotherapy accelerated the decline in the risk of infection by 10–14% in developed countries, whereas in developing countries, which today carry 95% of the world’s burden of tuberculosis, the annual decrease rates were very low during the last four decades—as low as 1 or 2% in certain African countries such as Tanzania (9). This could be ascribed mainly to poor chemotherapeutic services in these countries. Therefore, the picture emerging in 1964 when the rationale for the WHO national tuberculosis program was being formulated and in 1974 when it was further refined by a WHO expert committee (10) was that tuberculosis control as well as
Tuberculosis Laboratories
97
prevention could be achieved by adequate chemotherapy and that the detection of contagious sources of tuberculosis in the community could best be attained by inexpensive bacteriological means. By that time, tuberculosis in developed countries was perceived as virtually eradicated, and it was only in some developing countries that the principles of tuberculosis control and prevention described in the 1974 WHO document were formally adopted and implemented, with varying degrees of success. Since the late 1970s, the focus of the International Union Against Tuberculosis and Lung Disease’s (IUATLD) activities with respect to tuberculosis has been the development of an appropriate model for the NTPs of developing countries (11). This model was developed in Tanzania and subsequently applied to six other countries in Africa as well as to Nicaragua and Vietnam. In 1989, this model was evaluated by the Health Sector Priority Review of the World Bank and assessed as being among the most cost-effective of any health intervention strategy in developing countries. II. National Tuberculosis Programs The major sources of infection in the community are smear-positive pulmonary tuberculosis patients (2,12); smear-negative, culture-positive patients are much less infectious. The rapid discovery of infectious cases is a high priority, because it usually leads to the cure of the individual and the elimination of a source of infection in the community. Where resources are scarce, case-finding methods are limited to activities that have been shown to bring the highest rewards at the lowest possible cost. In most low-income countries, passive case finding for smear-positive cases, active case finding for contacts, and the simultaneous raising of community and medical profession awareness have become the method of choice for their tuberculosis control programs (13). Experience from recent decades indicates no improvement of tuberculosis rates in developing countries without a well-run NTP. The rationale for a NTP is based on the following facts (14): 1. Tuberculosis can be controlled with available tools under any socioeconomic circumstances because the infectious agent has only one major reservoir—the diseased patient—who can quickly be rendered noninfectious. This is particularly true for epidemiologically significant M. tuberculosis infections, which are almost exclusively confined to humans and captive primates (15,16). 2. Since there is a natural balance between the tubercle bacillus and the human host, any reduction of sources of infection will inevitably improve the epidemiological situation. A sputum smear–positive patient, if left untreated, will infect on average 10–15 close contacts per year; if
98
Laszlo this patient is properly treated one case will be eliminated and up to 15 cases of tuberculosis will be prevented. 3. Smear microscopy detects almost all sources of infection, and highly efficient chemotherapy regimens can cure almost all discovered cases. Experience in IUATLD field programs has shown that maintaining a detection rate of 70% of smear-positive cases and a cure rate of 85%, the tuberculosis endemic would, in time, come under control.
The principles for the NTPs reviewed and expanded in the Ninth Report of the Expert Committee on Tuberculosis (10) are the following: 1. The distribution of tuberculosis cases is fairly even, and since populations in developing countries, in spite of rapid urbanization, are still predominantly rural, the program has to be delivered countrywide. Due to the disease’s transmissibility and the high mobility of populations, solutions must be found for the entire community; failing this, the part of the population without coverage will keep transmitting the disease to the part of the population receiving coverage. This is one condition that is often difficult to fulfill because of inadequate primary health service coverage in most developing countries. Fragmentation of tuberculosis control efforts in many countries between different governmental agencies and nongovernmental organizations poses a severe problem because of lack of uniformity in diagnostic and treatment guidelines. This lack of uniformity inevitably leads to poor treatment practices and to less than ideal program performance. 2. Most of the population in developing countries has been infected with tubercle bacilli and the risk of infection remains high, therefore the program must be permanent. Tuberculosis infection is chronic in character, with the possibility of endogenous reactivation many years after infection. This implies that once established, the NTP should be continued until tuberculosis is under control. Nowhere did the potential of modern tuberculosis-control measures became more apparent than in the Yukon Territory, Canada, where the Inuit (Eskimo) population’s rates of infection and disease in 1950 were among the highest ever reported and where by the 1970s the incidence of new infection was too low to be determined with accuracy (18,19). 3. To satisfy the demand of the populations, the program should provide universal accessibility and be effective enough to maintain credibility. Nothing can hurt the credibility and reputation of a NTP more than an interruption of tuberculosis-control activities leading to poor treatment practices and the creation of multidrug resistance. 4. To meet these requirements, the program must be integrated within the community health-delivery structure. Diagnosis and treatment of tuber-
Tuberculosis Laboratories
99
culosis should be conducted at the district level with supervision, training, monitoring, and leadership provided by the NTP (19). These principles were subsequently adapted and reformulated by WHO as the DOTS (directly observed therapy, short course), an appropriate model for tuberculosis control in developing countries (20). The DOTS strategy for tuberculosis control in developing countries is meant to provide short-course chemotherapy under direct observation to at least all identified smear-positive tuberculosis cases. Its targets are 1) to cure 85% of new detected cases of sputum smear–positive pulmonary tuberculosis worldwide and 2) to detect 70% of existing cases of sputum smear–positive pulmonary tuberculosis. The success of this strategy depends on the implementation of the five following points: political will, passive case finding, short-course chemotherapy for all smear-positive pulmonary tuberculosis cases, regular, uninterrupted supply of all essential antituberculosis drugs, and a monitoring system for program supervision and evaluation. The DOTS network has expanded from 11 countries in 1992 to 96 countries in 1997; patients under effective tuberculosis therapy consistent with the DOTS approach have increased 10-fold from fewer than 100,000 in 1993 to about 1 million in 1997 (21). III. Tuberculosis Diagnostic Services Tuberculosis bacteriology is a complex and demanding branch of clinical microbiology. Unlike in some other infectious diseases, the tuberculosis clinical laboratory plays a critical role, not only in the diagnosis of the disease and the management of the patient, but also in control and elimination strategies. Laboratory results are used to: Detect and confirm cases with diagnostic smear microscopy. Follow-up treatment by performing control smear at the end of the initial phase of treatment to verify significant reduction in the population of bacilli, at the middle of the continuation phase to check patient evolution and to detect possible treatment failure, and at the end of treatment to verify cure. Increase case finding by the introduction of culture once smear microscopy has reached its maximum case-finding capability. Guide the treatment of relapses and treatment failures by providing drug-resistance information on these cases. Measure the success of treatment strategies and adjust treatment policies by monitoring trends in drug resistance in the community. Define outbreaks by establishing relationships between M. tuberculosis isolates.
100
Laszlo
Tuberculosis laboratory diagnostic services must be closely coordinated with the administrative, epidemiological, and clinical components of the NTP. They must be developed jointly and concurrently with the other NTP components in order to achieve the widest possible coverage by integrating activities within the structure of the general health services in a country or region. The bacteriological diagnostic services must work as part of the integrated NTP, and the NTP managers along with the managers of the general health laboratory programs must determine the organization of these services while observing the following principles: National standards for methods, procedures, and laboratory techniques Executive decentralization down to the least complex diagnostic levels Effective supervision and quality assurance from the immediately superior level Interdependence of the various diagnostic levels with full reciprocal access and feedback between them In the context of a developing country’s NTP, case finding refers to the diagnosis of sputum smear–positive disease and passive case finding, where the first move toward diagnosis is made by the patient, is the method of choice. From the NTP’s perspective, the order of priority for the TB laboratory network diagnostic bacteriological techniques is direct sputum smear examination, culture of sputum specimens, and drug susceptibility of M. tuberculosis complex isolates.
IV. Tuberculosis Diagnostic Techniques Direct sputum smear bright-field microscopy examination with ZN staining is recommended for peripheral laboratories. The use of fluorescence microscopy can be justified if large numbers of smears are examined (i.e., more than 50 per day), a situation that is only likely to happen in intermediate or in central laboratories. Culturing of clinical specimens in addition to smear microscopy will increase case finding by 20–30%. Since this mode of diagnosis is considerably more expensive than smear microscopy, it will probably be introduced when smear microscopy alone has reached the limit of its diagnostic capability, i.e., when the number of smears needed to diagnose a case of tuberculosis becomes too large and when increasing the number of smear examinations per tuberculosis suspect is no longer cost-effective. Culturing is obviously a prerequisite for drug susceptibility testing; it also can be used to confirm cure. Decontamination using 4% NaOH (22) and inoculation on egg-based media are time-honored, recommended procedures. Drug susceptibility testing capability is needed for laboratory-based surveillance of primary and acquired drug-resistant tuberculosis. The proportion method performed on egg-based Loewenstein-Jensen (LJ) medium is the most widely used drug susceptibility testing method for M. tuberculosis.
Tuberculosis Laboratories
101
V. The NTP National Tuberculosis Laboratory Network Implicit in the organization principles enunciated above is the concept of the national tuberculosis laboratory network as a tool for delivering tuberculosis diagnostic services. This laboratory network consists of a structure in which various laboratories, working at different levels of complexity of service, are united by the common objectives of the NTP. This unity manifests itself mainly through a common set of standards, information systems, goods and services offered, and quality assurance. A network provides a structure within which many laboratories are linked by information, supplies, supervision, and quality assurance programs. The network is necessary because smear microscopy must be carried out in accordance with standards, as near as possible to the patient’s home, and with an assurance of quality. In turn, the network will provide information at all levels required for the planning and the evaluation of the NTP. This information essentially refers to: 1.
2.
3.
4.
5.
Tuberculosis suspects: periodic and continuing information on the number of people presenting with chest symptoms examined by the network makes it possible to evaluate case-finding activities and to identify possible difficulties that may arise and the places where they may occur, in order to take remedial action. Case finding: if coverage is good, the trend in tuberculosis cases detected by smear microscopy is known to be the best indicator of the NTP’s diagnostic effectiveness. Cases diagnosed and treated: comparison of information in the tuberculosis laboratory register, the district tuberculosis register, and the patient’s treatment cards. Trends in bacteriological confirmation: a good operational indicator of the quality of the NTP—the higher it is, the better the NTP is likely to be. Cure rate: negative bacteriology at the end of treatment is the best indicator of the NTP’s efficacy and efficiency.
VI. Structure and Function of the National Tuberculosis Laboratory Network Ideally, a TB laboratory network would consist of the following levels: A. The Central Level (Type I or A) Laboratory
A central, national tuberculosis reference laboratory for the whole country, staffed with highly qualified personnel working in an adequate physical environment,
102
Laszlo
with up-to-date equipment and quality reagents, represents the highest level of technical complexity and excellence in the field. It should be able to: Elaborate national guidelines for diagnostic, quality assurance, and biosafety procedures and techniques Perform direct smear microscopy and culture for its catchment area, drugsusceptibility testing, and species identification of the M. tuberculosis complex Coordinate the activities of the laboratory network Supervise, evaluate, and provide a program of quality assurance for the diagnostic services of the NTP Train technical/scientific personnel in all aspects of the network’s activities Certify TB laboratories of the private sector and promote the incorporation of new laboratories into the network Advise health professionals and institutions of this sector on available diagnostic technologies and on the interpretation of results Evaluate and introduce new diagnostic technologies for use in the network Collect and help evaluate the laboratory data obtained within the network and participate in epidemiological research of interest to the NTP B. The Intermediate-Level (Type II or B) Laboratory
Regional or provincial laboratories reflecting the political, administrative, or health structures of the country. Their main functions are: To coordinate the activities of the laboratories under their jurisdiction To provide logistic support (supplies and reagents) to the laboratories under their jurisdiction To perform smear microscopy and culture for their catchment area To train, supervise, and evaluate the local or peripheral laboratories under their jurisdiction To refer smear microscopy slides to the national reference laboratory for quality-control purposes, to perform quality control of smear microscopy, and to implement quality-improvement measures in the laboratories of their jurisdiction To refer cultures to national reference laboratory for drug-susceptibility testing To generate and provide laboratory-based surveillance data to the national reference laboratory. C. The Peripheral-Level (Type III or C) Laboratory
These laboratories, at the local or district level, are usually located in hospital health centers or posts and are staffed with at least one clinical laboratory tech-
Tuberculosis Laboratories
103
nologist, who should be able to: Collect samples during regular laboratory opening hours Collect samples from specimen collecting units Perform smear microscopy for the area (district) of jurisdiction Refer specimens for further testing to the corresponding intermediate laboratory Participate in the network smear microscopy quality-assurance program Specimen-collecting units are health establishments that do not possess a laboratory; they collect clinical specimens for referral to the district laboratory.
VII. The National Tuberculosis Laboratory Network as a Source of Data An increasing number of countries are following recommendations developed by IUATLD and adopted by WHO on recording and reporting of tuberculosis suspects and cases. Proper recording and reporting will facilitate budgeting and planning, provide better understanding of the epidemiology of tuberculosis, and assist in developing hypotheses about phenomena observed in the descriptive epidemiology of tuberculosis case-finding and treatment activities. A tuberculosis laboratory register is kept in all laboratories of the network. The IUATLD tuberculosis laboratory register (11) assigns a single line to each person examined and should contain the serial number of each consecutive sputum smear starting with #1 each year. The date of examination, the name, address, gender, and age of the patient, the name of the health unit requesting the examination, the purpose of the examination (diagnosis or treatment follow-up), and the result of the examination should be noted. Two additional columns provide space for the technologist’s signature and for remarks. The laboratory register therefore provides the following information: Number of examinees Number of tuberculosis suspects examined Number of diagnostic smears per suspect Number of new smear-positive cases detected Number of patients with follow-up Number of follow-up smears per patient Number of smear-negative patients at the end of the initial phase of treatment Number of smear-negative patients at the middle of the continuation phase of treatment Number of smear-negative patients at the end of treatment
104
Laszlo VIII. The National Tuberculosis Laboratory Network as a Source of Operational and Epidemiological Information
The laboratory register can provide useful information on the laboratory workload, performance, and demographic characteristics of the examinees (23), for example: The number of smears examined per working day The relative smear microscopy diagnostic laboratory workload The proportion of smear-positive cases among suspects The proportion positive on first sputum smear examination The incremental yield with second sputum smear examination The incremental yield with third examination The proportion of patients with follow-up The number of smears examined per case The relative treatment-control smear microscopy laboratory workload The gender-specific proportions of suspects by age The gender-specific proportions of cases by age The age-specific ratios by gender
IX. Conclusion There probably is no contagious disease that relies more for its control and prevention on laboratory-generated test results than tuberculosis. A tuberculosis laboratory network functioning in concert with a model NTP is an essential tool providing efficient, yet inexpensive, support for the diagnostic and treatment activities of the NTP. Laboratory diagnostic services used intelligently with the support of simple yet efficient information systems, such as those afforded by the District Tuberculosis Register, the Tuberculosis Laboratory Register, the Register for TB Suspects, as well as the Patient’s Treatment Card, provide all the elements required for program evaluation without which a modern NTP cannot exist. Results derived from the tuberculosis laboratory network can also be used to obtain laboratory operational indicators that are needed to improve the overall quality of the NTP. They can also be used to obtain essential tuberculosis epidemiological information about the population covered by the NTP. Drug-susceptibility testing services, by measuring the extent and trend of drug-resistant tuberculosis, can predict the efficiency of treatment and help guide treatment policy by adjustment of chemotherapeutic regimens. In spite of their importance to the NTP, tuberculosis laboratory support activities have all too often been neglected in many countries. This circumstance could be the main reason for the poor performance of these
Tuberculosis Laboratories
105
NTPs, since it can be noted that no successful NTP is without an efficient tuberculosis laboratory network. References 1. 2. 3.
4. 5.
6. 7. 8. 9.
10. 11. 12. 13.
14.
15. 16. 17.
Toman K. Tuberculosis case-finding and chemotherapy. Questions and answers. Geneva: World Health Organization, 1979. Meijer J, Barnett GD, Kubík A, Sty´blo K. Identification of sources of infection. Bull Int Union Tuberc 1971; 45:5–50. Sty´blo K., Danˇková D, Drápela J, Galliová J, Jez´ek Z, Krˇivánek J, Kubík A, Langerová M, Radkovsky´ J. Epidemiological and clinical study of tuberculosis in the District of Kolin, Czechoslovakia, Report of the first 4 years of the study (1961–64). Bull WHO 1967; 37:819–874. Shinnick TM, Good RC. Diagnostic mycobacteriology laboratory practices. Clin Infect Dis 1995; 21:291–299. Githui W, Kitui F, Juma FS, Obwana DO, Mwai J, Kwamanga D. A comparative study on the reliability of the fluorescence microscopy and Ziehl-Neesen method in the diagnosis of pulmonary tuberculosis. East Afr Med J 1993; 70:263–266. Tuberculosis Prevention Trial. Trial of BCG vaccines in south India for tuberculosis prevention Bull WHO 1979; 57:819–827. Sty´blo K, Meijer J. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 1976; 57:17–43. Crofton J. The contribution of treatment to the prevention of tuberculosis. Bull Int Union Tuberc 1962; 32:643–653. Bleiker MA, Chum HJ, Nkinda SJ, Sty´blo K. Tanzania National Tuberculin Survey, 1983–1986. In: Tuberculosis and Respiratory Diseases. Singapore: Professional Postgraduate Services, 1987. WHO Expert Committee on Tuberculosis. Ninth report. Tech. Rep. Ser. 552. Geneva: WHO, 1974. Enarson DA. The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes. Tuberc Lung Dis 1995; 76:95–99. Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954; 69:724–732. International Union Against Tuberculosis and Lung Disease. Tuberculosis Guide for High Prevalence Countries. 2d ed. Paris: International Union Against Tuberculosis and Lung Disease/Misereor, 1991. Sty´ blo K. Tuberculosis control and surveillance. In: Flenley DS, Petty TL, eds. Recent Advances in Respiratory Medicine. Edinburgh: Churchill-Livingstone, 1986:77–108. Francis J. Bovine Tuberculosis Including a Contrast with Human Tuberculosis. London: Staples Press Ltd, 1947:220. Thoen CO, Richards WD, Jarnagin JL. Mycobacteria isolated from exotic animals. J Am Vet Med Assoc 1977; 170:987–990. Comstock GW. Tuberculosis—a bridge to chronic disease epidemiology. Am J Epidemiol 1986; 124:1–16.
106
Laszlo
18. Grzybowski S. Tuberculosis in the third world. Thorax 1991; 46:689–691. 19. Tuberculosis Control Programme: Report of the first meeting of the coordination, advisory and review group. Geneva: WHO, WHO/TB Carg (C1)/1991. 20. Kochi A. The role of the World Health Organization in tuberculosis. In: Reichman LB, Hershfield ES, eds. A Comprehensive International Approach, 1st ed. New York: Marcel Dekker, 1993:699–717. 21. WHO: Ad Hoc Committee on the Tuberculosis Epidemic Report, London, 1998. 22. Petroff SA. A new and rapid method for the isolation and cultivation of tubercle bacilli from the sputum and feces. J Exp Med 1915; 21:38–42. 23. Enarson DA, Rieder HL, Arnadottir T, Trébucq A. In: International Union Against Tuberculosis and Lung Disease, ed. Tuberculosis Guide for Low Income Countries. 4th ed. Frankfurt: pmi Verlagsgruppe GmbH, 1996:1–65. 24. Rieder HL, Arnadottir T, Tardencilla Gutierrez AA, Kasalika AC, Salaniponi FLM, Ba F, Diop AH, Anagonou S, Gninafon M, Ringdal T, Trébucq A, Enarson DA. Evaluation of a standardized recording tool for sputum smear microscopy for acid-fast bacilli under routine conditions in low income countries. Int J Tuberc Lung Dis 1997; 1:339–345.
5 Evaluation of Applied Strategies of Tuberculosis Control in the Developing World
PIERRE CHAULET
EARL S. HERSHFIELD
University of Algiers Algiers, Algieria
University of Manitoba Winnipeg, Manitoba, Canada
I. Introduction It is currently estimated that 95% of cases of tuberculosis and 98% of deaths due to tuberculosis worldwide occur in the developing world annually (1). The evolution of the global tuberculosis epidemic is therefore dependent on the tuberculosis-control strategies that are applied in developing countries and on their ability to respond to the needs of the most vulnerable sections of the population in each country during the next 20 years. It seems clear that in the year 2020 tuberculosis will still be, as it is today, seventh on the list of diseases principally responsible for the burden of mortality worldwide, and that during 2000–2020 the gap between rich and poor countries will only increase (2). As a result, a careful evaluation of the tuberculosis control strategies that are applied is of crucial importance, in order both to adopt the most efficient methods of containing, and then reducing, tuberculosis, and to measure the impact of these strategies. At the beginning of the 1990s, the World Health Organization (WHO) proposed two goals to be achieved by the year 2000: to cure at least 85% of smearpositive pulmonary tuberculosis cases and to detect at least 70% of existing infectious cases (1). Apart from in countries such as Tanzania, Peru, Vietnam, or Morocco, these goals (particularly the latter) will most likely not be reached by 107
108
Chaulet and Hershfield
2000 (3), mainly due to insufficient health coverage of the populations in poorer countries and to the fact that tuberculosis-control activities are not included in the “minimum package of health activities” at the district level. The current challenge is to create a global surveillance system in order to measure the evolution of the results obtained by applying these strategies and to determine exactly when—between 2000 and 2020—the WHO objectives will be achieved in each country. Since the first research activities were conducted in Africa in conjunction with the British Medical Research Council (4–6) and then under the aegis of the International Union Against Tuberculosis and Lung Disease (IUATLD) in its Mutual Assistance Program (7–9), the methods of evaluation have been refined and actively promoted on an international scale by WHO, which has for the last 2 years published the results of the applied strategies from countries that reported their data (10,11). II. Prerequisites for Evaluating a Tuberculosis-Control Strategy There are three prerequisites for evaluating a tuberculosis control strategy at the national level: the existence of a clearly defined control strategy, the existence of a network of laboratories capable of performing tuberculosis microscopy in all the country’s districts, and the implementation of an information system (registers and quarterly reports), which is essential for supervising and evaluating the activities. A. A Clearly Defined Control Strategy
Evaluation of results can only be done by respecting the norms set for the tuberculosis diagnosis and case-finding procedures and for the recommended chemotherapy regimens. The national tuberculosis program’s (NTP) technical manual should take into account the strategy recommended by WHO (1): priority given to detection of infectious cases, diagnosed by microscopic examination of the sputum of respiratory symptomatic individuals presenting spontaneously to the health services, standardized treatment of all tuberculosis cases identified using short-course chemotherapy regimens (of 6 or 8 months) under direct observation at least during the initial intensive phase of treatment and at least for infectious patients. Long-term chemotherapy regimens (of 12 months or more) no longer have a role in the modern revised strategy (13). B. A Network of Efficient, Quality-Controlled Laboratories for Smear Microscopy
In order to identify infectious cases and to monitor cure after treatment, it is essential that the patients and/or the health personnel have access to laboratories
Applied Strategies of TB Control
109
where routine, reliable smear microscopy is performed for tuberculosis. These laboratories can be located in hospitals or clinics that do not necessarily need to specialize in tuberculosis—they are for the most part multipurpose laboratories where 10–40 samples are examined per week. In general, a laboratory should be located no further than 15–20 km from the patients’ homes (or from the health post that collects the patients’ smear samples) for easy accessibility. One microscopy laboratory per 100,000 inhabitants in rural areas, or 200,000 in urban areas, can handle the needs of NTPs in high-prevalence countries. The laboratory technicians should be supervised by a technician from a higher level (intermediate, provincial, or regional level, depending on the country), and a permanent system of quality control is essential for guaranteeing the reliability of the results. C. The Information System
The information system perfected by the IUATLD and recommended by WHO should be implemented in all districts in the country, even if the revised program has not yet been set up. This information system can provide proof of the need to apply the revised strategy rapidly, as it gives better results than traditional methods. The information system is based on registers and quarterly reports (12). In the district tuberculosis register, all tuberculosis cases that begin treatment (new and retreatment cases) are recorded in chronological order. For each patient, site of disease, initial bacteriological status, and standardized chemotherapy regimen are entered. During treatment and at its completion, results of smear testing and the patient’s final status are recorded in the register, which also serves as a basis for the evaluation. In the laboratory register, patients for whom smear microscopy tests are requested (for initial diagnosis and for treatment monitoring) are recorded, as are their results before they are sent to the health service. A comparison of the results recorded in the laboratory register and the district tuberculosis register is an important task for the tuberculosis coordinator during quarterly supervisory visits in order to check or complete the data. The quarterly reports are completed every 3 months, based on data recorded in these two registers. The annual evaluation of the tuberculosis program is done by adding the results together. 1.
The report on tuberculosis case finding provides basic data for epidemiological analysis (Table 1) and allows the different rates and indicators of the case-finding activities to be calculated. 2. The report on treatment outcome analyzes the results of the treatments applied to two groups of patients: new cases of smear-positive pul-
110
Chaulet and Hershfield
Table 1
Case Notification: Data to Be Collected
Pulmonary tuberculosis Smear-positive: new cases; retreatment cases (relapses, failures, retreatment after interruption) Smear-negative Smear not done Extrapulmonary tuberculosis Total tuberculosis, all forms Distribution of new smear-positive cases by age and sex (absolute number) Age groups: 0–14, 15–24, 25–34, 35–44, 45–54, 55–64, 65 Source: Ref. 12.
monary tuberculosis recorded one year previously during the same quarter and cases of smear-positive pulmonary tuberculosis enrolled for retreatment during the same period. The patients are classified according to the six possible outcome categories observed (Table 2). The cure and success rates (addition of cases cured and cases having completed treatment without a final microscopy examination) are calculated according to the number of cases recorded the previous year. 3. The report on program management provides a synthesis of the information on the application of the program (distribution of recorded tuberculosis cases according to type of treatment, rate of smear conver-
Table 2 Definitions of Treatment Outcome in Smear-Positive Pulmonary Tuberculosis Patients Cure Treatment completed Treatment failure Died Treatment interrupted (default) Transfer out Source: Refs. 11, 12.
Patient who is smear-negative at (or one month prior to) the completion of treatment and on at least one previous occasion Patient who has completed treatment but without bacteriological proof of cure Patient who remains or becomes again smear-positive at 5 months or later during treatment Patient who dies for any reason during the course of treatment Patient whose treatment was interrupted for 2 months or more any time after registration Patient who has been transferred to another reporting unit and for whom the treatment outcome is not known
Applied Strategies of TB Control
111
sion at the second or third month for initially positive cases) and on the stocks of antituberculosis drugs and laboratory reagents used. III. Evaluation of the Strategies Applied in Tuberculosis Treatment A. Basic Method: Patient Cohort Analysis
The basic method of evaluation is cohort analysis of patients with pulmonary tuberculosis. Patients with extrapulmonary tuberculosis do not form a homogeneous enough group, because the criteria for diagnosis and cure differ depending on the site of the disease. The cohort consists of all patients recorded consecutively with smear-positive pulmonary tuberculosis who have received (or should have received) the same chemotherapy regimen. This is why, when the chemotherapy regimens are standardized, at least two patient cohorts are analyzed: New patients who have never been treated or who have received treatment for less than one month, and who have been prescribed a primary treatment regimen of 6 or 8 months, depending on the national program guidelines Previously treated cases (failures, relapses, or retreatment after interruption) who have been prescribed the 8-month retreatment regimen recommended by the national program When regimens other than short, standardized chemotherapy are used, they are analyzed separately. In the cohort analysis performed to evaluate the treatment strategies applied in an NTP, several points need to be highlighted: Contrary to the evaluation of a chemotherapy regimen, where cohort analysis excludes those patients who have not received treatment as prescribed, thus reducing the number of different rates to only those cases that can be analyzed, the evaluation of a treatment program (cure rate, success rate) uses the number of cases recorded in the district tuberculosis register one year before as the denominator of all the indicators (10). The patients recorded who have not begun treatment and are not known to have died or to have been transferred are classified as “defaulters before treatment” (13). Treatment Outcome
The results of treatment are interpreted according to the patients’ final status and the duration of treatment. The basic criteria are the cure rate (proportion of pa-
112
Chaulet and Hershfield
tients recorded who can be defined as cured at the end of treatment) and the success rate (proportion of patients who correspond to the definitions “cured” and “treatment completed without smear examination at the end of treatment”). The other rates (failure, death, default, and transfer) are used to identify the priority measures that need to be taken in order to improve the success rate. The main interest of the cohort analysis is to provide, for each district, a complete evaluation of the results of tuberculosis treatment based on the addition of the individual results observed for each patient. As described and recommended by WHO this permits a comparison of the results obtained within a country as well as between countries or groups of countries. Supervision Enhances the Validity of the Method
When the district coordinators are left to their own devices and are required to report the data collected in the registers (which they themselves have filled in), certain types of bias can appear in the patient cohort analysis: Bias in patient selection due to errors in recording (smear-negative mistakenly recorded as smear-positive, or vice versa) or errors in classification into treatment category (old cases and new cases). Bias in the data on the treatment actually received by the patients (treatment cards not completed; errors of dosage in the prescriptions; minor interruptions in taking treatment; absence of interviews with the patients by an external observer from the district). Bias in the final distribution of results into the six groups: confusion between “cured” and “treatment completed” and between “treatment interrupted” and “transferred out.” These errors are more frequent when the evaluation results might be perceived to have an influence on health staff assessment and eventual professional promotion or advancement (14). These different types of bias can be corrected or minimized when the district coordinators receive regular visits from supervisors from a higher administrative level (department or province) and when the data recorded in the district register and the laboratory register and the treatment cards are checked at least quarterly. Another bias may be due to the uneven quality of the results provided by the microscopy laboratory in the districts. This bias can be reduced by organizing a permanent, centralised system of quality control for smear examination. The effect of supervisory visits on treatment results was demonstrated in Algeria (15), where the results observed in two groups of districts equal in size and population coverage were compared. In the districts that were supervised regularly, not only was case finding more effective, but treatment success rate reached 83%, compared to a rate of only 70% in the districts that were not supervised (Table 3).
Applied Strategies of TB Control
113
Table 3 Treatment Results: Evaluation of a National Representative Sample of 719 New Smear-Positive Tuberculosis Cases Treated with a 6-Month Regimen in Algeria Patient status 6 months after end of treatment Patients assessed
Cured
Completed treatment
Failed
Died
Lost
Transferred out
503 216 719
69.8 48.5 63.3
13 22.2 16
2.5 2 2.3
2.2 2.3 2.2
6.5 12 8.2
6 13 8
Districts supervized Districts not supervized Total districts Source: Ref. 15.
Results International
In 1997, 181 of the 212 WHO member states reported their treatment results for patient cohorts recorded in 1995; 97% of the world’s population lives in these countries, and all of the most populated countries (more than 40 million inhabitants) provided data. Of these 181 member states, 164 are developing countries (11). Approximately half of the countries provided interpretable results and had implemented the WHO-recommended strategy more or less fully. Of the 96 countries that adopted the WHO strategy, 91 are developing countries. In 1995 in all countries and in all regions of the world there were zones where the WHO strategy was applied and others where it was not yet applied. One can observe that where the WHO strategy was applied (Table 4) the majority of recorded cases are evaluated (94% versus 55%), with a success rate of 78%, as opposed to only 45% in zones where it was not applied. Developing Countries
Data collected during the period 1995–1997 in certain countries where HIV prevalence among tuberculosis patients is high (Ivory Coast, Democratic Republic of Congo), moderate (Guinea, Djibouti), or low (Morocco, the Philippines) (16–21) confirm worldwide trends (Table 5). Success rates of 78–86% are observed in zones where the strategy is applied and are lower in Djibouti, where a large proportion of the population is highly mobile (50% of patients are foreigners from neighboring countries). A variety of surveys (in Djibouti, Congo, and the Ivory Coast) have shown that the death rate is higher in HIV-positive than among HIVnegative tuberculosis patients. A success rate of 85% can therefore be obtained in program conditions in developing countries except when HIV seroprevalence is very high (12), in which case the success rate is about 75–80%.
114
WHO non-WHO WHO non-WHO WHO non-WHO WHO non-WHO WHO non-WHO WHO non-WHO WHO non-WHO
AFR
105, 245 71, 312 53, 517 74, 945 18, 138 28, 302 4, 732 28,702 26, 574 291, 836 152, 274 143, 970 360, 480 639, 067
15 8 8 57 1 2 13 14 4 68 1 22 6 45
Not evaluated 52 38 69 22 69 51 50 60 66 4 89 43 72 23
Cured (%) 10 19 8 10 13 23 19 7 8 25 2 26 6 22
Treatment completed (%) 10 14 6 6 9 15 7 4 12 1 2 5 6 5
Defaulted (%) 1 2 1 1 1 5 2 7 2 0 1 1 1 1
Failed (%) 7 6 5 2 2 1 7 6 4 0 2 2 4 2
Died (%)
5 14 3 2 5 4 2 2 4 1 3 2 3 3
Transferred out (%)
62 57 77 31 83 73 69 57 74 29 91 68 78 45
Treatment success rate (%)
AFR Africa Region; AMR America Region; EMR Eastern Mediterranean Region; EUR European Region; SEAR Southeast Asia Region; WPR Western Pacific Region. Source: Ref. 11.
Global
WPR
SEAR
EUR
EMR
AMR
Strategy used
Number of smear-positive cases registered
Treatment outcome
Treatment Outcome by WHO Region and Applied Strategy of Tuberculosis Control, 1995
WHO region
Table 4
115
WHO HIV HIV Total WHO (pilot areas)
WHO
a HIV seroprevalence in patients 39%. Source: Refs. 16–21.
Philippines (1996–1997)
8052 8195 2158
WHO non-WHO WHO
550 5636 7086 769
14 621
63.5
7221a
non-WHO
52.4 64.7 63.8 82.3
79.2
63.9 46 58
Cured (%)
Strategy applied
No. of smear-positive cases assessed
7 6.5 6.6 1.4
6.8
15.9 23 20
6
Treatment completed (%)
Treatment outcome
11.1 2.1 2.8 2.6
2
5.5 5.2 7
4.4
Died (%)
0.5 0.9 0.8 2.2
1
1.4 1.3 3
1.5
Failed (%)
Treatment Outcomes in Certain Countries by Tuberculosis-Control Applied Strategy
Ivory Coast (1995) Dem. Rep. of Congo (1995) Guinea (1994) Morocco (1994) Djibouti (1990–1995)
Country
Table 5
29 25.8 26 8.2
5
8.3 11.2 10
17.6
Treatment interrupted (%)
3.3
6
5 13.3 3
7
Transferred out (%)
59.4 71.2 70.4 83.7
86
79.8 69 78
69.5
Treatment success rate (%)
116
Chaulet and Hershfield B. Surveillance of Mycobacterium tuberculosis Resistance to Antituberculosis Drugs
An indirect method of evaluating the tuberculosis-treatment strategies applied is to monitor the evolution of bacterial resistance to antituberculosis drugs in representative patient samples on a regular basis. A direct link exists between the quality of chemotherapy applied in the community (efficacy of the regimens selected and quality of patient monitoring during treatment) and the rate of drug resistance (22). The more ineffective and poorly observed the chemotherapy regimens are, the higher are the rates of acquired drug resistance among previously treated patients who present after treatment failure, relapse, or premature interruption of treatment. The higher the proportion of already (and poorly) treated patients in the community, the greater will be the risk of transmission of resistant bacilli to new patients, and consequently the risk of witnessing the appearance of high rates of primary resistance among never-treated patients. These facts have once again been demonstrated in the WHO/IUATLD study of the surveillance of drug resistance in the world (23). Treatment Strategies and Evolution of Drug Resistance in Korea
The results of treatment were monitored in Korea for all smear-positive pulmonary tuberculosis patients treated by the public health services from 1983 to 1995 (24). In 1983–1984, the main primary treatment consisted of an 18-month regimen combining isoniazid and ethambutol, with a daily or intermittent supplement of streptomycin. From 1985 to 1990, primary treatment consisted of a 9month regimen with isoniazid, rifampicin, and ethambutol. Since 1991, the primary treatment generally applied is a 6-month regimen combining isoniazid and rifampicin, supplemented by pyrazinamide and streptomycin (or ethambutol) during the first 2 months. The success rates increased from 61–65% in the first period to 69–78% in the second, and reached 82% in the final period. The failure rates fell gradually from 10% in 1983 to 2% since 1989, as did the default rate. At the same time, the proportion of already treated patients among all smear-positive cases started on treatment fell from 47.2% in 1980 to 25.4% in 1994. The prevalence of primary drug resistance (23.8% in 1980, 5.8% in 1995), measured during the prevalence surveys (25), fell as the treatment strategy improved in efficiency (Table 6). Treatment Strategies and Evolution of Drug Resistance in Algeria
In Algeria, a similar pattern was observed (26–28). From 1965 to 1970, the chemotherapy routinely applied was not standardized, and the regimen that was generally prescribed consisted of isoniazid, PAS (para-aminosalicylic acid), and streptomycin for 12–18 months.
Applied Strategies of TB Control Table 6
117
Prevalence of Drug Resistance in Korea
Prevalence survey
Old cases tested
1975 1980 1985 1990 1995
45 55 70 35 28
Resistant strains n
(%)
New cases tested
33 41 41 19 7
(73.3) (74.5) (58.6) (54.3) (25.0)
143 63 100 78 103
Resistant strains n
(%)
39 15 19 12 6
(27.3) (23.8) (19.0) (15.4) (5.8)
Source: Ref. 25.
From 1970 treatment was standarized, using the same drugs for 12 months, until 1980 (rifampicin was used exclusively for retreatment cases). From 1980, short-course chemotherapy was applied nationwide and consisted of 6 months of daily isoniazid and rifampicin, supplemented with streptomycin and pyrazinamide during the first 2 months. The success rates, measured by cohort analysis, rose from 54% in 1971 (28) to 65% in 1977, 78% in 1983, and 84% in 1988 (27), with a corresponding drop in the failure and default rates. During this time drug resistance prevalence was monitored in the national reference laboratory. The fall in resistance rates, which had begun as soon as treatment was standardized, accelerated when the more effective short-course chemotherapy came into general use (Table 7). A Complementary Method
Drug-resistance surveillance is a method of epidemiological surveillance that provides information on the treatment strategy applied in the community in recent
Table 7
Prevalence of Drug Resistance in Algeria
Years
Old cases tested
1965–1970 1971–1979 1980–1985 1986–1990 Source: Refs. 26, 27.
858 1490 606 408
Resistant strains n
(%)
New cases tested
703 917 145 86
(81.9) (61.5) (35.7) (21.0)
145 825 805 1111
Resistant strains n
(%)
217 83 51 58
(15) (10.1) (6.3) (5.2)
118
Chaulet and Hershfield
years. As a result it complements cohort analysis and provides confirmation of the results. However, the implementation of this kind of surveillance system is not simple. It requires close coordination between the tuberculosis program and the national reference laboratory, and a rigorous methodology: quality control of susceptibility testing, selection of a representative patient sample, and reporting of reliable information on previous treatment by the clinicians (23). Finally, the impact of a good treatment strategy on the rate of primary resistance becomes apparent only 3–5 years after its implementation. C. An Alternative Method: The Prospective Survey
To evaluate the applied treatment strategy with more precision, it is possible to conduct community-based prospective surveys. These surveys, which are more costly and can be conducted at intervals of 5–10 years, confirm or clarify the results of cohort analyses performed regularly during the running of the program. They provide more complete information on the quality of initial diagnoses, on drug resistance prevalence, on the quality and regularity of treatment, and on treatment results (depending on the regimens used and the results of initial susceptibility testing) at the end of treatment and after follow-up. The main measurement consists of centralizing, in a reference laboratory, all sputum smear samples collected before, during, and after treatment (samples taken in addition to those examined locally) in order to obtain complete, comparable results (including culture and susceptibility testing). X-rays taken before and after treatment are also centralized and interpreted by an independent reader. This method was applied in Algeria under routine conditions to evaluate two short-course regimens of different durations (6 and 8 months). The bacteriological data collected in a single reference laboratory were analyzed. The survey continued for 4 consecutive years in 30 districts, covering a population of about 4 million (29,30). The cure rate 2 years after completion of treatment by 2218 patients was 86.5%, with no major differences observed between the two regimens. The percentage of patients who needed an additional course of chemotherapy was 2.3%, and the rate of persistent positive cultures (chronic cases) was only 1.5% (Table 8). Despite its usefulness, this type of survey has a number of limitations: Districts participating in the study must have access to a central reference laboratory. Sufficient health staff must be available (clinicians, bacteriologists, local surveyors, secretarial staff) to undertake the coordination of the survey and district supervision. It needs adequate financing to cover the costs of coordination and supervision.
Applied Strategies of TB Control
119
Table 8 Results of Evaluation of Smear-Positive New Cases Initially Treated by Short-Course Chemotherapy Regimens Under National Programme Conditions Regimen initially prescribed Results 2 years after end of chemotherapy Negative cultures After 18th month Between end of treatment and 18th month Completed treatment without control since end of treatment Positive cultures when last seen after end of treatment Deaths Total
6 months
8 months
Patients analyzed
n
%
n
%
678 (16)
69
810 (18)
66
1488 (34)
174 (3)
18
258 (4)
20
432 (7)
19.5
7
101 (1)
8
167 (1)
7.5
66
13 (2) 46 977 (21)
1 5 100
22 (7) 50 1241 (30)
2 4 100
n
35 (9) 96 2218 (51)
% 67
1.5 4.5 100
Numbers in parentheses refer to patients who have received an additional course of chemotherapy for failure, relapse, or development of a nonpulmonary lesion. Source: Refs. 29, 30.
In the evaluation of treatment strategies, cohort analysis performed routinely for all tuberculosis cases recorded is therefore the essential, and the optimal, method, which can be applied in all situations in the developing world. IV. Evaluation of Strategies Applied in the Detection of Tuberculosis Cases Evaluation of the strategies applied in case detection is generally based on data collected by the public health services and by approved health structures that have adopted the same system of notification. In many countries it is unusual for the profit-making private sector to report tuberculosis cases detected in private clinics. A. Sources of Information
Three information sources need to be consulted in each district: 1. The consultation registers in the primary health services, where all care seekers are recorded by age, sex, and reason for their visit
120
Chaulet and Hershfield 2. The register of the laboratory where tuberculosis microscopy is performed, in which are recorded the numbers of suspects for whom one or more smear tests have been requested for diagnosis 3. The district tuberculosis register, in which all identified tuberculosis cases are recorded
Based on these registers, the quarterly reports on tuberculosis case finding and program management are completed every 3 months. By adding together the quarterly reports, the annual incidence of tuberculosis cases can be calculated, as can the different rates and indicators associated with case-finding activities. B. Indicators
The indicators that need to be collected are used not only to show the results of case finding, but also to analyze the procedures leading to case detection, which involves all of the basic health services. The data that should be collected on a quarterly and annual basis are the following: The number of patients seeking care The number of adults presenting with respiratory symptoms The number of adults with respiratory symptoms suggestive of tuberculosis The number of smear microscopy tests performed for tuberculosis suspects The number of cases of pulmonary (smear-positive or smear-negative) and extrapulmonary tuberculosis recorded. From this information two series of indicators can be calculated. Indicators of the case-finding process consist of: 1. The proportion of adults (aged 12 years or 15 years) presenting with respiratory symptoms among the totality of care seekers. This varies from 15 to 30% in developing countries; it is higher among children under 5 years. 2. The proportion of tuberculosis suspects among the totality of adults presenting with respiratory symptoms (this proportion differs according to whether or not x-ray is used for selection of tuberculosis suspects). 3. The proportion of tuberculosis suspects, among all of the tuberculosis suspects selected, who have undergone three sputum smear examinations. This proportion should be over 90%, to increase the chances of detecting infectious cases. These indicators reflect the ability of the staff of the basic health services to identify tuberculosis suspects and to send the necessary samples to the laboratory for diagnosis of pulmonary tuberculosis.
Applied Strategies of TB Control
121
Performance indicators in case detection (12) consist of: 1. The proportion of smear-positive cases among all tuberculosis suspects. This proportion can vary depending on the criteria used to identify suspects: duration of the symptoms presented by the patients, confirmation by the number and type of medical examinations (e.g., x-ray). If the respiratory symptoms presented by the patient are the only criterion for inclusion as a tuberculosis suspect, the proportion will be on average 10% (range 5–15%). 2. The proportion of new smear-positive pulmonary cases out of all new pulmonary cases (smear-positive, smear-negative, and smear not done) recorded. This should be at least 65% of cases. If it is less than 65%, the diagnosis of pulmonary tuberculosis (by microscopy and/or radiology) is of poor quality. The proportion can reach 80% (range 75–85%) if radiological facilities are used appropriately and if smear microscopy is repeated (at least two series of three smear examinations for those tuberculosis suspects who have three negative smears in the first series). A lower proportion can be observed in HIV-positive patients, particularly at later stages of AIDS. However, even in African countries with high HIV prevalence, the overall proportion of smear-positive cases is frequently over 65%. 3. Ratio of new smear-positive cases to new smear-negative and extrapulmonary cases. This ratio is approximately 1:1 in the developing world, due to the large numbers of extrapulmonary cases. 4. Reported case-notification rate for new smear-positive cases (per 100,000 population). This rate is usually calculated annually. The numerator is the number of new smear-positive cases registered in a year from within a defined population (district, region, or country). The denominator is the estimated total midyear population of that district, region, or country. An estimated incidence rate is used in program planning (e.g., to estimate drug needs). The reported case-notification rate of new smear-positive cases by age and sex is the number of new smear-positive cases detected in specific age and sex groups per 100,000 population; it provides information on the trend of tuberculosis in a specific country over the years. C. Results
At the global level, as at a national level, the notification of tuberculosis cases of all forms has only an indicative value: the wide variations from one year to the next have a number of explanations, and in general, radiology is used more for diagnosis than as a means of selection (11).
122
Chaulet and Hershfield
Nevertheless, in regions where there are a number of developing countries, the proportion of new smear-positive cases among the totality of newly notified cases of pulmonary tuberculosis can be compared. It can therefore be observed that in countries or regions where the WHO strategy has been applied, the proportion of new smear-positive pulmonary cases is higher than in those where it has not (Table 9). Regular supervision of case-finding activities in the districts can have a considerable impact on results (15). During a retrospective study of a representative sample of 52 districts in Algeria for the year 1984, case-finding results were compared. It was observed that the public health services were delivered in out-patient clinics at the same rate to patients in both groups of districts (one regularly visited for supervision of activities, and the other not visited); however, in the supervised group, individuals with suspected tuberculosis were selected at a much higher rate, the number of smear examinations was 46% higher, and the number of cases identified was twice that of the nonsupervised districts (Table 10). D. How to Detect 70% of Existing Infectious Tuberculosis Cases
Although the aims of the treatment strategy are simple, those of the detection strategy are much more difficult both to reach and to measure. Reaching the case-de-
Table 9 Proportion of New Smear-Positive Pulmonary Cases Out of All New Pulmonary Cases by Region, 1996
WHO region AFR AMR EMR SEAR WPR
Tuberculosis-control strategy
No. of new smear-positive cases notified
New smear-positive/New pulmonary cases (%)
WHO non-WHO WHO non-WHO WHO non-WHO WHO non-WHO WHO non-WHO
155, 146 93, 833 52, 220 81, 773 21, 651 36, 499 51, 075 322, 044 206, 582 146, 592
65 32 70 64 76 45 64 25 68 27
AFR Africa Region; AMR America Region; EMR Eastern Mediterranean Region; SEAR Southeast Asia Region; WPR Western Pacific Region. Source: Ref. 11.
Applied Strategies of TB Control
123
Table 10 Influence of Supervision Activities of Health Staff on Case-Detection Results Health districts (n 52)
Population covered Adjusted population Outpatients attending health services (per year) Number of smear examinations performed in suspects Number of smear-positive pulmonary tuberculosis cases identified
With periodic supervision of activities (n 27)
Without periodic supervision of activities (n 25)
3.4 million 100,000
3.2 million 100,000
68,578
65,713
1,910
1,302
47
24
Source: Ref. 15.
tection rate of 70% of infectious cases depends on a number of variables, particularly the health coverage of the population, the population’s means of communication with and accessibility to the health services, and the ability of health workers to select tuberculosis suspects and to identify cases of smear-positive pulmonary tuberculosis. Estimation of Existing Cases from the Annual Risk of Tuberculous Infection
Until recently this estimation was based on data published in 1993 by the World Bank (31), with adjustments for those countries that had more recent information available (11). It is based on tuberculin surveys conducted in different countries, at different times, using different methodologies (the threshold of positivity of tuberculin reactions varied from one period to the next, due to the growing use of BCG vaccination). Tuberculin surveys that are done well are still an important tool for monitoring the trend of tuberculosis in a country (32). However, they rarely provide a clear picture of the situation at the provincial or district level, and as a result they can only estimate case-finding objectives on a national basis. Furthermore, the spread of the HIV/AIDS epidemic in many African countries has resulted in a considerable increase in numbers of cases, well above the numbers that were predicted, based on the annual risk of tuberculous infection (33,34).
124
Chaulet and Hershfield A Pragmatic Approach
While awaiting the creation of new epidemiological methods that will allow us to calculate, country by country, the number of cases expected annually for the next decade, a pragmatic approach has been adopted in several developing countries, based on the demonstration and training areas where the WHO strategy has been implemented. We know that in all countries the incidence varies from 1 to 4, depending on the district. Based on the make-up of the districts of a particular country (urban/rural, high/low population density, accessibility and effectiveness of the health services), we can establish goals for case detection for a limited period, based on the results of case-finding activities in the most efficient districts in each group of similar districts. This pragmatic approach means that realistic goals can be set and that the WHO strategy can be extended from those that were initially selected as demonstration and training areas for the program (12). V. Conclusion The strategies for tuberculosis control that are applied in the developing world are still quite varied. They are gradually being simplified and standardized as the WHO strategy becomes more widely accepted and implemented. However, the aims of tuberculosis control cannot be reached if a broader sectorial approach to health activities is not envisaged (35). As long as health coverage extends to no more than 50% of the population, as occurs in many developing countries, it is an illusion to imagine that rapid progress can be made in tuberculosis control. As long as the activities defined by national tuberculosis programs are not fully integrated into the “minimum package of health activities,” it will be impossible to detect and treat tuberculosis patients in rural and periurban areas that are neglected, and particularly in the most vulnerable sections of the population. As long as peripheral district health activities do not receive support from the intermediate and central levels, with a strong technical structure and an adequate budget, so-called integration will remain an empty concept, devoid of any meaning. References 1.
WHO Tuberculosis Programme. Framework for Effective Tuberculosis Control. WHO/TB/94.179. Geneva: WHO, 1994. 2. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press, 1996. 3. Raviglione MC, Dye C, Schmidt S, Kochi A. Assessment of worldwide tuberculosis control. Lancet 1997; 350:624–629.
Applied Strategies of TB Control
125
4. Kenyan-British Medical Research Council Cooperative Investigation. Tuberculosis in Kenya: a third national survey and a comparison with earlier surveys in 1964 and 1974. Tubercle 1989; 70:5–20. 5. Tanzanian-British Medical Research Council Cooperative Investigation. Tuberculosis in Tanzania: a national survey of newly notified cases. Tubercle 1985; 66:161–178. 6. Bignall JR, Leal Gonsalves A, Cabral J, Anastasatu C, Mihailescu P, Gartner A, Chaulet P. Enquêtes nationales sur les résultats du traitement de la tuberculose en pratique quotidienne. Bull Union Int Tuberc 1979; 54:37–48. 7. Broekmans JF. Control strategies and programme management. In: Porter JDH, McAdam KPWJ, eds. Tuberculosis, Back to the Future. Chichester: John Wiley and Sons, 1994:171–188. 8. International Union Against Tuberculosis and Lung Disease. Type of collaboration provided by IUATLD to national tuberculosis programmes in developing countries. In: IUATLD Tuberculosis Surveillance Research Unit Progress Report. The Hague: TSRU, 1987; Vol. 2:138–140. 9. Styblo K. IUATLD assisted National Tuberculosis Programmes in developing countries. In: IUATLD Tuberculosis Surveillance Research Unit Progress Report. The Hague: TSRU, 1987; Vol 2:102–105. 10. World Health Organization Global Tuberculosis Programme. Global Tuberculosis Control Report 1997. Geneva; WHO, 1997 (WHO/TB/97.225). 11. World Health Organization Global Tuberculosis Programme. Global Tuberculosis Control, WHO Report 1998. Geneva: WHO, 1998 (WHO/TB/98.237). 12. World Health Organization Global Tuberculosis Programme. Managing tuberculosis at national level. Geneva: WHO, 1996 (WHO/TB/96.203). 13. Maher D, Chaulet P, Spinaci S, Harries AD. Treatment of Tuberculosis: Guidelines for National Programmes. 2d ed. Geneva: World Health Organization, 1997 (WHO/TB/97.220). 14. Chaulet P, Zidouni N. Evaluation of applied strategies of tuberculosis control in the developing world. In: Reichman LB, Hershfield ES, eds. Tuberculosis, A Comprehensive International Approach. 1st ed. New York: Marcel Dekker, Inc., 1993:601–627. 15. Berkani M, Aït-Khaled N, Bouchahda K. Les mesures techniques de la lutte antituberculeuse. In: Chaulet P, ed. L’organisation de la lutte antituberculeuse en Algérie. Soc Alger Pneumophtisiologie 1985:75–77. Ed Un Med Alg, 1985. 16. Revue du programme de lutte antituberculeuse en République de Côte d’Ivoire. Abidjan-Genève: WHO, 1997. WHO/TB/98. 17. Programme antituberculeux intégré de la République Démocratique du Congo. Données statistiques du Bureau Central de la Tuberculose, Kinshasa, 1997. 18. Revue du programme de lutte antituberculeuse de la République de Guinée. ConakryGenève: WHO, 1995. WHO/TB/96/201. 19. Revue du programme de lutte antituberculeuse au Maroc. Rabat-Genève: WHO, 1996. WHO/TB/96/206. 20. Revue du programme de lutte antituberculeuse de la République de Djibouti. WHO/TB/97/226. Geneva: WHO, 1996. 21. Results of DOTS strategy in demonstration areas. Tuberculosis Control Services, Department of Health, Manila, Philippines, 1997.
126
Chaulet and Hershfield
22. Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and how? Tubercle Lung Dis 1995; 76:487–492. 23. World Health Organization Global Tuberculosis Programme. Antituberculosis drug resistance in the world. The WHO/IUATLD Global project on antituberculosis drug resistance surveillance 1994–1997. Geneva: World Health Organization, 1997 WHO (WHO/TB/97.229). 24. Hong YP, Kim SJ, Lew WJ, Lee SH, Lee EK. Cohort analysis of the treatment of smear-positive pulmonary tuberculosis patients under programme conditions in Korea, 1983–1994. Int J Tuberc Lung Dis 1998; 2:365–371. 25. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea. Int J Tuberc Lung Dis 1998; 2:27–36. 26. Boulahbal F, Khaled S, Tazir M. The interest of follow-up of resistance of the tubercle bacillus in the evaluation of a programme. Bull Int Union Tuberc Lung Dis 1989; 64(3):23–25. 27. Chaulet P. Tuberculose et transition épidémiologique: le cas de l’Algérie. AnnInstitut Pasteur–Actual 1993; 4:181–187. 28. Cheikh El Ghanami Z. L’organisation de la chimiothérapie de la tuberculose en Algérie. Résultats d’une enquête nationale menée en 1971. Thèse de Doctorat en Médecine, Université d’Alger, Algiers, 1971. 29. Algerian Working Group/British Medical Research Council cooperative study. Short course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks’ duration in Algeria. Tubercle 1991; 72:88–100. 30. Zidouni N, Chaulet P. Evaluation of the treatment results of pulmonary tuberculosis in a community survey in Algeria, including the comparison of two (6-month and 8month) short course chemotherapy regimens. In: IUATLD Tuberculosis Surveillance Research Unit. Progress report. Vol. 1. The Hague: TSRU, 1991:29–44. 31. World Bank. World Development Report 1993. Investing in Health. New York: Oxford University Press, 1993:3491. 32. Arnadottir T, Rieder HL, Trébucq A, Waaler HT. Guidelines for conducting tuberculin skin test surveys in high-prevalence countries. Tuberc Lung Dis 1996; 77(suppl 1):1–20. 33. Rieder HL. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuberc Lung Dis 1995; 76:114–121. 34. Menzies D. Tuberculin surveys—Why? Int J Tuberc Lung Dis 1998; 2:263–264. 35. Chaulet P. After health sector reform, whither lung health? Int J Tuberc Lung Dis 1998; 2:349–359.
Part Two BASIC ASPECTS
6 Epidemiology of Tuberculosis
GEORGE W. COMSTOCK School of Hygiene and Public Health Johns Hopkins University Baltimore, Maryland
I. Introduction Tuberculosis is still a leading contender for the dubious distinction of being the most important plague of humankind. The World Health Organization (WHO) has estimated that in 1990 7.5 million people had tuberculosis and that there were 2.5 million deaths due to tuberculosis (1). Accentuating the impact of tuberculosis on the world’s well-being is its concentration among young adults throughout most of the developing world and its airborne spread from person to person, especially to household members. As noted in Chapter 1, tuberculosis has been exacting a toll for many centuries. Of particular interest from an epidemiological point of view is the reported frequency of skeletal lesions suggestive of tuberculosis among pre-Columbian populations of North America (2). While such lesions were occasionally noted in skeletons of the Late Woodland peoples (800–1050 A.D.), their successors, the Mississippians, had a much higher frequency of tuberculosis-like bony lesions, associated with their coming together in larger and relatively permanent settlements. That tuberculosis and crowding go together is now so generally accepted that the reason(s) for the association is rarely considered. Is it solely because crowding increases the risk of becoming infected if infectious cases are present? 129
130
Comstock
Is it because there is something associated with crowding that makes it more likely that an infected person will develop tuberculous disease? Is it some combination of these sets of risks? Answers to these questions comprise the etiological epidemiology of tuberculosis. This chapter will first address etiological epidemiology by reviewing what is known about risk factors for becoming infected with tubercle bacilli, then risk factors for developing disease given that infection has occurred, and finally risk factors for relapse following apparent cure or spontaneous healing of the disease. This approach is consistent with the oft-stated goals of tuberculosis control: (1) prevent the uninfected from becoming infected; (2) prevent the infected from developing tuberculous disease; and (3) prevent relapse, disability, and death among those who have tuberculosis. Administrative epidemiology will then be reviewed. This aspect of epidemiology deals with the occurrence of tuberculosis based on routine reporting or special surveys. These data are vital for tuberculosis control workers and other persons interested in health policy, who must know the distribution of cases by time, place, and personal characteristics regardless of the cause of these distributions. II. Etiological Epidemiology A. Risk of Becoming Infected with Tubercle Bacilli
Causes of Tuberculous Infection
Three related organisms—Mycobacterium tuberculosis, M. africanum, and M. bovis—are the necessary causes of tuberculosis. M. tuberculosis is by far the most common. M. africanum is rarely found outside of northwestern Africa, and disease due to M. bovis is limited in developed countries by widespread pasteurization of milk and in the developing world by the low consumption of milk along with the practice of boiling much that is consumed. The probability of having been infected with one of the three tubercle bacilli is assessed by the size of induration caused by the tuberculin test (see Chap. 12). Risk of Infection by Time and Place
The best estimate of the decrease in the risk of becoming infected for residents of the United States comes from the extensive and carefully standardized tuberculin testing of Navy recruits (3,4). Among white males aged 17–21 years, the proportion of positive reactors fell from 6.6% in 1949–51 to 3.1% in 1967–68. Subsequent testing on a routine basis showed the prevalence of positive reactors among all recruits to be 1.5% from 1980 to 1986 and to have risen to 2.5% in 1990 (5). While the mean age of recruits had probably changed little since 1950, the two later study populations included sizable proportions of nonwhites, who in the earlier study had much higher proportions of infected persons than the white recruits. In addition, the
Epidemiology
131
positive reactors throughout this entire period undoubtedly included some who were infected with nontuberculous mycobacteria and not with M. tuberculosis. Correcting for this mixture of infections led to an estimate that only 1.4% of the white male recruits tested in 1968 had been infected with M. tuberculosis (4). Very little is known about the prevalence of positive tuberculin reactions among adults in the United States. The only data that might be considered representative of the total adult population come from the first Health and Nutrition Examination Survey in 1971–1972. Among 1494 adults aged 25–74 years, 16.1% were classified as reactors (6). The likelihood of having been infected among household contacts of infectious cases of tuberculosis has also declined with time, at least in the United States (7). In Williamson County, Tennessee, in the period 1931–55, 67% of household contacts aged 5–9 years were positive tuberculin reactors. In a large study of contacts in 1958, this proportion was 48%. In 1996, only 17.7% of children under the age of 15 years who were household contacts of pulmonary tuberculosis cases were positive tuberculin reactors (8). It is believed that the risk of becoming infected has been declining throughout most of the world, most rapidly in industrialized nations and least in sub-Saharan Africa and the Indian subcontinent, where the annual rate of decline is estimated to be less than 3% per year (9). Reasonably good estimates can be obtained in countries where there are enough children and young adults who have not been vaccinated with bacille Calmette-Guérin (BCG) to allow the risk to be estimated (10,11). For example, in the Netherlands the risk of becoming infected was 0.5% per year in 1950 and only 0.02% in 1971. In contrast, several African countries had an estimated risk of becoming infected of 3.0% per year in 1950, with only a slight decrease during the next 20 years. Similar findings were reported from a rural area of South India (12). Among children 1–4 years of age at the initial examination, the average annual risk of infection during the next 4 years was estimated to be 2.8% with some evidence of a decrease during the 4-year period. The most dramatic decrease in the risk of infection was documented among the Inuit residents of the Yukon and Kuskokwim river deltas in Alaska (13). In 1949–51, 62% of children aged 0–6 years were infected with tubercle bacilli, equivalent to an average annual risk of becoming infected of approximately 25% per year. An intensive program of case finding and treatment, supplemented by isoniazid preventive therapy, was instituted. By 1963–64, only 2.4% were infected, and in 1969–70 there were only two reactors among 1535 tested children in this age group. Personal Risk Factors for Acquiring Infections Degree of Contact and Intensity of Exposure
Because tuberculosis is a communicable disease primarily spread by the airborne route, it is not surprising that the risk of an uninfected person becoming infected
132
Comstock
is strongly associated with the probability of coming in contact with someone with infectious tuberculosis, the closeness or intimacy of that contact, its duration, and the degree of infectiousness of the case. Crowding increases both the likelihood of coming into contact with a case and the closeness of the contact. The Navy recruit testing program illustrates the risk associated with urban or rural residence for white males aged 17–21 years (3). Lifetime residents of metropolitan areas had a prevalence of positive tuberculin reactions of 4.2%; lifetime residents of farms, 2.8%; and lifetime residents of other nonmetropolitan areas, an intermediate 3.6%. The associations of infection risk with closeness of contact, with factors related to race, and with the degree of infectiousness of the source case are shown in Table 1 (14). In the Canadian provinces of British Columbia and Saskatchewan, Indian contacts were more likely to have been infected than whites, probably because Indian households were more crowded. For both Indians and whites, infection risk was greater if the contact was intimate (e.g., household associates or sweethearts) than if it was casual (e.g., other friends, fellow employees). If sputum of the source case contained so many tubercle bacilli that they were demonstrable by microscopic examination of a stained sputum smear, the risk of infecting a contact was also greatly increased. In this population, there was only equivocal evidence that cases with positive sputum cultures were more infectious than those with negative cultures. In other populations, the infectiousness of cases with positive sputum cultures was appreciably greater than those with negative cultures (15). Other characteristics of the source case are related to the prevalence of positive tuberculin reactions among children who are household contacts (14). Extent of pulmonary involvement was strongly associated with infectivity: 62% of contacts of cases with far advanced disease were reactors compared to only 16% reTable 1 Age-Adjusteda Percentages of Positive Tuberculin Reactors Among White and Indian Children Aged 0–14 Years in British Columbia and Saskatchewan, by Sputum Status of Source Case, 1966–1971 Race and closeness of tuberculosis contact Indian children Sputum status of source case Positive smear Positive culture only Negative culture a
Intimate (n 1012) 44.7 27.7 25.7
White children
Casual (n 619)
Intimate (n 1873)
Casual (n 3,031)
37.4 15.6 18.7
34.7 8.9 7.2
10.1 2.4 3.3
Adjusted to age distribution of total study population aged 0–14 years. Source: Ref. 14.
Epidemiology
133
actors among contacts to minimal cases. Also related to the risk of infection was cough frequency, which decreased appreciably during the first week of chemotherapy. Similar findings were noted in a study in Mysore State, India (16). Duration of Exposure
Duration of exposure is important in comparing the infectiousness of tuberculosis with other communicable diseases. Although an occasional tuberculous patient can be as infectious as a child with measles (17), in most instances the proportion of exposed contacts who become infected with tubercle bacilli is much lower than the risk of infection from cases of other acute communicable diseases. When the duration of exposure is taken into account, the average tuberculosis patient has a low degree of infectiousness per unit of time. Virulence of Organism
It has been known for some time that strains of M. tuberculosis from different parts of the world show considerable variation in their virulence for guinea pigs (18). Isoniazid-resistant organisms also have decreased virulence for guinea pigs (19). Until recently, however, the possibility of strain resistance has not been seriously considered in the pathogenesis or epidemiology of human tuberculosis. During 1994–1996, 21 cases of tuberculosis developed in a small rural community in the midwestern part of the United States (20). Investigation of the outbreak showed an unusually high rate of infection among contacts of the source case. Of the 42 identified and tested contacts of the source case, 37 (88.1%) were positive reactors, and 8 (21.6%) of the reactors had documented tuberculin conversions. High proportions of the contacts of the later index case were also tuberculin reactors and converters. Environmental investigations revealed no explanation for these high infection rates. The strain of tubercle bacilli responsible for the outbreak was initially reported to be more virulent than the standard virulent Erdman strain. However, subsequent laboratory investigations have not been able to confirm this finding (Cynthia L. Kelley and Arthur M. Dannenberg, Jr., personal communications, 1998). Whether or not M. tuberculosis varies in its virulence for humans remains uncertain. Foreign Residence
There is little evidence that a period of foreign residence is associated with an important risk of infection for persons born in the United States. Navy recruits who had lived abroad at a time when tuberculosis was common even in many developed countries were only slightly more likely to be tuberculin reactors than lifetime residents of this country (3). At least some of the difference must have resulted from BCG vaccinations received in the foreign country. The fact that the excess risk was so low is probably attributable to the lifestyle of most expatriate Americans, most of whose exposures must have occurred in public places and have been very short in duration.
134
Comstock
Age
There is some evidence that the risk of acquiring infections increases with age during the period from infancy to early adult life (21), probably because of increasingly numerous contacts with other persons. Although tuberculin sensitivity, once acquired as a result of infection with tubercle bacilli, persists for many years, the prevalence of positive tuberculin reactions tends to level off at around 50–60 years of age. In some populations, there is even a decreased prevalence in older ages, possibly because the infecting bacilli in some persons had died out at an early age. Sex and Race
In nearly all populations around the world, adult males are more likely to have been infected than females, again probably reflecting their opportunity for more and varied contacts in most societies (22). This sex difference was clearly illustrated in a large tuberculin testing program among New York City school employees (23,24). The prevalence of positive reactors was also higher among nonwhites than whites. Socioeconomic Status
In the New York City study, the prevalence of positive tuberculin reactors decreased steadily with increasing socioeconomic status of their neighborhood. In the highest socioeconomic areas, the frequency of reactors was similar among whites and nonwhites (23,24). Among high school students in Washington County, Maryland, large tuberculin reactions typical of those resulting from tuberculous infection were much more common among students living in crowded, inadequate housing (25). Chemotherapy of Source Case
Effective chemotherapy of the source case appears to reduce infectiousness rapidly, perhaps even more rapidly than is indicated by results of sputum examinations (17,26,27). Although isoniazid-resistant organisms have reduced virulence for guinea pigs, there is no indication that drug resistance per se has any effect on infectiousness for humans (28). However, when source cases with drug-resistant organisms had a history of prior and probably ineffective treatment, their contacts were at increased risk of being infected. It is likely that this increased risk resulted from the long duration of exposure that is associated with multiple episodes of treatment. Institutionalization
Both voluntary and involuntary confinement in two types of institutions has also been shown to be associated with an increased risk of becoming infected with tubercle bacilli. In a continuing survey of nursing homes in Arkansas, it was found that the risk of becoming a positive tuberculin reactor was 3.5% per year even if there had been no recognized tuberculosis cases in the home within the previous
Epidemiology
135
3 years (29). Periodic tuberculin testing in an elderly population in poor health can be misleading in individuals because of the relatively high degree of instability of the tuberculin reaction in such persons (30). Using the two-step procedure at the time of initial testing will identify many of the conversions due to “boosting” (anamnestic reaction), which might otherwise be subsequently classified as new infections (30–32). Identification of new tuberculosis infections among persons in long-term correctional institutions also faces the problem of differentiating new infections from boosted reactions. This problem can be minimized by the use of two-step testing at the initial examination (32,33). A conversion from a negative to a positive test within the week or two interval in two-step testing is highly likely to be a boosted reaction. A subsequent conversion at a semi-annual or annual retest among persons negative to the second of the two tests should be considered as evidence of a new infection. Repeated tuberculin testing in state prisons in two states showed conversion rates from a negative to a positive tuberculin test of 6.3 and 9% per year (34,35). Since that time, tuberculosis has been recognized as a serious threat because of gross overcrowding in correctional institutions and the ease of airborne spread of infection (33,34). A growing problem concerns tuberculosis transmission in homeless shelters. The presence of an untreated infectious case of tuberculosis in these often crowded, poorly ventilated buildings confers a considerable risk of infection upon the other clients and the shelter personnel (36). Intrinsic Susceptibility
A review of the foregoing shows that the known determinants of becoming infected are extrinsic to the exposed person or, in other words, environmental. Whether or not there is also an intrinsic risk factor is still uncertain. In one study, blacks were more likely to become positive tuberculin reactors than whites when exposed similarly in nursing homes and prisons (37). However, a careful study of a primary school outbreak found no difference in infection rates among white and black children similarly exposed to an infectious physical education teacher (38). At present, the issue of intrinsic susceptibility to infection remains unsettled, kept alive by the fact that individuals do differ in almost all characteristics and by anecdotal reports of persons who are still negative tuberculin reactors after a lifetime of caring for tuberculosis patients. B. Risk of Developing Tuberculosis Following Infection
Relatively few studies have been able to investigate the factors that influence whether or not an infected person will develop tuberculosis. Although most studies were done 25 or more years ago, the relative risks are still likely to be relevant.
136
Comstock Reinfection
For the past 100 years, there have been many discussions and opinions about the relative importance of exogenous reinfection and endogenous reactivation in the development of clinical tuberculosis following the initial infection with M. tuberculosis (39). As noted in Chapter 20, it is now clear that reinfection from a new source case can occur. However, it is still uncertain how often reinfection is responsible for the development of manifest disease. In any case, it is likely that the risks of being exposed to possible reinfection are similar to the risks of first becoming infected, as reviewed in the previous section. Time and Place
The change in risk of disease occurring after infection is not known with respect to calendar time. There are, however, some data showing that the risk of disease is highest shortly after initial infection and that it declines thereafter. Findings from a controlled trial of isoniazid prophylaxis among contacts of active tuberculosis cases and a trial among mental hospital patients can be combined to yield a reasonable estimate (40). In these two trials, 1472 persons allocated to the placebo regimen converted from a negative to a positive tuberculin reaction at some time within the first study year. Sixty-four percent of the 29 new cases that developed during a 7-year follow-up period occurred during that first year, the year in which they became reactors. Twenty-two percent developed during the next 3 years, and 13% during the last 3 years. In South India, the risk of developing tuberculosis was 2.6% within the first year after tuberculin conversion, and only 0.5% during the next 3 years (41). Incidence of tuberculosis among tuberculin reactors varies by place, probably related to intensity of exposure. Among 265,488 tuberculin reactors with negative chest radiographs who participated in a mass campaign in 1950–52 in Denmark (exclusive of Copenhagen), the average annual incidence over the next 12 years was 29 per 100,000 (42). At the other extreme was the Inuit population in the Yukon-Kuskokwim river delta of Alaska, where the average annual incidence rate from 1957–64 was more than 500 per 100,000 persons with initially negative chest radiographs, virtually all of whom were tuberculin reactors (43). In Denmark in the 1960s, rural tuberculin reactors 15–44 years of age had a risk of subsequently developing tuberculosis that was only 60% of the risk for their urban counterparts (42). Personal Characteristics Age
Among tuberculosis contacts in British Columbia and Saskatchewan, Canada, who had positive tuberculin reactions, the frequency of active tuberculosis dis-
Epidemiology
137
covered during a 6-month period following diagnosis of the index case varied markedly with the age of the contact (14). The inverse association with age held true for total active cases as well as those whose diagnosis was confirmed by sputum examination. A similar pattern by age was observed in South India (41). The higher risk among younger contacts may have resulted in part from the fact that a higher proportion of infections among young people are likely to have been recent. The incidence of tuberculosis among tuberculin reactors by age was investigated as a by-product of a controlled trial of BCG vaccination in Puerto Rico (44). Among 82,269 tuberculin reactors aged 1–18 years who were followed for 18–20 years, 1400 cases of tuberculosis were identified. As shown in Figure 1, there were two peaks of incidence. One occurred among children in the 1- to 4year age group, probably reflecting the fact that these infections must have been recent. The second peak occurred during late adolescence and early adult life and was experienced by all birth cohorts as they passed through this period of life. A similar peak was noted among British adolescents, although at a slightly lower age
Figure 1 Incidence of tuberculosis among Puerto Rican children who were reactors to tuberculin, by age when tuberculosis was first diagnosed. (From Ref. 44.)
138
Comstock
(45). The cause of increased incidence at this age, even for persons infected in early childhood, is unknown. The risk among older adults is not well established, but all evidence points to the persistence of at least a low risk of developing tuberculosis during the lifetime of infected persons. For this reason, life expectancy becomes a major determinant of the lifetime risk of developing tuberculosis among tuberculin reactors. Sex
In seven studies that reported sex- and age-specific incidence rates among positive tuberculin reactors, female rates were higher during their child-bearing ages than male rates; at older ages, male rates were higher (22). An exception to this pattern occurred in the large BCG trial in the Chingleput area of South India (12). Among persons with tuberculin reactions of 12 mm or larger, males had higher incidence rates than females at all ages. Race
Race per se appears to have little influence on the risk of disease once infection has occurred. Case rates were not significantly different among black and white reactors in Georgia and Alabama (46) or among Navy recruits (47). As can be seen in Table 2, Indian and white reactors in Canada also had similar rates when age, intimacy of contact, and infectiousness of source case had been controlled (14). Dosage of Infection
The findings shown in Table 2 also bear on the relationship of dosage of infection to the risk of developing tuberculosis (14). All the subjects in this study were tuberculin reactors and can be considered to have been infected. Because the risk of disease was greatest among those exposed to the most infectious cases and among
Table 2 Age-Adjusteda Prevalence of Active Tuberculosis Among Infected Tuberculosis Contacts in British Columbia and Saskatchewan by Race, Type of Contact, and Sputum Status of Source Case 1966–1971 Prevalence (%) Indian contacts Sputum status of source case Positive smear Positive culture only Negative culture a
White contacts
Intimate (n 352)
Casual (n 169)
Intimate (n 412)
Casual (n 216)
14.4 5.1 3.0
10.0 3.9 0
14.0 5.0 2.3
8.2 6.2 0
Adjusted to age distribution of total study population aged 0–14 years. Source: Ref. 14.
Epidemiology
139
those with the closest contact, the conclusion seems inescapable that persons infected with larger numbers of tubercle bacilli are at greater risk than those infected with smaller numbers of organisms. A study in Mysore State, India, also showed that among contacts who were strongly positive tuberculin reactors, development of pulmonary disease was most likely among those with the most intense exposure, i.e., the contacts most likely to have received larger doses of infections (48). Size of Tuberculin Reaction
It has been known for several decades that infections with nontuberculous mycobacteria often cause tuberculin sensitivity but rarely result in disease, and also that cross-reactions to tuberculin caused by these organisms are usually smaller than those caused by M. tuberculosis (49). Consequently, it is not surprising that where nontuberculous mycobacterial infections are present, small tuberculin reactions are less likely to be caused by infections with tubercle bacilli and hence are less likely to be associated with a risk of subsequent disease than larger reactions. The importance of this risk was illustrated by a study of Puerto Rican children (50). Children with reactions measuring 16 mm or more in diameter to 1 tuberculin unit (TU) of a purified tuberculin had a subsequent risk of tuberculous disease more than five times greater than children with reactions of 6–10 mm following a test with 10 TU of a purified tuberculin. The prognostic importance of this widely available risk factor has recently been recognized in recommended standards for tuberculosis control (51). Immunosuppression
The fact that the great majority of persons do not develop tuberculosis after they have been infected indicates the ability of the normal immune system to hold the infecting organisms in abeyance or even in some instances to eradicate them. Treatment with immunosuppressive agents can upset this balance, as can infections with the human immunodeficiency virus (HIV). Tuberculosis is reported to be rampant in populations throughout the world who have dual infections with both the tubercle bacillus and HIV. An illustration of the enormous magnitude of this risk is afforded by a longitudinal study among intravenous drug users in New York City (52). No cases of tuberculosis were observed among 298 reactors who were HIV-negative, compared to 8 among 215 HIV-positive persons. Seven of the 8 tuberculosis cases occurred among 36 who were known to have been positive tuberculin reactors but who had not received isoniazid chemoprophylaxis, an average annual case rate on the order of approximately 8,000 per 100,000. The well-documented, temporary loss of tuberculin sensitivity following measles has been equated with immunosuppression and hence increased susceptibility to activation of a latent tuberculosis infection. However, a careful review of the pertinent literature failed to substantiate the widespread belief that measles predisposes tuberculin reactors to the development of tuberculous disease (53).
140
Comstock
Relative Weight
Among the few benefits of being overweight is its association with protection against tuberculosis. Among white male recruits with positive tuberculin reactions and negative chest radiographs on entry to the Navy, those who were 10% or more underweight were 3.4 times more likely to develop tuberculosis than those who were 10% or more overweight (54). Socioeconomic Status
There is almost no evidence on the relationship of social and economic factors to the development of tuberculous disease among tuberculin reactors. In Muscogee County, Georgia the incidence of tuberculosis among reactors during the period 1950–62 showed no association with the quality of their housing as recorded in a private census in 1946 (46). This held true for both whites and blacks. There are no data on reactors living under conditions of extreme deprivation, although anecdotal evidence indicates a high risk. C. Risk of Reactivation of Disease
The third risk to be considered in etiological epidemiology is relapse, namely the risk of developing active disease following spontaneous or therapeutically associated “cure.” Relatively little is known about these risks except for those related to chemotherapy. Adherence to Chemotherapy
Chemotherapy has resulted in an almost miraculous improvement in the prognosis for persons who develop tuberculosis. Conscientious adherence to an appropriate regimen even in the earlier days of chemotherapy came close to guaranteeing a lasting cure (55). It is not surprising, therefore, that poor compliance with therapy is a major risk factor not only for treatment failure but also for relapse after apparent cure (56–58). Presence of drug-resistant tubercle bacilli is also an important risk factor for relapse. In 12 controlled trials of short-course chemotherapy, patients with bacilli resistant to streptomycin or isoniazid were much more likely to relapse than patients with bacilli sensitive to these drugs (59). Even though Fox considered completion of an appropriate regimen to come close to guaranteeing a cure (55), close is not perfection. As one example, among 582 patients who completed a 6-month regimen with isoniazid and rifampin throughout and pyrazinamide plus either ethambutol or streptomycin for the first 2 months and were followed for 5 years, the relapse rate was 3.4% (60). This rate is equivalent to an average annual rate of 680 per 100,000. Life-table reanalysis of the data from the USPHS tuberculosis short-course chemotherapy trial 21 showed a relapse rate of approximately 600 per 100,000 per year for the two regimens combined (61).
Epidemiology
141
Time
The risk of relapse by calendar time has clearly been influenced by the markedly reduced risk following the introduction of chemotherapy. In Denmark, after the introduction of isoniazid into the therapeutic regimen, the relapse rate fell from nearly 13 to 6% (62). The risk of relapse by time following completion of therapy has also been influenced by the introduction of antibiotic chemotherapy. Prior to its introduction, relapse was most likely to occur shortly after treatment stopped (63,64); after chemotherapy was introduced, relapses were less likely during the year or two following adequate treatment (61,64). Long-term risk after adequate chemotherapy is not known. Age, Sex, and Race
Relapse rates by age do not show a consistent pattern. In untreated persons whose disease was judged to be inactive or fibrotic at the time of diagnosis, reactivation was less likely with increasing age (63,65). Among persons whose disease became inactive after treatment, relapse rates went up with age in Denmark (62) and showed no significant trend with age in India (66). There was a tendency for relapse rates to be somewhat higher in males than females (62,65,66), though not in all populations (67). Reactivation rates were more common among Canadian Indians than other Canadians (68) and, in the state of Georgia, more common among blacks than whites (63). Socioeconomic Status
Among blacks in Georgia, degree of skin pigmentation was not related to the risk of relapse, suggesting that socioeconomic factors might be more important than race per se (63). Another indication that socioeconomic factors might play a role came from a geographic comparison of relapse rates in Denmark (62). Relapse rates among residents of Copenhagen were higher than among persons living in the more rural areas of Denmark. Extent of Disease
In the state of Georgia (United States) and in Europe, reactivation in untreated persons was much more likely among persons with extensive fibrotic disease than among those with only minimal lesions (63,69). A similar finding was reported among previously treated patients in Wisconsin and South Africa (56,70). III. Administrative Epidemiology Information on tuberculosis morbidity and mortality is voluminous compared to that available for etiological epidemiology. Even so, most of it is based on official
142
Comstock
reports and can be related only to time, place, race, sex, and age. Hard data on other risk factors are sparse. The available information on many aspects of administrative epidemiology is included in other chapters of this volume. A. Time and Place
The reported incidence of tuberculosis in the United States had been declining at an average rate of 5.9% per year for several decades until 1985 (71) (Fig. 2). The case rate then rose from 9.3 per 100,000 in 1985 to a high of 10.5 in 1992. Since then the case rate has fallen steadily to 7.4 in 1997 (72). The so-called resurgence of tuberculosis from 1985 to 1992 was far from uniform among U.S. states and cities, with marked variation in case rate changes both during and after the resurgence period (73; G.W. Comstock, unpublished data). Seven states (California, Nevada, New Jersey, New York, Texas, Utah, and Washington) showed average annual increases of 4–17% during the period 1984–1991. Table 3 shows the case rates for the years 1984, 1992, and 1996 for these seven states, the rest of the United States, and the entire country (74–76). For the seven
Figure 2 Tuberculosis case rates, United States, 1975–1997, all ages. (Adapted from Ref. 72.)
Epidemiology
143
Table 3 Tuberculosis Cases per 100,000 Population for 1985, 1992, and 1996 for the Total United States, Seven States with Highest Average Annual Increases 1984–1991, and the Rest of the Country
Total Seven statesa Rest of United States
1985
1992
1996
9.4 11.2 8.5
10.5 16.8 7.4
8.0 11.9 6.2
a
Seven states with average annual increases in tuberculosis case rates of 4% per year or higher. See text for details. Source: Refs. 74–76.
states, the 1992 rates at the peak of the resurgence were 50% higher than in 1984; by 1996, their average rate was almost as low as it had been in 1984 and this trend has continued through mid-1999 (CDC, personal communication, 1999). Rates for the rest of the country showed a slight decline throughout this entire period. Most Western European countries and Canada showed a slowing of the previous decline in tuberculosis rates after 1985, and some even showed slight increases (73). A notable exception was Finland, where the decrease in case rates accelerated after 1985. In Eastern European countries, case and death rates from tuberculosis are higher than in Western Europe, but in most of these countries, reported tuberculosis case rates were still declining up to 1992. In only a few, however, were tuberculosis death rates going down (77). In Southeast Asia and in sub-Saharan Africa, where dual infections with HIV and tuberculosis are becoming increasingly more common, tuberculosis case rates are increasing to an alarming degree (1,78). Various factors have been suggested as the cause of the resurgence in the United States (79). These include HIV infection, poverty, homelessness, drug abuse, immigration, and, usually last, decreased funds for tuberculosis control. However, the only one of these factors to have changed in a favorable direction since 1985 was the considerable increase in tuberculosis control funds during the 1990s, which led to a revitalization of tuberculosis-control activities in critical areas (80). In Southeast Asia and sub-Saharan Africa, there is little doubt that dual infections with HIV and tuberculosis are the major cause of increasing case rates, but even in Africa the increase has been mitigated where tuberculosis control activities are more effective (78). Tuberculosis is more common in large cities than in rural areas (75,81). In the United States in 1996, metropolitan statistical areas with populations greater than 500,000 had 74% of the new cases, for a case rate of 9.6 per 100,000. In the less populous areas, the rate was only 5.5 per 100,000. Forty-six percent of the 3143 U.S. counties reported no cases in 1996; most were located in the northern plains and Rocky Mountain areas (76).
144
Comstock
An influx of immigrants from areas where the prevalence of tuberculosis is high can also affect temporal trends in some areas. In British Columbia, Canada, tuberculosis case rates decreased from 1970 to 1985 except for the city of Vancouver (82). On investigation, it was found that the failure of the rates to decline in Vancouver was selective immigration into the poorer areas of the city of a group of high-risk, socially disadvantaged immigrants. Not all of the considerable geographic differences can be explained by stage of economic development, immigration, or prevalence of HIV infections. Case rates within the original European community varied from 7.4 to 31.9 per 100,000 in 1983; among six members of the Eastern Bloc the range was 20.3–72.8 (83). The Netherlands and four of the Scandinavian countries had the lowest rates. Rates in England and Wales ranged from 3.1 in Anglia to 37.0 per 100,000 in some boroughs of London in 1983 (81), while among the 50 United States the case rate in 1996 ranged from 0.7 in Vermont to 16.9 in Hawaii (76). Unfortunately, interpretation of geographic variations is more difficult than generally recognized. Within the United States in 1992, the percentage of pulmonary cases not bacteriologically confirmed varied from 0 to 35.4% among states with 25 or more reported cases (84). Considerable variations between nations in both the extent and nature of cases of pulmonary tuberculosis have also been recorded (85). B. Age, Race, and Sex
The numbers of reported tuberculosis cases among ethnic groups in the United States are shown in Figure 3 for the years 1980 through 1996 (8,33,71,72, 74,76,84,86–94). For all ethnic groups there was a downward trend until 1985. For American Indian/Alaskan natives, the general downward trend continued to 1996. All other ethnic groups showed an increase until 1992; for Asian/Pacific Islanders, however, numbers of cases increased until 1995. In the United States in 1996, case rates were low in infancy and decreased somewhat during early childhood (76). After the age of puberty, they showed a generally steady increase with age (Fig. 4). For all ethnic groups, rates among females are lower than among males. White rates are the lowest at all ages, and Asian/Pacific Islanders are the highest. Rates among blacks, Hispanics, and American Indian/Alaskan Natives are intermediate, except that rates among adult black males are appreciably higher than the other two groups except at the oldest ages. In under-developed countries, the highest reported rates are among young adults (11,48). C. Socioeconomic Status
The association of tuberculosis with poor socioeconomic status has long been noted (3,95) and perhaps is even stronger today. Decades ago, homeless men in New York City were found to have high rates of tuberculosis (96); a similar ex-
Figure 3 Reported tuberculosis cases by race/ethnicity group, United States, 1980–1996. *Up to 1993, Hispanics are also included in one of the other groups. (Adapted from Refs. 74–76, 84, 86, 87, 91, 92, 94.)
Figure 4 Tuberculosis case rates, United States, 1996, by race/ethnicity and age groups. A American Indian/Alaskan Native; A/P Asian/Pacific Islander; B black; H Hispanic; W white; M male; F female. (Adapted from Ref. 76.)
145
146
Comstock
cess was noted among unmarried men living in central Copenhagen (97). The situation has been aggravated recently by the increase in homeless persons and the continued high frequency of tuberculosis among them (98). Further aggravation comes from the tendency of poor immigrants to crowd into large cities (82,99). Their tuberculosis risk reflects the prevalence of the disease in their native countries; the risk decreases with their duration of stay in their adopted homes (87,100–102). Based on a survey from 29 states in 1984–1985, occupational status was strongly associated with tuberculosis case rates (103). Executives and professionals had the lowest rates, and laborers, farm workers, and household servants had the highest rates. Health care workers had rates of tuberculosis about the same as that of the general population, except for higher rates among inhalation therapists, nursing aides, orderlies, and attendants. An interesting exception to the inverse association of tuberculosis with occupational status was the higher-than-expected rate among funeral directors. A recent study showed that funeral home employees who performed embalming were twice as likely to have been infected with tubercle bacilli as other employees (104). D. Institutional Living
Because poverty is associated with both crime and tuberculosis, it is not surprising that tuberculosis is often a problem among inmates of correctional institutions. Various surveys have estimated the frequency of tuberculosis to be increasing among such populations and to be three to six times higher than expected from rates in the general population (33,105). Tuberculosis among persons living and working in nursing homes and other facilities providing long-term medical care has only recently been recognized as a problem (29). A survey of 29 states suggested that the case rate for patients was approximately 50% higher and the rate among employees was three times higher than expected from the rates in similar age sex groups in the general population (90,105) (see also Chap. 24). E. Special Medical Situations
A variety of medical conditions are associated with tuberculosis. Although these risk factors are presumably limited to persons already infected with M. tuberculosis, studies to substantiate this presumption are few and rarely definitive. By far the most important is immunosuppression, particularly that resulting from infection with the human immunodeficiency virus (88,106) (see also Chap 20). Other causes of immunosuppression also accompanied by an increased tuberculosis risk include treatment with immunosuppressive drugs, including prolonged adrenocorticosteroid therapy, some hematologic and reticuloendothelial diseases such as leukemia and lymphoma, and end-stage renal disease (107).
Epidemiology
147
Silicosis has long been linked with tuberculosis, so much so that silico-tuberculosis is an accepted disease entity. Although the causal nature of this association is largely based on uncontrolled reports (108), silica dust has long been known to have an adverse effect on tuberculosis in animals (39). Diabetes, too, has long been accepted as a risk factor for tuberculosis (109). Two studies in the 1950s indicated that the prevalence among diabetics was approximately four times that in a comparable general population and that the risk was greatest among those with severe diabetes (110,111). Alcoholism and drug addiction are also associated with tuberculosis, although it is not clear whether these diseases increase susceptibility to tuberculosis or whether conditions conducive to substance abuse are similar to those leading to tuberculosis. In any case, alcoholism was well known to physicians in tuberculosis sanatoria, since 10–30% of patients were reported to be alcoholics (3). Current surveys also show a high prevalence of tuberculosis among alcoholics and drug addicts (112). Multiple drug resistance, currently defined as resistance to at least isoniazid and rifampin, has become a major problem in many areas throughout the world (113). Although multiple drug–resistant tubercle bacilli have been involved in many outbreaks of tuberculosis during the past decade or two, there is at present no evidence that their virulence differs from that of susceptible organisms. Rather, their association with outbreaks appears to be due largely to the situations in which outbreaks occur, namely persons at high risk because of immunosuppression, crowding, homelessness, drug abuse, and/or poverty, especially in circumstances where chemotherapeutic regimens are poorly administered or accepted, often because of inadequate tuberculosis-control programs. F. Infection with HIV
The greatly increased risk of clinical tuberculosis among persons infected with M. tuberculosis and HIV has been clearly demonstrated in this country and abroad (52,78,106,114). Only in the study by Selwyn et al. (52) is it clear that new tuberculous infection was not the major contributor to the increased risk. In recent years, there have been frequent reports of localized outbreaks (clusters) of tuberculosis cases among groups at high risk of developing tuberculosis. Many of these persons were known to be HIV-positive. In these clusters, a very high proportion of cases were found to have tubercle bacilli with the same restriction fragmentlength polymorphism pattern, strongly suggesting that all cases came from a single source, probably recent (115,116). In these cluster situations, it is reasonable to believe that there was a high risk of becoming infected and consequently a high attack rate of tuberculous disease. Only in populations with a low risk of becoming infected is it reasonable to assume that most HIV-associated tuberculosis is the result of reactivation of latent infection.
148
Comstock
Two features distinguish the epidemiology of HIV-associated tuberculosis. First is the speed with which clinical disease becomes manifest following exposure. In two outbreaks among HIV-infected persons, attack rates of 16.7 and 29.4% were observed within somewhat less than a 2-year period (117,118). For comparison, during the first 2 years of observation of HIV-negative household contacts admitted to the placebo arm of an isoniazid prophylaxis trial, only 1.3% of 6608 initially positive reactors and 2.2% of 867 tuberculin converters developed tuberculosis (40). The likelihood of developing manifest tuberculosis depends on the stage of the HIV infection. Most cases of tuberculosis are recognized at about the same time that other AIDS-defining conditions occur; the majority of the remaining cases occur somewhat prior to that time (119). The other feature is that HIV-related tuberculosis under usual circumstances appears to be somewhat less infectious than tuberculosis not associated with HIV infection (120). Although this decreased infectiousness might appear to be related to the tendency for HIV-infected persons to have noncavitary and extrapulmonary disease, the decreased risk of infection persisted after allowing for these and other conditions considered to be related to infectiousness. G. Genetic Susceptibility
In the nineteenth century, it was commonly believed that tuberculosis was a hereditary disease (121). In the early part of the twentieth century, Karl Pearson and Raymond Pearl each attempted to disentangle the hereditary and environmental factors that led to the familial concentration of tuberculosis (109), investigations that were continued in the Williamson County Tuberculosis Study by Ruth Puffer (122). Subsequent studies of monozygotic and dizygotic twins indicated that some degree of susceptibility was inherited (123). Because of these indications of genetic susceptibility, investigators have looked for associations of tuberculosis with various genetic markers. Among Inuits in Alaska, tuberculosis was more prevalent among persons with blood groups B and AB than among those with blood groups 0 or A (124). Although various human leukocyte antigen types have also been suspected of playing a role in tuberculosis susceptibility, no consistent associations have been found (125,126). H. Nontuberculous Mycobacterial Infections
In a series of experiments unlikely to be rivaled in size and sophistication, Palmer and Long showed that infections with a variety of mycobacteria increased the resistance of guinea pigs against tuberculosis (127). Evidence of protection was also found among British adolescents who reacted only to the 100 TU dose of tuberculin and U.S. Navy recruits who reacted to antigens prepared from M. avium-intracellulare or M. scofulaceum but not to the intermediate dose of PPD-tuberculin (128,129). These findings were not confirmed in a large study in Puerto Rico (50),
Epidemiology
149
although it is possible that the nonreactors to the strong dose of tuberculin were like some of Palmer’s guinea pigs who showed some evidence of protection even after failing to develop hypersensitivity after two injections of nontuberculous mycobacteria. Although the question is unsettled, there is a strong possibility that human infections with nontuberculous mycobacteria do confer some protection against tuberculosis. I. Psychosocial Stress
Although medical scientists are often hesitant to study the possible effects of mind on the body, there have been persistent hints in the tuberculosis literature that psychological, social, and economic stresses have an adverse effect on tuberculosis (130–132). Stress is a common thread running throughout the risk factors of poverty, homelessness, marital disruption, institutionalization, and substance abuse. A study that controlled for many other risk factors involved Navy recruits (47). White, black, and Filipino recruits who were tuberculin reactors on entry to the Navy had very similar housing, diet, and income during the first 4 years of their enlistment. Case rates among white and black reactors decreased during this period; case rates among Filipino reactors increased, possibly because of stresses associated with separation from families and with being a small minority with few social supports. IV. Conclusion Although this review of risk factors seems lengthy, it should be noted that much of the information rests on relatively few studies and that some of the most important ones were performed 30–40 years ago. Of concern is the current risk of disease following tuberculous infection in a variety of populations. Some way of reliably identifying persons who continue to harbor tubercle bacilli after having been infected would allow tuberculosis control efforts to be much more sharply focused on the seedbed of disease. Even small and individually nondefinitive studies of these and other risk factors would be helpful if they all pointed to the same conclusion. Increased knowledge of current risks of infection and subsequent disease could help greatly in efforts to bring tuberculosis back under control and, in developed countries, could even lead to its elimination in the near future. References 1. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273:220–226. 2. Buikstra JE, Cook DC. Pre-Columbian tuberculosis in west-central Illinois. prehistoric disease in biocultural perspective. In: Buikstra JE, ed. Prehistoric Tuberculosis
150
3. 4. 5. 6.
7. 8. 9. 10. 11. 12. 13. 14. 15. 16.
17.
18.
19.
20.
21.
Comstock in the Americas. Evanston, IL: Northwestern University Archeological Program, 1981:115–139. Lowell AM, Edwards LB, Palmer CE. Tuberculosis. Cambridge, MA: Harvard University Press, 1969:129–166. Rust P, Thomas J. A method for estimating the prevalence of tuberculous infection. Am J Epidemiol 1975; 101:311–322. Trump DH, Hyams KC, Cross ER, Struewing JP. Tuberculosis infection among young adults entering the U.S. Navy in 1990. Arch Intern Med 1993; 153:211–216. Engel A, Roberts J. Tuberculin skin test reaction among adults 25–74 years, United States, 1971–72. DHEW Publication No. (HRA) 77-1649. Vital and Health Statistics: Series 11, No. 204. Hyattsville, MD: National Center for Health Statistics, 1977. Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol 1975; 101:363–382. Centers for Disease Control. Tuberculosis program management report, contact followup, 1997. Unpublished. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72:1–6. Styblo K. Surveillance of tuberculosis. Int J Epidemiol 1976; 5:63–68. Styblo K. The impact of HIV infection on the global epidemiology of tuberculosis. Bull IUATLD 1991; 66:27–32. Tuberculosis Prevention Trial, Madras. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J Med Res 1980; 72(suppl):1–74. Kaplan GJ, Fraser RI, Comstock GW. Tuberculosis in Alaska, 1970. The continued decline of the tuberculosis epidemic. Am Rev Respir Dis 1972; 105:920–926. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975; 50:90–106. Loudon RG, Spohn SK. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 1969; 99:109–111. Raj Narain, Nair SS, Ramanatha Rao GR, Chandrasekhar P. Distribution of tuberculous infection and disease among households in a rural community. Bull WHO 1966; 34:639–654. Riley RL, Mills CC, O’Grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 1962; 85:511–525. Dickinson JM, Lefford MJ, Lloyd J, Mitchison DA. The virulence in the guinea-pig of tubercle bacilli from patients with pulmonary tuberculosis in Hong Kong. Tubercle 1963; 44:446–451. Morse WC, Weiser OL, Kuhns DM, et al. Study of the virulence of isoniazid-resistant tubercle bacilli in guinea pigs and mice. A preliminary report. Am Rev Tuberc 1954; 69:464–468. Valway SE, Sanchez MPC, Shinnick TF, et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 1998; 338:633–639. Sutherland I, Fayers PM. The association of the risk of tuberculous infection with age. Tuberculosis Surveillance Research Unit Report No. 3. Bull Int Union Tuberc 1975; 50:70–81.
Epidemiology
151
22. Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 1998; 2:96–104. 23. Reichman LB, O’Day R. Tuberculous infection in a large urban population. Am Rev Respir Dis 1978; 117:705–712. 24. Comstock GW, O’Brien RJ. Tuberculosis. In: Evans AS, Brachman PS, eds. Bacterial Infections of Humans. Epidemiology and Control. 2d ed. New York: Plenum, 1991:745–771. 25. Kuemmerer JM, Comstock GW. Sociologic concomitants of tuberculin sensitivity. Am Rev Respir Dis 1967; 96:885–892. 26. Kamat SR, Dawson JJY, Devadatta S, et al. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in south India. Bull WHO 1966; 34:517–532. 27. Riley RL, Moodie AS. Infectivity of patients with pulmonary tuberculosis in inner city homes. Am Rev Respir Dis 1974; 110:810–812. 28. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985; 132:125–132. 29. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985; 312:1483–1487. 30. Perez-Stable EJ, Flaherty D, Schecter G, Slutkin G, Hopewell PC. Conversion and reversion of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1988; 137:801–804. 31. Barry MA, Regan AM, Kunches LM, Harris ME, Bunce SA, Craven DE. Two-stage tuberculin testing with control antigens in patients residing in two chronic disease hospitals. J Am Geriatr Soc 1987; 35:147–153. 32. Thompson NJ, Glassroth JL, Snider DE Jr, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119:587–597. 33. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional institutions: Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1996; 45(No. RR-8):1–27. 34. MacIntyre CR, Kendig N, Kummer L, Birago S, Graham NM. Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. Clin Infect Dis 1997; 24:1060–1067. 35. Stead WW. Undetected tuberculosis in prison. JAMA 1978; 240:2544–2547. 36. Nolan CM, Elarth AM, Barr H, Mahdi Saeed A, Risser DR. An outbreak of tuberculosis in a shelter for homeless men. Am Rev Respir Dis 1991; 143:257–261. 37. Stead WW, Senner JW, Reddick WT, Lofgren JP. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990; 322:422–427. 38. Hoge CW, Fisher L, Donnell HD Jr, et al. Risk factors for transmission of Mycobacterium tuberculosis in a primary school outbreak: Lack of racial difference in susceptibility to infection. Am J Epidemiol 1994; 139:520–530. 39. Rich AR. The Pathogenesis of Tuberculosis. Springfield, IL: Charles C Thomas, 1944:779–810. 40. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970; 17:28–106.
152
Comstock
41. Krishna Murthy VV, Nair SS, Gothi GD, Chakraborty AK. Incidence of tuberculosis among newly infected population and in relation to the duration of infected status. Indian J Tuberc 1976; 33:3–7. 42. Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull WHO 1969; 41:95–113. 43. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95:935–943. 44. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99:131–138. 45. Sutherland I. The evolution of clinical tuberculosis in adolescents (abstr). Tubercle 1966; 47:308. 46. Comstock GW, Palmer CE. Long-term results of BCG vaccination in the southern United States. Am Rev Respir Dis 1966; 93:171–183. 47. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974; 110:572–580. 48. Raj Narain, Naganna K, Murthy SS. Incidence of pulmonary tuberculosis. Am Rev Respir Dis 1973; 107:992–1001. 49. Palmer CE, Edwards LB, Hopwood L, Edwards PQ. Experimental and epidemiologic basis for the interpretation of tuberculin sensitivity. J Pediatr 1959; 55:413– 429. 50. Comstock GW, Livesay VT, Woolpert SF. Evaluation of BCG vaccination among Puerto Rican children. Am J Public Health 1974; 64:283–291. 51. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990; 142:725–735. 52. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545–550. 53. Flick JA. Does measles really predispose to tuberculosis? Am Rev Respir Dis 1976; 114:257–265. 54. Edwards LG, Livesay VT, Acquaviva FA, Palmer CE. Height, weight, tuberculous infection, and tuberculous disease. Arch Environ Health 1971; 22:106–112. 55. Fox W. The John Barnwell Lecture. Changing concepts in the chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1968; 97:767–790. 56. Stead WW, Jurgens GH. Productivity of prolonged follow-up after chemotherapy for tuberculosis. Am Rev Respir Dis 1973; 108:314–320. 57. Kopanoff DE, Snider DE Jr, Johnson M. Recurrent tuberculosis: Why do patients develop disease again? Am J Public Health 1988; 78:30–33. 58. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179– 1184. 59. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133:423–430. 60. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136:1339–1342.
Epidemiology
153
61. Combs DL, O’Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Int Med 1990; 112:397– 406. 62. Horwitz O. Public health aspects of relapsing tuberculosis. Am Rev Respir Dis 1969; 99:183–193. 63. Comstock GW. Untreated inactive pulmonary tuberculosis: risk of reactivation. Public Health Rep 1962; 77:461–470. 64. Edwards LB, Doster B, Livesay VT, Ferebee SH. Risk of tuberculosis in persons with not active-not treated lesions. Bull Int Un Tuberc 1972; 47:151–156. 65. Springett VH. Tuberculosis risk in persons with “fibrotic” lesions. Bull Int Un Tuberc 1972; 47:157–159. 66. Pamra SP, Prasad G, Mathur GP. Relapse in pulmonary tuberculosis. Am Rev Respir Dis 1976; 113:67–72. 67. Chan-Yeung M, Galbraith JD, Schulson N, Brown A, Grzybowski S. Reactivation of inactive tuberculosis in northern Canada. Am Rev Respir Dis 1971; 104:861–865. 68. Nakielna EM, Cragg R, Grzybowski S. Lifelong follow-up of inactive tuberculosis: its value and limitations. Am Rev Respir Dis 1975; 112:765–772. 69. International Union against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982; 60:555–564. 70. Cowie RL, Langton ME, Becklake MR. Pulmonary tuberculosis in South African gold miners. Am Rev Respir Dis 1989; 139:1086–1089. 71. Centers for Disease Control. Tuberculosis, final data—United States, 1986. MMWR 1988; 36:817–820. 72. Centers for Disease Control and Prevention. Tuberculosis morbidity—United States, 1997. MMWR 1998; 47:253–257. 73. Comstock GW. Variability of tuberculosis trends in a time of resurgence. Clin Infect Dis 1994; 19:1015–1022. 74. Centers for Disease Control. 1985 Tuberculosis Statistics. States and Cities. HHS Publication No. (CDC) 87-8249. Atlanta: Public Health Service, 1986. 75. Centers for Disease Control and Prevention. 1992 Tuberculosis Statistics in the United States. Atlanta: Public Health Service, 1994. 76. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 1996. Atlanta: Public Health Service, 1997. 77. Raviglione MC, Rieder HL, Styblo K, Khomenko AG, Esteves K, Kochi A. Tuberculosis trends in Eastern Europe and the former USSR. Tuberc Lung Dis 1994; 75:400–416. 78. Cantwell MF, Binkin NJ. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Int J Tuberc Lung Dis 1997; 1:205–214. 79. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144:745–749. 80. U.S. Congress, Office of Technology Assessment. The Continuing Challenge of Tuberculosis, OTA-H-574. Washington, DC: U.S. Government Printing Office, 1993. 81. Medical Research Council Tuberculosis and Chest Diseases Unit. The geographical distribution of tuberculosis notifications in a national survey of England and Wales in 1983. Tubercle 1986; 67:163–178.
154
Comstock
82. Enarson DA, Wang J-S, Dirks JM. The incidence of active tuberculosis in a large urban area. Am J Epidemiol 1989; 129:1268–1276. 83. Tala E. Registration of tuberculosis in Europe. Bull Int Union Tuberc Lung Dis 1987; 62(1–2):74–76. 84. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 1993. Atlanta: Public Health Service, 1994. 85. Horwitz O, Comstock GW. What is a case of tuberculosis? The tuberculosis case spectrum in eight countries evaluated from 1235 case histories and roentgenograms. Int J Epidemiol 1973; 2:145–152. 86. Centers for Disease Control. 1981–1984 Tuberculosis in the United States. HHS Publication No. (CDC) 86-8322. Atlanta: Public Health Service, 1986. 87. Centers for Disease Control. Tuberculosis among Asians/Pacific Islanders—United States, 1985. MMWR 1987; 36:331–334. 88. Centers for Disease Control. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for Elimination of Tuberculosis (ACET). MMWR 1989; 38:236–250. 89. Centers for Disease Control. 1987 Tuberculosis Statistics in the United States. HHS Publication No. (CDC) 89-8322. Atlanta: Public Health Service, 1989. 90. Centers for Disease Control. Prevention and control of tuberculosis in facilities providing long-term care to the elderly: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1990; 39 (No. RR-10):7–20. 91. Centers for Disease Control. 1989 Tuberculosis Statistics in the United States. HHS Publication No. (CDC) 91-8322. Atlanta: Public Health Service, 1991. 92. Centers for Disease Control and Prevention. 1990 Tuberculosis Statistics in the United States. Atlanta: Public Health Service, 1992. 93. Centers for Disease Control and Prevention. 1991 Tuberculosis Statistics in the United States. Atlanta: Public Health Service, 1993. 94. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 1995. Atlanta: Public Health Service, 1996. 95. Osler W, McCrae T. The Principles and Practice of Medicine. 10th ed. New York: D. Appleton and Company, 1926:161–231. 96. Chaves AD, Robins AB, Abeles H. Tuberculosis case finding among homeless men in New York City. Am Rev Respir Dis 1961; 84:900–901. 97. Horwitz O. Tuberculosis risk and marital status. Am Rev Respir Dis 1971; 104:22– 31. 98. VonVille P, Holtzhauer F, Long T, et al. Tuberculosis among residents of shelters for the homeless—Ohio, 1990. MMWR 1991; 40:869–877. 99. Froggatt K. Tuberculosis: spatial and demographic incidence in Bradford, 1980–2. J Epidemiol Commun Health 1985; 39:20–26. 100. Enarson DA, Wang JS, Grzybowski S. Case-finding in the elimination phase of tuberculosis: tuberculosis in displaced people. Bull IUATLD 1990; 65(2–3):71–72. 101. Sutherland I, Springett VH, Nunn AJ. Changes in tuberculosis notification rates in ethnic groups in England between 1971 and 1978/79. Tubercle 1984; 65:83–91. 102. Noland CM, Elarth AM. Tuberculosis in a cohort of southeast Asian refugees. A five-year surveillance study. Am Rev Respir Dis 1988; 137:805–809. 103. McKenna MT, Hutton M, Cauthen G, Onorato IM. The association between occu-
Epidemiology
104. 105. 106.
107. 108. 109. 110. 111.
112. 113.
114.
115. 116.
117. 118.
119. 120.
121.
155
pation and tuberculosis. A population-based survey. Am J Respir Crit Care Med 1996; 154:587–593. Gershon RRM, Vlahov D, Escamilla-Cejudo JA, et al. Tuberculosis risk in funeral home employees. J Occup Environ Med 1998; 40:497–503. Hutton MD, Cauthen GM, Bloch AB. Results of a 29-state survey of tuberculosis in nursing homes and correctional facilities. Public Health Rep 1993; 108:305–314. Braun MM, Badi N, Ryder RW, et al. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. Am Rev Respir Dis 1991; 143:501–504. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1994; 149:1359–1374. Snider DE Jr. The relationship between tuberculosis and silicosis. Am Rev Respir Dis 1978; 118:455–460. Pinner M. Pulmonary Tuberculosis in the Adult. Its Fundamental Aspects. Springfield, IL: Charles C Thomas, 1945:190. Boucot KR, Dillon ES, Cooper DA, Meier P, Richardson R. Tuberculosis among diabetics. The Philadelphia survey. Am Rev Respir Dis 1952; 65(No. 1, Part 2):1–50. Oscarsson PN, Silwer H. II. Incidence of pulmonary tuberculosis among diabetics. Search among diabetics in the county of Kristianstad. Acta Med Scand 1958; 161(suppl 335):23–48. Friedman LN, Sullivan GM, Bevilaqua RP, Loscos R. Tuberculosis screening in alcoholics and drug addicts. Am Rev Respir Dis 1987; 136:1188–1192. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 1997; 24(suppl. 1):S121–S130. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146:1439–1444. Genewein A, Telenti A, Bernasconi C, et al. Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet 1993; 342:841–844. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994; 330:1703–1709. Dooley SW, Villarino ME, Lawrence M, et al. Nosocomial transmission of tuberculosis in a hospital unit for HIV-infected patients. JAMA 1992; 267:2632–2635. Daley CL, Schechter GF, Rutherford GW. Tuberculosis outbreak among persons in a residential facility for HIV-infected persons—San Francisco. MMWR 1991; 40:649–652. Rieder HL, Cauthen GM, Bloch AB, et al. Tuberculosis and acquired immunodeficiency syndrome—Florida. Arch Int Med 1989; 149:1268–1273. Cauthen GM, Dooley SW, Onorato IM, et al. Transmission of Mycobacterium tuberculosis from tuberculosis patients with HIV infection or AIDS. Am J Epidemiol 1996; 144:69–77. Dubos R, Dubos J. The White Plaque. Tuberculosis, Man and Society. Boston: Little, Brown and Company, 1952:28–43.
156
Comstock
122. Puffer RR. Familial Susceptibility to Tuberculosis. Its Importance as a Public Health Problem. Cambridge, MA: Harvard University Press, 1944. 123. Comstock GW. Tuberculosis in twins: a re-analysis of the Prophit Survey. Am Rev Respir Dis 1978; 117:621–624. 124. Overfield T, Klauber MR. Prevalence of tuberculosis in Eskimos having blood group B gene. Human Biol 1980; 52:87–92. 125. Hwang C-H, Khan S, Ende N, Mangura BT, Reichman LB, Chou J. The HLA-A, B, and -DR phenotypes and tuberculosis. Am Rev Respir Dis 1985; 132:382–385. 126. Hawkins BR, Higgins DA, Chan SL, Lowrie DB, Mitchison DA, Girling DJ. HLA typing in the Hong Kong Chest Service/British Medical Research Council study of factors associated with the breakdown to active tuberculosis of inactive pulmonary lesions. Am Rev Respir Dis 1988; 138:1616–1621. 127. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966; 94:553–568. 128. Hart PD’A, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Final Report to the Medical Research Council. Br Med J 1977; 2:293–295. 129. Edwards LB, Acquaviva FA, Livesay VT. Identification of tuberculous infected. Dual tests and density of reaction. Am Rev Respir Dis 1973; 108:1334–1339. 130. Downes J, Price CR. The importance of family problems in the control of tuberculosis. Milbank Memorial Fund Quart 1942; 20:7–22. 131. Hendricks CM. Psychosomatic aspects of tuberculosis. In: Hayes EW, ed. The Fundamentals of Pulmonary Tuberculosis and Its Complications. Springfield, IL: Charles C Thomas, 1949:233–244. 132. Holmes TH. Multidiscipline studies of tuberculosis. In: Sparer PJ, ed. Personality, Stress and Tuberculosis. New York: International Universities Press, 1956.
7 Bacteriology of Tuberculosis
JACQUES GROSSET, CHANTAL TRUFFOT-PERNOT, and EMMANUELLE CAMBAU Faculté de Médecine Pitié-Salpêtrière Université Pierre et Marie Curie Paris, France
I. Introduction Although a search for acid-fast bacilli (AFB) on stained sputum smear, and culture and drug-sensitivity testing on enriched agar or egg-based medium are still the basic methods for the laboratory diagnosis of tuberculosis, they are far from being accurately implemented or performed in a majority of countries in the world, and a complete set of new technologies is now available. The use of a radiometric detection system for mycobacterial growth permits a reduction of the time required for obtaining the results of culture and drug-sensitivity tests. Nonisotopic probes for the identification of pure cultures and DNA fingerprinting of Mycobacterium tuberculosis for strain typing are important new developments. In addition, the application of nucleic acid–amplification techniques to the direct detection of M. tuberculosis in clinical specimens and the direct detection of drug resistance, especially to rifampin, is offering new tools, although they are still relatively expensive and sophisticated. The purpose of this chapter is to present conventional and modern methods for the laboratory diagnosis of tuberculosis in a pragmatic approach for developed as well as for developing countries. 157
158
Grosset et al. II. Biological Safety
Laboratories processing specimens that could contain tubercle bacilli should ensure that safety measures are appropriately implemented and controlled (1–3). Even more rigorous safety measures should be followed by technicians performing identification and drug-susceptibility testing since they work with large inocula of pathogenic mycobacteria. Workers in the mycobacteriology laboratory are particularly exposed to infectious aerosols generated by manipulations of tubercle bacilli. Therefore, manipulations, even the crucial direct sputum smear that is often the only possible laboratory diagnostic method performed in developing countries, must be performed in a dedicated room. The room should be under some kind of negative pressure and equipped with a biological safety cabinet, either a class I negative pressure or a class II laminar-flow safety cabinet, which should be regularly checked. Centrifugation should be carried out in sealed centrifuge cups to prevent aerosols in case of leakage. Workers must wear a laboratory coat or gown. An autoclave should be available in an adjacent room, and infectious waste should be removed and decontaminated frequently. All work surfaces should be cleaned with appropriate disinfectant such as fresh 3% dilution sodium hypochlorite or 2% alkaline glutaraldehyde. Personnel working in a mycobacteriology laboratory should have annual health exams including tuberculin testing with appropriate chest x-rays and preventive therapy. III. General Characteristics of Tubercle Bacilli The tubercle bacillus belongs to the Mycobacterium genus, the only genus of the Mycobacteriaceae family. It includes four species, namely M. tuberculosis, M. bovis, M. africanum, and M. microti, which constitute the M. tuberculosis complex. A. Physical and Chemical Characteristics
Microscopy
M. tuberculosis is a thin rod with rounded extremities, 2–5 m long and 0.2–0.3 m thick. Nonmotile, without capsule or spore, and true branching, it is difficult to stain with the usual methods, although it belongs to the gram-positive bacteria. But stained with the reference carbol fuchsin or Ziehl-Neelsen method, it resists decolorization with strong mineral acids and alcohol, hence is an acid-fast bacillus, appearing under microscope examination as a slightly curved or straight, small red or pink rod.
Bacteriology of Tuberculosis
159
Cell Wall
The mycobacterial cell wall is composed of a peptidoglycan, as in other bacteria, linked to a specific lipopolysaccharide made of arabinogalactan esterified at its distal end with fatty acids containing 60–90 carbon atoms, named mycolic acids (4). Mycolic acids play a major role in the acid-fastness of mycobacteria (5). In addition to the above components, a wide variety of other complex molecules are found within the outer layer of mycobacterial cell wall (6), e.g., sulfatides, trehalose-dimycolate, mycosides, and waxes Because of its thickness and high lipid content, the mycobacterial cell wall is much more impermeable to hydrophilic molecules than that of other bacteria (7,8). The penetration of hydrophilic molecules, at least small ones, might depend upon wall-associated proteins that play the same role as porins in gram-negative bacteria (9). The high lipid content of the cell wall is also responsible for the resistance of mycobacteria to chemical injury, in other words, to decontamination procedures with acids, sodium hydroxide, and/or detergents. However, M. tuberculosis is as susceptible as other bacteria to heat, x-rays, UV rays, and alcohol. M. tuberculosis remains viable for weeks at 4°C and for years at 70°C. Mycobacterial Antigens
Soon after the discovery of the tubercle bacillus, Robert Koch prepared a concentrated sterile filtrate from heat-killed liquid culture (10), which he named “tuberculin.” It soon became apparent that tuberculosis patients reacted to the injection of tuberculin more rapidly and intensely than uninfected persons, and the intradermal skin test with tuberculin became part of the diagnosis of tuberculosis infection. Among all antigens of M. tuberculosis and M. bovis that have been described, neither polysaccharides nor phenolglycolipids are specific to the tubercle bacilli. B. Nutrition and Growth
M. tuberculosis has two main growth characteristics. First, it does not grow on ordinary culture media, but only on enriched media. However, the absence of growth on ordinary culture media is not related to any particular requirement for a growth factor or vitamin, even though various compounds potentiate the in vitro growth. This is the case for bovine serum albumin, egg yolk, and even catalase. Second, it has a slow rate of growth, the generation time of the cells in the best conditions of culture being 13–20 hours on solid as well as in liquid medium. M. tuberculosis is a strict aerobe equipped with catalase, peroxidase, and superoxide-dismutase, the growth rate of which is highly dependent upon the oxygen concentration. When oxygen concentration is high, as in the tuberculosis cav-
160
Grosset et al.
ity of the lung, M. tuberculosis multiplies freely; when it is much lower, as in the caseous foci of the lung, M. tuberculosis multiplies slowly or not at all (11). Up to 8% carbon dioxide either as NaHCO3 /Na2CO3 in the medium or as CO2 in the gas phase above the medium considerably improves the growth of isolates from clinical specimens (12). M. tuberculosis can oxidize an extremely wide range of compounds. The preferred carbon sources for growth are, by order of preference, glycerol, pyruvate, and glucose. The growth of M. bovis, a species closely related to M. tuberculosis, is favored by 0.2% pyruvate but inhibited by a high concentration (5%) of glycerol. Asparagine is usually considered as the preferred source of nitrogen for growth of M. tuberculosis. In addition to carbon and nitrogen sources, M. tuberculosis requires four major inorganic elements for growth—potassium, magnesium, sulfur, and phosphorus—and a variety of trace elements, such as iron, zinc, and probably manganese (12). All of these elements are present in common semisynthetic culture media as well as in the human body. IV. Bacteriology for Diagnosis and Monitoring Treatment of Tuberculosis A. Specimen Collection and Transport
A number of clinical specimens may be submitted to the laboratory for detection of mycobacteria. The majority of these are from the respiratory tract, but sterile body fluids, urine, and tissues, and even blood and stools from AIDS patients are also submitted. The quality of the results depends in large part on the quality of their collection and transport, their repetition, and sometimes their conservation. Specimens must be collected before chemotherapy begins. The collection containers should be sterile if the specimen is taken from a closed cavity (cerebrospinal fluid, pleural effusion, abcess, etc.) and should not contain any fixative or preservative. The collected clinical specimens should be delivered to the laboratory as soon as possible. If delays in delivery or processing are anticipated, specimens should be kept at 4°C to avoid overgrowth by contaminants and to preserve the viability of mycobacteria. In case of transportation, the collection container must be sealed to prevent leakage and cushioned to prevent breakage according to regulations. Sputum or Sputum-Containing Specimens
Three spontaneously produced specimens of sputum are usually collected in clean but not necessary sterile containers. If satisfactory sputum samples, distinct from saliva or nasopharyngeal discharge, cannot be produced, specimens can be obtained by either nebulization with sterile hypertonic saline or gastric lavage or laryngeal swabs. Bronchofibroscopy for collection of aspirates, brushing, or
Bacteriology of Tuberculosis
161
lavages may be necessary for some patients (13). The collection of sputum-containing specimens, especially by nebulization or bronchoscopy, should be performed in a special area and by qualified personnel to minimize the risk of infectious aerosols. Non–Sputum-Containing Specimens
Most specimens from extrapulmonary tuberculosis (pleural, pericardial, spinal, synovial, and ascitic fluids, blood and bone marrow samples, surgical biopsies, etc.) are normally free of organisms other than mycobacteria and usually contain a limited number of tubercle bacilli. Therefore, it is necessary to collect the largest possible volume aseptically and in sterile containers in order to avoid the decontamination procedure, which threatens the viability of bacilli. Special emphasis should be given to the collection of blood for culture of mycobacteria in subjects suffering from HIV infection. Blood may be collected using the Isolator LysisCentrifugation System (Vampole Laboratories, Cranbury, NJ) or the BACTEC 13A bottle (Becton-Dickinson Diagnostic Instruments System, Cockeysville, MD), both of which contain lysing agents that allow the release of intracellular bacilli (14). Specimens expected to be contaminated (i.e., urine, stools, pus from an open abcess) may be collected in containers similar to those used for sputum specimens. Urine specimens should be collected after appropriate cleaning of the external genitalia. Early morning midstream specimens collected on three consecutive days provide the best results. B. Microscopy
Microscope examination of the stained smear is the first step in the search for tubercle bacilli in the laboratory. Direct smear prepared from necrotic or bloodtinged particles of the specimen, usually sputum, is done in most laboratories worldwide. Often, especially when all specimens are processed for culture, a portion of the digested, decontaminated specimen is used for preparing a concentrated smear. The property of acid-fastness is used to detect mycobacteria. A variety of acid-fast staining procedures are available (13). The most classic is the carbol fuchsin procedure or Ziehl-Neelsen stain. After staining, the smear is examined under the 100 oil immersion objective of a light microscope equipped with a 10 ocular lens. Acid-fast bacteria (AFB) appear as pink-red thin rods against a blue background when methylene blue is used as a counterstain. In laboratories that have a large number of smears to scan daily, fluorescent staining procedures may be used with auramine O or auramine-rhodamine as the primary fluorochrome dye. After decolorization with an acid-alcohol preparation, the smear is counterstained with either potassium permanganate, acridine orange, or thiazine
162
Grosset et al.
red, and scanned at a lower magnification with a 25 dry objective and a fluorescent microscope (13). AFB appear as yellow-green or orange fluorescent thin rods against a dark background. In these conditions, the examination is easier, more rapid, and finally more sensitive (15). Once detected on the stained smear, AFB should be reported using a 10-fold quantitative scale in order to assess the severity of the disease at the time of diagnosis and monitor the patient response to therapy (16). Though search for AFB on the stained smear is the easiest and most rapid procedure for the detection of the most infectious tuberculosis patients, it has several limitations. First, its sensitivity is relatively weak: more than 5,000–10,000 bacilli must be present per milliliter of specimen before the bacilli can be detected under the microscope. Second, because acid-fast artifacts may be present in a smear, especially after fluorochrome stain, it is necessary to carefully control bacillary morphology and to consider as doubtful any number of AFB less than 3 by fuchsin stain observed at a total magnification of 1000 or 10 by fluorochrome stain observed at 250 (13). Third, all mycobacterial species being acid-fast, the observation of AFB in a stained smear under the microscope is only evidence of mycobacterial disease, not necessarily of tuberculosis. C. Culture
Although microscopy is an essential tool in today’s tuberculosis-control programs, culture is much more sensitive than microscopy and enables specific identification and drug-sensitivity testing of the mycobacterial pathogen. Digestion and Decontamination
Most specimens submitted for culture, except those collected from closed aseptic lesions, are contaminated with more rapid growing organisms and should be decontaminated to eliminate these organisms before culture is attempted. They must be decontaminated by mixing with chemical compounds (acid, alkali, quaternary ammonium) that kill contaminant organisms more rapidly than tubercle bacilli. As tubercle bacilli are frequently included in organic debris, for example, mucus globules in the sputum, specimens must first be liquefied or digested with detergents or enzymes. In practice, both liquefaction and decontamination are accomplished simultaneously using either a single compound with both capacities, e.g., sodium hydroxide (NaOH), or a mixture of two compounds, e.g., N-acetyl-L-cysteine (NALC) and NaOH, sodium dodecyl sulfate (sodium lauryl sulfate) and NaOH, or benzalkonium chloride and trisodium phosphate (13). At the end of the procedure, decontaminated specimens are generally neutralized with a dilute acid solution and centrifuged to concentrate the tubercle bacilli. Then the supernate is decanted and the sediment inoculated onto culture medium.
Bacteriology of Tuberculosis
163
Whatever digestion-decontamination procedure is used, the procedure must be critically timed to minimize the killing of tubercle bacilli by the decontaminating agent, and great care must be taken to avoid laboratory cross-contamination (17). No one method of digestion-decontamination is ideal for all specimens and all laboratories, but the most widely used is the NALC-NaOH, which is compatible with the BACTEC culture system and molecular biology tests (18). Some procedures, using slow-acting compounds, such as pancreatin-desogen or cetylpiridinium chloride–sodium chloride, can be used for the digestion-decontamination of specimens that must be transported for several days before culture (19). Quality control methods should ensure that the specimens are being decontaminated adequately without killing excessive numbers of mycobacteria. A simple control is given by the percentage of contaminated cultures: 5% indicates that the digestion-contamination procedure is insufficient, 2% indicates that the procedure is too strong and will likely kill too many mycobacteria. All digestion-decontamination procedures, even critically done, kill 50–90% of the tubercle bacilli present in clinical specimens. Because body fluids from closed cavities usually contain small numbers of mycobacteria, these fluids should be collected aseptically and inoculated without decontamination. Culture Medium
The numerous culture media presently available may be simply classified into solid and liquid media. Solid Media
The most commonly used solid media are egg or agar based (13). Egg media (modified Löwenstein-Jensen, American Trudeau Society, Ogawa, Petragnani, etc.) are more laborious to prepare but are less expensive and have a longer shelf life than agar media. They do not require additional CO2-enriched atmosphere to initiate primary growth of mycobacteria and consequently may be placed in screw-capped tubes. The morphology of mycobacterial colonies is more typical. Conversely, agar media are easier to prepare, enable a more rapid detection of growth, but require a CO2-enriched atmosphere to initiate primary growth of mycobacteria and therefore should be placed in plates (Petri dishes) and not in screwcapped tubes. For all these reasons, egg media are more commonly used in countries where tuberculosis is still highly prevalent. On the other hand, agar media, which are better standardized than egg media, are often required for scientific work. Selective drug-containing media, either 7H10 agar based or LöwensteinJensen based, have been proposed to control contamination on primary isolation. Although useful in some circumstances, such as isolation of mycobacteria from stools (20), these media are not used in routine practice.
164
Grosset et al.
Whatever the solid medium used, two to six tubes or plates should be inoculated with 0.1–0.5 mL of the decontaminated or aseptically processed specimen. The number of tubes or plates to be inoculated depends on many factors, among which are the space available in the incubator and the clinical importance of the specimen [e.g., cerebrospinal fluid (CSF)]. In countries where M. bovis and/or M. africanum is suspected, one or two tubes or plates of 0.2% pyruvate-containing medium may be inoculated in supplement, because sodium pyruvate enhances the growth of both organisms. All media should be incubated at 35–37°C. They should be examined within 3–5 days after inoculation to enable early recognition of rapidly growing mycobacteria and of contaminated cultures, followed by once-weekly examination for at least 6 weeks, at most 3 months, before being discarded as negative. Culture is reported as positive as soon as colonies of characteristic morphology constituted of acid-fast bacilli are recognized. The report of culture should contain the amount of growth (number of colonies) recorded in a semi-quantitative way (e.g., no colonies, exact number if less than to 50, 50–100, 100–200, or 200 colonies in case of confluent growth. This is of importance for monitoring patient response to therapy (21). Liquid Media
Numerous liquid media have been developed for the culture of M. tuberculosis. Among them, only the Middlebrook 7H12 broth is routinely used for the primary isolation of mycobacteria in conjunction with the BACTEC TB 460 System (Becton-Dickinson Instrument Systems, Sparks, MD). The system is based upon the semi-automated measurements of 14CO2 produced by the growth of tubercle bacilli in the headspace of a 7H12-containing vial that has 14C-labeled palmitic acid as the only carbon source (22). In practice, 0.5 mL aliquots of the decontaminated specimen are added to vials containing 4 mL Middlebrook 7H12 broth (BACTEC 12B vial) along with an antibiotic mixture. The vials are incubated at 37°C for a total of 6 weeks (23). They are read three times a week for the first 2 or 3 weeks and weekly thereafter. As soon as a significant amount of 14CO2 is produced, a smear is performed to determine if the vials contain AFB. Because an increase in the 14CO2 amount is more rapidly detected than colonies on a solid medium, the time to detection for positive growth with the BACTEC system is significantly shorter than that with solid media; on average, 8 days with AFB smear–positive specimens and 14 days with AFB smear–negative specimens (24,25). The 7H12 broth has also been reported to yield more positive cultures from clinical specimens than solid media (26,27). The BACTEC 460 TB system may also be used to recover mycobacteria from blood and to test drug susceptibility. However, it has several limitations: inability to observe colony morphology, difficulty in recognizing mixed cultures, overgrowth by contaminants, cost, radioisotope disposal, and extensive use of needles (3).
Bacteriology of Tuberculosis
165
To reduce the difficulties inherent in the use of radioisotopes, new nonisotopic liquid media, all modified Middlebrook 7H9 broth-based, have been developed. The SeptiCheck (Roche Diagnostics Systems Inc., Nutley, NJ) and MBCheck systems (Hoffman-LaRoche, Basel, Switzerland) are broth plus solid media biphasic systems. The rates of recovery for M. tuberculosis with these systems are similar to that of BACTEC 460 system. The average time to detection is longer than with the BACTEC system but shorter than with solid media (28,29). The mycobacterial growth indicator tube, or MGIT (BBL, Becton-Dickinson, Cockeysville, MD), is a culture broth that contains a fluorescence quenching–based oxygen sensor. Under UV light, bright orange fluorescence at the bottom of the inoculated tube indicates microbial growth. In two studies, the average time to detection of M. tuberculosis was similar between MGIT and the BACTEC 460 TB system, whereas the rate of recovery was slightly inferior with MGIT (27,30). A fully automated system, the BACTEC 9000 MB system, can monitor fluorescence levels and detect the growth of microorganisms from blood and other specimens (31). Three other nonisotopic liquid media are in development. The ESP culture system II (Difco Laboratories, Detroit, MI) and the MB/Bact T (Organon Teknika Corp., Durham, NC) are fully automated, continously monitoring systems whose technology is based on detection of pressure changes in the headspace above the broth culture (32) or color changes of a sensor under the effect of CO2 release (33), respectively. With the MB Redox medium (Biotest, Dreieich, Germany), growth is monitored by a macroscopically sensible color change (34,35). Tubes are ready to use and reading is possible without any additional aid. Initial results obtained with these three systems are attractive. D. Identification of the Isolated Mycobacterial Strain
Because numerous mycobacterial species other than M. tuberculosis complex are frequently recovered from human sources in the clinical laboratory, speciation of the isolated mycobacteria is of prime importance. Identification of the Tuberculosis Complex
The careful observation of growth properties and colonial morphology on solid media directs the identification of the isolated mycobacteria. The mycobacteria belonging to the tuberculosis complex grow slowly and produce colonies after incubation for 3–6 weeks at 35–37°C. Typical colonies of M. tuberculosis, the prominent species of the tuberculosis complex and the organism responsible for human tuberculosis, are well-developed (eugonic) with a rough surface and headed up with a characteristic buff color. Colonies of mycobacteria other than those of the M. tuberculosis complex, i.e., “atypical” or nontuberculous my-
166
Grosset et al.
cobacteria (NTM), may produce pigment after exposure to light (photochromogens, such as M. kansasii and M. marinum) or even when grown in the dark (scotochromogens, such as M. gordonae and M. xenopi). Some, referred as to “rapidly growing mycobacteria,” are able to grow in less than 7 days. Others, especially those belonging to nonphotochromogenic species, such as M. terrae complex and M. avium complex (MAC), have unpigmented, sometimes rough colonies that may be easily confused with colonies of M. tuberculosis complex. Three conventional biochemical tests enable differentiation between M. tuberculosis complex and NTM: the heat-stable (68°C) catalase test, a niacin test, and growth on 0.5 g/mL para-aminosalicylic acid (PAS). M. tuberculosis complex has heat-labile catalase and is PAS susceptible; in addition, the species M. tuberculosis is niacin-test positive. With few exceptions, NTM give opposite results. Two other differential tests are now commonly used: the DNA probe assay and the BACTEC NAP test. DNA probes complementary to rRNA of M. tuberculosis complex, MAC, M. avium, M. intracellulare, M. gordonae, and M. kansasii (AccuProbe; GenProbe, San Diego, CA) are commercially available. These probes can be used to identify isolates on solid culture media and in broth culture. Because the results of probe assays are obtained in about 2 hours with excellent sensitivity and specificity and low cost, DNA probes have supplanted conventional biochemical tests. Cultures of M. tuberculosis complex in the Bactec vial can also be identified with the p-nitro- -acetylamino- -hydroxypropiophenone (NAP) test. Growth of M. tuberculosis complex is affected by NAP, whereas growth of any NTM is not. Speciation Among the M. tuberculosis Complex
Within the M. tuberculosis complex, DNA probes do not differentiate between M. tuberculosis, M. bovis, M. bovis BCG, M. africanum, and M. microti. Although closely related to M. tuberculosis, M. microti is responsible for naturally acquired tuberculosis in the vole and never encountered in the clinical laboratory. M. tuberculosis, M. bovis, M. bovis BCG, and M. africanum have clear-cut cultural, biochemical, and epidemiological differences but on the basis of DNADNA hybridization could be considered simple varieties of a single species, M. tuberculosis (36). Differentiation between them (Table 1) relies upon colony morphology, rate of growth, niacin production, and nitrate reduction as well as growth in medium containing 2 g/mL of thiophene-2-carboxylic acid hydrazide or TCH (37), and sometimes susceptibility to cycloserine and guinea pig inoculation. At isolation, colonies of M. bovis do not develop before one month of culture, are smooth, tiny (dysgonic), and white. However, after several in vitro subpassages, the small (dysgonic) colonies of M. bovis often give rise to large rough colonies having a morphology similar to those of M. tuberculosis. Colonies of M.
Bacteriology of Tuberculosis
167
Table 1 Speciation Among the Mycobacterium tuberculosis Complex
Mycobacteria M. tuberculosis M. bovis M. bovis BCG M. africanum M. microti
Growtha Colonies rate (weeks) Morphology Pigmentation 3–4 ≥4 ≥4 ≥4 3–4
Re Sd Re Rd Re
Buff White Buff Matte Buff
Niacin production
Nitrate reduction
Growth on cycloserine (30 mg/L)
to
to
?
Growth on Virulenceb TCHb for (2 mg/L) guinea pig to
a
For primary isolation on solid media. For strain susceptible to isoniazid. R rough; S smooth; e eugonic; d dysgonic; positive; negative; TCH thiophene-2-carboxylic hydrazide.
b
bovis BCG have growth and morphology characteristics similar to those of M. tuberculosis. Different geographic varieties of M. tuberculosis have been observed. In Europe and the United States the organisms grow slowly in culture into well-developed (eugonic), rough colonies with a characteristic buff color. In Southeast Asia, colonies of M. tuberculosis are small and smooth like those of M. bovis but with the characteristic M. tuberculosis buff color. M. africanum strains often grow poorly and slowly as minute flat and rough colonies with a matte color. M. bovis and M. bovis BCG neither accumulate niacin nor have nitrate reductase. Their growth is generally inhibited by TCH except when the strains are isoniazid resistant. They are naturally resistant to pyrazinamide. M. africanum strains may or may not have nitrate reductase activity and accumulate more or less niacin. Their growth may or may not be inhibited by TCH. In eastern regions of Central Africa (Rwanda variety), they have characteristics close to those of M. tuberculosis, but in West Africa (Dakar variety), they are closer to those of M. bovis. They are often resistant to thiacetazone. Inoculation into the guinea pig enables one to assess the virulence of the different strains of the M. tuberculosis complex. Lack of virulence is a crucial characteristics of M. bovis BCG, and decreased virulence is a characteristic of the normally virulent M. tuberculosis and M. bovis when they are resistant to isoniazid. Identification of Atypical or Nontuberculous Mycobacteria
Elaborate species differentiation of atypical mycobacteria is accomplished with a series of tests, including growth at different temperatures, pigment production, biochemical properties and drug susceptibility; for details on the identification procedures, the reader should consult specialized references (3,13). However, it should be emphasized that the identification of NTM has benefited from the development of specific DNA probes (GenProbe, San Diego, CA) and the determi-
168
Grosset et al.
nation of the mycolic acid pattern (38). The latter method, particularly useful for the identification of difficult-to-identify NTM, requires high-performance liquid chromatography, thin-layer chromatography, or gas-liquid chromatography and, therefore, is still reserved to large reference laboratories.
V. Strain Typing of M. tuberculosis Typing of M. tuberculosis strains is of great epidemiological value for tracing transmission of M. tuberculosis in the community, deciding whether relapse of tuberculosis in a given patient is due to endogenous reactivation or exogenous reinfection, and demonstrating laboratory contamination of specimens or even of laboratory workers (see Chap. 11). Since the beginning of drug therapy for tuberculosis, unusual drug-susceptibility patterns have been used for epidemiological purposes but with great limitations. The development of a phage-typing system based on the use of 12 mycobacterial phages raised many expectations (39). Unfortunately, only four phage types were officially recognized: Ao, Aox, B, and C. Type B was common in Europe and the United States, type A was more common in Japan and Hong Kong. No relationship existed between phage typing and drug resistance. More recently, a method based on the study of DNA polymorphism caused by an insertion sequence (IS) 6110 or 986 (40) integrated at various sites in the chromosome and specific of the M. tuberculosis complex has been developed (41). The M. tuberculosis chromosome is first digested into DNA fragments of different sizes by a restriction endonuclease. DNA fragments are then transferred and hybridized with an IS 6110 probe. Thus, only the restriction fragments carrying the IS are revealed (Fig. 1). This method is referred to as restriction fragmentlength polymorphism (RFLP) or DNA fingerprinting (42). As the distribution of IS 6110 is variable from one strain to another in the number of copies (1–20) and their integrations sites, the banding patterns differ from one DNA to another. If two patients were infected with the same strain, the banding pattern of their DNA would be similar; if they were infected with different strains, the banding pattern would usually be different. Identical or similar patterns are generally observed in case of relapse (44). Analysis and comparisons of RFLP patterns need the use of a computer-assisted method when more than 10 strains are compared (45). DNA fingerprinting is at present the most elaborate technique used to characterize individual strains of M. tuberculosis and conduct scientifically based epidemiological studies, thus to trace strains in the community. Standardization of the method (reference strains used as markers, standardization of all steps of the technique, universal computer-assisted method) means that it is now possible to compare strains isolated around the world.
Bacteriology of Tuberculosis
169
Figure 1 IS 6110-based DNA fingerprint of 13 Mycobacterium tuberculosis complex isolates. The sizes of restriction fragments are given in kilobases (kb) on the left. Lane 1 corresponds to the Mt 14323 reference strain. Other lanes are from isolates of different patients. Note similar patterns between lanes 6 and 8 and between lanes 12 and 14 that are, respectively, from epidemiologically related patients. (Courtesy of W. Sougakoff and N. Lemaitre.)
A new method, “spoligotyping,” which is easier and more rapid, is currently under investigation (46). VI. Drug Activity Against M. tuberculosis Since the beginning of the antibiotic era, assessing the activity of different compounds against M. tuberculosis and conversely the susceptibility of different strains of M. tuberculosis to a given compound became common. Well-defined in
170
Grosset et al.
vitro methods have been developed to measure the minimal inhibitory concentration (MIC) of drugs with known activity and of compounds with unknown activity against M. tuberculosis. The activity of a drug or a combination of drugs can also be assessed in vivo in an experimental animal model. Even more important, several methods have been devised to test, in the clinical laboratory, the susceptibility of M. tuberculosis to the drugs that are routinely used in the chemotherapy of tuberculosis. A. In Vitro Assessment of Drug Activity (MIC Determination)
The MIC determination may be performed on solid or liquid culture media. When solid media are used, the following protocol may be recommended. The drug to be tested is initially dissolved, subsequently diluted with distilled water, and incorporated into 10% oleic acid albumin dextrose catalase–enriched 7H10 or 7H11 agar medium, with twofold diluted final concentrations that may range from 16 to 0.03 g/mL. The reference H37Rv strain of M. tuberculosis is subcultured in Tween 80–containing 7H9 broth at 37°C for 7 days; then the turbidity of the resultant suspension is adjusted with distilled water to match that of a standard suspension of 1 mg/ml M. bovis BCG (similar to a McFarland 1 standard) and 0.05 mL of 103 and 105 mg/mL of the diluted suspensions are plated, respectively, on the drug-free and drug-containing media. The MIC is defined as the lowest drug concentration that inhibits more than 99% of the bacterial growth, as compared with the growth on drug-free medium, after incubation at 37°C for 21–28 days. Among liquid media, 7H9 broth without Tween 80 (which may enhance the antimicrobial activity of the test drug) and BACTEC broth are recommended. As with solid media, the drug to be tested should be dissolved, diluted, and incorporated into the broth, with twofold dilutions. Then the drug-free and drug-containing broths are inoculated with the H37Rv strain and incubated at 37°C. The MIC is also defined as the lowest drug concentration that inhibits bacterial growth, as compared with the growth in drug-free broth. B. In Vivo Assessment of Drug Activity in the Animal Model
Because of its great susceptibility to M. tuberculosis infection, the guinea pig has been used for many years in the clinical laboratory to detect the presence of tubercle bacilli in clinal specimens. It has also been used to assess the airborne transmission of tuberculosis (47), the comparative virulence of differents strains of M. tuberculosis (48), and the protective value of M. bovis BCG (49). It might be the experimental animal of choice for all these purposes. Although it has been used to test the antituberculous activity of several drugs (50,51), the model of choice for experimental chemotherapy is the mouse (52–55) because it is a small and robust animal that is easy to reproduce and handle, even though it is far from being as
Bacteriology of Tuberculosis
171
sensitive as the guinea pig to M. tuberculosis. Furthermore, the course of the disease that follows experimental infection with M. tuberculosis is different from that of the disease in humans. However, the mouse model is able to reproduce bacillary populations of comparable size to those observed in the lung cavity of human tuberculosis (54), and the infection can be treated with antimicrobial drugs used at equipotent (56) dosages to those given to humans (for a vast majority of drugs, with the noticeable exception of rifampin, the equipotent dosages are 12 times larger in the mouse than in humans). With the exception of aminoglycosides, which should given subcutaneously, drugs are given orally with an esophageal cannula (gavage) to each individual animal, thus mimicking human treatment. If used with great care, the mouse model provides responses to treatment that are predictive of the responses in humans (56). Because the aim of experimental chemotherapy is to obtain results that can be extrapolated to human beings, there is no need to use inbred mice such as BalbC, C57BL6, or C3H; the most frequently strain of mice used is the common outbred “Swiss” mouse. As in clinical trials, a sufficient number of mice should be used to compensate for individual variations. Inbred mice are, however, of great interest when factors other than drugs must be excluded. Mice are usually infected by the intravenous route with a standard amount of tubercle bacilli (56). The aerogenic route (57), more closely mimicking clinical infection than the intravenous route but requiring special devices and sophisticated safety measures, is more useful for testing the host-parasite relationship than for chemotherapy studies (58). The reference H37Rv strain of M. tuberculosis, the virulence of which is maintained through regular passages in the mouse and which is naturally susceptible to all antituberculous drugs, is the strain of choice. After intravenous infection with about 5 106 colony-forming units (CFU), up to 90% of mice die within the first month after infection from overwhelming tuberculosis with more than 108 CFU in the lungs and 107 CFU in the spleen (59,60). When the inoculum is smaller (about 5 103 CFU) mice are able to contain and control the initial multiplication of bacilli in such a way that the infection remains chronic and nonfatal, the size of the bacillary population not exceeding 106 CFU. A still more limited population of M. tuberculosis can be obtained if mice are vaccinated with M. bovis BCG one month before they are infected with a small inoculum (61). The activity of a single drug or a combination of drugs is monitored by the survival/mortality rate, the evolution of body weight, the extent of gross lesions, and the enumeration of CFU in the organs (spleen, lung) before, during, and after the course of treatment. Experimental chemotherapy had contributed to the assessment of all antituberculosis drugs, of standard streptomycin plus isoniazid long-course therapy, and also of short-course therapy with the combination of isoniazid, rifampin, and pyrazinamide. It enabled the demonstration in vivo of the bactericidal activity of the new fluoroquinolones, especially ofloxacin, lev-
172
Grosset et al.
ofloxacin, and sparfloxacin, against M. tuberculosis (59,62). It permitted the study of the role of the rifamycin derivatives in preventive and curative treatments of tuberculosis, emphasizing the potential role of rifapentine, a long-lasting rifamycin derivative, in directly observed intermittent preventive therapy (63). C. The Drug-Susceptibility Test
In tuberculosis, drug resistance appearing during treatment designated as acquired or secondary resistance is the consequence of monotherapy; it results from the selection and multiplication of resistant mutants preexisting in the tubercle bacillus population before therapy. Multiple drug resistance is the consequence of sequential monotherapies. Drug resistance observed before treatment, designated as primary resistance, is the consequence of exposure to a drug-resistant source of infection. As the emergence of secondary drug-resistant M. tuberculosis strains and even of multidrug-resistant strains, particularly in AIDS patients (64), is increasingly reported from many countries (65), it is essential to determine the drug sensitivity of isolates from previously treated patients in order to design an effective treatment regimen. At least in theory it is less essential to determine the drug sensitivity of isolates from newly diagnosed, previously untreated patients because these patients usually harbor drug-susceptible organisms and are started on standard therapy well before the results of the pretreatment drug susceptibility test might be known. However, newly diagnosed patients may have developed disease with primary drug-resistant organisms. They also may have been previously treated, and the previous treatment may have remained undetected because it was not disclosed by the patients (66) or was forgotten by them. For these reasons, the American Thoracic Society (ATS) recommended that initial isolates from all patients be tested for drug susceptibility to confirm the anticipated effectiveness of chemotherapy or to choose the best combination of active drugs (67). In addition, ATS recommended that the tests be repeated if cultures were still positive after 2 months of treatment. Of course, such recommendations are only applicable to those countries having the potential to perform cultures for all cases of tuberculosis. For other countries, the priority should be given to isolates from previously treated patients. The antituberculous drugs that should be tested in priority include the firstline drugs isoniazid, rifampin, ethambutol, and streptomycin. Although pyrazinamide is also a first-line drug, it is not included in the priority list because its susceptibility is difficult to test. Pyrazinamide, a drug active only at an acid pH, should be incorporated in a culture medium in which the pH has been lowered to 5.5; at such a low pH, only 1–10% of the colonies grow in a control medium compared to the number of colonies growing at the usual pH 6.8. Despite the inclusion
Bacteriology of Tuberculosis
173
of control media at pH 6.8 and 5.5, the results of pyrazinamide-susceptibility testing cannot be interpreted in two frequently observed instances: when there is no growth in the control at pH 5.5 and in the pyrazinamide-containing medium or when there is extensive growth in both controls at pH 6.8 and at pH 5.5 and in the pyrazinamide-containing medium. Further susceptibility tests should be performed if resistance to the main drugs isoniazid and rifampin is suspected because of previous treatment history or infection with multidrug-resistant organisms. Secondary drugs for testing include pyrazinamide, ethionamide, kanamycin or amikacin, capreomycin, cycloserine, and at least a fluoroquinolone. The Standard Procedures
Four methods have been described for determining the antimicrobial susceptibilities of M. tuberculosis: the proportion method, the radiometric or BACTEC method, which is based on the same principle as the proportion method, the absolute concentration method, and the resistance ratio method (68). The proportion method and the BACTEC method are the most generally used. The proportion method is performed either on a solid egg-based or agarbased 7H10 medium containing an uniform, specified concentration of drug (“critical concentration”) (69). The BACTEC method (70) is performed in 12B broth vials also containing a critical drug concentration (68). The critical concentration (Table 2) is that which inhibits the growth of susceptible organisms without affecting the growth of the drug-resistant mutants. With the proportion method, the enumeration of M. tuberculosis colonies growing on drug-free and on drug-containing media inoculated with different dilutions of M. tuberculosis suspension enables the calculation of the proportion of drug-resistant mutants. If the proportion is less than the “critical proportion” that Table 2 Critical Concentration of Drugs for Susceptibility Testing with the Proportion Method on 7H10, 7H11, or Loewenstein-Jensen (LJ) Media or with the BACTEC Method Drug concentration (mg/L) Drugs
7H10
7H11
LJ
Isoniazid Rifampin Pyrazinamide Ethambutol Streptomycin PAS
0.2 1 25 5 2 2
0.2 1 ? 7.5 2 8
0.2 40 200 2 4 0.5
BACTEC 12B broth 0.1 2 100 2.5 2 4
174
Grosset et al.
defines drug resistance, the strain is considered susceptible; if it is greater, the strain is considered resistant. Using 7H10 agar, the critical proportion is 1% for all drugs (71); using Löwenstein-Jensen medium, it is 1% for isoniazid, rifampin, streptomycin and PAS and 10% for other drugs (69). With the BACTEC method, drug-containing vials are inoculated with a suspension of the primary culture, the turbidity of which has been adjusted to a McFarland 0.5 standard. A 1:100 dilution of the inoculum is used as control. As soon as the growth index (GI) of the control is positive, the drug-susceptibility test is ready for interpretation: if the GI of the control vial is greater than the GI of the drug-containing vial, the strain is susceptible; if it is less, the strain is resistant. The solid medium may be directly inoculated with the decontaminated smear-positive specimen (direct susceptibility test) or with a suspension prepared from the primary culture (indirect susceptibility test). In the direct test, the specimen is diluted according to the number of AFB observed in the stained smear (Table 3) and two dilutions are inoculated. In the indirect test, a well-dispersed suspension of the primary culture is diluted to 103 and 105 mg wet weight per mL. In both cases, two dilutions are inoculated under the volume of 0.1 or 0.2 mL onto drug-containing (at the critical concentration) and drug-free media to provide a valid interpretation of the proportion of drug-resistant CFU. Due to the time required for the growth of colonies, the results of susceptibility tests on solid media are obtained after 3–6 weeks of incubation at 37°C. If a direct susceptibility test has been performed from the patient’s specimen, the results are available at the same time as those of culture, 3–6 weeks after inoculation (68). Those of an indirect susceptibility test are obtained 2 or 3 months after the inoculation of the patient’s specimen. Using the BACTEC 460 TB system, the results of drug-susceptibility testing can be obtained in as little as 5 days, depending on the inoculum size. The 14 CO2 is measured in drug-containing vials and in drug-free (control) vials (100fold lower inoculum). When the amount of 14CO2 in the drug-containing vial is equal or greater to the amount of 14CO2 in the control vial, at least 1% of the bacilli are resistant to the drug and the strain is considered resistant. The method is reliTable 3 Dilutions of Decontaminated Specimen for Inoculation in Direct Drug Susceptibility Testing by the Proportion Method No. of AFB observed per field Suspensions to be inoculated Undiluted and 102 101 and 103 102 and 104 Source: Adapted from Ref. 68.
Niehl-Neelsen (100)
Fluorochrome (40)
1 1–9 10
1–9 10–99 100
Bacteriology of Tuberculosis
175
able and at present widely used to test the susceptibility of M. tuberculosis to the first-line drugs, including pyrazinamide (72,73). It is not yet standardized for the second-line drugs. M. tuberculosis drug-susceptibility tests can be performed by comparing the fluorescence of a drug-containing MGIT with that of a growth-control MGIT without drug. The evaluation of the system is in progress (74). A newer, more elegant method for testing drug susceptibility is based on the use of a luciferase reporter mycobacteriophage (75). As only viable mycobacteria can multiply specific mycobacteriophages, drug resistance results in the production of light by organisms first cultivated in the presence of a given antimicrobial and then submitted to luciferase reporter mycobacteriophages. Detection of Mutations Associated with Drug Resistance
The genes encoding for the target of the first-line antituberculosis drugs as well as the mutations responsible for the resistant phenotypes have been identified (76–80). Because the mutations are localized in limited regions of the genes encoding for the drug target, they can be detected. After PCR amplification, the mutation is identified by sequencing the PCR products or by submitting them to simpler methods. One of these is the single strand conformation polymorphism method or PCR-SSCP (81). After denaturation of the PCR product, the single strands of DNA are subjected to electrophoresis on polyacrylamide gel. Their position on the gel, which depends on the presence or absence of mutations, is then characterized. In theory, the method is simple and rapid (48–72 hr) and may be applied to smear-positive specimens. In practice, the method is costly, rather sophisticated, and above all does not permit detection of all mutations conferring resistance, especially to rifampin. Another method that is much easier to perform is the Line Probe Assay, or LIPA (82). After denaturation of the PCR product, the single strands are hybridized with nine probes immobilized at known locations on a membrane strip. Five of these hybridize exclusively with wild-type sequences and each of the four others with a sequence carrying a particular mutation (Fig. 2). The presence of hybrids is revealed by an enzymatic color reaction. The method, which is available as a commerical kit, Inno-LIPA RIF.TB (Immunogenetic NV Zwijndrecht, Belgium) for the detection of rifampin resistance, is relatively simple and cheap and may be applied to smear-positive specimens. It gives promising results although it is not able to detect all mutations conferring rifampin resistance (83,84). VII. Immunodiagnostic Tests for Tuberculosis The tuberculin skin test (see Chap. 12) is well established as an immunodiagnostic test for tuberculosis infection. However, it can distinguish neither between ac-
176
Grosset et al.
Figure 2 Rifampin susceptibility testing of Mycobacterium tuberculosis complex with the Line Probe Assay (LIPA). Lane 1: rifampin-susceptible strain (hybridization with the five susceptible sequences of the rpoB gene and no hybridization with any of the four resistant sequences of the rpoB gene); Lanes 2–6: rifampin-resistant strains with mutations at different sites of the gene. (Courtesy of W. Sougakoff and N. Lemaitre.)
tive tuberculosis disease and latent infection nor between M. tuberculosis infection and infection with other mycobacteria (85). Because of the common antigens shared by all species of the genus Mycobacterium, numerous efforts have been made to obtain and purify antigens specific to the M. tuberculosis complex. In addition, the most sophisticated procedures to detect corresponding antibodies, such as immunoelectrophoresis, hemagglutination tests, fluorescent antibody tests, radioimmunoassays, and enzyme-linked immunosorbent assays (ELISA), have been used. Despite all efforts, increased specificity often resulted in decreased sensitivity (86–88). Even with the
Bacteriology of Tuberculosis
177
most purified antigens, specificity remains about 96% and sensitivity is no better than 70% (89). Specificity and sensitivity are increased if ELISA results obtained with a set of purified antigens are combined (88,90). Although, for the present time, no immunodiagnostic test can be recommended for clinical use, research efforts should continue in order to develop an immunological test which enables the discrimination of patients with active disease among the sputum smear-negative, symptomatic patients suspected of having tuberculosis.
VIII. Direct Detection of M. tuberculosis by Nucleic Acid Amplification Because of the lengthy time required for cultivating M. tuberculosis, the application of nucleic acid amplification for the rapid detection of M. tuberculosis nucleic acids in clinical specimens has been extensively studied (3). Of the multiple PCRbased (18,91) and non–PCR-based (92–96) amplification procedures developed, three have been made commercially available: the Gen-Probe Amplified Mycobacterium tuberculosis Direct Test, or MTD (Gen-Probe Incorporated, San Diego, CA), the AMPLICOR Mycobacterium tuberculosis Test (Roche Diagnostic Systems, Inc., Branchburg, NJ), and the LCX Probe System (Abbott Laboratories, Diagnostic Division, Chicago). With these tests, and for smear-positive and smear-negative clinical specimens, the sensitivity has been demonstrated to be 95–96% and 48–53%; the specificity to be 100% and 96–99%; and the positive predictive value to be 100% and 24–58%, respectively (18,92,93,97–101). These values are in favor of the clinical use of MDT, AMPLICOR, and LCX in smear-positive specimens (102,103). In these specimens, the nucleic acid amplification tests may rapidly confirm the diagnosis of tuberculosis or identify the presence of nontuberculous mycobacteria, information of clinical value especially for HIV-infected patients (104,105). In smear-negative specimens, the nucleic acid amplification tests would, in spite of their relatively high specificity, add a relatively limited number of tuberculosis cases but a relatively high number of false-positive results because of the low prevalence of M. tuberculosis complex in these specimens. As a consequence, the U.S. Food and Drug Administration (FDA) stated in 1996 that the sole indication of nucleic acid amplification in the diagnosis of tuberculosis was the “smear-positive respiratory tract specimens from patients who have not been on antituberculosis medication for seven or more days; or have not been treated for tuberculosis within the last twelve months” (106). Of course, what holds true for respiratory tract specimens holds true also for extrarespiratory specimens because of the still lower prevalence of M. tuberculosis complex in extrarespiratory than in respiratory specimens (107,108).
178
Grosset et al.
Although the wise recommendations of FDA emphasize the amount of care clinicians should take in prescribing and interpreting the nucleic acid–amplification tests for a rapid diagnosis of tuberculosis, these tests remain full of potential (109). In particular, it is likely that the future lies in the use of amplification tests for sputum-negative patients suspected of tuberculosis. All research efforts should be made for that future to occur as soon as possible. References 1. Kent PT, Kubica GP. Public Health Mycobacteriology: A Guide for the Level III Laboratory. Atlanta: Centers for Disease Control, U.S. Department of Health and Human Services, 1985. 2. Cernoch PL, Enns RK, Saubolle MA, Wallace RJ, Jr. Cumitechs 16A. Washington, DC: American Society for Microbiology, 1994. 3. Nolte FS, Metchock B. Mycobacterium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, ed. Manual of Clinical Microbiology, 6th ed. Washington, DC: American Society for Microbiology, 1995:400–437. 4. Connell ND, Nikaido H. Membrane permability and transport in Mycobacterium tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: American Society for Microbiology, 1994:333–352. 5. Barsdale L, Kim KS. Mycobacterium. Bacteriol Rev 1977; 41:217–372. 6. Minnikin DE. Lipids: complex lipids, their chemistry, biosynthesis and roles. In: Ratledge C, Stanford J, eds. The Biology of the Mycobacteria. Section 3. Vol. I. London: Academic Press Ltd., 1982:95–184. 7. Jarlier V, Nikaido H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonae. J Bacteriol 1990; 172:1418–1423. 8. Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 1994; 123:11–18. 9. Trias J, Jarlier V, Benz R. Porins in the cell wall of mycobacteria. Science 1992; 258:1479–1481. 10. Koch R. Weitere Mitteilung über das Tuberkulin. Dtsch Med Wochenschr 1891; 17:1189–1192. 11. Wayne LG. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. Am Rev Respir Dis 1976; 114:807–811. 12. Ratledge C. Nutrition, growth and metabolism. In: Ratledge C, Stanford J, eds. The Biology of the Mycobacteria. Section 5. Vol. I. London: Academic Press Ltd., 1982:186–271. 13. Kubica GP. Clinical microbiology. In: The Mycobacteria: A Sourcebook. Part A. Section 7. New York: Marcel Dekker, 1984:133–175. 14. Gill VJ, Park CH, Stock F, Gosey LL, Witebsky FG, Masur H. Use of lysis centrifugation (Isolator) and adiometric (Bactec) blood culture systems for the detection of mycobacteremia. J Clin Microbiol 1985; 22:543–546. 15. Strumpf IJ, Tsang AY, Sayre JW. Reevaluation of sputum staining for the diagnosis of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119:599–602.
Bacteriology of Tuberculosis 16. 17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
179
Canetti G. The Tubercle Bacillus in the Pulmonary Lesion of Man. New York: Springer, 1955. Burman WJ, Stone BL, Reves RR, Wilson ML, Yang Z, El-Hajj H, Bates JH, Cave MD. The incidence of false positive cultures for Mycobacterium tuberculosis. Am J Respir Crit Care Med 1997; 155:321–326. Brisson-Noël A, Aznar C, Chureau C, Nguyen S, Pierre C., Bartoli M, Bonete M, Pialoux G, Gicquel B, Garrigue G. Diagnosis of tuberculosis by DNA amplification in clinical practice evaluation. Lancet 1991; 338:364–366. Smithwick RW, Stratigos CB, David HL. Use of the cetylpyridinium chloride and sodium chloride for the decontamination of sputum specimens that are transported to the laboratory for the isolation of Mycobacterium tuberculosis. J Clin Microbiol 1975; 31:1677–1682. Yajko DM, Nassos PS, Sanders CA, Gonzalez PC, Reingold AL, Horsburgh CR, Hopewell P, Chin DP, Hadley WK. Comparison of four decontamination methods for recovery of Mycobacterium avium complex from stools. J Clin Microbiol 1993; 28:1451–1453. Jindani A, Aber V, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939–949. Middlebrook G, Reggiardo Z, Tigert WD. Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir 1977; 115:1066–1069. Good RC, Mastro TD. The modern mycobacteriology laboratory: how it can help the clinician. In: Snider DE, ed. Clinics in Chest Medicine. Vol. 10. No. 3. Philadelphia: Saunders, 1989:315–322. Roberts GD, Koneman EW, Kim YK. Mycobacterium. In: Hausler WJ Jr., Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of Clinical Microbiology. 5th ed. Washington, DC: American Society for Microbiology, 1991:304–339. Morgan MA, Horstmeier CD, De Young DR, Roberts GD. Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18:384–388. Wilson ML, Stone BL, Hilbred MV, Reves RR. Comparison of recovery rates for mycobacteria from BACTEC 12B vials, Middlebrook 7H11-selective 7H11 biplates and Löwenstein-Jensen slants in a public health mycobacteriology laboratory. J Clin Microbiol 1995; 33:2516–2518. Pfyffer GE, Welscher HM, Kissling P, Cieslak C, Casal MJ, Gutierrez J, RüschGerdes S. Comparison of the mycobacteria growth indicator tube (MGIT) with radiometric and solid culture for recovery of acid fast bacilli. J Clin Microbiol 1997; 35:364–368. Isenberg HD, D’Amato RF, Heifets L, Murray PR, Scardamaglia M, Jacobs MC, Alperstein P, Niles A. Collaborative feasibility study of a biphasic system (Roche Septi Check AFB) for rapid detection and isolation of mycobacteria. J Clin Microbiol 1991; 29:1719–1722. Piersimoni C, Morbiducci V, De Sio G, Scalise G. Comparative evaluation of the MB-check system for recovery of mycobacteria from clinical specimens. Eur J Clin Microbiol Infect Dis 1992; 11:1174–1177.
180
Grosset et al.
30.
Casal M, Gutierrez J, Vaquero M. Comparative evaluation of the mycobacteria growth indicator tube with the Batec 460 TB system and Löwenstein-Jensen medium for isolation of mycobacteria from clinical specimens. Int J Tuberc Lung Dis 1997; 1:81–84. Van Griethuysen AJ, Jansz AR, Buiting AGM. Comparison of fluorescent Bactec 9000 MB System, SeptiCheck AFB System and Löwenstein-Jensen medium for detection of mycobacteria. J Clin Microb 1996; 34:2391–2394. Woods GL, Fish G, Plaunt M, Murphy T. Clinical evaluation of Difco ESP culture system II for growth and detection of mycobacteria. J Clin Microbiol 1997; 35:121–124. Thorpe TC, Wilson ML, Turner JE, Di Guiseppi JL, Willert M, Mirrett S, Barth Reller L. BacT/Alert: an automated colorimetric microbial detection system. J Clin Microbiol 1990; 28:1608–1612. Naumann L, Lehn N, Wolf H, Reischl U. New rapid cultural nonradiometric method for the detection of mycobacteria. Abstract U-144, American Society Microbiol Meeting, Miami, May 4–8, 1997. Benjamin WH, Beverly A, Gibbs L, Waller M, Nix S, Mose SA, Waites KB, Willert M. Comparison of the MB/Bact with a revised reconstitution fluid to the Bactec 460 for detection of mycobacteria in clinical specimens. Abstract D-98, 37th ICAAC Toronto, Canada, Sept. 28–Oct. 1, 1997. Wayne LG. Mycobacterial speciation. In: Kubica GP, Wayne LG, eds. The Mycobacteria: A Sourcebook. Part 1. Section 2. New York: Marcel Dekker, 1984:25–65. Bönicke R. Die Differenzierung humaner und boviner Tuberkelterien mit Hilfe von Thiophen-2-carbonsaure-hydrazid. Naturewissenschaften 1958; 46:392–393. Butler WR, Jost KC, Kilburn JO. Identification of mycobacteria by high-performance liquid chromatography. J Clin Microbiol 1991; 29:2468–2472. Crawford J, Bates JH. Phage typing of mycobacteria. In: Kubica GP, Wayne LG, eds. The Mycobacteria: A Sourcebook. Part A. Section 6. New York: Marcel Dekker, 1984:123–132. Thierry D, Brisson-Noël A, Vincent-Levy-Frebault V, Nguyen S, Gueston JL, Gicquel B. Characterisation of a Mycobacterium tuberculosis insertion sequence IS6110 and its application in diagnosis. J Clin Microbiol 1990; 28:2668–2673. Van Embden JDA, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM, Small PM. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommandations for a standardized methodology. J Clin Microbiol 1994; 31:406–409. Daley CL, Small PM, Schecter GF, Schoolnil GK, Mc Adam RA, Jacobs R Jr, Hopewell PC. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restrictionfragment-length polymorphisms. N Engl J Med 1992; 326:231–235. Mazurek G, Cave M, Eisenach K, Bates J, Crawford J. Chromosomal DNA fingerprint patterns produced with IS6110 as strain-specific markers for epidemiology study of tuberculosis. J Clin Microbiol 1991; 29:2030–2033. Cave MD, Eisenach KD, Templeton G, Salfinger M, Mazurek G, Bats JH, Crawford JT. Stability of DNA fingerprint pattern produced with IS6110 in strains of Mycobacterium tuberculosis. J Clin Microbiol 1994; 32:262–266.
31.
32.
33.
34.
35.
36.
37. 38. 39.
40.
41.
42.
43.
44.
Bacteriology of Tuberculosis 45.
46.
47. 48.
49. 50. 51. 52. 53. 54. 55. 56.
57.
58.
59. 60.
61.
62.
181
Van Soolingen D, Hermans PWM, de Haas PEW, Soll DR, van Embden JDA. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991; 29:2578–2586. Groenen PMA, Bunschoten AE, van Soolingen D, van Embden JDA. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method. Mol Microbiol 1993; 10:1057–1085. O’Grady F, Riley RL. Experimental airborne tuberculosis. Adv Tuberc Res 1963; 12:150–190. Mitchison DA, Wallace JG, Bhatia AL, Selkon JB, Subbaiah TV, Lancaster MC. A comparison of the virulence in guinea-pigs of South Indian and British tubercle bacilli. Tubercle 1960; 41:1–22. Smith DW. Protective effect of BCG in experimental tuberculosis. Adv Tuberc Res 1985; 22:1–99. Dickinson JM, Mitchison DA. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 1970; 51:82–94. Dickinson JM, Mitchison DA. Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle 1976; 57:251–258. Raleigh GW, Youmans GP. The use of mice in experimental chemotherapy of tuberculosis. I. Rationale and review of litterature. J Infect Dis 1948; 82:197–204. Pierce SH, Dubos RJ, Schaefer WB. Multiplication and survival of tubercle bacilli in the organs of mice. J Exp Med 1953; 97:189–205. Grumbach F. Etudes chimiothérapiques sur la tuberculose avancée de la souris. Adv Tuberc Res 1965; 14:31–96. Lefford MJ. Diseases in mice and rats. In: Kubica GP, Wayne LG, eds. The Mycobacteria: A Sourcebook,. New York: Marcel Dekker, 1984:947–977. Grosset J, JI B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria. Vol. II. Chemotherapy. New-York: Chapman & Hall, 1998:51–97. Orme IM, Collins FM. Mouse model for tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: ASM Press, 1994:113–134. Valvay SE, Sanchez MPC, Shinnick TF, Orme I, Agerton T, Hoy D, Jones JS, Westmoreland H, Onorato I. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 1998; 338:633–639. Truffot-Pernot C, Ji B, Grosset, J. Activities of pefloxacin and ofloxacin against mycobacteria: in vivo and mouse experiments. Tubercle 1991; 72:110–114. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O’Brien RJ, Olliaro P, Roscigno G, Grosset J. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148:1541–1546. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989; 140:1189–1193. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against M. tuberculosis in mice. Antimicrob Agents Chemother 1993; 37:407–413.
182
Grosset et al.
63. Chapuis L, Ji B, Truffot-Pernot C, O’Brien R, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 1994; 150:1355–1362. 64. Sepkowitz KA, Raffalli J, Riley L, Kiehn TE, Armstrong GD. Tuberculosis in the AIDS era. Clin Microbiol Rev 1995; 8:180–199. 65. Pablos-Méndez A, Laszlo A, Bustreo F, Binkin N, Cohn DL, Lambregts-van Weezenbeek CSB, Kim SJ, Chaulet P, Nunn P, Raviglione MC. Anti-Tuberculosis Drug Resistance in the World. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO/TB/97.229, Geneva, 1997. 66. Cohn DL, Bustreo F, Raviglione MC. Drug resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997; 24(suppl 1):S121–S130. 67. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359–1374. 68. Inderlied CB, Salfinger M. Antimicrobial agents and susceptibility tests: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology, 1995:1385–1404. 69. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, Meissner G, Mitchison DA, Sula L. Mycobacteria. Laboratory methods for testing drug sensitivity and resistance. Bull WHO 1963; 29:565–578. 70. Siddiqi SH, Hawkins JE, Laszlo A. Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by radiometric and two conventional methods. J Clin Microbiol 1985; 22:919–923. 71. Kubica GP, Dye WE. Laboratory Methods for Clinical and Public Health Mycobacteriology. Washington, DC: U.S. Government Printing Office, 1967. 72. Bird BR, Denniston MM, Huebner RE, Good RC. Changing practices in mycobacteriology: a follow-up survey of state and territorial public health laboratories. J Clin Microbiol 1996; 34:554–559. 73. Miller MA, Thibert L, Desjardins F, Siddiqi SH, Dascal A. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of BACTEC method with pyrazinamidase assay. J Clin Microbiol 1995; 33:2468–2470. 74. Walters SB, Hanna BA. Testing susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterial growth indicator tube method. J Clin Microbiol 1996; 34:1565–1567. 75. Jacobs WR Jr, Barlett RG, Udani R, Chan J, Kalkut G, Sosne G, Kieser T, Sarkis GJ, Hatfull GF, Bloom BR. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science 1993; 260:819–822. 76. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopper K, Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341:647–650. 77. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358:591–593. 78. Banerjee A, Dubnau E, Quemard A, Balausubramanian V, Sun Um K, Wilson T, Collins D, de Lisle G, Jacobs WR. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263:227–230.
Bacteriology of Tuberculosis
183
79. Honoré N, Cole S. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994; 38:238–242. 80. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to antituberculous drug pyrazinamide in tubercle bacillus. Nature Med 1996; 2:662–667. 81. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. Direct, automated detection of rifampin resistant Mycobacterium tuberculosis by polymerase chain reaction and single stand conformation polymorphism analysis. Antimicrob Agents Chemother 1993; 37:2054–2058. 82. De Beenhouver H., Lhiang Z, Jannes G, Mijs W, Machtelinckx L, Rossau R, Traore H, Portaels F. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tubercle Lung Dis 1995; 76:425–430. 83. Cooksey RC, Morlock GP, Glickman S, Crawford JJ. Evaluation of a Line probe assay kit for characterization of rpo mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New-York City. J Clin Microbiol 1997; 35:1281–1283. 84. Rossau R, Traore H, De Beenhouwer H, Mijs W, Jannes G, De Ruk P, Portaels F. Evaluation of the InnoLipa Rif TB Assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 1997; 41:2093–2098. 85. Chaparas SD. Immunologically based diagnostic tests with tuberculin and other mycobacterial antigens. In: Kubica GP, Wayne LG, eds. The Mycobacteria: A Sourcebook. Part A. Section 9. New York: Marcel Dekker, 1984:195–220. 86. Daniel TM, Dehanne SM. The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme linked immuno-assay. Am Rev Respir Dis 1987; 158:678–680. 87. Chan SL, Reggiardo Z, Daniel TM, Guilling DJ, Mitchison DA. Serodiagnosis of tuberculosis using an ELISA with antigen 5 and a hemagglutination assay with glycolipid antigens. Am Rev Respir 1990; 142:385–390. 88. Verbon A, Weverling GJ, Kuijper S, Speelman P, Jansen HM, Kolk AHJ. Evaluation of different tests for the serodiagnosis of tuberculosis and the use of likelihood ratios in serology. Am Rev Respir Dis 1993; 148:378–384. 89. Bothamley GH, Rudd RM. Clinical evaluation of a serological assay using a monoclonal antibody (TB72) to the 38 kDa antigen. Eur Respir J 1994; 7:240–248. 90. Simonney N, Molinard M, Oksen Hendler E, Perronne C, Lagrange PH. Analysis of the immunological humoral response to Mycobacterium tuberculosis glycolipid antigens (DAT, PGLTB1) for diagnosis of tuberculosis in HIV seropositive and seronegative patients. Eur J Clin Microbiol Inf Dis 1995; 14:883–891. 91. Moore DF, Cuirry JI. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by Amplicor PCR. J Clin Microbiol 1995; 33:2686–2691. 92. Bodmer T, Gurtner A, Schopper, Matter L. Screening of respiratory tract specimens for the presence of Mycobacterium tuberculosis by using the Gen-Probe amplified Mycobacterium tuberculosis test. J Clin Microbiol 1994; 32:1483–1487. 93. Ausina V, Gamboa F, Gazapo E, Manterola JM, Lonca J, Matas L, Manzano JR, Rodrigo C, Cardona PJ, Padilla E. Evaluation of the semi automated Abbott Lex My-
184
94.
95.
96.
97.
98.
99.
100.
101.
102. 103.
104. 105.
106.
107.
Grosset et al. cobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis in respiratory specimens. J Clin Microbiol 1997; 35:1996–2002. Down JA, O’Connell MA, Dey MS, Walters AH, Howard DR, Little MC, Keating WE, Zwadyk P Jr, Haaland PD, McLaurin DA III, Cole G. Detection of Mycobacterium tuberculosis in respiratory specimens by strand displacement amplification of DNA. J Clin Microbiol 1996; 34:860–865. An Q, Buxton D, Hendricks A, Robinson L, Shah J, Lu L, Vera-Garcia M, King W, Olive DM. Comparison of amplified Q replicase and PCR assays for detection of Mycobacterium tuberculosis. J Clin Microbiol 1995; 33:860–867. van der Vliet GME, Schepers P, Scheellink RAF, van Gemen B, Klaster PR. Nucleic acid sequence based amplification (NASBA) for identification of mycobacteria. J Gen Microbiol 1993; 139:2423–2429. Nolte FS, Metchock B, McGowan Jr JE, Edwards A, Okwumabua O, Thurmond C, Mitchell PS, Plikaytis B, Shniick T. Direct detection of Mycobacterium tuberculosis in sputum by polymerase chain reaction and DNA hybridization. J Clin Microbiol 1993; 31:1777–1782. Bergmann JS. Woods GL. Clinical evaluation of the Roche AMPLICOR PCR Mycobacterium tuberculosis test for the detection of M. tuberculosis in respiratory specimens. J Clin Microbiol 1996; 34:1083–1085. Carpentier E, Drouillard B, Dailloux M, Moinard D, Vallée A, Dutilh B, Maugein J, Bergogne-Berezin E, Carbonnelle B. Diagnosis of tuberculosis by AMPLICOR Mycobacterium tuberculosis test: a multicenter study. J Clin Microbiol 1995; 33:3106–3110. Cartuyvels R, de Ridder C, Jonckheere S, Verbist L, van Eldere L. Prospective clinical evaluation of Amplicor Mycobacterium tuberculosis PCR test as a screening method in a low-prevalence population. J Clin Microbiol 1996; 34:2001–2003. Clarridge JE. Large scale use of PCR for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory, reply. J Clin Microbiol 1994; 32:273– 274. Grosset J. Place des examens microbiologiques et anatomopathologiques dans la decision diagnostique et therapeutique. Med Mal Infect 1995; 25:327–333. Leven M, Goosens H. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. Clin Microbiol Rev 1997; 10:242–256. Doern GV. Diagnostic mycobacteriology: Where are we today? J Clin Microbiol 1996; 34:1873–1876. Doucet-Populaire F, Lalande V, Carpentier E, Bourgoin A, Dailloux M, Bollet C, Vachee A, Moinard D, Texier-Maugein J, Carbonnelle B, Grosset J. A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Tubercle Lung Dis 1996; 77:358–362. Cantanzaro A, Davidson BL, Fujiwara PI, Golberger MJ, Gordin F, Salfinger M, Sbarbaro J, Schluger NW, Sierra MF, Woods GL. Proceedings of the American Thoracic Society Workshop. Rapid diagnostic tests for tuberculosis. What is the appropriate use? Am J Respir Crit Care Med 1997; 155:1804–1814. Pfyffer GE, Kissling P, Jahn EMI, Welscher HM, Salfinger M, Weber R. Diagnostic performance of amplified Mycobacterium tuberculosis direct test with cere-
Bacteriology of Tuberculosis
185
brispinal fluid, other nonrespiratory and respiratory specimens. J Clin Microbiol 1996; 34:834–841. 108. Gamboa F, Manterola JM, Vinado B, Matas L, Gimenes M, Lonca J, Manzano JR, Rodriguo C, Cardona PJ, Padilla E, Domingues J, Ausina V. Direct detection of Mycobacterium tuberculosis complex in nonrespiratory specimens by Gen Probe Amplified Mycobacterium Direct Test. J Clin Microbiol 1997; 35:307–310. 109. Barnes PF, Rapid diagnostic tests for tuberculosis. Progress but not gold standard. Am J Respir Crit Care Med 1997; 155:1497–1498.
8 Immunology of Tuberculosis
THOMAS M. DANIEL and W. HENRY BOOM Case Western Reserve University School of Medicine and University Hospitals of Cleveland Cleveland, Ohio
JERROLD J. ELLNER UMDNJ–New Jersey Medical School Newark, New Jersey
I. Introduction When 39-year-old Robert Koch announced to a stunned audience at the Berlin Physiological Society on March 24, 1882, that he had discovered the cause of tuberculosis (1), he opened a new era in microbiology. Not long thereafter, in 1891, he described what has become known as the Koch phenomenon (2) and in so doing similarly opened a new era in immunology. Koch reported that an animal with prior experience with the tubercle bacillus dealt with the introduction of virulent organisms by walling off and containing the infection, something that naive animals could not do. Perhaps this observation led him to his ill-conceived recommendation of tuberculin injections for the treatment of tuberculosis. This therapy certainly paved the way for von Pirquet’s observation that delayed tuberculin skin reactions were an indicator of tuberculous infection. The subsequent story of the development of the tuberculin skin test as a well-accepted hallmark of tuberculin cellular hypersensitivity and immunity is familiar to many and has been well recounted in review articles (3,4). Pathologists had long recognized granulomas as the central histopathological lesions of tuberculosis, and the role of granulomas in containing the spread of disease was recognized from studies of clinical pathological material. Koch’s ob187
188
Daniel et al.
servations provided experimental support for this view. Mackaness and coworkers demonstrated that tuberculous immunity depended on the activation of macrophages, the central cells of granulomas, and that some aspects of this macrophage activation were not antigen-specific (5). The elegant studies of Warren and colleagues, who worked primarily with schistosomiasis, demonstrated the immunological nature of infectious tissue granulomas and the dependence of these granulomas on immunologically specific T lymphocytes (6). To Merrill Chase (7) goes credit for observing that delayed hypersensitivity could be transferred by lymphocytes, thus establishing the central memory function of these cells; as noted below, we now recognize diverse subsets of lymphocytes with specific functions in regulating cellular immunity. Subsequent seminal work by David and coworkers (8) led to the demonstration that immunologically competent lymphocytes produce soluble factors—lymphokines—that are responsible for the proliferation and activation of other immunoactive cells, a story that has subsequently unfolded to reveal an extraordinarily complex and highly regulated immune system. Not only by reason of history but also because of the elegant nature of the clinical model it produces, tuberculosis has become the paradigm for diseases mediated by cellular immunity. In this chapter we will review the immunology of tuberculosis, beginning with the organism that causes tuberculosis and induces the immunity and hypersensitivity characteristic of this infection. We will then move from the organism to the host and the highly regulated cellular immune system responsible for the host’s responses to tuberculous infection. II. Mycobacterial Protein Antigens Immunologically competent cells of the human host recognize Mycobacterium tuberculosis by its antigens, and scores of antigens of this organism have now been described. Indeed, when compared with other pathogens, mycobacteria have an extraordinarily large panoply of antigens. This may be related to the fact that these bacteria are rich in adjuvants, as noted below, so that many minor protein constituents are presented to host cells under circumstances that favor antigenicity. Following the description of an expression library for the entire genome of M. tuberculosis by Young and colleagues (9) and the cloning of genes for mycobacterial antigens in many laboratories, there has been a rapid increase in the number of antigenic proteins available for characterization and study. The elucidation of the entire DNA sequence of the M. tuberculosis genome will result in the identification of further increasing numbers of antigens. Banks of monoclonal antibodies have provided important reagents facilitating their characterization (10,11). We will not attempt a comprehensive review of mycobacterial antigens; we will, however, discuss several protein antigens about which a substantial body of
Immunology of Tuberculosis
189
knowledge exists. Readers interested in more detail about mycobacterial antigens will find the reviews by Young and coworkers (12) and Anderson (13) useful. A. The 65,000 Dalton Heat-Shock Protein Antigen
A 65,000 dalton antigen of M. tuberculosis and other mycobacteria has been extensively studied and found to be a heat-shock protein with substantial homology with other well-known heat-shock proteins, including the Escherichia coli GroEL protein (14,15). Heat-shock proteins are widely distributed in nature and highly conserved with substantial structural similarity crossing taxonomic lines. Named because they are produced in increased quantity by cells growing under stressful culture conditions such as high temperature, they are thought to have important functions in maintaining cell integrity and are produced by bacteria under many conditions of culture that are less than optimal. Similar proteins are produced by plant and higher animal, including mammalian, cells. The gene for the 65,000 dalton antigen has been cloned (16,17), and its structure is well known. This protein may exist in polymeric form in mycobacteria. The 65,000 dalton unit contains considerable helical structures and hydrophobic regions, characteristics typical of highly antigenic proteins. Studies with monoclonal antibodies have demonstrated that this protein has multiple epitopes (18), many of which are widely shared among mycobacteria, some of which appear to be species specific. Some epitopes appear to be shared with epitopes of mammalian proteins; these have been implicated in adjuvant arthritis and might be related to human autoimmune diseases (19). Because of the prominence of its nonspecific epitopes, this antigen has evoked less interest among investigators studying the immunology of tuberculosis than have more specific antigens. B. The 38,000 Dalton Species-Specific Antigenic Protein of M. tuberculosis
The goal of isolating a species-specific antigenic protein from M. tuberculosis has been elusive, yet hotly pursued by many investigators. Daniel and Anderson used immunoabsorbent affinity chromatography to isolate an antigen referred to as antigen 5 (20). Originally considered to have a molecular weight of 35,000 daltons, this protein was subsequently shown to be identical with the 38,000 dalton antigen later studied by Anderson and by Young, among others (21). With Ellner and others, the immunobiology of this protein was studied extensively, and it was found to be restricted to M. tuberculosis and M. bovis (22). This antigen elicited T- and B-lymphocyte responses in sensitized guinea pigs and infected humans, and it displayed substantial species-specificity in its reactions in guinea pigs. When used to skin-test populations of human subjects, it displayed less species specificity than had been observed in guinea pigs (23). This antigen formed the basis of a serodiagnostic ELISA test with excellent diagnostic test characteristics
190
Daniel et al.
(24,25), and again patients with nontuberculous mycobacterial disease were found to display reactivity to this antigen (26). Thus, despite substantial evidence of species-specificity, this potent antigen was not completely specific in infected humans. Ivanyi and colleagues developed a serodiagnostic ELISA test based on inhibition of a monoclonal antibody designated TB-72 (27,28). In contrast with the studies of Daniel and colleagues cited above, a high degree of mycobacterial species specificity was obtained in this test. Young used immunoabsorbents prepared from similar monoclonal antibody TB-71 to purify a protein reactive with TB-71 and TB-72, each monoclonal antibody apparently reacting with a distinct epitope of the same protein (29). The eluted protein was found to be the 38,000 dalton antigen. Anderson and Hansen also purified and characterized the 38,000 dalton protein, designating it antigen b (30). Anderson and coworkers later proposed that this protein is necessary for phosphate metabolism of the organism (31). Haslov and colleagues considered this protein to be immunodominant in 5 of 7 strains of in-bred guinea pigs (32). Kadival et al. described preparing a less specific 38,000 dalton antigen by immunoabsorbent affinity chromatography using a monoclonal antibody-derived absorbent (33). What is currently known about the 38,000 dalton antigen of M. tuberculosis is sufficient to conclude that it is not a major component of this organism but that it is secreted by growing mycobacterial cells, available on the cell surface, and highly antigenic. It is a leading candidate for species specificity, an important characteristic favoring its use for immunodiagnosis and perhaps also for immunization. C. Antigens of the 85 Complex: Alpha Antigen
Harboe, Wiker, and colleagues used elegant crossed immunoelectrophoretic techniques to show close immunological relationships between three antigens designated by them 85 A, B, and C (34–37). While these three antigens share epitopes and have many similar properties, they appear to be encoded by three separate genes (36,37). The best known of these antigens is 85B, which had been previously described as -antigen (38), antigen a2 (39), antigen 6 (40), and MPB59/MPT-59 (34,35). The designation -antigen has historic precedence and has come into widespread current use. With a molecular weight of 30,000 daltons, this antigen is secreted by growing mycobacteria (34,35,41), and it is the predominant antigen in culture medium from mycobacteria growing in stationary cultures. It binds fibronectin (42), raising the question of whether this property is important in mycobacterial recognition and ingestion by macrophages. The gene for the 30,000 dalton antigen has been cloned from M. bovis and M. kansasii, and its base sequence and corresponding amino acid sequence are known (43). This antigen is
Immunology of Tuberculosis
191
present in all mycobacteria that have been tested (44,45), and there is substantial evidence that the molecule contains both species-specific and shared epitopes (46). The 30,000 dalton antigen has been shown to be a mycolyltransferase that may be important in mycobacterial cell wall synthesis, suggesting that this molecule might be a potential chemotherapeutic drug target (47). The 30,000 dalton antigen evokes strong skin test responses in sensitized animals with somewhat more specificity of reactivity than tuberculin purified protein derivative (PPD) (46). Measuring IgG antibody to the 30,000 dalton antigen provides the basis for a good serodiagnostic test for active tuberculosis (48). The 30,000 dalton antigen also elicits in vitro correlates of cell-mediated hypersensitivity, and it is of considerable interest that T lymphocytes of healthy M. tuberculosis–infected individuals react strongly to this antigen whereas those of patients with active tuberculosis do not (49,50). This might suggest that decreased T-lymphocyte responsiveness to the 30,000 dalton antigen is a feature of the immune regulation in active tuberculosis, or it might mean that individuals who do not mount T-lymphocyte responses are predisposed to development of disease. This antigen induces in vitro production of interferon- and tumor necrosis factor- , an effect mediated in part through its fibronectin binding property (51). Perhaps no other antigen of M. tuberculosis has been as extensively studied as the 30,000 dalton protein antigen. It is an important constituent of mycobacteria with a major role for the microbial cell in cell-wall biosynthesis. It is equally important to the infected host, probably serving a major role in recognition of the pathogen by host defenses and induction of immune responses. It is expressed on the mycobacterial cell surface, where it is a dominant antigen recognized by all infected individuals. Thus, it is a strong candidate antigen for vaccine development. Other members of the 85 complex of antigens are less well studied. The 85A component, also known as antigen P32 (52) and MPT44 (36,37), is also a fibronectin-binding, secreted protein. It has a molecular weight of 31,000–32,000 daltons (53). Its gene has been cloned and has a high degree of homology with the gene of the 85B antigen. This antigen evokes antibodies in patients with tuberculosis (53). Currently ongoing studies with DNA vaccines using gene sequences for members of the 85 antigen complex should provide further information about the protective role of these antigens. D. The Low Molecular Weight ESAT-6 Antigen
Sorensen and colleagues purified a low molecular weight antigen from short-term, shake cultures of M. tuberculosis, which they designated ESAT-6 (54). When studied by physical chemical means and identified by the use of a specific monoclonal antibody, it was heterogeneous with respect to molecular mass, with identification of the antigenic epitope in constituents of estimated molecular weights ranging from 3,000 to 31,000 daltons. It is not glycosylated, and the molecular
192
Daniel et al.
heterogeneity is presumed to reside with the antigenic protein itself. The molecular weight deduced from its amino acid sequence is 9975 daltons. It is difficult to be certain with which constituents of preparations containing ESAT-6 protective immunity resides, and it is possible that the epitope by which this antigen is identified is expressed on a number of peptides and small proteins or that the structure is polymeric. ESAT-6 is prominently recognized by memory effector T lymphocytes in mice and guinea pigs and appears to have a major role in the recall of protective immunity in these animals, sharing this important characteristic with the 30,000 dalton -antigen described above (55). Its amino acid sequence has been determined, and two major epitopes that induce interferon (IFN)- production by T lymphocytes have been defined. ESAT-6 is secreted by growing cells of multiple strains of M. tuberculosis and M. bovis, but it is not produced by bacille CalmetteGuérin (BCG) (56). III. The Mycobacterial Cell Wall: Mycobacterial Adjuvants and Mycobacterial Polysaccharides The mycobacterial cell wall is a complex structure with many elements of immunological importance. The external aspect of the cell-wall surface comprises unique lipids containing long-chain mycolic aids. These are esterified to arabinogalactan, the principal structural element of the cell wall. Interiorly, linked to the arabinogalactan by phosphodiester bonds, is muramyl dipeptide. Each of these three major elements—mycolic acid lipid, arabinogalactan, and muramyl dipeptide—has importance to the immunology of tuberculosis. Brennan, whose laboratory has contributed so much to our recent knowledge of the mycobacterial cell wall, has provided a very helpful review of this topic that should be consulted by readers interested in pursuing this subject in depth (57). A. Arabinogalactan D-Arabino-D-galactan
serves as the backbone of the mycobacterial cell wall of mycobacteria and other actinomycetes and corynebacteria (57). An arabinofuranosyl side chain of arabinogalactan contains a major epitope that is identical among all organisms possessing arabinogalactan (58). This same side chain is also present on cell wall–associated arabinomannan. Arabinogalactan readily elicits antibodies in immunized experimental animals (58,59), but this polysaccharide induces and elicits few or no cellular immune responses. B. Lipoarabinomannan
Phosphorylated lipoarabinomannan (LAM) has been extensively studied by Hunter, Brennan, and their colleagues and shown to be antigenic (57,60–62). The
Immunology of Tuberculosis
193
carbohydrate structure of this polysaccharide was originally elucidated by Misaki, and it was shown to share an epitope-bearing polyarabinose side chain with arabinogalactan, which is the principal structural polysaccharide of the mycobacterial cell wall (63). Circulating antibodies to lipoarabinomannan are easily demonstrated in experimentally immunized animals (59) and are found in the majority of patients with active tuberculosis (62,64,65). Delayed-type hypersensitivity (DTH) reactions are not induced or evoked by this compound. Lipoarabinomannan from virulent strains of M. tuberculosis selectively induces immunosuppressive cytokines, including transforming growth factor (TGF)- but not tumor necrosis factor (TNF)- . C. Mycobacterial Adjuvants
In early but elegant and historically important studies, Raffel demonstrated that the adjuvant properties of mycobacterial cells resided in their lipids (66). Among these lipids, cord factor, a lipid associated with cording of mycobacterial colonies growing in liquid media and originally thought to be associated with virulence, was found to be of major importance as an adjuvant (67). This activity was further localized to the trehalose esters of mycolic acid, particularly trehalose dimycolate. The immune responses, both cellular and humoral, to any protein antigen are greatly potentiated when the antigen is administered in emulsions containing these mycolate adjuvants. Arabinogalactan, together with the underlying peptides phosphodiesterified to it, is a water-soluble adjuvant capable of potentiating a wide variety of immune responses (68,69). At the same time, it has major immunosuppressive properties (70). Cultured peripheral blood mononuclear cells from healthy tuberculin-positive donors had depressed responses to mycobacterial antigens when cocultured with arabinogalactan. This effect was mediated by monocytes, associated with their increased production of prostaglandin E2, and reversible with indomethacin or antibody to arabinogalactan. Immunoabsorption studies provided data suggesting that circulating arabinogalactan, possibly bound in immune complexes, might be responsible for the known immunosuppressive activity of some tuberculous plasma. The search for the minimal adjuvant unit in the water-soluble adjuvant led to the identification of muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine) as an extremely potent adjuvant (71). This small peptide is phosphodiesterified to cell-wall arabinogalactan, with which it forms water-soluble adjuvant. The extensive studies of analogs of muramyl dipeptide by many workers have explored the structural features of this small molecule that confer upon it adjuvant properties. Striking among these studies is the observation of Chedid and coworkers (72) that substitution of the D isomer for L-alanine created an immunosuppressive compound.
194
Daniel et al. IV. Granuloma Formation
If one phenomenon can be thought of as central among the multiple manifestations of the immunology of tuberculosis, it is the formation of tubercles—hypersensitivity granulomas. These lesions, which characterize and distinguish the tissue response to mycobacteria, are chiefly composed of macrophages activated in response to mycobacterial antigens and adjuvants. Mackaness demonstrated that macrophages became activated in response to contact with mycobacteria, although this activation lacked the specificity usually associated with immunological events (73). He hypothesized that monocytes, the circulating form of tissue macrophages, entered tissues at the site of tuberculous infection in response to chemotactic cytokines. Once aggregated in granulomas, monocytes transform to become the palisading histiocytes or epithelial cells characteristic of granulomas, and some of these cells fuse to form Langhans’ giant cells. In an elegant set of studies of the pathogenesis of schistosomiasis, Warren and colleagues (74,75) demonstrated the essential immune nature of granuloma formation. They showed that granuloma formation is antigen specific, that it is characterized by anamnesis, that it can be transferred by lymphocytes but not serum, and that it is dependent upon intact thymic but not bursal lymphocytes. Having thus firmly established granuloma formation as an immunological event in schistosomiasis, Boros and Warren extended their studies to tuberculin antigens and confirmed the immunological nature of the granulomas induced by these mycobacterial antigens (75). V. Cell-Mediated Immunity Natural immune mechanisms—macrophages, natural killer (NK) cells, neutrophils—likely have an important role in the primary response to M. tuberculosis and may suffice to control infection before development of the acquired immune response in few individuals (76). However, in the majority of infected persons the acquired immune response is responsible for control of M. tuberculosis infection. T cells, as antigen-recognition units, have critical regulatory and effector roles in the immune response to M. tuberculosis, as demonstrated by studies in animal models and in humans with cellular immune deficiencies (77–81). The traditional model for the role of T cells in tuberculosis is one in which macrophages present antigens obtained from phagocytosed bacilli to T cells. Antigen-activated T cells then secrete cytokines such as IFN-, which in turn stimulate macrophages to become more effective in controlling mycobacterial growth. Recent observations in basic immunology and in studies of the human immune response to mycobacteria require a revision of this simple model. First, besides the central role of CD4 T cells, other T-cell subsets such as T cells and CD8 T
Immunology of Tuberculosis
195
cells are activated by mycobacteria and have complementary roles to those of CD4 T cells (49,82). Second, T cells also serve as cytotoxic effector cells against M. tuberculosis–infected macrophages (83,84). Third, macrophages, upon exposure to mycobacteria, produce a large number of cytokines such as interleukin (IL)-10, IL-12, IL-15, IL-18, TNF- , IL-1, IL-6, and TGF- . Secretion of cytokines with immunoregulatory properties extends the macrophage’s role beyond that of antigen-presenting cell and inhibitor of mycobacterial growth (85,86). A. CD4 ␣ T Cells
CD4 T cells recognize peptide antigen fragments presented to their T-cell receptors by class II major histocompatibility (MHC) molecules on antigen-presenting cells (87). The CD4 T-cell molecule interacts with a constant domain of the class II MHC molecule while the T-cell receptor (TCR), consisting of an and a chain, recognizes short peptide fragments held within a groove of the class II MHC molecule. These antigenic peptide fragments are generated by proteolytic digestion of large protein antigens by antigen-presenting cells such as macrophages and dendritic cells in an orderly process called antigen processing. Class II MHC molecules are recognized by CD4 T cells, and the antigen-processing mechanisms differ for each one of these antigen-presenting molecules. In humans, successful containment of primary infection is characterized by a strong cutaneous DTH response (tuberculin reaction), mediated primarily by CD4 T cells. In addition, these sensitized individuals retain in vitro CD4 Tcell proliferative responses and brisk IFN- production to soluble mycobacterial protein antigens such as PPD (50). These memory CD4 T cells not only are responsible for controlling quiescent foci of infection but probably also provide protection against exogenous reinfection with the tubercle bacillus. Failure of CD4 T cells, as seen in persons infected with the human immunodeficiency virus (HIV), results in progressive primary infection, reactivation of endogenous mycobacteria, or enhanced susceptibility to reinfection (81,88). In a murine model, CD4 T cells transferred from immune mice to naive animals provided protection from challenges with both BCG and virulent M. tuberculosis (80,89). In vivo depletion of CD4 T cells by monoclonal antibody treatment reduced resistance to mycobacterial infections (90,91). CD4 T cells were the major source of IFN- and cytolytic effector function during the course of sublethal infection with M. tuberculosis (92). Recent studies in mice, in which the genes for class I and class II MHC molecules were inactivated by gene-targeting methods, reconfirmed the central role of CD4 T cells in the protective immune response to mycobacteria (93). CD4 T cells exert their influence in the immune response to M. tuberculosis through secretion of cytokines and cytotoxicity for M. tuberculosis-infected
196
Daniel et al.
macrophages. Through cytokines (IFN-, GM-CSF, TNF- / ), CD4 T cells enhance the effector function of macrophages and regulate the IL-2–mediated expansion of and CD8 T cells. Soluble protein antigens, such as those found in PPD and culture filtrates of M. tuberculosis, are strong stimuli for CD4 T cells. The majority of CD4 T cells produce large amounts of IFN- and varying amounts of IL-2, IL-4, IL-5, and IL-10 (94–96). Recent studies have demonstrated that CD4 T cells can directly help macrophages control intracellular growth of M. tuberculosis, both through secretion of cytokines and through a cell contact–dependent mechanism (97). These CD4 T cells do not fall into a clear-cut Th-1 and Th-2 dichotomy and are more accurately classified as Th-0. Classification of T-helper cells as Th-1 and Th-2 has been used in murine studies based on patterns of cytokine secretion, with Th-1 cells secreting IFN- and IL-2 and Th-2 cells producing predominantly IL-4 and IL-5. These cytokine phenotypes are associated with different functions, including macrophage activation and help for Bcell antibody production. In general, in humans the dichotomy among CD4 T cells is less clear-cut than the one observed among murine CD4 T cells, and in the human T-cell response to M. tuberculosis the Th-1 and Th-2 dichotomy does not enhance our understanding of the immune deficiency responsible for development of clinical tuberculosis. When cytotoxic effector function is evaluated, cytotoxicity is observed readily in healthy tuberculin individuals; it is mediated by CD4 T cells in response to M. tuberculosis–infected macrophages. Both CD4 T-cell clones and bulk T-cell populations stimulated with either PPD or live mycobacteria are efficient cytotoxic effector cells (95,98–100). Strong tuberculin skin test responses (DTH) and IFN- production coupled with cytotoxic effector function by CD4 T cells in response to macrophages are characteristic of the CD4 T-cell responses of healthy tuberculin positive donors and prototypic for the cellular immune response to intracellular bacterial pathogens. In patients with active pulmonary tuberculosis evidence for diminished CD4 T-cell function is reflected in decreased proliferative and IFN- responses to soluble protein antigens of M. tuberculosis, as well as diminished or absent tuberculin skin test responses in some patients. These diminished responses are not due to deviation of CD4 T-cell responses towards a Th-2 like pattern but due to secretion by macrophages of cytokines such as TGF- and IL-10, which inhibit CD4 T-cell function (85,86,101). Most studies of the human immune response are performed with peripheral blood T cells and do not address the nature of the CD4 T-cell response in the site of active infection in the lung. One recent study demonstrated that M. tuberculosis–specific CD4 T cells are readily detected in the alveolar spaces of healthy tuberculin-sensitized persons (102). The major antigens of M. tuberculosis recognized by CD4 T cells remain poorly defined despite the availability of a number of recombinant or purified na-
Immunology of Tuberculosis
197
tive antigens and numerous studies performed with them during the last 15 years (12). From these studies and others in which subfractions of M. tuberculosis bacilli or culture filtrates were tested, a number of general conclusions can be drawn. First, no single immunodominant antigen has emerged so far. Second, there is marked diversity in CD4 T-cell responses to mycobacterial antigens among individuals and most respond to a large rather than a restricted number of antigens (12,50,103,104). Third, there is significant cross-reactivity with antigens from other mycobacterial species or unrelated bacterial species. Thus no antigen recognized by CD4 T cells has been identified to date that is specific for infection with M. tuberculosis, although there may be some epitopes restricted to the M. tuberculosis group of organisms. Fourth, most T-cell antigens identified so far are expressed by M. bovis BCG, the vaccine strain considered suboptimal. Clearly further characterization of antigens recognized by CD4 T cells is necessary to define the T-cell repertoire and identify protective antigens. B. ␥␦ T cells
The other major T-cell subset that may have an important role in the cellular immune response to M. tuberculosis is the T-cell receptor (TCR)–bearing T cell (105). Gamma delta TCR–expressing T cells ( T cells) form a distinct subset of T lymphocytes, comprising 5% of T cells in lymphoid organs and 1–5% of circulating blood T lymphocytes. Gamma delta T cells express CD3, as do all T cells, but are CD4-negative, and fewer than 5% express low levels of CD8. The TCR consists of and chains, which are distinct from the and chains of the TCR on CD4 and CD8 T cells. How T cells recognize antigens and how antigens are processed and presented to them by antigen-presenting cells is still unknown. T cells do not use the class I and II MHC molecules, which are used for antigen presentation to CD4 and CD8 T cells. There is strong evidence both in humans and in animal models that T cells participate in the immune response to mycobacteria. Mice exposed to mycobacterial antigens in footpads or lungs or to live bacteria in the peritoneum had an expansion of T cells (106–108). Studies with T-cell knock-out mice in which expression of TCRs has been blocked suggest that T cells have a role in granuloma formation to M. tuberculosis. In humans, whole intact, in particular live mycobacteria induce expansion of human T cells and the V 2/V9 TCR subset (106–108). The activation of T cells by M. tuberculosis is dependent on antigen-presenting cells, and bloodderived monocytes are particularly effective in this regard (109). In addition, alveolar macrophages also can serve efficiently as antigen-presenting cells for T cells, suggesting that T cells can be directly activated in the human lung (110). Studies in tuberculosis patients suggest a diminished ability to activated T cells in response to M. tuberculosis (108). On the other hand, individuals sensitized to my-
198
Daniel et al.
cobacterial antigens have a greater ability to activate T cells in response to M. tuberculosis than tuberculin-negative persons (49). Functionally, T cells are very similar to CD4 T cells. They secrete as much IFN-, possibly more on a per cell basis, and are equally cytotoxic for macrophages as CD4 T cells (84). They produce less IL-2 than CD4 T cells, which may explain their dependence on CD4 T-cell help for their expansion in vitro (111). In the last few years, substantial insight has been gained into the mycobacterial antigen(s) recognized by V 2 T cells. Increasing evidence suggests that the V 2 T cells are activated by phosphate-containing molecules (112–114). The first of these antigens to be identified were four TUBags isolated from M. tuberculosis, described by Constant et al., which are small (/500 dalton) phosphorylated molecules (112). Two of these (TUBag4 and TUBag3) contain both phosphate and nucleotide (thymidine in TUBag4 and uridine in TUBag3). In addition, Tanaka et al. have proposed isopentenyl pyrophosphate (IPP) and related prenyl phosphates as possible antigens for V 2 T cells (115). Others have described a larger protease-sensitive antigen (10–14 kDa) from heattreated M. tuberculosis bacilli, which also is sensitive to phosphatase treatment, suggesting a carrier molecule for the small phosphate ligands (116). C. CD8 T Cells and Other T-Cell Subsets
Until recently, the role of CD8 T cells in the human immune response to M. tuberculosis was largely undefined. In murine studies a minor role for CD8 T cells was suggested by cell transfer and antibody blocking studies. Studies with gene knock-out mice in which CD8 T-cell development has been arrested due to the absence of class I MHC molecules ( 2-microglobulin knock-out mice) revealed a heightened sensitivity to both M. tuberculosis and M. bovis BCG (82,93). The lung appeared to be the most susceptible organ for progressive M. tuberculosis infection in CD8 T-cell–depleted mice. Consistent with these observations were recent studies in which class I MHC restricted CD8 T cells specific for M. tuberculosis were found in the alveolar spaces of healthy tuberculin skin test–positive persons. These CD8 T cells were found to be efficient cytotoxic effector cells and to secrete IFN- (102). Little is known about the specific antigens recognized by CD8 T cells or their role in protective immunity to M. tuberculosis in humans. Alpha beta TCR T cells, which do not express CD4 or CD8, make up less than 1% of circulating T cells and can use the nonpolymorphic MHC-like molecule CD1 as antigen-presenting molecule (117). Expression of CD1 on macrophages is dependent on IL-4 and GM-CSF. Recent studies have demonstrated that some of these TCR, CD4, CD8 T-cell clones recognize mycobacterial mycolic acids and LAM in the context of CD1 (118). Mycolic acids are complex glycol-
Immunology of Tuberculosis
199
ipids unique to mycobacterial cell walls. The role of this unique T-cell subset in the immune response to mycobacteria remains to be defined. Studies of the immune response to M. tuberculosis in humans and animal models have increased our understanding of the complex roles of T-cell subsets in protection against tuberculosis. Although CD4 T cells remain the dominant and critical T-cell subset, others such as and CD8 T cells have complementary roles. Since all three subsets are sources of IFN- and competent cytotoxic effector cells, in vivo kinetics and differences in antigen processing/recognition likely will define how each T-cell subset functions in different phases of the immune response to M. tuberculosis (119). Future studies in animal models, with human cells obtained from sites of infection such as lung or lymph node, characterization of the antigen repertoire, and longitudinal immuno-epidemiological studies should define more clearly how different T-cell subsets contribute to protection against M. tuberculosis. Such studies will determine how failure of T-cell subset function results in reactivation or progressive primary tuberculosis. VI. Humoral Immunity It is important to recognize that the pathogenesis of tuberculosis is almost exclusively determined by host T-lymphocyte–mediated cellular immune responses. At the same time, one must acknowledge that B-lymphocyte–mediated humoral responses to mycobacterial antigens occur in patients with tuberculosis, although these responses have no clearly demonstrated role in disease pathogenesis. Levels of immunoglobulin-G (IgG) antibody detectable by enzyme-linked immunosorbent assay (ELISA) or other immunoassay are usually an indicator of active tuberculous disease. Studies with many antigens using many techniques have found that few control subjects have measurable IgG antibody levels (120). Asymptomatic primary infection (121) and minimal pulmonary disease (122) usually are not sufficient to induce a significant antibody response. During the course of treatment, antibody levels rise somewhat for the first 1 or 2 months, falling thereafter but remaining detectable for up to several years (123). Patients with remote healed tuberculosis do not have readily detected IgG antibody to mycobacterial antigens. Many investigators have proposed serodiagnostic tests based upon the identification of IgG antibody to mycobacterial antigens, and new tests are being proposed almost daily. From the extensive work that has been done, one can state with reasonable confidence that it is possible to devise simple serodiagnostic tests using any of several antigens, but that the choice of antigen is a major determinant of diagnostic test specificity and predictive accuracy. Crude mycobacterial cell lysates and culture filtrates and tuberculin PPD do not provide as satisfactory diagnostic tests as do more highly purified antigens. No test has come into
200
Daniel et al.
widespread clinical use, however, probably because the sensitivity and specificity of serological tests has not exceeded that of the sputum smear. VII. Immune Spectrum and Immunoregulation Leprosy is the classical example of a granulomatous disease caused by a facultative intracellular pathogen in which the host immune response shows a predictable linkage to bacterial load in tissues and disease manifestations. At the tuberculoid end of the spectrum, there are vigorous granulomatous hypersensitivity, active Tcell immune reactivity, little in terms of antibody response, few bacilli, and localized disease. At the lepromatous end of the spectrum there are few and poorly formed granulomas, specific hyporesponsiveness of T cells to mycobacterial antigens, high titers of antibody, and multibacillary disease. There have been several attempts to define a spectrum of disease manifestations similar to that of leprosy in patients with tuberculosis (124,125). These classification schemes have not been entirely convincing, often requiring clinical and pathological distinctions that are not easily made. A few general comments concerning the immune spectrum of tuberculosis are, however, supportable. Healthy tuberculin skin test–positive donors express vigorous DTH and have low titers of antibody directed against mycobacterial products. Pulmonary tuberculosis, at least in the United States, usually is characterized by relative hyporesponsiveness to tuberculin; 20–25% of individuals with acute tuberculosis have a negative tuberculin skin test, and hyporesponsiveness to PPD in vitro is two to three times more common (126,127). Miliary tuberculosis and tuberculous meningitis are associated with a greater frequency of skin test anergy and more systemic signs and symptoms than localized disease (128). The local immune response in tuberculous pleurisy is of some interest since clinical and epidemiological evidence indicates that it is capable of initial selfcure (129). The pleural fluid is enriched in highly antigen-reactive CD4CDw29 lymphocytes (130), apparently the result of in situ expansion rather than sequestration of such cells from the circulating pool (131). Pleural fluid also contains 5- to 30-fold increased levels of IFN- and TNF relative to serum (130). Based on the data from tuberculous pleurisy, the hyporesponsiveness of peripheral blood mononuclear cells to PPD in pulmonary tuberculosis is not readily explained by shifts in the compartmentalization of antigen-responsive T cells. Likewise the ratio of CD4/CD8 lymphocytes is preserved in tuberculosis (126,132). Similarly, in pulmonary tuberculosis anergy is accompanied by reduction in CD4 lymphocytes in correlation with reduction in total lymphocyte counts (127). Active and specific immunosuppression is a factor in the depression of Tcell blastogenic responses and expression of IL-2 in response to PPD (85,133).
Immunology of Tuberculosis
201
The mechanism of suppression appears to be unique. Monocytes primed during the course of infection are stimulated directly by PPD or bacterial lipopolysaccharide to increased production of cytokines such as IL-1 (134), TNF (135,136), and IL-6 (136), and of immunosuppressive factors such as the receptor for IL-2 (101), IL-10, and TGF- . Recent studies demonstrate a profound depression of PPD-stimulated production of IFN- in patients with moderately and far-advanced tuberculosis. Two mechanisms appear to be involved: a transient overproduction of IL-10 and TGF and a longer-lasting primary T-cell defect. The T-cell defect may represent compartmentalization of antigen-reactive cells to sites of inflammation and/or selective cell depletion, possibly by apoptosis. Immunotherapy with IL-2 restored IFN- production; it was not clear whether this occurred by reversal of a defect in CD4 T cells or by recruitment of additional CD4 cells. The response to certain protein antigens of M. tuberculosis seems to be selectively suppressed in patients with tuberculosis. For example, despite comparable responses to sonicates of M. tuberculosis, 84% of healthy household contacts and only 52% of treated and 48% of untreated patients with tuberculosis responded to the MTP40 (14,000 dalton) antigen (137). Similarly, tuberculosis patients showed selective hyporesponsiveness to the 30,000 dalton antigen. Seven of eight healthy tuberculin reactors and none of six tuberculosis patients (post 6–20 weeks of treatment) were responsive to the 30,000 dalton antigen (138). Interpretation of these findings is complicated by the consistent finding that tuberculosis patients in the United States are hyporesponsive to PPD (139). Supportive observations are, however, available from Mexico City. None of 10 patients with newly diagnosed pulmonary tuberculosis and 73% of 21 household contacts showed responses to the 30,000 dalton antigen of M. tuberculosis, whereas responses to mycobacterial sonicates were comparable in both groups (140). These results raise two possibilities. First, the absence of response to the 30,000 dalton antigen may be a stable characteristic, perhaps genetically determined, and may predispose individuals to the development of tuberculosis. Second, the 30,000 dalton antigen may activate immunosuppressive pathways, possibly through direct stimulation of monocytes. The anergy occurring in patients with pulmonary tuberculosis is specific in some and nonspecific in other individuals. In fact, it may be appropriate to assume that patients with pulmonary tuberculosis usually show specific superimposed on nonspecific anergy. Specific anergy has been addressed above; the mechanism of nonspecific anergy is not well understood. It is of interest, therefore, that mycobacterial polysaccharides such as D-arabino-D-mannan and D-arabino-D-galactan stimulate monocyte-dependent suppression of blastogenesis induced by nonspecific mitogens (70,141), Detailed studies, in fact, suggest that the underlying mechanism involves circulating immune complexes containing polysaccharides that stimulate monocyte production of immunosuppressive prostaglandin E2 (70).
202
Daniel et al.
The finding that a polysaccharide antigen, presumably a major target of the antibody response to tuberculosis itself, suppresses T-cell reactivity is of interest as it may contribute to the inverse and reciprocal relationships between T-cell responses and B-cell responses in tuberculosis as considered above. Therapeutic intervention to modulate the spectral immune response in tuberculosis for the benefit of patients is a topic of increasing recent interest. Thalidomide and pentoxifylline are drugs known to ameliorate the adverse effects of TNF- , and as of this writing both drugs are being studied for their potential as therapeutic agents in tuberculosis. Mycobacterium vaccae, a nonpathogenic mycobacterium originally isolated from soil in Uganda, has been proposed as an immunogen potentially capable of augmenting beneficial protective immune responses in tuberculous patients (142,143). Early trials in Romania in which M. vaccae was administered to patients during the course of treatment show small but statistically significant results in the bacteriological response of patients being retreated for chronic disease but not significant effects in patients receiving treatment for the first time (145). Additional trials in Africa, which include HIV-infected patients, are underway as of this writing. VIII. HIV–M. tuberculosis Interactions HIV infection is the strongest known risk factor for the reactivation of a latent tuberculous infection. In a prospective study of a cohort of tuberculin skin test–positive intravenous drug users in a methadone-maintenance program in New York, the risk of developing tuberculosis was 7.9% per year during a 2-year period of follow-up (146). Studies in Africa yielded similar results, albeit with somewhat lower risk figures (147,148). This must be compared to the risk of developing tuberculosis in M. tuberculosis–infected, HIV-uninfected persons, which is estimated to be 5–10% per lifetime. It also is clear that primary infection with M. tuberculosis is likely to progress rapidly to active tuberculosis in HIV-infected persons. The current outbreaks of multidrug-resistant tuberculosis in HIV-infected persons (149) are clear evidence of this phenomenon. HIV infection increases the likelihood of a negative tuberculin skin test in M. tuberculosis–infected persons. For example, HIV-infected healthy women in Uganda were less likely to show reactions of over 3 mm to Old Tuberculin (48% vs. 82%) and had smaller reaction sizes (7.5 mm vs. 10.6 mm induration) as compared to HIV-negative age-matched post-partum females (150). The relationship between DTH reactions and CD4 counts in HIV-infected persons also has been studied using panels of nonmycobacterial antigens. Cutaneous anergy was infrequent (10%) in individuals with a CD4 count 500/L; below this level, however, the frequency of anergy varied inversely with the CD4 count and was 2/3 for CD4 200 and 80% for CD4 50 (151). Studies in Zaire demonstrated anergy as
Immunology of Tuberculosis
203
defined using the CMI-Multitest in 46% of 50 HIV-infected individuals (152). Importantly, 36% of HIV-infected tuberculin-positive persons had active tuberculosis as compared to 8% of the tuberculin-negative persons. The notion that tuberculosis may boost tuberculin reactivity rather than further depress it in the presence of HIV infection is further supported by recent observations from Uganda. Sixty-eight percent of HIV-positive tuberculosis patients were tuberculin skin test–positive with reaction sizes of 10 mm, as compared to 18% in the unmatched cohort of HIV-positive post-partum women discussed above (153). Tuberculosis is often an early event in the course of AIDS, occurring a mean of 6–9 months before other AIDS-defining conditions (154). Atypical radiographic presentations, often suggesting primary tuberculosis, are frequent and are related to low CD4 cell counts (155). The T-cell dysfunction of HIV-infected individuals is similar to but much more pronounced than the T-cell defect seen in HIV-uninfected patients with acute forms of tuberculosis. HIV infection not only accelerates the course of tuberculosis, but tuberculosis also accelerates the course of HIV disease (156). This effect requires active disease rather than latent M. tuberculosis infection and is related to anergy and CD4 lymphopenia (157,158). Bronchoalveolar lavage studies have found the HIV viral burden to be higher in lavaged cells from HIV-infected patients with pulmonary tuberculosis than from HIV-infected patients free of pulmonary disease (159). These clinical observations can be correlated with the laboratory demonstration that M. tuberculosis cells and PPD heighten the expression of HIV in cultured human monocytoid and lymphoid cell lines (160). On the basis of both in vivo and in vitro evidence, it is reasonable to believe that the immune activation that is a consistent concomitant of active tuberculosis activates cells harboring latent HIV infection to promote viral replication and disease progression. This notion, if substantiated by additional immunological, virological, and epidemiological data, would have profound impact on public health policy. Certainly, the potential benefits from preventive therapy for tuberculosis would be enhanced if, besides preventing tuberculosis, it prolonged the survival of HIV-infected individuals. IX. Conclusions Progress towards understanding the immune response to mycobacteria has accelerated in the last decade, but it remains for this progress to be translated into practical advances relevant to the control of tuberculosis. Although existing means of diagnosis and prevention clearly are generally satisfactory as currently applied, new understanding of the immunology of tuberculosis offers the promise of new and advanced modalities. It is reasonable to expect the pace of progress to continue to increase, driven by the magnitude of the global problem compounded by the pandemic of HIV infection and outbreaks of multidrug-resistant tuberculosis.
204
Daniel et al. References
1. Koch R. Die Aetiologie der Tuberculose, a translation by Berna Pinner and Max Pinner with an introduction by Allen K. Krause. Am Rev Tuberc 1932; 25:285–323. 2. Koch R. Weitere Mitteilungen über ein Heilmittel gegen Tuberculose. Dtsch Med Wschr 1891; 17:101–102. 3. Edwards PQ, Edwards LB. Story of the tuberculin test from an epidemiologic viewpoint. Am Rev Respir Dis 1960; 81(suppl):1–47. 4. Snider DE Jr. The tuberculin skin test. Am Rev Respir Dis 1982; 125(suppl): 108–118. 5. Mackaness GB. The immunological basis of acquired cellular resistance. J Exp Med 1964; 120:105–120. 6. Warren KS, Domingo EO, Cowan RBT. Granuloma formation around schistosome eggs as a manifestation of delayed hypersensitivity. Am J Pathol 1967; 51:735–756. 7. Chase MW. The cellular transfer of cutaneous hypersensitivity to tuberculin. Proc Soc Exp Biol Med 1945; 59:134–135. 8. David JR, Al-Askari S, Lawrence HS, Thomas L. Delayed hypersensitivity in vitro. I. The specificity of inhibition of cell migration by antigens. J Immunol 1964; 93:264–273. 9. Young RA, Bloom BR, Grosskinsky CM, Ivanyi J, Thomas D, Davis RW. Dissection of Mycobacterium tuberculosis antigens using recombinant DNA. Proc Natl Acad Sci USA 1985; 82:2583–2587. 10. Engers HD, Bloom BR, Godal T. Monoclonal antibodies against mycobacterial antigens. Immunol Today 1985; 6:345–347. 11. Engers HD, Houba V, Bennedsen J, Buchanan TM, Chaparas SD, Kadival G, Closs O, David JR, van Embden JDA, Godal T, Mustafa SA, Ivanyi J, Young DB, Kaufmann SHE, Khomenko AG, Kolk AHJ, Kubin M, Louis JA, Minden P, Shinnick TM, Trnka L, Young RA. Letter to the editor. Results of a World Health Organization-sponsored workshop to characterize antigens recognized by Mycobacteriumspecific monoclonal antibodies. Infect Immun 1986; 51:718–720. 12. Young DB, Kaufmann SHE, Hermans PWM, Thole JER. Mycobacterial protein antigens: a compilation. Mol Microbiol 1992; 5:133–145. 13. Anderson P. Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Scand J Immunol 1997; 45:115–131. 14. Shinnick TM, Vodkin MH, Williams JC. The Mycobacterium tuberculosis 65-kilodalton antigen is a heat shock protein which corresponds to common antigen and to the Escherichia coli GroEL protein. Infect Immun 1988; 56:446–451. 15. Young DB, Ivanyi J, Cox JH, Lamb JR. The 65kDa antigen of mycobacteria—a common bacterial protein? Immunol Today 1987; 8:215–219. 16. Shinnick TM. The 65-kilodalton antigen of Mycobacterium tuberculosis. J Bacteriol 1987; 169:1080–1088. 17. Thole JER, Keulen WJ, de Bruyn J, Kolk AHJ, Groothius DG, Berwald LG, Tiesjema RH, van Embden JDA. Characterization, sequence determination, and immunogenicity of a 64-kilodalton protein of Mycobacterium bovis BCG expressed in Escherichia coli K-12. Infect Immun 1987; 55:1466–1475.
Immunology of Tuberculosis
205
18. Buchanan TM, Nomaguchi H, Anderson DC, Young RA, Gillis TP, Britton WJ, Ivanyi J, Kolk AHJ, Closs O, Bloom BR, Mehra V. Characterization of antibody-reactive epitopes on the 65-kilodalton protein of Mycobacterium leprae. Infect Immun 1987; 55:1000–1003. 19. Thole JER, Hindersson P, de Bruyn J, Cremers F, van der Zee J, de Cock H, Tommassen J, van Eden W, van Embden JDA. Antigenic relatedness of a strongly immunogenic 65 kDa mycobacterial protein with a similarly sized ubiquitous bacterial common antigen. Microb Pathogen 1988; 4:71–83. 20. Daniel TM, Anderson PA. The isolation by immunoabsorbent affinity chromatography and physicochemical characterization of Mycobacterium tuberculosis antigen 5. Am Rev Respir Dis 1978; 117:533–539. 21. Daniel TM. The chemical composition of immunoaffinity-purified Mycobacterium tuberculosis antigen 5 (letter). Am Rev Respir Dis 1989; 139:1566–1567. 22. Daniel TM, Ellner JJ, Todd LS, McCoy DW, Payne VDN, Anderson PA, Bhe FT. Immunobiology and species distribution of Mycobacterium tuberculosis antigen 5. Infect Immun 1979; 24:77–82. 23. Daniel TM, Balestrino EA, Balestrino OC, Davidson PT, Debanne SM, Kataria S, Kataria YP, Scocozza JB. The tuberculin specificity in humans of Mycobacterium tuberculosis antigen 5. Am Rev Respir Dis 1982; 126:600–606. 24. Balestrino EA, Daniel TM, de Latini MDS, Latini OA, Ma Y, Scocozza JB. Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to Mycobacterium tuberculosis antigen 5 and tuberculin purified protein derivative. Bull WHO 1984; 62:755–761. 25. Ma Y, Wang YM, Daniel TM. Enzyme-linked immunosorbent assay using Mycobacterium tuberculosis antigen 5 for the diagnosis of pulmonary tuberculosis in China. Am Rev Respir Dis 1986; 134:1273–1275. 26. Benjamin RG, Daniel TM. Serodiagnosis of tuberculosis using the enzyme-linked immunoabsorbent assay (ELISA) of antibody to Mycobacterium tuberculosis antigen 5. Am Rev Respir Dis 1982; 126:1013–1016. 27. Ivanyi J, Krambovitis E, Keen M. Evaluation of a monoclonal antibody (TB72) based serological test for tuberculosis. Clin Exp Immunol 1983; 54:337–345. 28. Bothamley G, Udani P, Rudd R, Festenstein F, Ivanyi J. Humoral response to defined epitopes of tubercle bacilli in adult pulmonary and child tuberculosis. Eur J Clin Microbiol Infect Dis 1988; 7:639–645. 29. Young D, Kent L, Rees A, Lamb J, Ivanyi J. Immunological activity of a 38-kilodalton protein purified from Mycobacterium tuberculosis. Infect Immun 1986; 54:177–183. 30. Anderson AB, Hansen EB. Structure and mapping of antigenic domains of protein b, a 38,000-molecular weight protein of Mycobacterium tuberculosis. Infect Immun 1989; 57:2481–2488. 31. Anderson AB, Ljungqvist L, Olsen M. Evidence that protein antigen b of Mycobacterium tuberculosis is involved in phosphate metabolism. J Gen Microbiol 1990; 136:477–480. 32. Haslov K, Anderson AB, Ljungqvist L, Weis Bentzon M. Comparison of the immunological activity of five defined antigens of Mycobacterium tuberculosis in
206
33.
34.
35.
36.
37. 38. 39.
40.
41.
42.
43.
44. 45. 46.
47.
48.
Daniel et al. seven inbred guinea pig strains. The 38-kDa antigen is immunodominant. Scand J Immunol 1990; 31:503–514. Kadival GV, Chaparas SD, Hussong D. Characterization of serologic and cell-mediated reactivity of a 38-kDa antigen isolated from Mycobacterium tuberculosis. J Immunol 1987; 139:2447–2451. Wiker HG, Harboe M, Lea TE. Purification and characterization of two protein antigens from the heterogeneous BCG85 complex in Mycobacterium bovis BCG. Int Arch Allergy Appl Immunol 1986; 81:298–306. Wiker HG, Harboe M, Nagai S, Patarroyo ME, Ramirez C, Cruz N. MPB59, a widely cross-reacting protein of Mycobacterium bovis BCG. Int Arch Allergy Appl Immunol 1986; 81:307–314. Wiker HG, Harboe M, Nagai S, Bennedsen J. Quantitative and Qualitative studies on the major extracellular antigen of Mycobacterium tuberculosis H37Rv and Mycobacterium bovis BCG. Am Rev Respir Dis 1990; 141:830–838. Wiker HG, Sletten K, Nagai S, Harboe M. Evidence for three separate genes encoding the proteins of the mycobacterial 85 complex. Infect Immun 1990; 58:272–274. Yoneda M, Fukui Y. Isolation, purification, and characterization of extracellular antigens of Mycobacterium tuberculosis. Am Rev Respir Dis 1965; 92(suppl):9–18. Daniel TM, Ferguson LE. Purification and characterization of two proteins from culture filtrates of Mycobacterium tuberculosis H37Ra strain. Infect Immun 1970; 1:164–168. Janicki BW, Chaparas SD, Daniel TM, Kubica GP, Wright GL Jr, Yee GS. A reference system for antigens of Mycobacterium tuberculosis. Am Rev Respir Dis 1972; 104:602–604. Abou-Zeid C, Ratliff TL, Wiker HG, Harboe M, Bennedsen J, Rook GAW. Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun 1988; 56:3046–3051. Abou-Zeid C, Smith I, Grange JM, Ratliff TL, Steele J, Rook GAW. The secreted antigens of Mycobacterium tuberculosis and their relationship to those recognized by the available monoclonal antibodies. J Gen Microbiol 1988; 134:531–538. Matsuo K, Yamaguchi R, Yamazaki A, Tasaka H, Yamada T. Cloning and expression of the Mycobacterium bovis BCG gene for extracellular a antigen. J Bacteriol 1988; 170:3847–3854. Yoneda M, Fukui Y, Yamanouchi T. Extracellular proteins of tubercle bacilli. V. Distribution of and antigens in various mycobacteria. Biken J 1965; 8:201–223. Daniel TM. The immunology of tuberculosis. Clin Chest Med 1980; 1:189–201. Salata RA, Sanson AJ, Malhotra IJ, Wiker HG, Harboe M, Phillips NB, Daniel TM. Purification and characterization of the 30,000 dalton native antigen of Mycobacterium tuberculosis and characterization of six monoclonal antibodies reactive with a major epitope of this antigen. J Lab Clin Med 1991; 118:589–598. Belisle JT, Varalakshmi DV, Sievert T, Takayama K, Brennan PJ, Besra GS. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997; 276:1420–1422. Sada ED, Ferguson LE, Daniel TM. An ELISA for the serodiagnosis of tuberculosis using a 30,000-Da native antigen of Mycobacterium tuberculosis. J Infect Dis 1990; 162:928–931.
Immunology of Tuberculosis
207
49. Havlir DV, Ellner JJ, Chervenak KA, Boom WH. Selective expansion of human T-cells by monocytes infected with live Mycobacterium tuberculosis. J Clin Invest 1991; 87:729–733. 50. Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ. Human immune response to Mycobacterium tuberculosis antigens. Infect Immun 1991; 59:665–670. 51. Aung H, Toossi Z, Wisnieski JJ, Wallis RS, Culp LA, Phillips NB, Phillips M, Averill LE, Daniel TM, Ellner JJ. Induction of monocyte expression of tumor necrosis factor by the 30 kD antigen of Mycobacterium tuberculosis and synergism with fibronectin. J Clin Invest 1996; 98:1261–1268. 52. De Bruyn J, Huygen K, Bosmans R, Fauville M, Lippens R, Van Vooren JP, Falmagne P, Weckx M, Wiker HG, Harboe M, Turneer M. Purification, characterization and identification of a 32 kDa protein antigen of Mycobacterium bovis BCG. Microb Pathogen 1987; 2:351–366. 53. Borremans M, De Wit L, Volkaert G, Ooms J, De Bruyn J, Huygen K, Van Vooren JP, Stelandre M, Verhofstadt R, Content J. Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of Mycobacterium tuberculosis. Infect Immun 1989; 57:3123–3130. 54. Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. Purification and characterization of a low-molecular mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 1995; 63:1710–1717. 55. Brandt L, Oettinger T, Holm A, Andersen AB, Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 1996; 157:3527–3533. 56. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996; 64:16–22. 57. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995; 64:29–63. 58. Misaki A, Seto N, Azuma I. Structure and immunological properties of D-arabinoD-galactans isolated from cell walls of Mycobacterium species. J Biochem 1974; 76:15–27. 59. Daniel TM. The antigenicity in guinea pigs and monkeys of three mycobacterial polysaccharides purified by affinity chromatography with concanavalin A. Am Rev Respir Dis 1975; 111:787–793. 60. Hunter SW, Fujiwara T, Brennan PJ. Structure and antigenicity of the major specific glycoplipid antigen of Mycobacterium leprae. J Biol Chem 1982; 257:15072–15078. 61. Hunter SW, Gaylord H, Brennan PJ. Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J Biol Chem 1986; 261:12345–12351. 62. Brennan PJ. Structure of mycobacteria: Recent developments in defining cell wall carbohydrates and proteins. Rev Infect Dis 1989; 11(suppl):S420–S430. 63. Misaki A, Azuma I, Yamamura Y. Structural and immunchemical studies on D-arabino-D-mannans and D-mannans of Mycobacterium tuberculosis and other Mycobacterium species. J Biochem 1977; 82:1759–1770.
208
Daniel et al.
64. Benjamin RG, Debanne SM, Ma Y, Daniel TM. Evaluation of mycobacterial antigens in an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of tuberculosis. J Med Microbiol 1984; 18:309–318. 65. Sada E, Brennan PJ, Herrera, T, Torres M. Evaluation of lipoarabinomannan for the serological diagnosis of tuberculosis. J Clin Microbiol 1990; 28:2587–2590. 66. Raffel S, Arnaud LE, Dukes CD, Huang JS. The role of the “wax” of the tubercle bacillus in establishing delayed hypersensitivity. II. Hypersensitivity to a protein. J Exp Med 1949; 90:53–71. 67. Goren MB. Immunoreactive substances of mycobacteria. Am Rev Respir Dis 1982; 125(suppl):50–69. 68. Adam A, Ciorbaru R, Petit J-F, Lederer E. Isolation and properties of a macromolecular, water-soluble, immuno-adjuvant fraction from the cell wall of Mycobacterium smegmatis. Proc Natl Acad Sci USA 1972; 69:851–854. 69. Wahl SM, Wahl LB, McCarthy JB, Chedid L, Mergenhagen SE. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol 1979; 122:2226–2231. 70. Kleinhenz ME, Ellner JJ, Spagnuolo PJ, Daniel TM. Suppression of lymphocyte responses by tuberculous plasma and mycobacterial arabinogalactan. Monocyte dependence and indomethacin reversibility. J Clin Invest 1981; 68:153–162. 71. Ellouz F, Adam A, Cirobaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974; 59:1317–1325. 72. Chedid L, Audibert F, Lefrancier P, Choay J, Lederer E. Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci USA 1976; 73:2472–2475. 73. Mackaness GB. The immunological basis of acquired cellular resistance. J Exp Med 1964; 120:105–120. 74. Warren KS. Domingo EO, Cowan RBT. Granuloma formation around schistosome eggs as a manifestation of delayed hypersensitivity. Am J Pathol 1967; 51:735–756. 75. Boros DL, Warren KS. The bentonite granuloma. Characterization of a model system for infectious and foreign body granulomatous inflammation using soluble mycobacterial, histoplasma and schistosoma antigens. Immunol 1973; 24:511–529. 76. Vidal SM, Malo D, Vogan K, Skamene E, Gros P. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 1993; 73:469–485. 77. Ellner JJ. The immune response in human tuberculosis—implications for tuberculosis control. J Infect Dis 1997; 176:1351–1359. 78. Ellner JJ. Regulation of the human immune response during tuberculosis. J Lab Clin Med 1997; 130:469–475. 79. North RJ. Importance of thymus-derived lymphocytes in cell-mediated immunity to infection. Cell Immunol 1973; 7:166–176. 80. Lefford MJ. Transfer by adoptive immunity to tuberculosis in mice. Infect Immun 1975; 11:1174–1181. 81. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268:504–509.
Immunology of Tuberculosis
209
82. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89:12013–12017. 83. DeLibero G, Fiesch I, Kaufmann SHE. Mycobacteria reactive Lyt2 T cell lines. Eur J Immunol 1988; 18:59–66. 84. Tsukaguchi K, Balaji KN, Boom WH. CD4 alpha-beta T cell and gamma-delta T cell responses to Mycobacterium tuberculosis: similarities and differences in antigen recognition, cytotoxic effector function, and cytokine production. J Immunol 1995; 154:1786–1796. 85. Toossi Z, Kleinhenz ME, Ellner JJ. Defective interleukin-2 production and responsiveness in human pulmonary tuberculosis. J Exp Med 1986; 163:1162–1172. 86. Toossi Z, Gogate P, Shiratsuchi H, Young T, Ellner JJ. Enhanced production of TGF-beta by blood monocytes from patients with active tuberculosis and presence of TGF-beta in tuberculous granulomatous lung lesions. J Immunol 1995; 154:465–473. 87. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334:395–402. 88. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK. Exogenous reinfection with multidrug-resistant M. tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328:1137–1144. 89. Orme IM, Collins FM. Protection against Mycobacterium tuberculosis infection by adoptive transfer. J Exp Med 1983; 158:74–83. 90. Pedrazzini T, Hug K, Louis JA. Importance of L3T4 and Lyt-2 cells in the immunologic control of infection with Mycobacterium bovis strain bacillus CalmetteGuerin in mice. Assessment by elimination of T cell subsets in vivo. J Immunol 1987; 139:2032–2037. 91. Muller I, Cobbold SP, Waldmann H, Kaufmann SH. Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4 and Lyt-2 T cells. Infect Immun 1987; 55:2037–2041. 92. Orme IM, Miller ES, Roberts AD, Furney SK, Griffin JP, Dobos KM, Chi D, Rivoire B, Brennan PJ. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens. J Immunol 1992; 148:189–196. 93. Ladel CH, Daugelat S, Kaufmann SHE. Immune response to Mycobactetium bovis bacille Calmette Guerin infection in major histocompatability complex I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 1995; 25:377–384. 94. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, Ricci M, Romagnani S. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88:346–350. 95. Boom WH, Wallis RS, Chervenak KA. Human Mycobacterium tuberculosis-reactive CD4 T-cell clones: heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes. Infect Immun 1991; 59:2737–2793.
210
Daniel et al.
96. Haanen JB, de Waal-Malefijt R, Res PC, Kraakman EM, Ottenhoff TH, de Vries RR, Spits H. Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med 1991; 174:583–592. 97. Silver RF, Li Q, Boom WH, Ellner JJ. Lymphocyte-dependent inhibition of growth of virulent M. tuberculosis H37Rv within human monocytes: requirement for CD4 T cells in PPD-positive but not in PPD-negative subjects. J Immunol; 1998; 160:2408–2417. 98. Hansen PW, Petersen CM, Povlsen JV, Kristensen T. Cytotoxic human HLA class 11 restricted purified protein derivative reactive T lymphocyte clones. Scand J Immunol 1987; 25:295–303. 99. Mustafa AS, Godal T. BCG induced CD4 cytotoxic T cells from BCG vaccinated healthy subjects: relation between cytotoxicity and suppression in vitro. Clin Exp Immunol 1987; 69:255–262. 100. Kumararatne DS, Pithie AS, Drysdale P, Gaston JS, Kiessling R, Iles PB, Ellis CJ, Innes J, Wise R. Specific lysis of mycobacterial antigenbearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis. Clin Exp Immunol 1990; 80:314–323. 101. Toossi Z, Sedor JR, Lapurga JP, Ondash, RJ, Ellner JJ. Expression of functional interleukin 2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis. J Clin Invest 1990; 85:1777–1784. 102. Tan JS, Canaday DH, Boom WH, Balaji KN, Rich EA. Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: Role for CD4 and CD8 cytotoxic T cells and relative resistance of alveolar macrophages to lysis. J Immunol 1997; 159:290–297. 103. Pfeffer K, Schoel B, Gulle H, Moll H, Kromer S, Kaufmann SH, Wagner H. Analysis of primary T cell responses to intact and fractionated microbial pathogens. Curr Top Microbiol Immunol 1991; 173:173–178. 104. Schoel B, Gulle H, Kaufmann SH. 1992. Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to Mycobacterium tuberculosis antigens separated by high-resolution techniques. Infect Immun 1992; 60: 1717–1720. 105. Haas W, Pereira P, Tonegawa S. Gamma/delta cells. Ann Rev Immunol 1993; 11:637–685. 106. Modlin RL, Pirmez C, Hofman FM, Torigian V, Uyemura K, Rea TH, Bloom BR, Brenner MB. Lymphocytes bearing antigen-specific gamma delta T-cell receptors accumulate in human infectious disease lesions. Nature 1989; 339:544–548. 107. Kabelitz D, Bender A, Schondelmaier S, Schoel B, Kaufmann SH. A large fraction of human peripheral blood gamma/delta T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein. J Exper Med 1990; 171:667–679. 108. Barnes PF, Grisso CL, Abrams JS, Band H, Rea TH, Modlin RL. Gamma delta T lymphocytes in human tuberculosis. J Infect Dis 1992; 165:506–612. 109. Boom WH, Chervenak KA, Mincek MA, Ellner JJ. Role of the mononuclear phagocyte as an antigen-presenting cell for human gamma delta T cells activated by live Mycobacterium tuberculosis. Infect Immun 1992; 60:3480–3488. 110. Balaji KN, Schwander S, Rich EA, Boom WH. 1995. Alveolar macrophages as accessory cells for human T cells activated by M. tuberculosis. J Immunol 1995; 154:5959–5968.
Immunology of Tuberculosis 111.
112.
113.
114.
115.
116.
117. 118.
119.
120.
121.
122.
123.
124. 125. 126.
211
Pechhold K, Wesch D, Schondelmaier S, Kabelitz D. Primary activation of V gamma 9-expressing gamma delta T cells by Mycobacterium tuberculosis. Requirement for Thl-type CD4 T cell help and inhibition by IL-10. J Immunol 1994; 152:4984–4992. Pfeffer K, Schoel B, Gulle H, Kaufmann SH, Wagner H, Primary responses of human T cells to mycobacteria: a frequent set of gamma/delta T cells are stimulated by protease-resistant ligands. Eur J Immunol 1990; 20:75–79. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, Fournie JJ. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994; 264:267–270. Tanaka Y, Sano S, Nieves E, De Libero G, Rosa D, Modlin RL, Brenner MB, Bloom BR, Morita CT. Nonpeptide ligands for human gamma delta T cells. Proc Natl Acad Sci USA 1994; 91:8175–8179. Tanaka Y, Morita C, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 1995; 375:155–158. Boom WH, Balaji KN, Nayak R, Tsukaguchi K, Chervenak KA. 1994. Characterization of a 10–14 kDa protease sensitive Mycobacterium tuberculosis-H37Ra antigen that stimulates human gamma-delta ( ) T cells. Infect Immun 62:5511–5515. Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4-8T lymphocytes to a microbial antigen. Nature 1992; 360:593–597. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted alpha beta T cells. Nature 1994; 372:691–694. Balaji KN, Boom WH. Processing of Mycobacterium tuberculosis bacilli by human monocytes for CD4 alphabeta and gammadelta T cells: role of particulate antigen. Infect Immun 1998; 66:98–106. Daniel TM, Debanne SM. The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay. Am Rev Respir Dis 1987; 135:1137–1151. Daniel TM, McDonough JA, Huebner RE. Absence of IgM or IgG antibody response to Mycobacterium tuberculosis 30,000-Da antigen after primary tuberculous infection (letter). J Infect Dis 1991; 164:821. Chan SL, Reggiardo Z, Daniel TM, Girling DJ, Mitchison DA. Serodiagnosis of tuberculosis using an enzyme-linked immunosorbent assay (ELISA) with antigen 5 and a hemagglutination assay with glycolipid antigens. Results in patients with newly diagnosed pulmonary tuberculosis ranging in extent of disease from minimal to extensive. Am Rev Respir Dis 1990; 142:385–390. Daniel TM, Debanne SM, van der Kuyp F. Enzyme-linked immunosorbent assay using Mycobacterium tuberculosis antigen 5 and PPD for the serodiagnosis of tuberculosis. Chest 1985; 88:388–392. Malaviya AN, Sehgal KL, Kumar R, Dingley HB. Factors of delayed hypersensitivity in pulmonary tuberculosis. Am Rev Respir Dis 1975; 112:49–52. Lenzini L, Rottoli P, Rottoli L. The spectrum of human tuberculosis. Clin Exp Immunol 1977; 27:230–237. Cox RA, Downs M, Neimes RE, Ognibene AJ, Yamashita TS, Ellner JJ. Immunogenetic analysis of human tuberculosis. J Infect Dis 1988; 158:1302–1308.
212
Daniel et al.
127. Jones BE, Oo MM, Taikwel EK, Qian D, Kumar A, Maslow ER, Barnes PF. CD4 counts in human immunodeficiency virus-negative patients with tuberculosis. Clin Infect Dis 1997; 24:988–991. 128. Toossi Z, Ellner JJ. Tuberculosis. In: Kelley WN, ed. Textbook of Internal Medicine. 2d ed. Philadelphia: JB Lippincott Company, 1991: 1426–1434. 129. Ellner JJ, Barnes PF, Wallis RS, Modlin RL. The immunology of tuberculous pleurisy. Sem Respir Med 1988; 3:335–342. 130. Barnes PF, Misky SD, Cooper CL, Pirmez C, Ren TN, Modlin RE. Compartmentalization of a CD4 T-lymphocyte population in tuberculous pleuritis. J Immunol 1989; 142:1114–1119. 131. Fujiwara H, Tsuyuguchi I. Frequency of tuberculin-reative T-lymphocytes in pleural fluid and blood from patients with tuberculous pleurisy. Chest 1984; 89:530– 532. 132. Kleinhenz ME, Ellner JJ. Antigen responsiveness during tuberculosis: regulatory interaction of T-cell subpopulations and adherent cells. J Lab Clin Med 1987; 110:31– 40. 133. Ellner JJ. Suppressor adherent cells in human tuberculosis. J Immunol 1978; 121:2573–2578. 134. Fujiwara H, Kleinhenz, ME, Ellner JJ. Defective interleukin-2 production and responsiveness in human pulmonary tuberculosis. Am Rev Respir Dis 1983; 133:73–77. 135. Takashima T, Ueta C, Tsuyugushi I, Kishimoto S. Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis. Infect Immun 1990; 58:3286–3292. 136. Ogawa T, Uchida H, Kusumoto Y, Mori Y, Yamamura Y, Hamada S. Increase in tumor necrosis factor alpha and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis. Infect Immun 1991; 59:3021–3025. 137. Falla JC, Parra CH, Mendoza M, Franco LC, Guzman F, Forero J, Orozco O, Patarroyo ME. Identification of B- and T-cell epitopes within the MPT 40 protein of Mycobacterium tuberculosis and their correlation with the course of disease. Infect Immun 1991; 59:2265–2273. 138. Havlir DV, Ellner JJ, Chervenak KA, Boom WH. Selective expansion of human T-cells by monocytes infected with live Mycobacterium tuberculosis. J Clin Invest 1991; 87:729–733. 139. Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ. Human immune response to Mycobacterium tuberculosis antigens. Infect Immun 1991; 59:665–670. 140. Torres M, Mendez-Sampeiro P, Jimenez-Zamudio L, Teran L, Camarena A, Quezada R, Ramos E, Sada E. Comparison of the immune response against Mycobacterium tuberculosis antigens between a group of patients with active pulmonary tuberculosis and healthy household contacts. Clin Exp Immunol 1994; 96:75–78. 141. Ellner JJ, Daniel TM. Immunosuppression by mycobacterial arabinomannan. Clin Exp Immunol 1979; 35:250–257. 142. Stanford JL, Grange JM, Pozniak A. Is Africa lost? Lancet 1991; 338:557–558.
Immunology of Tuberculosis
213
143. Grange JM. Immunotherapy: a new strategy for tuberculosis control? Respir Med 1997; 91:1–4. 144. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease. Respir Med 1997; 91:13–19. 145. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med 1997; 91:21–29. 146. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545–550. 147. Braun MM, Badi N, Ryder RW, Baende E, Mukadi Y, Nsuami M, Matela B, Willame J-C, Kaboto M, Heyward W. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. Am Rev Respir Dis 1991; 143:501–504. 148. Allen S, Batungwanayo J, Kerlikowske K, Lifson AR, Wolf W, Granich R, Taelman H, van de Pierre P, Serofilira A, Bogaerts J, Slutkin G, Hopewell PC. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146:1439–1444. 149. Fischl M, Uttamchandani R, Reyes R, Cleary T, Otten J, Breeden A, Bigler W, Valdez H, Cacciatore R, Witte J, Hoskins RS, Grieco MH, Williams J, Sordillo E, Rivera P, Pitta A, Mullen MP, Gordon MT, Busillo CP, Boyle JF, Adler J, Ong KR, DiFerdinando JF Jr, Morse DL. Nosocomial transmission of multidrug resistant tuberculosis among HIV-infected persons—Forida and New York, 1988–1991. MMWR 1991; 40:585–591. 150. Okwera A, Eriki PP, Guay LA, Ball P, Daniel TM. Tuberculin reactions in apparently healthy HIV-seropositive and HIV-seronegative women—Uganda. MMWR 1990; 39:638–646. 151. Centers for Disease Control. Purified protein derivative (PPD)-tuberculin anergy in HIV infection: Guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR 1991; 40(No. RR-5):27–32. 152. Colebunders RL, Lebughe I, Nzila N, Kalunga D, Francis H, Ryder R, Piot P. Cutaneous delayed-type hypersensitivity in patients with human immunodeficiency virus infection in Zaire. J AIDS 1989; 2:576–578. 153. Vjecha M, Okwera A, Nyold S, Byekwaso F, Okot-Nwang M, Mugerwa RD, Eriki P, Aisu T, Ellner J, Huebner R, Hom D, Daniel TM, Edmonds K, Wallis R. Association between anergy, prior complications of HIV-1 infection, and increased mortality in HIV-1 infected patients with active tuberculosis in Uganda (abstr). Proceedings of the Seventh International Conference on AIDS, Florence, Italy, 1991; WB 2346. 154. Ellner JJ. Tuberculosis in the time of AIDS. The facts and the message. Chest 1990; 98:1051–1052. 155. Keiper MD, Beumont M, Elshami A, Langlotz CP, Miller WT Jr. CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis. A study of the relationship between these factors in patients with human immunodeficiency virus infection. Chest 1995; 107:74–80.
214
Daniel et al.
156. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129–135. 157. Whalen C, Okwera A, Johnson J, Vjecha M, Hom D, Wallis R, Huebner R, Mugerwa R, Ellner J. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 153:1977–1981. 158. Manoff SB, Farzadegan H, Muñoz A, Astemborski JA, Vlahov D, Rizzo RT, Solomon L, Graham NMH. The effect of latent Mycobacterium tuberculosis infection on human immunodeficiency virus (HIV) disease progression and HIV RNA load among injecting drug users. J Infect Dis 1996; 174:299–308. 159. Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S, Cao Y, Weiden M. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997; 155:996–1003. 160. Lederman MM, Georges DL, Kusner DJ, Mudido P, Giam C-Z, Toossi Z. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. J AIDS 1994; 7:727–733.
9 Transmission of Tuberculosis
EDWARD A. NARDELL
WILLY F. PIESSENS
Harvard Medical School Cambridge Hospital and Massachusetts Department of Public Health Cambridge and Boston, Massachusetts
Harvard School of Public Health Harvard Medical School Boston, Massachusetts
From the perspective of the organism Mycobacterium tuberculosis, both transmission and pathogenesis are essential for survival and propagation. However, this intracellular bacillus has exhibited itself as an entrenched, opportunistic pathogen, against which our best defenses and control strategies have thus far proven inadequate. Figure 1 depicts many of the biomedical factors known to be important in the propagation of tuberculosis (TB). Not shown are the equally important biosocial factors affecting propagation, such as crowded living conditions, malnutrition, and limited access to health care and effective treatment. This scheme will serve as an overview for this discussion of transmission and pathogenesis. Transmission begins with a human source, almost always a person with cavitary, pulmonary tuberculosis. The pathogenic process of liquefaction (caseating) necrosis is the destructive end result of ongoing delayed-type hypersensitivity (DTH) in response to overwhelming infection. Caseous foci erode into adjacent bronchi, where organisms find favorable aerobic conditions, multiply rapidly, cause characteristic local and systemic symptoms, and gain access to the environment. A variety of known and unknown factors influence transmission source strength, i.e., the number, viability, and infectivity of organisms put into the air by the source. These factors include a propensity to lung cavitation, cough strength 215
216
Figure 1
Nardell and Piessens
Tuberculosis propagation—biomedical model.
and frequency, and poorly defined characteristics of respiratory secretions that permit effective aerosolization and preserve the viability and infectiousness of organisms. Effective chemotherapy is the single most important factor in reducing infectiousness at any stage of the disease. Organisms that have developed resistance to the most effective chemotherapeutic agents (multidrug-resistant, or MDRTB) are difficult to control both in the individual and in the community. MDRTB can be lethal for the host, but death is often preceded by prolonged infectiousness, assuring propagation in the community (1,2). Tubercle bacilli are spread as droplet nuclei, the dried residue of larger respiratory droplets. Fluid lining the respiratory tract and any microorganisms contained in it may become aerosolized by high-velocity airflow during coughing, sneezing, and other forced expiratory maneuvers. Aerosolization (take off), aerial transport, and implantation (landing) of the tubercle bacilli in a suitable host is thought to be lethal for the vast majority of microbes, accounting in some part for the much lower infectiousness of tuberculosis compared, for example, to measles (3). The physical and chemical characteristics of respiratory secretions may be more or less conducive to droplet formation and, during aerial transport, variably protect tubercle bacilli from dehydration, oxygen injury, natural irradiation, and other environmental stresses such as air pollutants (4–6). Rehydration on inhalation is another critical environmental stress. Strains of tubercle bacilli undoubtedly vary in their innate resistance to environmental stresses, but these aspects of TB aerobiology have not been investigated. Transmission occurs most efficiently
Transmission of Tuberculosis
217
in enclosed environments where the source, infectious droplet nuclei, and potential hosts are concentrated. The upper respiratory tract, where most airborne droplet nuclei greater than 5 m in diameter are likely to impact, is highly resistant to TB infection (7). Tuberculosis begins as an infection of the alveolar macrophage, and this requirement defines the size of infectious droplet nuclei as approximately 1–3 m in diameter. Upon landing on an alveolar surface, tubercle bacilli are engulfed by resident macrophages, which have variable, inherited and acquired, innate (nonimmunological) microbicidal capacity. If organisms survive and replicate in the macrophage, cell-mediated immunity and delayed-type hypersensitivity are triggered, resulting in the arrest of infection at a subclinical stage or progression to active disease. If organisms are destroyed before they replicate to 10–15 generations, infection is aborted without an immunological record (tuberculin skin test negative). How often this occurs is, by definition, unknown. Successful infection can progress to clinical disease after a 4- to 8-week incubation period (primary or progressive primary TB) or reactivate after a prolonged period of latency (postprimary TB). Reactivation disease may occur at the site of implantation in the lung but more often occurs at a site of hematogenous dissemination in any organ, most commonly in the vulnerable upper lung zones where a propensity to cavitation assures continued propagation of the disease. I. Aerobiology of Tuberculosis A. Historical Perspective
Airborne spread of tuberculosis (TB) was a controversial theory for decades before it was proven 40 years ago. Earlier in this century, little credence was given to the risk of airborne transmission. For example, Hans Castorp, hero of Thomas Mann’s 1924 Nobel Prize–winning novel, The Magic Mountain, travels to the renowned international sanatorium Berghof at Davos, in the Swiss Alps, anticipating a 3-week visit with his cousin, Joachim, a patient with pulmonary tuberculosis (8). Mann was inspired by his own 3-week visit to Davos where his wife was evaluated and found not to have the disease. For uninfected persons, living, dining, and socializing for weeks with dozens of patients with infectious pulmonary TB would have been quite dangerous in the era before chemotherapy. In the novel, ironically, Castorp soon discovers that he had arrived at Davos not only infected, but febrile with active disease, and he joined his ill-fated cousin as a long-term patient. So common was TB in Europe and other industrialized countries in previous centuries that infection was presumed to be nearly universal, unavoidable, possibly hereditary, and difficult to link to so many potential exposures. Relative immunity derived from infection early in life (i.e., herd immunity), and the often long latency period between infection and reactivation further blurred the association between exposure and disease. Precautions to prevent transmission were un-
218
Nardell and Piessens
known in that era, although sanatoria treatment effectively served to isolate many patients from the general population. Contrast the cavalier risk perception evident in Mann’s novel with the 132-page, 1994 Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, intended to prevent even one health-care worker from becoming infected (9). Perhaps because TB infection is now uncommon in industrialized countries, the general public as well as the medical community have come to fear it. Concern escalated following well-publicized outbreaks of highly drug-resistant TB in congregate settings in the United States and Europe, leading to some deaths among patients, residents, and workers (10). Loss of herd immunity in low-prevalence populations makes such outbreaks more likely when exposures occur, however uncommon. In addition, the disciplines of occupational medicine and industrial hygiene have evolved over the years, and health expectations on the part of workers in resource-rich countries have increased (11). In resource-poor countries, however, complacency about the risk of TB infection still occurs, which is attributable to high prevalence rates, limited resources for better control, herd immunity, low health expectations, and inadequate education about the risk. Outbreaks of multidrug-resistant (MDR) TB among institutional patients and workers in developing countries is gradually changing that view, increasing awareness of the risk of airborne transmission of a potentially lethal infection (12). This chapter will review some of what is currently known about the aerobiology and epidemiology of TB transmission and the means available for control. B. History of Droplet Nuclei Transmission
Approximately 50 years after Koch’s discovery of the tubercle bacillus in 1882, William Firth Wells, working initially at Harvard University and later at the University of Pennsylvania, unraveled the mechanisms by which airborne infections spread (13). A sanitary engineer, Wells was under contract to the Massachusetts Department of Public Health to investigate the potential for respiratory illness among workers exposed to contaminated water that was aerosolized to keep the dust down in New England textile mills. Employing the air centrifuge he had earlier developed, Wells recovered culturable bacteria from the air as particles small enough to remain airborne and to be inhaled deeply into the lungs. From this observation, his brilliant intellectual leap was postulated: Respiratory droplets generated by human coughs and sneezes would also desiccate before impacting on surfaces, becoming particles so small they remain airborne as “droplet nuclei,” carrying infectious human pathogens from person to person. Working with Wells on the textile mill investigation was another sanitary engineer, Edward Riley, and his brother, Richard, then a medical student at Harvard. In the preface to his 1955 comprehensive monograph on the subject, Airborne Contagion and Air Hygiene, Wells shared credit with Richard Riley and Theodore Hatch for “the basic dis-
Transmission of Tuberculosis
219
tinction between infective droplet nuclei and germ-laden dust” (14). Wells, Riley, and their coworkers not only conceptualized droplet nuclei transmission, they conducted extensive quantitative laboratory and field tests that established the foundation of our current understanding of airborne infection and air disinfection. Riley’s 1961 monograph, Airborne Infection, summarized and updated Wells’s earlier work (3). In the 1960s, Loudon’s group focused on cough and the behavior of airborne mycobacteria. Experiments using a rotating drum established that the half-life of aerosolized virulent tubercle bacilli (H37Rv) is about 6 hours (15). As detailed below, Riley’s research on ultraviolet air disinfection continued through the 1970s, but there has been little basic work on the aerobiology of TB and its control since that time. However, recent outbreaks of MDRTB have stimulated new research focused on air disinfection. Although investigations on the aerobiology of TB stagnated, the aerobiology of other microorganisms has advanced steadily. A great deal more is known about factors that influence the take-off, transport, and landing of certain aerosolized viruses, fungi, and common test bacteria (Escherichia coli, Serratia, and Klebsiella) than is known about TB (4–6). For example, despite the striking prevalence of TB in tropical climates, the influence of temperature and humidity on TB transport remains completely unknown! Under experimental conditions it has been shown that aerosolized E. coli are adversely effected at high humidity, unless aerosolized in certain protective solutes. There are also data to suggest that high humidity protects some airborne microorganisms from natural irradiation, ozone, and other potentially lethal environmental factors. The mechanisms underlying these phenomena have been explored and mathematical models derived that correlate well with experimental data (4–6). These data have potential practical importance for TB control. Vulnerability of microorganisms during airborne transport relates directly to air-disinfection strategies, germicidal irradiation in particular. More basic research on the aerobiology of tuberculosis is needed if the institutional spread of TB worldwide is to be better controlled. C. Air Sampling for TB
Aerobiology research on TB has been greatly hampered by the slow growth rate of M. tuberculosis in culture. Using standard air-sampling methods and selective culture media, M. tuberculosis and M. bovis species can be recovered from room air only if artificially aerosolized at relatively high concentrations (16). From human sources, viable tubercle bacilli are few and far between in room air, and if captured by air sampling even highly selective culture media become overgrown with the much more numerous and rapidly growing ambient airborne fungi and bacterial species. Recently, pilot experiments have shown that it is possible to capture M. tuberculosis generated by highly infectious patients by having the patient cough into a box, thereby preventing dilution of droplet nuclei in room air (17).
220
Nardell and Piessens
Nucleic acid–amplification technologies have also been applied to air sampling for TB, with limited success (18). As already noted, it is believed that the vast majority of airborne tubercle bacilli are inactivated due to the stresses of aerosolization, transport, and air sampling, but it is difficult to judge viability, much less infectivity, by current molecular detection methods. However, a much older technology, guinea pig air sampling, has provided information much closer to the infectiousness of airborne TB for humans. This technique was employed by Riley and coworkers four decades ago to demonstrate and quantify the infectivity (for guinea pigs) of patients with symptomatic pulmonary TB residing on a six-bed experimental ward in the Baltimore Veterans Administration Hospital (19). The results of those classic experiments remain the best source of quantitative information on TB infectivity, its variability, the impact of chemotherapy, and the potential benefits of air disinfection (in ventilation ducts) with ultraviolet irradiation. D. The Wells-Riley Experimental Ward
Previous laboratory experiments by Ratcliff and Palladino had established that guinea pigs are extraordinarily susceptible to airborne M. tuberculosis (20). Guinea pigs became infected with TB by breathing aerosolized solutions of virulent human TB. Using quantitative culture methods, aerosols were made so dilute that inhalation of more than a single infectious droplet by test animals was statistically unlikely. Autopsies of the infected animals revealed single foci of infection in the periphery of lungs. For guinea pigs, TB infection correlated with inhalation of just one infectious droplet nucleus, which also correlated with a single colony on culture. Knowing how much air each animal breathed (on average, 240 cubic ft per month), Wells devised an experiment (later published by Riley) using guinea pigs as quantitative air samplers for human TB (19). Because of their small size, however, the practical application of this sampling method required more than 100 guinea pigs breathing the air exhausted from a six-bed ward housing patients with potentially infectious TB. These experimental conditions have been established only once, during the remarkable 4-year study at the Veterans Administration Hospital in Baltimore during the late 1950s and early 1960s. The results established five important facts about TB transmission and its control: (1) TB is a true airborne infection, requiring only air contact for transmission; (2) patients vary greatly in infectiousness; (3) infectiousness is rapidly reduced by effective treatment; (4) the average concentration of infectious droplet nuclei is low, on the experimental ward averaging 1 in 11,000 cubic feet of air; and (5) ultraviolet germicidal irradiation in the exhaust duct was a highly effective method of air disinfection (19,21–24). The study had limitations. Among 61 untreated patients with drug-susceptible organisms, only 8 infected any guinea pigs, and among 6 untreated patients
Transmission of Tuberculosis
221
with drug-resistant organisms, only 2 proved infectious to guinea pigs. From a total of 40 patients under chemotherapy, only 2 infected guinea pigs. Thus, the infectivity of many tuberculosis patients with positive sputum was too low to be detected in the Baltimore study. On the other hand, a patient with laryngeal TB infected 15 guinea pigs in 3 days. By calculation, the concentration of infectious particles in the air at that time was about 1 in 200 cubic ft, or more than 50 times the average concentration of 1 in 11,000 cubic ft of air. Then, as now, our attention is called to what Riley called “disseminators,” individuals who for various reasons infect a high proportion of their contacts (24,25). Although often the subject of epidemiological investigations, it is unclear how much these unusually infectious sources contribute to TB propagation in the community compared to the more common, less infections cases, which are never reported in the literature. As already noted, extensive transmission can result from a variety of factors, alone and in combination: source strength, exposure duration, environmental conditions, strain hardiness, virulence, and host susceptibility. While many of these factors were controlled in the guinea pig–exposure experiments, they are harder to separate in the epidemiological studies discussed below. II. Epidemiology of Transmission A. Historical Studies
TB infection rates among nurses in training and doctors were studied extensively in the 1930s and 1940s (26,27). As reported by Israel, about a third of student nurses began training at Philadelphia General Hospital already TB infected, using 5 mm reactions to 1 tuberculin unit as criteria for infection. This rate was a good indicator of household exposure risk at the time for the age and socioeconomic cohort represented by nursing students. The number of students infected increased each year, with nearly all infected by the end of 3 years of training, and about 10% developing clinical disease. These investigations provided an estimate of exposure intensity on general hospital wards in the prechemotherapy era, largely from unsuspected cases, as TB patients were commonly transferred to sanatoria upon diagnosis. Riley calculated that the infection rate of student nurses could be approximated by exposure to the average concentration of infectious droplet nuclei on his experimental ward, assuming that humans, like guinea pigs, became infected by a single infectious droplet nucleus. If, as now seems likely (see Sec. III), more than one inhalation may be required for innately resistant individuals, the infection rate among student nurses would have required higher concentrations than Riley’s guinea pig air samplers were able to detect. Of course, none of the patients on the experimental ward were unsuspected, and most were on therapy, greatly reducing infectivity. Insights into the behavior of airborne TB organisms have been gained over the years through epidemiological investigations of outbreaks, experiments of na-
222
Nardell and Piessens
ture, such as was the case on board the Navy vessel, U.S.S. Byrd (28). Sixty-six men shared one bunking compartment with the index case, who had a large cavity in his lung. Eighty-one men, with minimal direct contact with the others, shared a second compartment in which three quarters of the ventilation came through interconnecting ducts from the first compartment. Eighty percent of the men in the first compartment converted the tuberculin test from negative to positive, and 54% of the men in the second compartment converted. The rate of conversion in the first compartment was nearly the same as the expected rate based on the proportion of ventilation coming from the first compartment (0.75 0.8, or 0.6 vs. 0.54). In this inadvertent experiment, the men in the two compartments were infected roughly proportionally to the amount of contaminated air they breathed. But direct contact with the index case occurred only in the first compartment. Thus, close contact did not greatly increase the likelihood of infection. Under more ordinary exposure conditions, this observation suggests that close proximity to an infectious source may add little to the risk of exposure in the same breathing space. Despite intensive investigation by the Navy, no evidence for transmission from environmental sources could be found after the infectious cases had been removed. Airborne droplet nuclei from the source constituted the only mechanism of transmission, and shared air, rather than proximity per se, the principal environmental risk. B. Mathematical Models of Transmission
In a report on a measles outbreak in a suburban elementary school, the quantitative assessment of airborne infection was further refined (29). The results are directly applicable to TB transmission because both diseases are spread by droplet nuclei. The issue of infectious dose must be introduced here as it is relevant to any quantitative discussion. It is discussed again in more detail in the next section. The number of infectious droplet nuclei required to infect humans with any airborne infection is unknown, in contrast to TB in guinea pigs where one culturable bacillus is sufficient. To circumvent this obstacle, Wells coined the term “quantum” of infection to mean an infectious dose, which could be one or more than one inhaled infectious particle, usually referring to the same exposure. As discussed below, we have extended the definition of dose for TB to include repeated inhalations during one or more exposure until one inhalation results in infection. The Wells-Riley ward data had confirmed epidemiological observations that TB is much less infectious than most of the airborne viral infections, in part because average concentrations of infectious droplet nuclei are so low that infection during ordinary exposures is statistically unlikely. Poisson’s law of low-probability events comes into play. Even when highly susceptible guinea pigs were exposed experimentally to concentrations of tubercle bacilli low enough that each animal should inhale no more than an average of one droplet nucleus, only 63.2%
Transmission of Tuberculosis
223
became infected (some animals, by chance, inhaling more than one droplet nuclei), whereas 36.8% escaped infection. Thus, a quantum of infection is that dose that results in the infection of 63.2% of exposed subjects. For humans, it is clear that infectious dose for tuberculosis will vary with the resistance of exposed persons and the virulence of the TB strain. However, for the purpose of mathematical modeling, we will use Wells’s “quanta” of infection, understanding that for humans a quantum of infection for TB and most other infections cannot be converted to numbers of droplet nuclei inhaled over one or many exposures. This convenience, however, permits useful quantitative insights into transmission and its control. In studying the school measles outbreak in upstate New York, Edward Riley expanded and modified Wells’s use of the Soper mass balance equation for epidemiological investigations to allow for low-probability events and multiple generations of infection, as occurs in measles. The equation for a single generation of infection is: C S(1 eIqpt/Q) where: C number of new cases S number of susceptibles exposed e natural logarithm I number of infectious sources q number of quanta (infectious doses) generated per unit min p human ventilation rate (L/min) t exposure duration Q infection-free ventilation (L/sec) Ideally applied to a single room or enclosed space, the model has been applied with less validity to spaces served by the same heating, ventilating, and air conditioning (HVAC) system. The larger the space, the less convincing the assumption of complete room air mixing. Other assumptions include uniform susceptibility of exposed persons to infection and uniform virulence of organisms from one outbreak to another. In analyzing successive generations of the measles epidemic, C, S, I, p, t, and Q were either known or estimated for each room throughout the school, and the value of q was calculated. The infectiousness, q, of the index case was found to be 5580 quanta per hour, about 10 times that of secondary cases appearing in the next generation. Measles patients thus showed great variability in infectiousness, as was seen in tuberculosis patients on Riley’s experimental ward, but the rate of production of infectious airborne particles was much higher. The mathematical model developed to analyze the measles outbreak has been applied to several episodes of TB transmission, of which two instructive examples will be men-
224
Nardell and Piessens
tioned here: a prolonged exposure in an office building and a brief but explosive exposure in a hospital intensive care unit. A 30-year-old woman returned sick to her duties from a month-long holiday, but she continued to work in a welfare office for an additional month before she was diagnosed with cavitary, sputum smear–positive TB, at which time contact with fellow employees ended (30). Of 67 coworkers initially tuberculin skin test negative, 27 (40%) had conversions to positive upon repeat testing 3 months later. One noninfectious secondary case resulted in a worker who had declined treatment of latent infection. The office building had been the subject of repeated air-quality complaints, and several air-quality assessments had been done before and after the TB exposure. A mathematical analysis of the exposure was prompted by the suspicion of several workers that inadequate ventilation was responsible for the large number of infected workers. As in the measles outbreak, all values of the Wells-Riley equation were known or estimable except q, the number of infectious quanta generated by the source case. By calculation, the source generated 13 infectious quanta per hour, compared to an average of only 1.25 for the entire six-bed experimental ward and a high value of 60 for the case of laryngeal TB studied by Riley. Further calculations showed that outdoor air ventilation at the low end for acceptable air quality (15 cubic feet per minute per occupant, based on average room CO2 values of 1000 ppm) contributed to transmission. However, the model indicated that doubling ventilation would reduce the risk of infection only by approximately half (Fig. 2). Thirteen workers would still have been infected, according to the model. Moreover, an additional doubling, to an unrealistic 60 cfm per occupant, would again reduce risk by half, leaving approximately 6 workers unprotected. Both the potential of a moderately infectious patient to infect many contacts over a prolonged period and the limitations of building ventilation to prevent transmission were demonstrated, within the assumptions and limitation of the model. Catanzaro applied the Wells-Riley equation to an episode of transmission in an intensive care unit where an unsuspected patient, initially smear negative for TB, underwent intubation and bronchoscopy (31). During the 21⁄2 hours of the procedures, 10 of 13 susceptible room occupants became infected (31). By calculation, the source produced a remarkable 250 quanta per hour (compared to 1.25/hr for the experimental ward, and 13/hr for the office building). However, the ventilation rate in the intensive care unit was extremely low, and further calculations predicted substantial improvements by increases in ventilation that were achievable (Fig. 2). The episode illustrates the ever-present risk of the unsuspected case, the wide range of infectivity, and the potential for environmental controls to greatly reduce transmission when existing ventilation is low. Recently, mathematicians have endeavored to further refine the Wells-Riley model. However, the results differ only slightly from those using the original model, and given the nature of the assumptions and estimates necessary to apply modeling to real-world situations, it is unclear that embellishments of the model
Transmission of Tuberculosis
225
Figure 2 Two different situations of extensive transmission are represented. In both cases I was 1 and p was assumed to be 0.353 cfm, a constant. Thereafter the transmission factors for the Nardell and Catanzaro exposures were, respectively, q 13 and 250 qph; t 9600 and 150 minutes; and Q 1450 and 150 cfm.
at the expense of simplicity will serve any practical purpose (32). Although derived from an epidemiological model, the Wells-Riley equation has much in common with engineering mass balance equations, some of which have been validated by experimental measurements of airborne contaminant concentrations, such as the concentrations of airborne antigens in an animal facility (33). Epidemiological models predicting infection and disease rates, mortality, drug resistance, and financial consequences in response to demographic changes and other factors have become highly sophisticated (34). For epidemiological purposes, the details of transmission at the level of the room or building are not considered. It is assumed that populations interact in ways that permit the transmission of infectious diseases, whatever the mechanisms (35). III. Infectious Dose for Humans The concept of an infectious dose is somewhat different for tuberculosis than for some of the other common respiratory infections. For example, thousands of potentially pathogenic oral-pharyngeal bacteria are routinely aspirated without caus-
226
Nardell and Piessens
ing pneumonia—apparently cleared by lung defenses. In guinea pigs and susceptible strains of inbred rabbits, however, experimental exposure studies using dilute aerosols (confirmed by culture) have shown that a single inhaled droplet nucleus, estimated to carry no more than three organisms, was sufficient to cause infection, manifested by a tuberculin skin test conversion and a single peripheral lung lesion (20). In humans, resistance to initial tuberculosis infection appears to be variable, among different individuals and among different populations, due to acquired and inherited resistance. This observation suggests that inhalation of more than one droplet nucleus, possibly many, may be necessary to cause infection in resistant individuals. Because the concentration of droplet nuclei in the air under ordinary exposure conditions is believed to be extremely low, averaging only 1 in 11,000 cubic feet in the air exhausted from Riley’s experimental tuberculosis ward over a 4-year period, multiple or recurrent inhalations are unlikely unless exposure is prolonged or the source strength is unusually strong (22). In the bronchoscopy exposure discussed above, a concentration of approximately 1 quanta in 70 cubic feet was estimated, making multiple inhalations likely (31). Whereas multiple pulmonary foci of infection are seen in persons exposed to high concentrations of histoplasmosis spores, primary tuberculosis on chest radiographs is almost always a single focal site. Thus, for tuberculosis an infectious dose may require repeated inhalations over time until one implantation results in infection. The dose of droplet nuclei required to cause infection depends on the probability of a successful defense by alveolar macrophages in each encounter with those tubercle bacilli reaching the alveoli. A successful defense depends on the microbicidal capacity of the macrophage relative to the virulence of inhaled tubercle bacilli (see Chap. 10). In theory, the infecting dose will be high in persons whose macrophages generally have great microbicidal capacity or where bacilli are of low virulence. In contrast, persons whose macrophages generally have relatively little microbicidal capacity or where bacilli are fully virulent even hypervirulent, the infecting dose will be low, probably as little as a single droplet nucleus. Chance plays an important role in several ways: (1) the variable innate microbicidal capacity of alveolar macrophages that happen to be in the vicinity of the bacillary implantation site, (2) the low likelihood of inhaling even one droplet nucleus during most exposures, and (3) the relatively low probability that inhaled droplet nuclei will reach the especially vulnerable apical or subapical region of the lung. Subapical implantation may be more important for exogenous reinfection than for initial infection, since previously infected persons have highly effective cell-mediated immunity to reinfection (36–38). The belief that TB infection is caused by the chance implantation of single infectious droplet nuclei containing few organisms does not explain epidemiological observations over the years that more extensive disease has been associated with situations of high exposure. For example, in Canada, Grzybowski and col-
Transmission of Tuberculosis
227
leagues observed among both Caucasians and indigenous peoples, that household contacts of smear-positive tuberculosis cases not only had higher rates of infection, but were almost three times more likely to go on to active disease (39). Earlier, Grzybowski had also shown more extensive calcifications of primary lesions (more disease) among children infected through household contact (greater exposure) than children infected outside the home (40). IV. Recent Outbreaks The resurgence of TB in North America and Western Europe between 1985 and 1992 was characterized by numerous well-publicized outbreaks in congregate setting, including homeless shelters, residential AIDS facilities, prisons, and, most strikingly, health-care facilities (41–48). Among the earliest and best studied outbreaks were those in Miami and New York City, epicenters of AIDS-associated MDRTB among intravenous drug users and their contacts (47). The availability of RFLP fingerprinting as well as well-characterized drug-resistance patterns permitted a new level of epidemiological tracing of cases, for example, throughout the New York State prison system (43). A new assumption was proposed that cases clustered by RFLP pattern represented recent transmission, while unclustered cases were more likely the result of reactivation of remote infection (49) (see Chap. 11). Based on this assumption, studies in New York City and elsewhere suggested that as many as 30–40% of new cases were recently transmitted, whereas it had previously been believed that reactivation of old foci accounted for 90% of active TB in low-prevalence countries like the United States. Among RFLP-linked MDRTB in New York City, epidemiological investigations showed remarkably focal transmission, primarily associated with a small number of hospitals (50). Molecular markers were also used in the investigation of an extensive outbreak in a rural setting, providing evidence that organisms of increased virulence may have been responsible (25). While these outbreaks added relatively little to our understanding of the basic aerobiology of M. tuberculosis, they do teach many lessons about its spread in communities and congregate settings. Health-care providers, institutional administrators, and even infection-control practitioners had grown lax about the potential for transmission in close communities, where most exposed persons are now fully susceptible to infection. Moreover, no one could have predicted the potentiating effect of HIV co-infection on TB transmission, where newly infected persons progressed rapidly and almost invariably to secondary, infectious disease. Ineffective treatment due to drug resistance further accelerated transmission. Unfortunately, awareness of these intertwined factors was achieved only slowly as transmission episodes were investigated (51). Early in the resurgence, for example, it was common to administer aerosolized pentamidine, an effective agent
228
Nardell and Piessens
for preventing pneumocystis pneumonia, to groups of AIDS patients in the same room. Coughing, a common side effect of such treatments, effectively helped spread TB from unsuspected, infectious cases to other immunocompromised patients (47). In persons with HIV infection, cough, fever, weight loss, and lung infiltrates are common and have a low predictive value for TB, whereas lung cavities and positive skin tests characteristic of TB were less often present in those with both diseases. Among HIV-infected persons, new TB cases were not suspected isolated, diagnosed, or treated early, but remained infectious on hospital wards for days or weeks. Prior to the recent resurgence, methods for TB isolation had not been defined in great detail—particularly respirator usage and the maintenance and testing of isolation rooms. Surgical masks permitted extensive faceseal leakage, and upon testing, many negative pressure isolation rooms were found to be under positive pressure relative to hallways and adjacent rooms, potentially contributing to transmission. The use of upper room ultraviolet germicidal air disinfection to prevent transmission, a popular technology in the 1940s and 1950s had never been fully defined or field-tested, and expertise on its use was lacking. Even conventional room ventilation and air filtration were not optimally applied and maintained. Older guidelines had suggested that after 2 weeks of effective treatment, isolation procedures could be relaxed. Patients with unsuspected MDRTB were often allowed to mingle with other patients after 2 weeks of what would turn out to be inadequate treatment. Laboratory results showing drug resistance and continued sputum smear positivity were often slow to return to the chart, further prolonging exposure. Once these and other lapses were brought to the attention of the medical community and governmental agencies, meetings were held, interventions debated, and infection control guidelines developed, disseminated, and broadly implemented (9). Since 1992, TB case rates have continued to fall, and reports of outbreaks have also declined. Improved TB control both in the community and in institutions has been credited with this reversal (50,52). V. Preventing Transmission Because some of the early, extensive MDRTB outbreaks occurred in New York City and Miami, much of the initial response to the renewed treat of institutional TB transmission happened in the United States. As outbreaks were recognized elsewhere, other countries formulated their own responses, often influenced by events in the United States. By 1990, the U.S. Centers for Disease Control (CDC) revised its guidelines for preventing transmission in health-care facilities. These were again revised, expanded, and published in their current form in 1994 (9). The U.S. National Institute for Occupational Safety and Health (NIOSH) became fully involved in the choice of personal respirator protection for health-care workers in
Transmission of Tuberculosis
229
1992, ultimately revising its testing and classification of respirators to the current system in 1995 (53). The American College of Chest Physicians and The American Thoracic Society held a consensus conference on the subject of institutional TB transmission in 1993 and issued an official joint statement in 1995 (54). The Occupational Health and Safety Administration (OSHA) began enforcing compliance of health-care facilities with CDC guidelines, under the General Duty Clause of the OSHA Act, in the absence of a specific tuberculosis standard to guide enforcement. However, at the request of several labor unions, the process of developing a tuberculosis standard was set in motion, culminating in the publication of a draft standard in November, 1997, followed by public hearings, which were concluded in June 1998. A final OSHA TB standard is expected to adhere closely to the 1994 CDC guidelines (9). A review of currently available guidelines, including those from Canada and the United Kingdom, has been published (55). VI. Governmental Recommendations: An Overview Although the CDC guidelines (9) have been applied to a variety of acute and chronic health-care facilities, their main focus has been the control of TB transmission in acute care hospitals. These recommendations, their rationale, and extensive supporting materials cannot be presented here in detail. In essence, the guidelines suggest that institutions assess their risk status for TB transmission based on the rate of known TB admissions, the TB risk of the specific population served, and evidence of TB transmission in the facility. Based on the risk assessment, institutions are expected to formulate comprehensive TB infection–control plans, with clear lines of administrative accountability. In the 1994 CDC guidelines (9), five levels of risk are defined, ranging from minimal to high, with increasing control measures recommended for each risk level. Staff TB risk-awareness training at all levels is recommended, including knowledge of the signs and symptoms of TB, to encourage prompt identification of suspect cases. Administrative controls, including identification and triage of suspect cases, is the cornerstone of the CDC control strategy. Suspects are to be identified promptly and placed in special TB isolation rooms. Engineering controls for isolation and procedure rooms include negative pressure (relative to adjacent hallways and rooms) to assure directional airflow into contaminated spaces. Air disinfection in rooms to protect workers is primarily by dilutional ventilation, supplemented where needed by high-efficiency particulate air (HEPA) filtration, or ultraviolet irradiation. A controversial part of the CDC guidelines (9) has been the role of personal respiratory protection (56–58). Although generally considered least desirable in the hierarchy of controls in industrial settings, the inability to effectively eliminate
230
Nardell and Piessens
risk by administrative and environmental controls has resulted in a prominent role for respirators in the CDC strategy. Two analyses of the protection provided by respirators have recently been published (59,60). The latter study analyzed the protection afforded by various levels of respiratory protection relative to ventilation under various exposure scenarios, and concluded that against most exposures achievable levels of ventilation and modest levels of respirator protection provide near maximal benefit. Only under extraordinary exposure conditions was the highest level of respiratory protection needed. The cost-effectiveness of routine respiratory use in hospital under low-prevalence conditions has been challenged (56,58). Fortunately, NIOSH has developed a new certification method for disposable respirators appropriate for droplet nuclei-size particles in clean, nonindustrial settings. The result has been the introduction to the market of a variety of respirators similar in appearance, cost, and comfort to ordinary, tight-fitting surgical masks. While the original concerns over the cost and practicality of industrial-type respirators in health-care facilities have been allayed, the issue of mandatory fit testing remains controversial. Good industrial hygiene practice views qualitative fit testing as a minimal requirement for an acceptable respirator program, with periodic refitting to assure that workers can use respirators effectively (61,62). Many hospital infection-control experts, however, find the practice burdensome and unlikely to be very effective when applied to disposable respirators that inherently have relatively large percentages of face-seal leak. Critics argue that good respirator educational program alone, without formal fit-testing, would lead to comparable protection (63). There are no scientific studies on either side of the argument, and the fit-testing requirement is likely to remain under the OSHA standard. Although several hospitals have reported fewer skin test conversions after the implementation of vigorous infection control plans (see Chap. 23), the contribution of each of the components—education, early detection, triage, isolation, skin testing, air disinfection, and respirator use—is not known (64,65). VII. Preventing Transmission from Unsuspected Cases of Tuberculosis In the view of many experienced observers, unsuspected cases of infectious, pulmonary TB have always been and remain the principal source of transmission in institutions (66,67). At the height of the resurgence, one study from two medical centers in Washington, DC, found that 49 (58%) of 85 hospitalized cases were missed initially, 22 (26%) had their diagnosis delayed 4 weeks, 17 (20%) were not diagnosed or treated while in the hospital, and 7 (8%) died with TB diagnosed at autopsy (68). Of the infection-control interventions mentioned, only increased surveillance and general air disinfection addresses the risk of transmission from
Transmission of Tuberculosis
231
unsuspected cases (67). The nonspecificity of the signs and symptoms of TB, against a background of extremely common symptoms due to other respiratory illnesses, together with often insensitive and nonspecific diagnostic tests assures that both underdiagnosis and overdiagnosis will persist as obstacles to effective and efficient TB infection control in the future, especially as cases decline. Increased surveillance results in fewer missed cases and less risk of transmission, but at the price of overisolation. Scott and colleagues estimated that in a low-prevalence, Midwest setting, 92 patients without TB are isolated in order to identify just one patient with the disease (69). Isolation rates as high or higher are common throughout the United States, and the rate of overisolation should continue to climb as TB case rates fall, due to the unchanging high background rate of respiratory illnesses. Lowering the index of suspicion for TB isolation is the appropriate response to falling cases rates, but it is certain to result in additional missed cases. There are no immediate solutions to the dilemma of over- and underdiagnosis of low-prevalence diseases with common presenting symptoms as long as screening and diagnostic tools have low predictive value (70). Fortunately, progress has been made, and more progress is expected in the near future (71). VIII. Engineering Approaches to Preventing Transmission A. Industrialized Countries
Identifying and isolating every potentially infectious TB case, however desirable, will be increasingly impractical in years to come, unless rapid, sensitive, and highly specific diagnostic tests are developed that can be utilized for every patient with TB risk factors and respiratory symptoms consistent with TB. Even then, often subtle respiratory symptoms in patients with other medical problems would have to be recognized to apply such a test. The dilemma of unsuspected cases and susceptibles moving freely within buildings led Riley to consider the value of engineering controls throughout environments where transmission occurs, such as enhanced air disinfection in emergency rooms, shelters, and jails (72). Dilution of infectious droplet nuclei within surrounding air, with subsequent removal by passive or active ventilation, is the mainstay of general air disinfection in most institutions in resource-rich countries (73). However, as noted above, dilutional ventilation is inherently limited, even under optimal conditions, producing an exponential decline in the concentration of air contaminants (30). Ventilation is further constrained by practical engineering issues, such as incomplete air mixing, energy costs, drafts, and noise. However, in operating rooms, procedure rooms, and special isolation rooms, it is possible to achieve more than 10 air changes per hour, which should offer substantial protection under ordinary circumstances against all but the most intensive exposure to airborne infection. Templeton and
232
Nardell and Piessens
colleagues have reported transmission during a 3-hour autopsy that was so intense that it is doubtful that any environmental controls would have been substantially protective (74). Under these circumstances, highly effective personal respiratory protection is needed (60). Supplemental Air Disinfection
Because it is often cost-prohibitive to greatly increase mechanical ventilation in older buildings, supplemental air disinfection using air filtration or ultraviolet irradiation has been recommended (9). Although air filters less efficient than HEPA should be highly effective in retaining airborne particles in the range of 1–5 m in diameter, HEPA has become the standard for air disinfection in clinical and laboratory settings (75). HEPA filters can be used in the return ducts of central ventilating systems, but this adds greatly to flow resistance, requiring larger, louder fans or blowers to maintain airflow. Moreover, air filtration is most effective when applied close to the source of contamination. In the building’s general ventilating system, where droplet nuclei have been greatly diluted, large volumes of mostly infection-free air must be filtered to protect occupants. Where air is filtered close to the source of contaminants (e.g., an infectious TB patient), air disinfection is more efficient. Thus, HEPA filtration is being used in free-standing air-disinfection room units and even more efficiently in booths and partial enclosures designed for sputum induction and aerosol therapy. In large rooms, free-standing airfiltration units require high flow rates and good room air mixing to substantially increase the number of air changes per hour. Tests of particle clearance rates using room units of various design have generally shown rapid and effective air disinfection (75). In practice, as with building ventilating systems, motor noise, drafts, noise, and design issues limit the number of equivalent room air changes and, therefore, the practical benefit of filtration as a means of general air disinfection. The exponential decay curve in Figure 2 suggests that doubling room ventilation, in general, reduces the risk of infection by approximately half. Depending on the baseline conditions in a room, it may or may not be possible to double or quadruple ventilation through room air-filtration units, and the expected reductions by half to a quarter in the risk of infection may or may not be a satisfactory level of protection. Ultraviolet Germicidal Irradiation
DNA absorbs irradiation predominantly in the vicinity of 260 nm wavelength (UV-C, or germicidal UV). Living cells exposed to such irradiation are killed or inactivated due to damage to DNA, producing pyrimidine dimers, and due to damage to other essential proteins (76). Sublethal genetic mutations may also occur, some of which are reversible. As depicted in Figure 1, exposure to natural environmental irradiation is believed to be one of the stresses that limits airport trans-
Transmission of Tuberculosis
233
port of microorganisms (5). However, indoors, where person-to-person transmission of infection is most likely, natural radiation in the germicidal range is nearly absent. This is because short-wavelength UV irradiation is so readily absorbed that it is almost entirely removed from sunlight as it passes through the earth’s atmosphere. Because it cannot pass through ordinary window glass, whatever solar radiation is present in enclosed spaces is the more penetrating, but much less biologically active, longer-wavelength UV (UV-A and, to a lesser extent, UV-B). Fortunately, germicidal UV is easily produced indoors by inexpensive lamps that resemble ordinary fluorescent lamps but are made of quartz or fused silica glass that permits transmission of short-wavelength UV. Using a common mercury source, germicidal lamps produce a narrow spike of radiation at 253.7 nm wavelength, close to the 260 nm peak of the germicidal action spectrum. The availability of inexpensive germicidal irradiation provides another attractive supplement to room ventilation and filtration as a means of air disinfection. Whenever radiation is considered, human safety concerns are raised, and these are discussed first. Because short-wavelength UV is so biologically active, it is nearly completely absorbed by the outer, dead layer of human skin—the stratum corneum (77). Skin overexposure to germicidal UV can result in significant erythema but not tanning or the potentially severe sunburn associated with UV-A and UV-B in sunlight. Whereas the 8-hour exposure limit for less penetrating germicidal UV is 6 mJ, 4 hours of mid-day sunbathing can result in an estimated 740 mJ exposure of more penetrating, longer-wavelength UV (78). Thus, while airborne microorganisms are highly vulnerable to germicidal UV, human exposure has few or no serious health consequences, especially when compared to other common sources of UV exposure. Germicidal UV is classified as a potential human carcinogen because intensive exposure has caused skin cancer in hairless mice, but in an unpublished presentation at the National Centers for Disease Control in Atlanta, Urbach calculated that human skin cancer under the current exposure limits would require more than 300 years (79). Likewise, short-wavelength UV cannot penetrate the eye to reach the lens, so cataracts associated with longer-wavelength UV are not a complication of germicidal UV exposure. The human cornea, having no protective covering, is the organ most vulnerable to germicidal UV (80). Corneal irritation, called photoconjunctivitis, is a transient but painful response of the eye to UV overexposure. Corneal repair is nearly complete by 48 hours, and there are no known long-term consequences to germicidal or, much more common, solar UV corneal irritation. Most photoconjunctivitis due to UV-C occurs due to accidental direct exposure to high-intensity lamps, most often among maintenance and other workers. Because the onset of symptoms is delayed for hours, early photoconjuctivitis is not a useful warning sign. Well-designed fixtures, proper installation, metering with a sensitive 254 nm instrument, warning labels, and worker education are the most important ways to assure safe use of germicidal UV.
234
Nardell and Piessens
The efficacy of germicidal UV in killing or inactivating a wide range of microorganisms is well established, having been quantified by countless experiments over more than 50 years (81). How best to apply germicidal UV in buildings to prevent airborne transmission, however, remains controversial. UV has been employed in ventilation ducts in an effort to reduce the recirculation of infectious airborne organisms and has the advantage over HEPA filtration of adding little flow resistance to the system. While UV air disinfection in ducts avoids exposure of room occupants, this application has limitations similar to those of ventilation and air filtration. That is, it is necessary to move enough air through the system to substantially increase the number of equivalent air changes over baseline conditions. For large-volume spaces, such as emergency rooms and homeless shelters, noise and drafts due to the high flow rates required are significant limitations. Another approach to the application of germicidal UV is upper room air disinfection. The advantages of upper room UV air disinfection have been appreciated for over 50 years (82). Much of the upper room is used to kill or inactivate slowly moving microorganisms carried into the irradiated zone by convection currents generated by body heat and a variety of other forces. Several room studies have demonstrated that passive air movement can result in air-disinfection rates well in excess of what is practical by forced air-disinfection systems, depending on the UV susceptibility of the test organism (16,83–85). Because the system is passive, it is inexpensive, quiet, and draftless relative to comparable forced-air systems. Although the potential for occupant UV exposure exists, this is not a serious limitation, as noted above. Perhaps the greatest limitation of upper room UV air disinfection is the uncertainty over the equivalent germ-free ventilation produced under field conditions, because this depends on the extent of room air mixing, which is not controlled. Details on the application of upper room UV air disinfection are beyond the scope of this chapter, but have been published recently in the engineering literature (86,87). These guidelines reflect current practice based on decades of experience and experiments. However, several universities are engaged in new research intended to fill in missing gaps in our current understanding, particularly with regard to optimal fixture design and deployment in rooms in relation to mechanical ventilation. In addition to bench-scale and room-scale experiments on such factors as the effects on high humidity, a multicenter, placebocontrolled trial of upper room UV air disinfection in homeless shelters is underway. This field trial tests two hypotheses at once: whether any air disinfection makes a difference to infection rates in a highly complex community, and whether upper room UV is an effective means of air disinfection. The results of such studies are essential if the technology is to be used where it is most needed—in many parts of the developing world where institutional transmission of multidrug-resistant TB is common and where alternative technologies are either unaffordable or unavailable.
Transmission of Tuberculosis
235
B. Transmission in High-Prevalence Countries
Although the recent TB resurgence focused attention on institutional TB transmission in North America and Europe, there is good reason to believe that more extensive transmission, increasingly of MDRTB, is occurring in high-prevalence countries. Outbreaks have occurred, for example, in an AIDS health-care facility in Argentina, in prisons in Russia (see Chap. 24), and in an entire community outside of Lima, Peru (2,88,89). In South Africa, workers are convinced that patients recovering from drug-susceptible TB are becoming reinfected with drug-resistant organisms shed by patients sharing the same open wards (90). WHO has recently published recommendations for practical interventions to prevent transmission (12,91). They focus on prompt diagnosis and treatment rather than on generally unavailable technologies such as negative pressure isolation rooms and personal respirators. Clearly there are no easy solutions to the problem of transmission in overcrowded places where an uninterrupted supply of first-line medications cannot be assured. However, there are approaches that should reduce transmission at little additional cost. In many high-prevalence countries TB patients spend far longer in hospitals than is required medically. Because drug susceptibility testing is usually unavailable, the first clue to drug resistance often is clinical failure. By the time treatment failure becomes obvious, patients and staff have been exposed. By reducing unnecessary hospitalization, the number of potential exposures can be reduced greatly, because both potential sources and potential victims are fewer. Still, there will always be congregate settings where transmission occurs from known TB cases and from unsuspected cases. For known infectious cases, effective treatment remains the most important infection-control intervention, especially when treatment occurs primarily in the community (2). In high-prevalence countries, respiratory isolation is often difficult but may be possible in some settings. For unsuspected cases the options are few, as in low-prevalence countries. General air disinfection, by dilution in the volume of the occupied space and through natural ventilation, is the most commonly available intervention. As noted, transmission of drug-resistant TB is increasingly being recognized in developing countries (12). The general unavailability of individualized treatment based on culture and drug susceptibility studies means that cases remain infectious for prolonged periods, generally until they die. Molecular and conventional epidemiology studies on cultures obtained from patients who have failed treatment in a poor region section of Lima, Peru, have proven transmission within households, within the community, and in health-care facilities. A unique program of community-based treatment for persons with MDRTB, based on individual susceptibility studies (see Chap. 17), is reducing transmission through effective treatment and also by keeping patients out of hospitals while they are being treatment (2). Several other pilot projects utilizing a similar strategy, called “DOTS-Plus,” are being initiated by WHO in other focal areas of MDRTB (92). A current barrier are
236
Nardell and Piessens
the considerable financial resources needed to diagnose and effectively treat MDRTB in developing countries. References 1. Farmer P. Social scientists and the new tuberculosis [see comments]. Soc Sci Med 1997; 44(3):347–358. 2. Farmer P, Kim J. Community based approaches to the control of multidrug resistant tuberculosis: introducing “DOTS-plus.” BMJ 1998; 317:671–674. 3. Riley R, O’Grady F. Airborne Infection. New York: The Macmillan Company, 1961. 4. Cox C. Roles of water molecules in bacteria and viruses. Origins of Life and Evolution of the Biosphere 1993; 23:29–36. 5. Cox C. The Aerobiological Pathway of Microorganisms. Chichester: John Wiley and Sons, 1987. 6. Cox C. Airborne bacteria and viruses. Science Prog (Oxon.) 1989; 73:469–500. 7. Riley RL. Airborne infection. Am J Med 1974; 57(3):466–475. 8. Mann T. The Magic Moutain. New York: Alfred A. Knopf, 1924. 9. Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare facilities, 1994. Centers for Disease Control and Prevention. MMWR 1994; 43(RR-13):1–132. 10. Jarvis WR. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. Am J Infect Control 1995; 23(2):146–151. 11. Gerberding JL. Occupational infectious diseases or infectious occupational diseases? Bridging the views on tuberculosis control [editorial]. Infect Control Hosp Epidemiol 1993; 14(12):686–688. 12. Harries AD, Maher D, Nunn P. Practical and affordable measures for the protection of health care workers from tuberculosis in low-income countries. Bull WHO 1997; 75(5):477–489. 13. Wells W. On air-borne infection: II. Droplets and droplet nuclei. Am J Hyg 1934; 20:611–618. 14. Wells W. Airborne Contagion and Air Hygiene. Cambridge, MA: Harvard University Press, 1955. 15. Loudon RG, Bumbarna LR, Lacy J, Coffman GK. Aerial transmission of mycobacteria. Am Rev Respir Dis 1969; 100:165–171. 16. Riley R, Knight M, Middlebrook G. Ultraviolet susceptibility of BCG and virulent tubercle bacilli. Am Rev Respir Dis 1976; 113:413–418. 17. Fennelly K, Martyny J. Isolation of viable airborne Mycobacterium tuberculosis: a new method to study transmission. (abstract). Am J Respir Crit Care Med 1998; 157:A706. 18. Mastorides S, Oehler R, Greene J, Sinnott J, Sandin R. Detection of airborne Mycobacterium tuberculosis by air filtration and polymerase chain reaction. (letter). Clin Infect Dis 1997; 25:756–757. 19. Riley R, Mills C, Nyka W. Aerial dissemination of pulmonary tuberculosis—a two year study of contagion in a tuberculosis ward. Am J Hyg 1959; 70:185–196.
Transmission of Tuberculosis
237
20. Ratcliff H, Palladino V. Tuberculosis induced by droplet nuclei infection; intial homogeneous response of small mamals (rats, mice, guinea pigs and hamsters) to human and bovine bacilli, and the rate and pattern of tubercle development. J Exp Med 1953; 97:61. 21. Riley R, Wells W, Mills C, Nyka W, McLean R. Air hygiene in tuberculosis: quantitative studies of infectivity and control in a pilot ward. Am Rev Tuberc Pulmon Dis 1957; 75:420–431. 22. Riley R, Mills C, O’Grady F. Infectiousness of air from a tuberculosis ward—ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 1962; 84:511–525. 23. Riley R. Aerial dissemination of pulmonary tuberculosis—The Burns Amberson Lecture. Am Rev Tuberc Pulmon Dis 1957; 76:931–941. 24. Sultan L, Nyka C, Mills C, O’Grady F, Riley R. Tuberculosis disseminators—a study of variability of aerial infectivity of tuberculosis patients. Am Rev Respir Dis 1960; 82:358–369. 25. Valway SE, Sanchez MP, Shinnick TF, et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis [see comments] [published erratum appears in N Engl J Med 1998; 338(24):1783]. N Engl J Med 1998; 338(10):633–639. 26. Israel H, Hetherington H, Ord J. A study of tuberculosis among student nurses. JAMA 1941; 117:839. 27. Amberson J, Riggins H. Tuberculosis among student nurses: a five-year study at Bellevue Hospital. Ann Int Med 1936; 10:156. 28. Houk V, Kent D, Baker J, Sorensen K. The epidemiology of tuberculosis transmission in a closed environment. Arch Environ Health 1968; 16:26–35. 29. Riley E, Murphy G, Riley R. Airborne spread of measles in a suburban elementary school. Am J Epidemiol 1978; 107:421–432. 30. Nardell E, Keegan J, Cheney S, Etkind S. Airborne infection: theoretical limits of protection achievable by building ventilation. Am Rev Respir Dis 1991; 144:302– 306. 31. Catanzaro A. Nosocomial tuberculosis. Am Rev Respir Dis 1981; 123:559–562. 32. Gammaitoni L, Nucci MC. Using a mathematical model to evaluate the efficacy of TB control measures. Emerg Infect Dis 1997; 3(3):335–342. 33. Swanson M, Campbell A, O’Hallaren M, Reed C. Role of ventilation, air filtration, and allergen production rate in determining concentrations of rat allergens in the air of animal quarters. Am Rev Respir Dis 1990; 141:1578–1581. 34. Anderson R, May R. Infectious Diseases of Humans: Dynamic and Control. Oxford: Oxford University Press, 1992. 35. Blower SM MA, Porco TC, Small PM, Hopewell PC, Sanchez MA, Moss AR. The intrinsic transmission dynamics of tuberculosis epidemics. Nature Med 1995; 1(8):815–821. 36. Nardell E, McInnis B, Thomas B, Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986; 315:1570–1575. 37. Smith D, Wiengeshaus E. What animal models can teach us about the pathogenesis of tuberculosis in humans. Rev Infect Dis 1989; 11:S385–S393.
238
Nardell and Piessens
38. Balasubramanian V, Wiegeshaus E, Taylor B, Smith D. Pathogenesis of tuberculosis: pathway to apical location. Tubercle Lung Dis 1994; 75:168–178. 39. Grzybowski S, Barnett G, Styblo K. Contacts of cases of active pulmonary tuberculosis. Selected Papers of the Royal Netherlands Tuberculosis Association 1975; 16:90–99. 40. Bentley F, Grzybowski S, Benjamin B. Calcification of primary lesions. In: Tuberculosis in Childhood and Adolescence: With Special Reference to the Pulmonary Forms of the Disease. London: The National Association for the Prevention of Tuberculosis, 1954. 41. Nosocomial transmission of multidrug-resistant tuberculosis to health-care workers and HIV-infected patients in an urban hospital—Florida. MMWR 1990; 39(40):718– 722. 42. Guerrero A, Cobo J, Fortun J, et al. Nosocomial transmission of Mycobacterium boyis resistant to 11 drugs in people with advanced HIV-1 infection [see comments]. Lancet 1997; 350(9093):1738–1742. 43. Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system—New York, 1991. MMWR 1992; 41(28):507–509. 44. Tuberculosis transmission in a state correctional institution—California, 1990–1991. MMWR 1992; 41(49):927–929. 45. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome [see comments]. N Engl J Med 1992; 326(23):1514–1521. 46. Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993; 168(4):1052–1055. 47. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons—Florida and New York, 1988–1991. MMWR 1991; 40(34):585–591. 48. Sepkowitz KA. Occupationally acquired infections in health care workers. Part I. Ann Intern Med 1996; 125(10):826–834. 49. Alland D, Kalkut G, Moss A, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330:1710–1716. 50. Frieden T, Sherman L, Maw K, et al. A multi-institutional outbreak of highly drugresistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276:1229– 1235. 51. Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIVinfected patients. JAMA 1992; 268(10):1280–1286. 52. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City—turning the tide. N Engl J Med 1995; 333(4):229–233. 53. Centers for Disease Control. NIOSH Guide to the Selection and Use of Particulate Respirators Certified Under 42 CFR 84. Cincinnati, OH: National Institute for Occupational Safety and Health, HHS, CDC, 1996: i–ix, 1–22. 54. Institutional control measures for tuberculosis in the era of multiple drug resistance. ACCP/ATS Consensus Conference. American College of Chest Physicians and the American Thoracic Society. Chest 1995; 108(6):1690–1710.
Transmission of Tuberculosis
239
55. Nardell E. Tuberculosis. In: Abrutyn E, Goldman D, Scheckler W, eds. Saunders Infection Control Reference Service. Philadelphia: W.B. Saunders Co., 1998:195–224. 56. Adal KA, Anglim AM, Palumbo CL, Titus MG, Coyner BJ, Farr BM. The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis. A cost-effectiveness analysis [see comments]. N Engl J Med 1994; 331(3):169–173. 57. Jarvis WR, Bolyard EA, Bozzi CJ, et al. Respirators, recommendations, and regulations: the controversy surrounding protection of health care workers from tuberculosis. Ann Intern Med 1995; 122(2):142–146. 58. Nettleman MD, Fredrickson M, Good NL, Hunter SA. Tuberculosis control strategies: the cost of particulate respirators [see comments]. Ann Intern Med 1994; 121(1):37–40. 59. Barnhart S, Sheppard L, Beaudet N, Stover B, Balmes J. Tuberculosis in health care settings and the estimated benefits of engineering controls and respiratory protection. J Occup Environ Med 1997; 39(9):849–854. 60. Fennelly K, Nardell E. The relative efficacy of respirators and room ventilation in preventing occupational tuberculosis. Inf Control Hosp Epidemiol 1998; 19:754–759. 61. Qian Y, Willeke K, Grinshpun SA, Donnelly J. Performance of N95 respirators: reaerosolization of bacteria and solid particles. Am Ind Hyg Assoc J 1997; 58(12):876–880. 62. Willeke K, Qian Y. Tuberculosis control through respirator wear: performance of National Institute for Occupational Safety and Health-Regulated Respirators. Am J Infect Control 1998; 26(2):139–142. 63. SHEA’s response to proposed OSHA TB exposure rule [news]. Infect Control Hosp Epidemiol 1998; 19(4):288. 64. Blumberg HM, Watkins DL, Berschling JD, et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med 1995; 122(9):658–663. 65. McGowan JE, Jr. Nosocomial tuberculosis: new progress in control and prevention. Clin Infect Dis 1995; 21(3):489–505. 66. Moran GJ, McCabe F, Morgan MT, Talan DA. Delayed recognition and infection control for tuberculosis patients in the emergency department. Ann Emerg Med 1995; 26(3):290–295. 67. Nardell EA. Interrupting transmission from patients with unsuspected tuberculosis: a unique role for upper-room ultraviolet air disinfection. Am J Infect Control 1995; 23(2):156–164. 68. Mathur P, Sacks L, Auten G, Sall R, Levy C, Gordin F. Delayed diagnosis of pulmonary tuberculosis in city hospitals. Arch Intern Med 1994; 154:306–310. 69. Scott B, Schmid M, Nettleman M. Early identification and isolation of inpatients at high risk for tuberculosis. Arch Intern Med 1994; 154:326–330. 70. Nardell E. Needles in haystacks: diagnosing tuberculosis under low prevalence conditions. Tuberc Lung Dis 1996; 77:389–390. 71. Foulds J, O’Brien R. New tools for the diagnosis of tuberculosis: the perspective of developing countries. Int J Tuberc Lung Dis 1998; 2:778–783. 72. Riley R. Ultraviolet air disinfection: rationale for whole building irradiation. Infect Control Hosp Epidemiol 1994; 15:324–325.
240
Nardell and Piessens
73. Nardell E. The role of ventilation in the nosocomial transmission of tuberculosis. Int J Tuberc Lung Dis 1998; 2(suppl 1):S110–S117. 74. Templeton G, Illing L, Young L, Cave D, Stead W, Bates J. The risk of transmission of Mycobacterium tuberculosis at the bedside and during autopsy. Ann Intern Med 1995; 15:955–956. 75. Miller-Leiden S, Lobascio C, Nazaroff WW, Macher JM. Effectiveness of in-room air filtration and dilution ventilation for tuberculosis infection control. J Air Waste Manage Assoc 1996; 46(9):869–882. 76. Shechmeister I. Sterilization by ultraviolet irradiation. In: Block S, ed. Disinfection, Sterilization, and Preservation. 4th ed. Philadelphia: Lea and Febiger, 1991:553–565. 77. Bruls W. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths. Photochem Photobiol 1984; 40:485–494. 78. Sterenborg H. The dose-response relationship of tumorgenesis by ultraviolet radiation of 254 nm. Photochem Photobiol 1988; 47:245–253. 79. Cancer IAfRo. IARC Monographs on the Evaluation of Carcinogenic Effects to Humans: Solar and Ultraviolet Light. Lyons, France: World Health Organization, 1992. 80. Sliney D. Ultraviolet radiation and the eye. In: Grandolfo M, ed. Light, Lasers and Synchrotron Radiation. New York: Plenum Press, 1990:237–242. 81. Riley R, Nardell E. Clearing the air: the theory and application of ultraviolet air disinfection. Am Rev Respir Dis 1989; 139:1286–1294. 82. Luckiesch M. Application of Germicidal, Erythemal, and Infrared Energy. New York: D. Van Nostrand, 1946. 83. Riley R, Permutt S, Kaufman J. Conection, air mixing, and ultraviolet air disinfection in rooms. Arch Environ Health 1971; 22:200–207. 84. Riley R, Permutt S. Room air disinfection by ultraviolet irradiation of upper air–air mixing and germicidal effectiveness. Arch Environ Health 1971; 22:208–219. 85. Riley R, Permutt S, Kaufman J. Room air disinfection by ultraviolet irradiation of upper room air. Arch Environ Health 1971; 23:35–40. 86. First M, Nardell E, Chaission W, Riley R. Guidelines for the application of upperroom ultraviolet germicidal irradiation for preventing transmission of airborne contagion—Part I: basic principles. ASHRAE Trans 1999; 105. In press. 87. First M, Nardell E, Chaission W, Riley R. Guidelines for the application of upperroom ultraviolet germicidal irradiation for preventing transmission of airborne contagion—Part II: design and operations gudidance. ASRAE Trans 1999; 105. In press. 88. Ritacco V, DiLonardo M, Reniero M, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 1997; 176:637–642. 89. Banatvala N. Big problems in Moldova: eBMJ (website:htp://www.bmj.com/cgi/ eletters/317/7159/671), 1998. 90. Koornhof HJ, Fourie PB, Weyer K, Blumberg L, Pearse J. Prevention of the transmission of tuberculosis in health-care workers in South Africa. Infect Control (South Africa) 1996; 1(1):6–9. 91. Control of tuberculosis transmission in health care settings. A joint statement of the WHO Tuberculosis Programme and the International Union Against Tuberculosis and Lung Disease (IUATLD). Wkly Epidemiol Rec 1993; 68(50):369–371. 92. Pablos-Mendes A, Raviglione M, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. N Engl J Med 1998; 338:1641–1649.
10 Pathogenesis of Tuberculosis
WILLY F. PIESSENS
EDWARD A. NARDELL
Harvard School of Public Health Harvard Medical School Boston, Massachusetts
Harvard Medical School Cambridge Hospital and Massachusetts Department of Public Health Cambridge and Boston, Massachusetts
I. Introduction Host immune responses determine to a large extent the ultimate outcome of infection with Mycobacterium tuberculosis in at least two disparate ways: by participating in the resistance to the pathogen and by contributing to the development of disease. Thus, a better understanding of the cellular and molecular components of the immune system that mediate and regulate these beneficial and deleterious phenomena should lead to improved and novel approaches to the diagnosis, prevention, and control of human tuberculosis. In this chapter the mechanisms of innate and acquired resistance to M. tuberculosis, various strategies used by tubercle bacilli to survive in this hostile environment, and the nature of host immune responses with pathogenic potential are reviewed. The emphasis of this chapter is on studies done in human beings or with cells and materials from human donors. Data from animal models are reviewed only when similar studies have not yet been, or cannot be, performed in humans or to highlight contrasts between animal and human data that illustrate the inherent limitations of animal models of tuberculosis. The chapter also describes some of the changes in host immune responses to tubercle bacilli resulting from coinfection with HIV. However, it is not intended to be a comprehen241
242
Piessens and Nardell
sive review of the complex interplay of these two life-threatening infections (see Chap. 20). For simplicity and convenience, we have used the chronology of a prototypical infection to organize the topics reviewed in this chapter. Educated readers will easily recognize that our outline follows the conceptual framework of the pathogenesis of tuberculosis first described by Dannenberg (1), to whom we dedicate this chapter. II. Stage 1 (Week 1): Invasion Tuberculosis infection can be initiated by ingesting, inoculating, or inhaling virulent mycobacteria, but inhalation of droplet nuclei containing tubercle bacilli is by far the most common route of infection. Ordinarily, large droplets are efficiently excluded from the lower respiratory tract, as they land on the ciliated epithelium of the airways, are carried up the mucociliary escalator, swallowed, and rendered harmless. The bronchial epithelium also appears highly resistant to infection by M. tuberculosis. Thus, in most cases virulent mycobacteria must reach the alveolar surface to begin infection through inhalation of droplet nuclei that are small enough (~1–2 m) to reach the lower respiratory tract. Three main factors determine whether exposure to tubercle bacilli results in infection: the infecting dose, the strength of innate host resistance, and the virulence of the infecting mycobacteria. The outcome of the initial contest between the host and M. tuberculosis determines whether infection occurs. If the bacilli are inhibited or killed by the alveolar macrophage that ingested it, infection is aborted. If not, ingested bacilli multiply, kill the alveolar macrophage, and initiate infection. A. Infecting Dose
This subject is discussed in greater detail in Chapter 9. In contrast to many other respiratory infections, the infecting dose needed to initiate human tuberculosis is largely unknown. Experimentally, a single inhaled droplet nucleus containing no more than one to three virulent organisms is sufficient to cause infection in guinea pigs and susceptible strains of inbred rabbits (2,3). It is unknown whether the same is true in human tuberculosis. A single droplet nucleus might cause infection if it contains fully virulent mycobacteria and is implanted in a site where perchance local innate resistance is low, such as in the vulnerable apical or subapical region of the lungs (see below). On the other hand, it has been assumed that inhalation of many droplet nuclei may be necessary to cause infection in innately resistant individuals. Multiple or recurrent inhalations are unlikely, however, unless exposure is prolonged or at close range or the source case is unusually infectious. Under ordinary exposure conditions the concentration of droplet nuclei in the air is extremely low: it averaged only 1 in 312 cubic meters in air exhausted from a tuberculosis ward over a 4-year period (4).
Pathogenesis of Tuberculosis
243
B. Innate Host Resistance
Resident alveolar macrophages derived from blood monocytes are the first line of defense against pulmonary tuberculosis. These phagocytic cells scavenge the alveolar surface and ingest inhaled organisms and particles. The innate bacteriostatic and bacteriocidal activities of alveolar macrophages vary with the cells’ state of activation, which in turn is influenced by the genetics of the host and by multiple factors in the cells’ milieu. Mycobacteria are ingested by alveolar macrophages via conventional receptor-mediated phagocytosis, in which cellular pseudopodia move circumferentially around the bacilli and then fuse, leaving M. tuberculosis in a membranelined vacuole, the phagosome. The bacillus is a passive participant in the invasion process. Alveolar and other types of mononuclear phagocytes possess many different receptors involved in phagocytosis of various particles and pathogens. IgG antibody–coated mycobacteria can be ingested via Fc receptors on macrophages, but when the host has no antibodies to M. tuberculosis, the principal receptors that mediate phagocytosis of tubercle bacilli by human monocytes and macrophages are the receptors for complement (CR1, CR3, and CR4) and for mannose (5). Lung macrophages secrete complement proteins into the alveolar fluid (6). Complement receptors interact with C3 deposited on M. tuberculosis when the bacterial surface glycolipid trehalose dimycolate (cord factor) activates the alternative complement pathway or when pathogenic mycobacteria recruit C2a directly to form a C3 convertase (7,8). Mannose receptors interact with terminal mannosyl units on the major bacterial surface lipoglycan, lipoarabinomannan (LAM) (9). It has been shown that LAM can also bind to the endotoxin receptor CD14 and that sulfatides from M. tuberculosis can bind to scavenger receptors, but it is unclear whether these receptors by themselves can mediate phagocytosis of tubercle bacilli by alveolar macrophages. Cooperation between distinct types of receptors may be required for optimal binding and ingestion of tubercle bacilli. Which receptors are used for phagocytosis of M. tuberculosis may also be influenced by the state of differentiation and activation of the macrophage. The expression of CR4 and mannose receptors increases and the abundance of CR3 decreases as monocytes mature into tissue and alveolar macrophages. In addition, several host molecules modulate the interaction of complement and mannose receptors with their ligands and therefore can augment the baseline activity of alveolar macrophages. Some of these molecules are present before acquired immunity develops and thus modulate innate resistance. For example, human surfactant protein A (SP-A), which regulates the level of lung surfactant, enhances phagocytosis of M. tuberculosis by alveolar macrophages (10). SP-A is a member of the collectin family of proteins that participate in various aspects of innate resistance (11). Activation of macrophages by cytokines from M. tuberculosis–specific T cells will be discussed below in the context of acquired immunity.
244 Table 1
Piessens and Nardell Bactericidal Effector Mechanisms of Phagocytes
1. Oxygen-dependent mechanisms: The respiratory burst generates superoxide anion, hydrogen peroxide, singlet oxygen, and hydroxyl radicals. The efficiency of hydrogen peroxide as a microbicidal agent is increased in the presence of halide and peroxidase. [If Cl is present, hypochlorite (bleach) is formed.] 2. Lysosomal mechanisms: Lysosomes contain hydrolytic enzymes and other ill-characterized antimicrobial substances. 3. Peptide antibiotics: These proteins and peptides kill bacteria in a manner that does not depend on enzymatic activity. The group includes defensins, cationic antimicrobial proteins, bactenecins, and permeability-increasing protein. 4. Iron chelators: Molecules such as lactoferrin and transferrin inhibit the growth of intracellular pathogens by sequestering intracellular iron. 5. Polyamines: Oxidative deamination of polyamines such as spermine and spermidine produces the toxic molecules aminoaldehyde, ammonia, and hydrogen peroxide. 6. Tryptophan degradation: Enzymatic degradation of tryptophan depletes an essential nutrient and produces picolonic acid, which acts synergistically with IFN- to activate macrophages. 7. Reactive nitrogen oxides (RNOs) and intermediates (RNIs): Enzymatic conversion of Larginine into citrulline generates nitric oxide and related nitrogen intermediates. Their biological effects are similar to those of reactive oxygen intermediates.
Mononuclear phagocytes have a large repertoire of mechanisms that can kill intracellular organisms. It has not been unequivocally demonstrated that human macrophages can kill or inhibit the replication of M. tuberculosis in vitro, but some of the effector mechanisms implicated by studies in animal models can be activated in human macrophages and, therefore, may contribute to antitubercular activity in vivo. Table 1 lists the major types of antibacterial effector mechanisms of phagocytic cells. A detailed review of these mechanisms and of the evidence for or against their involvement in antitubercular activity has been published recently (12), but some points deserve emphasis. First, while important in mice, the role of reactive nitrogen intermediates (RNIs) in the antibacterial activity of human macrophages remains controversial. Antimicrobial effector mechanisms are also considerably redundant (Table 1), and it is likely that different combinations of them act in concert to control a given pathogen. The dominant effector mechanism in human tuberculosis also may change over time and in different settings depending on the phenotypes of both the mycobacteria and the mononuclear phagocytes change. Indeed, M. tuberculosis isolates vary in their susceptibility to hydrogen peroxide and RNIs, and the state of differentiation and activation of blood-derived alveolar macrophages affects the cells’ ability to control the growth of virulent pathogens.
Pathogenesis of Tuberculosis
245
C. Bacillary Virulence
Virulent tubercle bacilli have evolved a wide range of mechanisms to resist hostdefense mechanisms. Historically, many different criteria have been used to define the virulence of nycobacteria. Most relevant to the early phase of infection are factors and mechanisms that allow mycobacteria to survive within alveolar macrophages. Several of these have been described (Table 2) (13,14). A DNA fragment of M. tuberculosis that is associated with entry and survival of bacilli inside nonphagocytic cells has been identified and cloned (15). Its mode of action is unknown, but different parts of the “invasion gene” encode the factors responsible for entry and survival. Mutation of a different gene causes loss of virulence in a strain of the M. tuberculosis complex (16). Particles phagocytosed by macrophages normally are routed to acidic lysosomal compartments for degradation. Mycobacteria avoid this fate in several ways. Sulfatides and other cell-surface components of M. tuberculosis can inhibit the fusion of lysosomes with phagosomes (17). Tubercle bacilli also selectively inhibit the fusion of phagocytic vacuoles with vesicles containing the proton-ATPase (which is involved in phagosomal acidification) and thus prevent the normal evolution of a phagosome into an acidified hydrolase-rich compartment in which engulfed pathogens ordinarily are digested (18). Other studies suggest that M. tuberculosis escapes from fused phagolysosomes into nonfused vesicles or the cytoplasm, where virulent but not avirulent bacilli are able to multiply (19). Mycobacteria also resist digestion by scavenging O2 with LAM, by inducing detoxifying enzymes such as catalase and superoxide dismutase and protective heat-shock proteins, and by resisting RNIs via unknown mechanisms (12,20,21). Mycobacterial LAM interferes with cell signaling pathways, inhibits macrophage activation by interferon (IFN)-, and stimulates the production of cy-
Table 2
Mechanisms of Intracellular Survival of Mycobacteria
1. Invasion gene: A DNA fragment associated with entry and survival of M. tuberculosis inside cells has been cloned. Its mode of action is unknown. 2. Inhibition of lysosome-phagosome fusion: Both complete and selective inhibitions of lysosome-phagosome fusion have been reported. 3. Escape into the cytoplasm: Both avirulent and virulent M. tuberculosis appear capable of escaping from phagolysosomes, but only virulent bacilli multiply in the cytoplasm. 4. Inactivation of toxic effector molecules: LAM scavenges O 2; virulent bacilli induce detoxifying enzymes such as catalase and superoxide dismutase and protective heatshock proteins and resist RNIs. 5. Macrophage deactivation: LAM blocks macrophage activation by IFN- by stimulating the production of inhibitory cytokines such as transforming growth factor (TGF- ) and interleukin (IL)-10.
246
Piessens and Nardell
tokines such as transforming growth factor (TGF- )- and interleukin (IL)-10, which inhibit macrophage functions (22,23). Infected macrophages also poorly present mycobacterial antigens to T cells and thereby promote suboptimal immune responses or even immune tolerance (24). D. Innate Resistance and Variation in Susceptibility to Tuberculosis
Studies on familial clustering and twins suggest that susceptibility to tuberculosis has a genetic component, but the biological basis of the increased risk remains unknown. It is also well known that certain populations suffer disproportionately from tuberculosis. Often this can be explained by high exposure to the pathogen (as in nosocomial infections) or a high rate of progression to active disease due to a variety of circumstances that impact on acquired immunity (as in AIDS). The basis of other empirical observations remains controversial. It has been reported, for example, that the high incidence of tuberculosis among African Americans has a biological basis, namely that it reflects racial differences in susceptibility to initial tuberculosis infection (25). Others contest this explanation because it is difficult to separate biological from socioeconomic and demographic risk factors associated with race (26–28). This is perhaps best illustrated by the finding that racial differences in susceptibility to infection were observed among elderly residents of nursing homes but not during an outbreak of tuberculosis in a primary school (25,29). Nevertheless, evidence that genetic variation in innate resistance may contribute to racial differences in the prevalence of tuberculosis is accumulating. The natural resistance of mice to infection with several intracellular pathogens is controlled by a single autosomal dominant gene, Bcg (30). Mice with the resistant allele of the gene (Bcgr ) control the growth of BCG Montreal during the first 3 weeks of infection. This form of innate resistance occurs before acquired immunity develops and does not require BCG-specific T cells. In mice with the sensitive phenotype, the initial growth of BCG Montreal is unchecked, but the infection is controlled at a later stage by T-cell–dependent immune effector mechanisms. The mouse gene, which has been renamed the gene for natural-resistanceassociated macrophage protein 1 (Nramp 1), encodes an integral membrane protein that is expressed only in a late endocytic subcellular compartment. Upon phagocytosis, the protein is recruited to the membrane of the phagosome and remains associated with this structure as it matures into a phagolysosome. The Nramp 1 protein is part of a group of ion transporters or channels; it may eliminate divalent cations from the phagosomal interior and thereby deplete this compartment from essential cofactors for many enzymes (30). Humans have a homolog of the mouse gene on chromosome 2q35. Four polymorphisms in the human NRAMP1 gene are significantly associated with
Pathogenesis of Tuberculosis
247
susceptibility to tuberculosis in West Africa (31). One of the variant NRAMP1 alleles associated with susceptibility to tuberculosis is very uncommon in European populations. This may explain in part the higher prevalence of tuberculosis among African Americans than among whites in the United States. The possibility of a Bcgs gene–like effect in human macrophages had been previously suggested by the observation that virulent tubercle bacilli replicate faster within unstimulated macrophages of African American than of white donors (32). However, the differential permissiveness observed in vitro may have a phenotypic rather than a genetic underpinning, because the difference is magnified when the cells are cultured in medium supplemented with autologous serum, and the permissiveness of macrophages from African American donors is corrected by addition of 1, 25OH 2 D3, a hormonally active form of vitamin D, to the in vitro cultures. In mice, the Bcg gene also controls early growth of M. lepraemurium, M. intracellulare, and two other intracellular pathogens, Salmonella typhimurium and Leishmania donovani, but not of BCG Pasteur or of virulent M. tuberculosis. Thus, variation in macrophage activity is not the only biological basis for the differential susceptibility of mouse strains to infection with various mycobacteria. Innate resistance of mice to M. tuberculosis is dependent on the presence of the Tbc-1 gene, the function of which remains unknown (33). A recent report associates an HLA-DQ allele with clinical tuberculosis, but this phenotype is likely to influence acquired rather than innate resistance to infection (34). Of note, the biological basis for the differential resistance of inbred rabbit strains developed by Lurie is unknown (2). E. Initial Infection Among HIV-Infected Persons
Several outbreaks of tuberculosis (TB) in which transmission from an index case within a known period of exposure could be documented have been reported. These outbreaks clearly show that some persons immunocompromised by HIV infection who secondarily become infected with TB progress rapidly to clinical disease, often with multiorgan involvement (35–38). This extraordinarily rapid rate of progression to active disease may reflect the inability of HIV-infected individuals to develop immune resistance to tuberculosis (39). However, these outbreaks also document higher-than-expected infection rates (actual intensity of exposure was not measured or estimated in the reports) and thus suggest that HIV infection also lowers the host’s innate resistance to a primary infection with tubercle bacilli. A report on airborne nosocomial transmission of M. bovis is consistent with this hypothesis (40). HIV has pleotropic effects on virus-infected macrophages that affect the cells’ phenotype and functions during progression of HIV infection (39,41). The virus alters the pattern of cytokine production, impairs the ability of monocytes and macrophages to serve as accessory cells for T-cell proliferation, and affects the elaboration by resident macrophages of proinflammatory leukotrienes and other 5-lipoxygenase metabolites of arachidonic acid (42,43). The resulting decrease in
248
Piessens and Nardell
macrophage activating cytokines (e.g., IL-12) and the concomitant increase in deactivating cytokines (e.g., IL-10) combined with defects in chemotaxis, receptormediated phagocytosis, and oxidative burst activity (44,45) may very well reduce innate resistance of alveolar macrophages and thereby increase the risk of primary infections with M. tuberculosis in HIV-infected subjects (see also Chap. 20). III. Stage 2 (Weeks 2 and 3): Logarithmic Bacillary Growth and the Early Tuberculous Lesion A. Logarithmic Bacillary Growth
When the innate microbicidal capacity of alveolar macrophages fails to destroy the initial few M. tuberculosis of the droplet nucleus, the tubercle bacilli replicate within the macrophage and cause the cell to rupture. Released bacilli are then taken up by other macrophages in the vicinity. Monocytes in the circulation are attracted to the focus and develop into immature macrophages. The latter cells readily ingest the released tubercle bacilli but appear incapable of killing virulent M. tuberculosis or inhibiting their growth. Thus, the bacillary multiplication cycle is repeated within immature phagocytes. In both innately resistant and susceptible inbred rabbits, tubercle bacilli grow logarithmically during the first 3 weeks after infection until about 10 4 organisms are present and local cell-mediated immune responses are triggered (2). In both immunized and nonimmunized guinea pigs, bacillary growth is unimpeded for about 2 weeks until approximately 103 organisms are present. At this point, growth is inhibited in vaccinated animals but continues in nonvaccinated animals until a larger antigenic stimulus triggers cell-mediated immunity that controls the infection (46). B. The Early Tuberculous Lesion
Successive waves of intracellular multiplication followed by lysis of the infected macrophages lead to the formation and enlargement of the primary lesion. Early lesions consist mostly of concentric layers of immature macrophages containing mycobacteria. Mice, hamsters, guinea pigs, rabbits, and humans all develop histologically similar reactions to inhaled virulent or avirulent strains of tubercle bacilli during the first 3 weeks of infection (47). C. Bacillary Dissemination
During the stage of uncontrolled growth, some mycobacteria are transported to draining lymph nodes where the pathological process is repeated. The initial lesion and its inflamed draining lymph nodes form the so-called primary complex of tuberculosis. Bacilli also widely disperse to distant metastatic sites via the bloodstream. The propensity of human tubercle bacilli for hematogenous dissem-
Pathogenesis of Tuberculosis
249
ination to the spleen and lungs in guinea pigs is considered a measure of intrinsic virulence of M. tuberculosis isolates. IV. Stage 3 (After Week 3): Infection Control A. Control of Bacillary Growth
After about 3 weeks, the growth of tubercle bacilli rather suddenly ceases in both susceptible and resistant rabbits and in other animals infected via aerosol. This coincides with the development of acquired immune resistance and the formation of characteristic tuberculous granulomas. Traditionally, the terms of cell-mediated immunity (CMI) and delayed-type hypersensitivity (DTH) have been used to describe two distinct processes. CMI refers to the cell-mediated immune process that results in the accumulation of large numbers of activated microbicidal macrophages around solid caseous tuberculous foci. Delayed-type hypersensitivity refers to the cytotoxic immune process that kills the nonactivated immature macrophages that permit intracellular multiplication of tubercle bacilli (48). Despite much debate over details, the prevailing view in the past was the CMI is the main effector mechanism of acquired immunity and that DTH is the major cause of lung damage in tuberculosis (49,50). Advances in basic and applied immunology indicate that this classic concept is only partially correct. Cell depletion and reconstitution studies and observations in animals with spontaneous or genetically engineered defects [so-called gene knock-outs (gKO)] in specific components of the immune system clearly indicate that, at least in mice, acquired immunity to M. tuberculosis is mediated by two different effector pathways (51–53). The first pathway, intracellular killing of M. tuberculosis by macrophages that have been activated by cytokines, corresponds to the traditional CMI process. The major source of macrophage-activating cytokines are Th1-like, CD4 CD8 T-helper cells. These lymphocytes produce the cytokines when activated by the binding of mycobacterial antigen to the cells’ specific T-cell receptor for antigen (TCR) plus an appropriate second signal from the antigen-presenting cell. Neutralization and gKO experiments indicate that both IFN- and TNF- are essential cytokines for resistance of mice to primary mycobacterial infections and that intracellular killing in this model is mediated primarily by NO/RNIs (53). Recent reports of disseminated mycobacterial infections in children with IFN- receptor 1 deficiency suggest that this cytokine is important in the control of human tuberculosis as well (54,55). IFN- has been used with success to treat human tuberculosis and nontuberculous mycobacterial infections (56,57). However, the in vivo activity of IFN- may be due to effects other than the activation of macrophages by the cytokine, because IFN- inconsistently stimulates the ability of human macrophages mycobacteria in vitro (58–60). As noted earlier, the role of RNIs in the killing of M. tuberculosis by human macrophages remains uncertain.
250
Piessens and Nardell
In the second pathway, M. tuberculosis–infected macrophages are killed by cytolytic T lymphocytes (CTL). This DTH-like process benefits the host by destroying immature macrophages that provide a permissive environment for bacillary growth. The liberated tubercle bacilli can survive for many years extracellulary, but they are unable to multiply in the solid caseous necrotic material that forms the center of the developing granuloma. Released bacilli can also be ingested and killed by T-cell–activated macrophages in the vicinity and killed intracellularly. Several types of M. tuberculosis–specific CTL have been described. Some are classic CD4 CD8 CTL that recognize mycobacterial antigens presented by infected macrophages in the context of class I major histocompatibility complex (MHC) determinants. Other CTL are CD4 CD8 killer T cells, which appear to be more common in mycobacterioses than in other infections with intracellular pathogens (61). CD4 CTL recognize bacterial antigens, including the 65 kDa heat-shock protein of M. tuberculosis, that are complexed to MHC class II determinants on the target macrophages. The cells kill infected target cells by inducing Fas-mediated apoptosis; the latter process also can reduce the viability of intracellular M. tuberculosis (62). Yet another CTL subset recognizes antigen in the context of CD1, a MHC-like surface molecule with a unique ability to present nonpeptide antigens to T cells, including mycobacterial lipids. CD4 CD8 CD1restricted CTL induce apoptosis of infected macrophages but have no effect on the viability of the mycobacteria. CD8 CD1-restricted CTL lyse infected macrophages by a granule-dependent mechanism that also kills the mycobacteria (63). Because CD1-restricted T cells lack CD4, they are not infectable with HIV and therefore may play an important role in patients with AIDS (64). Of note, infected alveolar macrophages are relatively resistant to CTL (61). Other cells, including T cells with the variant of the TCR and natural killer (NK) cells, may contribute to the overall strength of acquired immunity to tuberculosis. However, studies in mice suggest that these cell populations are not essential for resistance to primary M. tuberculosis infections. These cells may play an immunoregulatory role by promoting Th0 to Th1 development of T-helper cells and thus expanding the pool of T cells capable of producing macrophage-activating cytokines (65). Alternatively, T cells influence local cellular traffic to tuberculous lesions by promoting the influx of monocytes and lymphocytes and limiting the inflow of other inflammatory cells that do not contribute to protection but may cause tissue damage (66). Observations in animal models suggest that the relative importance of activated macrophages and CTL in the control of primary tuberculosis may vary over time. Whether the same is true in human tuberculosis is unknown. Regardless of the underlying mechanisms, the bacillary population in the normal host remains stable, as growth is counterbalanced by bacillary destruction and inhibition. It is believed that the primary complex and most of the metastatic sites gradually become sterile over time. However, in “vulnerable” regions of the lungs (67) and other or-
Pathogenesis of Tuberculosis
251
gans, caseation necrosis reduces the bacillary population to a low level of organisms that remain dormant and viable, but the immune response does not sterilize the lesion. This leaves behind bacilli that may later reactivate (68). The biological mechanisms leading to latency in M. tuberculosis remain poorly understood (69). B. The Caseous Tuberculous Granuloma
In a typical tuberculous granuloma, activated “mature” macrophages accumulate around a caseous lesion and prevent its further extension (2,70). Tuberculin-like products secreted by intracellular bacilli are thought to be important early stimulants of caseous necrosis, which involves several poorly defined processes in addition to the so-called DTH reaction that kills immature infected macrophages of the early lesion. Some processes implicated in caseous necrosis are listed in Table 3, but direct evidence supporting their postulated role in the process is scant. The activated macrophages within tuberculous granulomas are derived from bloodborne monocytes. Turnover rates of these cells are high in early lesions and decline over time as the reaction subsides and a steady state is reached. The chemotactic stimuli leading to macrophage extravasation into tuberculous granulomas have not yet been identified, but they likely include chemokines such as monocyte chemoattractant protein (MCP)-1 and IL-8, which are secreted by monocytes and alveolar
Table 3
Mechanisms Implicated in Caseous Necrosis
1. “Targeted” killing of infected host cells: Exuberant killing of infected macrophages presenting mycobacterial antigens by M. tuberculosis–specific CTL. 2. “Bystander” killing of host cells: Uninfected cells can be killed by locally high concentrations of cytokines with cytotoxic potential (e.g., TNF- , TGF- ) or bacteriostatic effector molecules (e.g., NO). Caseating necrosis is present in mice treated with antisera to TNF- , even though the number of organisms in the lesions is only marginally increased. The possible therapeutic use of thalidomide, a specific inhibitor of TNF- mRNA expression, is under investigation. Alternatively, cells in the center of the granuloma degenerate because they are exposed to concentrations of cytokines that are too low to suppress mycobacterial growth. 3. Ischemia from thrombosed blood vessels: Activated macrophages produce procoagulant factors; so-called tissue factors released by damaged host cells can also activate the clotting system. 4. Complement-mediated cell damage: Locally formed antigen-antibody immune complexes may trigger this reaction. 5. Cell and tissue digestion by enzymes: Hydrolytic proteases and lipases released by activated macrophages and other dying host cells may damage surrounding tissues. 6. Cytopathic effects: Some components of M. tuberculosis (e.g., cord factor, M. tuberculosis virulence gene product) may be toxic for host cells.
252
Piessens and Nardell
epithelial cells infected with M. tuberculosis (71–73). Levels of IL-8 are elevated in bronchoalveolar lavage fluid from patients with pulmonary tuberculosis (74). Caseous granulomas in the lung are microscopic or barely visible during the first 4 or 5 weeks of infection. Lung lesions in resistant rabbits contain relatively few bacilli, some lymphocytes, many activated macrophages (also called mature epithelioid cells), multinucleated giant (Langhans’) cells, and relatively little necrosis. Lesions in susceptible rabbits contain many bacilli and few activated macrophages and are more necrotic (2,48). At the sites of lymphohematogenous dissemination, accelerated tubercle formation in resistant rabbits rapidly controls the metastatic foci with minimal necrosis, whereas bacillary growth leads to progressively caseating foci in susceptible animals. Ultimately, susceptible rabbits died of disseminated tuberculosis, not unlike tuberculosis patients with AIDS. Studies of tuberculous adenitis in HIV-infected persons confirm the important role of T cells in granuloma formation (75). When CD4 counts exceed 200/L, epithelioid and giant cells (i.e., activated macrophages) are present in the granulomas. When CD4 counts are lower, the lesions are less organized, more necrotic, and contain foamy macrophages. Memory CTL and NK cells present in normal granulomas are replaced with virgin CD8 cells and granulocytes in the necrotic lesions. Studies in gKO mice indicate that TNF- and IFN- are essential for granuloma formation. These cytokines are not sufficient, however, because their levels are elevated in SCID mice that do not develop tuberculous granulomas (53). Administration of exogenous TNF receptor 1 not only prevents the formation but also causes the disappearance of established granulomas in mice, an observation that might have therapeutic implications for the future (76). Thalidomide treatment decreases TNF- production by monocytes from tuberculosis patients and reduces the systemic toxicity of the cytokine without inhibiting CMI (77). Mice with gKO of ICAM-1 are unable to form granulomas but are resistant to primary infection with M. tuberculosis, suggesting that intercellular adherence through this molecule is required for the morphogenesis of a typical tuberculoid granuloma (78). V. Stage 4 (Months to Years Later): Endogenous Reactivation and Transmission A. Tissue Liquefaction and Cavitation
Liquefaction, the end stage of caseation, is believed to result mainly from the progressive hydrolysis of protein, lipid, and nucleic acid components of caseated tissues by hydrolytic enzymes from host cells and/or mycobacteria. Exactly what triggers the onset of liquefaction is unknown, but mycobacterial “toxins” are believed to play an important role (79). Observations in mice are consistent with this notion. In contrast to normal control mice, mice with gKOs of CD8 or IFN- fail to control infection and empty their tuberculous lesions into bronchi much in the same manner as Lurie’s rabbits. Host factors also contribute to tissue damage.
Pathogenesis of Tuberculosis
253
Langhans’ and epithelioid cells in tuberculous granulomas express mRNA for TGF- . Thus, local production of TGF- may directly cause immunopathology (80). It has also been suggested that tubercle bacilli increase the sensitivity of host cells to the cytolytic effect of TNF- , and thereby predispose to tissue damage via a mechanism akin to the Koch phenomenon (81). When a liquefied caseous lesion discharges its contents into a nearby bronchus, a cavity is formed—the characteristic radiographic and pathological presentation of tuberculosis and other chronic, granulomatous infections. The local inflammatory response to the sudden spillage of necrotic, highly antigenic, infectious liquid within the lungs is recognized clinically as a tuberculous pneumonitis. Cavitation is largely responsible for the transmission and perpetuation of human tuberculosis. B. Resumption of Bacterial Growth
In most infected persons, the immune response maintains the bacillary population in “reactivatable sites” in a steady-state dormant level. The continuous release of small amounts of mycobacterial antigens from caseated granulomas presumably maintains both tuberculin reactivity and protective immunity, which are separate phenomena (82). When some event—stress, treatment with steroids or chemotherapeutic drugs, HIV infection, alcohol, malnutrition, etc.—perturbs this equilibrium, liquefaction of the caseous center of the granuloma permits extracellular growth and multiplication of M. tuberculosis. Several cytokines and other host factors can “deactivate” macrophages and thereby promote mycobacterial growth (Table 4). Presumably, host defenses are inoperative within liquefied necrotic tisTable 4 Effect of Cytokines and Other Mononuclear Cell Products on Macrophage Activation for M. Tuberculosis Control Activating molecules
Deactivating molecules
IL-2 IL-4 IL-7 IL-12 GM-CSF TNFTFNIFN1,25-(OH)2D3 (Calcitriol)
IL-1 IL-3 IL-6 IL-10 TGFProstaglandin E2
Information shown is based on a variety of models for human tuberculosis. Source: Adapted from Refs. 22, 85, 86.
254
Piessens and Nardell
sue, but the cavitary fluid permits extracellular multiplication of mycobacteria, of which large numbers accumulate in tuberculous cavities (108 in Lurie’s rabbits). Given the baseline mutation rate in mycobacteria, this favors the emergence of drug-resistant tubercle bacilli. VI. Clinical Correlates of Immune Events in Human Tuberculosis In most immune-competent persons, primary tuberculosis is a subclinical infection or a mild self-limited illness that does not proceed past the third stage in the pathogenic scheme described in this chapter. Although progressive primary disease occasionally leads to cavitary tuberculosis, this outcome usually results from a second (postprimary) phase of disease activity that occurs months to decades after apparent recovery from the initial infectious process. As was noted above, it is unclear what event triggers this endogenous reactivation at the cellular and molecular level, but many known risk factors for development of clinical tuberculosis adversely affect the human immune system. Once a subject of considerable debate, “fingerprinting” mycobacteria by genetic methods (see Chap. 11) clearly indicates that exogenous (re)infection can also lead to cavitary tuberculosis. The relative frequency of endogenous reactivation and exogenous reinfection as the cause of cavitary tuberculosis is likely to vary with the local prevalence of infection, the former being more common in situations of low prevalence and vice versa. Even though they lead to the same clinical endpoint, distinguishing the two pathogenic pathways may be important for optimal management of tuberculosis. Primary tuberculous lesions occur throughout the lungs but are most common in the lower lobes because of the air flow distribution; postprimary disease occurs most commonly in the upper parts of the lung (83). To explain the existence of this so-called “vulnerable region,” Medlar postulated that foci in the apical region of the lung are incompletely sterilized by lung defenses, whereas other sites elsewhere become sterile (67). Smith and coworkers later hypothesized that tubercle bacilli reach the upper lung through lymphohematogenous dissemination that occurs during the primary infection. During subsequent reinfection, inhaled bacteria are destroyed by long defenses, except if they are implanted directly into an airspace in the lung apex, where resistance is weak (68,84). In the guinea pig model on which this hypothesis is partially based, BCG does not protect against a primary infection but reduces the resultant bacillemia. If the same is true in human tuberculosis, BCG should reduce the odds of cavitary tuberculosis (and of metastatic extrapulmonary disease) due to endogenous reactivation but not to exogenous reinfection, a prediction consistent with the results of some human BCG trials. Liquefaction necrosis is of major public health importance because the resulting cavitation connects the infected site with the environment and thus pro-
Pathogenesis of Tuberculosis
255
motes transmission of mycobacteria. It is also likely that some of the molecular components of the process that leads to cavitation (e.g., TNF- , and I1-1 from activated macrophages) contribute to the systemic symptoms of fever, weight loss, and anorexia that are associated with cavitary disease. VII. Conclusion The human immune response to M. tuberculosis is a complex reaction that is both beneficial and deleterious to the infected individual. It requires the interaction of several types of cells that cross-regulate each other’s activities via mixtures of soluble cytokines. The latter often must act in concert or sequentially to stimulate a given cellular function and may have opposing effects on different cell types. Virulent tubercle bacilli dysregulate this delicate balance and pervert some host responses to ensure their own survival. Much of our knowledge of host responses to mycobacteria is based on in vitro and animal studies. Advances in basic biology now render it possible to directly analyze immune responses in infected or diseased human tissues and body fluids. This approach should permit a reappraisal of concepts based on the older models and improve our understanding of the pathogenesis of human tuberculosis infection and disease. In turn, this should spawn improved and novel approaches to the prevention and control of tuberculosis by manipulating the host immune response to this formidable pathogen. References 1. Dannenberg AM, Jr. Pathogenesis of pulmonary tuberculosis. Am Rev Respir Dis 1982; 125:25–29. 2. Lurie MB. Resistance to Tuberculosis: Experimental Studies in Native and Acquired Defensive Mechanisms. Cambridge, MA: Harvard University Press, 1964. 3. Ratcliffe HL. Tuberculosis induced by droplet nuclei infection: pulmonary tuberculosis of predeterminded initial intensity in mammals. Am J Hyg 1952; 55:36–48. 4. Riley RL, Mills CC, O’Grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. Am Rev Respir Dis 1962; 85:511–525. 5. Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun 1998; 66:1277–1281. 6. Fels A, Cohen ZA. The alveolar macrophage. J Appl Physiol 1986; 60:353–369. 7. Ramanathan VD, Curtis J, Turk JL. Activation of the alternative pathway of complement by mycobacteria and cord factor. Infect Immun 1980; 29:30–35. 8. Schorey JS, Carroll MC, Brown EJ. A macrophage invasion mechanism of pathogenic mycobacteria. Science 1997; 277:1091–1093. 9. Schlesinger LS, Hull SR, Kaufman TM. Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. J Immunol 1994; 152:4070–4079.
256 10.
11.
12.
13. 14. 15.
16.
17.
18.
19. 20.
21.
22. 23.
24.
25.
Piessens and Nardell Gaynor CD, McCormack FX, Voelker DR, McGowan SE, Schlesinger LS. Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. J Immunol 1995; 155:5343–5351. Reid KB, Colomb MG, Loos M. Complement component C1 and the collectins: parallels between routes of acquired and innate immunity. Immunol Today 1998; 19:56–59. O’Brien L, Roberts B, Andrew PW. In vitro interaction of Mycobacterium tuberculosis and macrophages: activation of anti-mycobacterial activity of macrophages and mechanisms of anti-mycobacterial activity. Curr Top Microbiol Immunol 1996; 215:97–130. Quinn FD, Newman GW, King CH. In search of virulence factors of human bacterial disease. Trends Microbiol 1997; 5:20–26. Quinn FD, Newman GW, King CH. Virulence determinants of Mycobacterium tuberculosis. Curr Top Microbiol Immunol 1996; 215:131–156. Arruda S, Bomfim G, Knights R, Huima-Byron T, Riley LW. Cloning of an M. tuberculosis DNA fragment associated with entry and survival inside cells. Science 1993; 261:1454–1457. Collins DM, Kawakami RP, de Lisle GW, Pascopella L, Bloom BR, Jacobs WR, Jr. Mutation of the principal sigma factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 1995; 92:8036–8040. Armstrong JA, Hart PD. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 1971; 134:713–740. Xu S, Cooper A, Sturgill-Koszycki S, et al. Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages. J Immunol 1994; 153:2568–2578. McDonough KA, Kress Y, Bloom BR. Pathogenesis of tuberculosis: interaction of Mycobacterium tuberculosis with macrophages. Infect Immun 1993; 61:2763–2773. Chan J, Fan XD, Hunter SW, Brennan PJ, Bloom BR. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 1991; 59:1755–1761. O’Brien L, Carmichael J, Lowrie DB, Andrew PW. Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infect Immun 1994; 62:5187–5190. Wallis RS, Ellner JJ. Cytokines and tuberculosis. J Leukoc Biol 1994; 55:676–681. Knutson KL, Hmama Z, Herrera-Velit P, Rochford R, Reiner NE. Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. J Biol Chem. 1998; 273:645–652. Pancholi P, Mirza A, Bhardwaj N, Steinman RM. Sequestration from immune CD4 T cells of mycobacteria growing in human macrophages. Science 1993; 260: 984–986. Stead WW, Senner JW, Reddick WT, Lofgren JP. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990; 322:422–427.
Pathogenesis of Tuberculosis
257
26. Aoki SK. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990; 322:1670. 27. Felton CP, Smith JA, Ehrlich MH. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990; 322:1670–1671. 28. Rosenman KD. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990; 322:1670. 29. Comer WJ, Jr., Felix R. Re: “Risk factors for transmission of Mycobacterium tuberculosis in a primary school outbreak: lack of radical difference in susceptibility to infection.” Am J Epidemiol 1995; 142:666–668. 30. Skamene E, Schurr E, Gros P. Infection genomics: Nrampl as a major determinant of natural resistance to intracellular infections. Annu Rev Med 1998; 49:275–287. 31. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998; 338:640–644. 32. Crowle AJ, Elkins N. Relative permissiveness of macrophages from black and white people for virulent tubercle bacilli. Infect Immun 1990; 58:632–638. 33. Nickonenko BV, Apt AS, Moroz AM, Averbakh MM, Skamene E. Genetic analysis of susceptibility of mice to H37Rv tuberculosis infection: sensitivity versus relative resistance. Progr Leukoc Biol 1985; 3:291–296. 34. Goldfeld AE, Delgado JC, Thim S, et al. Association of an HLA-DQ allele with clinical tuberculosis. JAMA 1998; 279:226–228. 35. Sudre P, Hirschel BJ, Gatell JM, et al. Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study Group. Tuberc Lung Dis 1996; 77:322–328. 36. DiPerri G, Danzi MC, DeChecchi G, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989; 2:1502–1504. 37. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immuonodeficiency virus: an analysis using restriction-fragment-length polymorphism. N Engl J Med 1992; 326:231–235. 38. Couldwell DL, Dore GJ, Harkness JL, et al. Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room [see comments]. AIDS 1996; 10:521–525. 39. Rose RM. Immunology of the lung in HIV infection: the pathophysiologic basis for the development of tuberculosis in the AIDS setting. Bull Int Union Tuberc Lung Dis 1991; 66:15–20. 40. Guerrero A, Cobo J, Fortun J, et al. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection [see comments]. Lancet 1997; 350:1738–1742. 41. Trial J, Birdsall HH, Hallum JA, et al. Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, transendothelial migration, and cell surface phenotype. J Clin Invest 1995; 95:1690–1701. 42. Yoo J, Chen H, Kraus T, et al. Altered cytokine production and accessory cell function after HIV-1 infection. J Immunol 1996; 157:1313–1320.
258
Piessens and Nardell
43. Coffey MJ, Phare SM, Kazanjian PH, Peters-Golden M. 5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. J Immunol 1996; 157:393–399. 44. Smith PD, Ohura K, Masur H, Lane HC, Fauci AS, Wahl SM. Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis. J Clin Invest 1984; 74:2121–2128. 45. Spear GT, Kessler HA, Rothberg L, Phair J, Landay AL. Decreased oxidative burst activity of monocytes from asymptomatic HIV-infected individuals. Clin Immunol Immunopathol 1990; 54:184–191. 46. Smith DW, Harding GE. Animal model of human disease. Pulmonary tuberculosis. Animal model: experimental airborne tuberculosis in the guinea pig. Am J Pathol 1977; 89:273–276. 47. Ratcliffe HL, Palladino VS. Tuberculosis induced by droplet nuclei infection. Initial homogeneous response of small mammals (rats, mice, guinea pigs, and hamsters) to human and to bovine bacilli, and rate and pattern of tubercle development. J Exp Med 1953; 97:61–68. 48. Dannenberg AM, Jr. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis [see comments]. Immunol Today 1991; 12:228–233. 49. Rich AR. The Pathogenesis of Tuberculosis. Springfield, IL: Charles C Thomas, 1951. 50. Youmans GP. Tuberculosis. Philadelphia: W.B. Saunders, 1979. 51. Kaufmann SHE. In vitro analysis of the cellular mechanisms involved in immunity to tuberculosis. Rev Infect Dis 1989; 11 (suppl):S448–S454. 52. Orme IM. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 1987; 138: 293–298. 53. Bloom BR, Flynn J, McDonough K, Kress Y, Chan J. Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection. Immunobiol 1994; 191:526–536. 54. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941–1949. 55. Jouanguy E, Altare F, Lamhamedi-Cherradi S, Casanova JL. Infections in IFN R-1deficient children. J Interferon Cytokine Res 1997; 17:583–587. 56. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol [see comments]. Lancet 1997; 349:1513–1515. 57. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994; 330:1348–1355. 58. Rook GA, Steele J, Fraher L, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986; 57:159–163. 59. Flesch I, Kaufmann SH. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol 1987; 138:4408–4413.
Pathogenesis of Tuberculosis
259
60. Denis M. Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitriol. Clin Exp Immunol 1991; 84:200–206. 61. Tan JS, Canaday DH, Boom WH, Balaji KN, Schwander SK, Rich EA. Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: role for CD4 and CD8 cytotoxic T cells and relative resistance of alveolar macrophages to lysis. J Immunol 1997; 159:290–297. 62. Oddo M, Renno T, Attinger A, Bakker T, MacDonald HR, Meylan PR. Fas ligandinduced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol 1998; 160:5448–5454. 63. Stenger S, Mazzaccaro RJ, Uyemura K, et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science 1997; 276:1684–1687. 64. Gong J, Stenger S, Zack JA, et al. Isolation of mycobacterium-reactive CD1-restricted T cells from patients with human immunodeficiency virus infection. J Clin Invest 1998; 101:383–389. 65. Havlir DV, Ellner JJ, Chervenak KA, Boom WH. Selective expansion of human gamma delta T cells by monocytes infected with live Mycobacterium tuberculosis. J Clin Invest 1991; 87:729–733. 66. D’Souza CD, Cooper AM, Frank AA, Mazzaccaro RJ, Bloom BR, Orme IM. An antiinflammatory role for gamma delta T lymphocytes in acquired immunity to Mycobacterium tuberculosis. J Immunol 1997; 158:1217–1221. 67. Medlar EM. The pathogenesis of minimal pulmonary tuberculosis: a study of 1225 necropsies in cases of sudden and unexpected death. Am Rev Tuberc 1948; 58:583– 611. 68. Smith DW, Wiegeshaus EH. What animal models can teach us about the pathogenesis of tuberculosis in humans. Rev Infect Dis 1989; 11 (suppl):S385–S393. 69. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998; 6:107–112. 70. Dannenberg AM, Jr. Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Immunobiology 1994; 191:461–473. 71. Kasahara K, Tobe T, Tomita M, et al. Selective expression of monocyte chemotactic and activating factor/monocyte chemoattractant protein 1 in human blood monocytes by Mycobacterium tuberculosis. J Infect Dis 1994; 170:1238–1247. 72. Zhang Y, Broser M, Cohen H, et al. Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. J Clin Invest 1995; 95:586–592. 73. Lin YG, Zhang M, Barnes PF. Chemokine production by a human alveolar epithelial cell line in response to Mycobacterium tuberculosis. Infect Immun 1998; 66:1121– 1126. 74. Law KF, Jagirdar J, Weiden MD, Bodkin M, Rom WN. Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung. Am J Respir Crit Care Med 1996; 153:1377–1384. 75. Muller H, Kruger S. Immunohistochemical analysis of cell composition and in situ cytokine expression in HIV- and non-HIV-associated tuberculous lymphadenitis. Immunobiology 1994; 191:354–368.
260
Piessens and Nardell
76. Senaldi G, Yin S, Shaklee CL, Piguet PF, Mak TW, Ulich TR. Corynebacterium parvum-and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996; 157:5022–5026. 77. Kaplan G. Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology 1994; 191:564–568. 78. Johnson CM, Cooper AM, Frank AA, Orme IM. Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intercellular adhesion molecule 1 gene. Infect Immun 1998; 66:1666–1670. 79. Dannenberg AM, Jr., Sugimoto M. Liquefaction of caseous foci in tuberculosis. Am Rev Respir Dis 1976; 113:257–259. 80. Toossi Z, Gogate P, Shiratsuchi H, Young T, Ellner JJ. Enhanced production of TGFbeta by blood monocytes from patients with active tuberculosis and presence of TGFbeta in tuberculous granulomatous lung lesions. J Immunol 1995; 154:465–473. 81. Rook GA, Stanford JL. The Koch phenomenon and the immunopathology of tuberculosis. Curr Top Microbiol Immunol 1996; 215:239–262. 82. Orme IM, Collins FM. Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin. Cell Immunol 1984; 84:113–120. 83. Sweany HC, Cook CE, Kegerreis R. A study of the position of primary cavities in pulmonary tuberculosis. Am Rev Tuberc 1931; 24:558–582. 84. Balasubramanian V, Wiegeshaus EH, Taylor BT, Smith DW. Pathogenesis of tuberculosis: pathway to apical localization [see comments]. Tuber Lung Dis 1994; 75: 168–178. 85. Sieling PA, Sakimura L, Uyemura K, et al. IL-7 in the cell-mediated immune response to a human pathogen. J Immunol 1995; 154:2775–2783. 86. Zhang M, Gately MK, Wang E, et al. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994; 93:1733–1739.
11 Mycobacterial Strain Genotyping
NANCY D. CONNELL
BARRY N. KREISWIRTH
New Jersey Medical School National Tuberculosis Center and and International Center for Public Health UMDNJ–New Jersey Medical School Newark, New Jersey
Tuberculosis Center Public Health Research Institute New York, New York and International Center for Public Health Newark, New Jersey
I. Introduction Historically, the microbiological tools used to differentiate or subspeciate clinical isolates of Mycobacterium tuberculosis were based on phage and/or drug susceptibility patterns (1). The comparison of strains has evolved from analysis of protein products (phenotyping) to the analysis of genetic content (genotyping). DNAbased fingerprinting of M. tuberculosis was introduced in 1990. In the ensuing years, more than 30,000 strains have been analyzed and cataloged, and thousands of unique patterns have been identified. Molecular fingerprinting is used in a wide range of epidemiological, clinical, and basic studies to demonstrate foci of transmission in cites (6–8), nosocomial outbreaks (9–11), and congregate settings (12–14); to study transmission among high-risk populations such as HIV-positive and homeless persons (16,17); to evaluate cross-contamination in the clinical laboratory (18–20); and to analyze sequence changes as they reflect rates of molecular evolution (21,22). On the basis of restriction enzyme analysis (23), hybridization with random DNA probes (24), and, most recently, direct sequencing (21), the DNA sequence of M. tuberculosis shows strikingly little variation (see below). It is surprising that within this homogeneous background there are several variable genetic elements. 261
262
Connell and Kreiswirth
One of these, IS6110, is an ideal genotyping tool, able to discriminate among thousands of clinical isolates worldwide. II. Methodologies A. DNA Fingerprinting
DNA fingerprinting is based on the distribution (both in number and location) of the target sequence in the chromosome of M. tuberculosis complex strains. Total DNA from the sample strain is digested with a restriction enzyme that cuts outside of the element, resulting in a collection of DNA fragments. Among this collection are a finite number of fragments of various lengths containing the target sequence restriction fragment length polymorphism (RFLP). The fragments are separated by size, and those fragments bearing the target sequence are identified by Southern blot analysis. Each strain contains a distinct pattern of different-sized bands marked by the target sequence, although some caveats must be invoked (see below). The most commonly used target sequence is the bacterial insertion element, IS6110 (4). This mobile genetic element is 1355 bp in size, has an imperfect 28 bp inverted repeat, and generates a 3- to 4-bp target duplication upon insertion. It is present in 0–30 copies in the M. tuberculosis complex genome. In San Francisco, clinical strains of M. tuberculosis lacking IS6110 are estimated to occur at a frequency of less than 1% (25). The laboratory strain H37Rv, whose genome has been sequenced (26), contains 17 copies of IS6110. The IS6110 RFLP pattern of H37Rv is illustrated in Figure 1, lane 20. Pulsed field gel electrophoretic analysis and physical mapping of IS6110 copies in the chromosome of strain H37Rv have provided evidence that these insertions are randomly dispersed around the chromosome (26,27). The genomic context of these elements is the subject of several recent studies and will be discussed below. Other genetic markers used for RFLP analysis include a second insertion element, IS1081, first identified in M. bovis and shown to be present in members of the M. tuberculosis complex strains (28). Also useful are the repeated elements such as the DR (direct repeat) locus (29) (see spoligotyping, below), MPTR (major polymorphic tandem repeats) (30), and PGRS (polymorphic GC-rich repetitive sequence). B. Polymerase Chain Reaction
There are a number of fingerprinting techniques that exploit polymerase chain reaction (PCR) amplification. Using nucleotide primers of sequence derived from IS6110, for example, yields products using template concentrations as low as 10 pg. The DNA sequence of these products reveals priming from one of the IS6110 elements at one end and nonspecific sites in the chromosome at the other (17,31). PCR with random primers has also been used to analyze clustered cases (24).
Mycobacterial Strain Genotyping
263
Figure 1 IS6110-based DNA fingerprint patterns from the collection of isolates of Mycobacterium tuberculosis maintained by the Public Health Research Institute, New York. Molecular weight makers are along the right margin. Lanes 1–12 are examples of the W strain group from various locales, as follows: 1–2, Singapore; 3–7, Russia; 8, Kenya; 9–11, New York City; 12, New Jersey. Lanes 13–19 are strains reflecting the range of RFLP fingerprint patterns found in New York City, with the exception of lane 14, the U strain, which is from New Jersey. Lane 20 shows the fingerprint pattern of Mycobacterium tuberculosis H37Rv, a laboratory strain.
264
Connell and Kreiswirth C. Single-Strand Conformational Polymorphism
The analysis of drug-resistant isolates of M. tuberculosis on the basis of comparing the sequence of resistance genes has proven to be a very precise genotyping tool. Single-strand conformational polymorphism (SSCP) has distinguished strains on the basis of differences in the rpoB region among rifampin-resistant strains (32) and gyrA among quinolone-resistant strains (33) A more direct method uses PCR amplicons derived from drug-resistant isolates followed by automated sequencing. The finding that 21 rpoB genes sequenced from W-type strains have identical base pair changes supports the notion that these strains are clonal and are derived from a common ancestor (see below). D. Spoligotyping (Spacer Oligotyping)
This technique is based on sequence variation within a specific region of the M. tuberculosis chromosome, the highly polymorphic DR (direct repeat) locus (34). Its structure is a series of 36-bp imperfectly matched DR elements interrupted by spacer sequences. The DR elements vary in size from 35 to 41 bp and the spacers are 5–7 bp. In addition, the number of spacers is variable: BCG has 49 DR spacers and M. tuberculosis (H37Rv) has 39. PCR is used to amplify the DR region from each strain, and the PCR products are hybridized to membranes containing hundreds of immobilized random oligonucleotides. Each strain has a characteristic series of spacer regions in its DR locus, which is then reflected in the patterns detected by spoligotyping. Although the sequences vary, strains can be grouped on the basis of their spoligotype pattern. An advantage of this technique is that the first step is PCR amplification and can be applied directly to clinical samples without waiting for expansion of the culture. IS6110 fingerprinting becomes less differentiating as a strain’s copy number decreases. Clinical strains with fewer than five copies of IS6100 are generally analyzed by alternate means (see below). Several direct comparisons of spoligotyping and IS6110-based RFLP indicate that the DR locus can discriminate among strains containing as few as one copy of IS6110 (34–36). In addition, there was an occasional splitting of a group of high-copy-number strains by spoligotyping (37,38). E. Variable Number Tandem Repeat
A recent technique analyzed genetic loci containing tandem repeat sequences (39) Eleven variable number tandem repeat (VNTR) loci in the M. tuberculosis genome were examined. Two types of repeat loci were identified. Five of the loci were major polymorphic tandem repeat (MPTR) loci and contained 15-base-pair variable repeats. The remaining six loci were exact tandem repeat (ETR) loci and contained identical sequences in large adjacent repeats. Spacer regions do not in-
Mycobacterial Strain Genotyping
265
terrupt these tandem repeat loci, as in the DR loci discussed above. Primers were designed that recognize the termini of the repeat sequences, and the 11 loci were analyzed by PCR. The number of repeats present in each locus determined the length of the PCR product. These lengths were then compared among 48 strains. Seven of the 11 tandem repeat loci showed discriminating polymorphisms. For example, 22 of 25 M. tuberculosis strains and 5 of 23 M. bovis BCG strains had distinct allele profiles. This technique should be useful for both strain differentiation and evolutionary analyses. F. Direct DNA Sequencing
Finally, the application of automated sequencing techniques has permitted the analysis of several genes from large numbers of clinical strains (21,40). In addition, the complete H37Rv genome sequence has been annotated and published (26). The circular chromosome contains 4,411,529 base pairs with 3,918 proteincoding regions. Most of these genes contain recognizable sequences, unlike gene sequences from other organisms, suggesting the function of their gene products. However, approximately 600 of the genes are entirely unknown. The availability of this information has significantly increased the pace of tuberculosis research. The applications of this approach are discussed below. III. Interpreting Genotypes The molecular subtyping of bacterial isolates has proven to be a necessary tool in the identification, control, and monitoring of nosocomial transmission. Specific for M. tuberculosis, IS6110 DNA fingerprinting has become the prototype molecular tool in the study of bacterial molecular epidemiology. This robust Southern blot hybridization method has been standardized among laboratories throughout the world leading to the creation of three large networks (Public Health Research Institute in New York and Baylor College of Medicine in Texas, Houston, Texas) and in Europe (RIVM in the Netherlands, BA Bilthoven, The Netherlands) to track on an international basis the spread of this airborne pathogen. In general, these tools are able to determine whether the isolates recovered from a localized outbreak of disease are the same or different strains and support short-term or local epidemiology. It is currently accepted that two or more isolates with an identical IS6110 DNA fingerprint pattern but cultured from different patients are genetically related as a consequence of recent spread. Examples of related and unrelated IS6110 DNA fingerprint patterns are illustrated in Figure 1. Lanes 1–12 are W strains from Singapore, Russia, Kenya, and New York City. Their similarity is in marked contrast to the remaining patterns in the gel (lanes 13–19), which illustrate the range of RFLP patterns exhibited by clinical strains found among those collected in New York City and environs. Although this subtyping approach has been suc-
266
Connell and Kreiswirth
cessful in outbreak investigations on a local level and in identifying laboratory contamination, it is clear that use of IS6110 alone has limitations. The molecular epidemiology among strains with limited copies of IS6110 (5 insertions) requires additional subtyping methods (41). As discussed above, secondary tools such spoligotyping, VNTR, and PGRS hybridization have all proved useful in either discriminating or verifying the IS6110 grouping. These methods have become necessary in understanding the epidemiological significance among related strains from geographically diverse regions. A further limitation in IS6110 subtyping is reflected in large outbreak studies in assessing the relatedness among selected isolates. For example, the largest characterized multidrug-resistant outbreak occurred in New York City during the early 1990s (7,8). One clone, termed strain W, with a unique 18-band IS6110 pattern caused disease in more than 350 patients. In the same outbreak investigation, eight additional multidrug-resistant strains were identified that shared the majority of IS6110 bands with the W pattern but were not identical. Were the members of this second group related to the W outbreak? To address this question it was necessary to use additional genotyping methods. In this instance the multidrug phenotype provided an additional approach as resistance target genes in M. tuberculosis have been identified and sequenced. Svreevatsan et al. (42) determined the sequence of the pncA locus in 67 pyrazinamide-resistant and 51 pyrazinamide-susceptible isolates recovered from diverse geographical localities and anatomical sites. The pncA gene encodes pyrazinamidase, which converts pyrazinamide to the active form pyrazinoic acid. Surprisingly, the wild-type alleles of all 51 susceptible strains were identical: this restricted alellic variation among strains M. tuberculosis is discussed below. In the 67 resistant strains, mutations all along the length of the pncA locus were found. The majority (72%) were mutations that altered the primary amino acid sequence of the enzyme, and a number of new mutations were found, including upstream mutations, missense changes, nucleotide insertions and deletions, and termination mutations. DNA sequence analysis of six genes with mutations conferring antibiotic resistance (katG—isoniazid; rpoB—rifampin; embB—ethambutol; rpsL—streptomycin; pncA—pyrazinamide, rrs—kanamycin) in large samples of W isolates confirmed the clonal relationship of these organisms by showing that all isolates had the identical mutation in each of the six genes (Table 1) (8). This same array of six mutant alleles is found in the eight MDR strains with IS6110 profiles differing from the W pattern by one or two hybridizing bands. This secondary typing approach confirmed the relatedness of the W strain and those with related IS6110 fingerprint patterns that we have called the W-MDR family. Further confirmation of the relatedness of the W-MDR family was found using other secondary typing methods. This family is now defined based on all of
Mycobacterial Strain Genotyping
267
Table 1 Antibiotic Resistance Loci Used to Confirm Genetic Relatedness of RFLP DNA Fingerprint Group W Strains Antibiotic Isoniazid Rifampin Ethambutol Streptomycin Pyrazinamide Kanamycin
Genetic locus
Alterationa
Ref.
katG rpoB embB rpsL pncA rrs
315:ST 526:HY 306:MI/V 43:KR 47:TA A1400Gb
8 8 43 8 42 44
a
The affected codon is indicated, followed by the specific amino acid change from susceptible to resistant. b The nucleotide A at position 1400 is changed to G in resistant strains.
the following molecular properties: 18–20 band W-like IS6110 pattern (8) Common spoligotype pattern (45) IS6110 insertion in the dnaA-dnaN intergenic region (46) Two IS6110 head-to-tail insertions in NTF (8) Unique dinucleotide change in codon 315 in katG (8) IV. International Applications of Molecular Fingerprinting The transposition of IS6110 is a time-dependent process: the degree of polymorphism among a collection of strains should represent the degree of divergence and reflect the length of time that has elapsed since that divergence. Several groups have noted that among strains originating in Africa there appeared to be significantly fewer polymorphisms when compared to strains collected in the Netherlands (47–49). Similarly, an analysis of clinical M. tuberculosis strain genotypes was carried out with isolates obtained from the People’s Republic of China and Mongolia (50). More than two thirds of the strains evaluated exhibited closely related IS6110 profiles. The similarities observed in RFLP lengths were analyzed by IS6110 hybridization and were confirmed when further analyzed by two secondary genotyping methods, using IS1081 and spoligotyping. Limited polymorphisms were found associated with other repetitive DNA elements such as the polymorphic GC-rich sequence and the direct repeat. Furthermore, strains related to this group were located in neighboring countries such as Thailand, Mongolia, and South Korea, in contrast to the low prevalence of these genotypes in unrelated
268
Connell and Kreiswirth
countries. The group was named the Beijing family, since the majority of the strains were isolated from patients living in that city. In addition, dissemination of the Beijing strain to other countries is described. Computer analysis (48) found that genotypes of members of the W-MDR and W-SUS (susceptible) families had many comigrating bands, suggesting genetic relatedness among these strains (46). Further examination of the specific insertion sites of copies of IS6110 in these groups confirmed their similarity. These specific insertion sites are discussed below. There is a very large global pool of individuals infected with the tubercle bacillus, and considerable chromosomal heterogeneity is suggested by the large number of RFLP patterns detected among the world’s M. tuberculosis strain collections. In striking contrast to the strain diversity observed by IS6110 subtyping, DNA sequencing of drug targets has revealed that there are very few specific changes in the DNA sequence. Even substitutions that would result in no change to the actual protein sequence (synonymous nucleotide substitutions) appear to be extremely rare. Musser and colleagues studied this phenomenon by comparing sequences (2 million base pairs) among 26 different genes in 842 clinical M. tuberculosis complex strains representing 40 countries on every continent (21). Three phylogenetic groups of M. tuberculosis were identified on the basis of two polymorphisms that occur at high frequency in the genes encoding catalase-peroxidase and the A subunit of gyrase enzyme. The products of these two genes are involved in the resistance to isoniazid and the quinolones, respectively. Each of the three phylogenetic groups has distinct characteristics (see Table 2). For example, Group 1 is closely related to M. bovis and appears to be evolutionarily old. A subset of this group, exhibiting closely related RFLP patterns, contains a copy of the IS6110 insertion sequence integrated in a region of the chromosome required for initiation of DNA replication. RFLP genotypes and detailed
Table 2 Genotypic Groups Mycobacterial Strains on the Basis of Specific Genetic Alterations Group
Species
1
2
M. microti M. africanum M. tuberculosis M. tuberculosis
3
M. tuberculosis
M. tuberculosis strains
Codon changes
W, Houston
katG463 CTG (leu) gyrA95 ACC (thr)
C, Houston Erdman H37Rv, H37Ra
katG 463 CGG (arg) gyrA95 ACC (thr) katG463 CGG (arg) gyrA95 AGC (ser)
Mycobacterial Strain Genotyping
269
epidemiological profiles for each case are available for 6000 isolates from New York and Houston. These data are interpreted to suggest that Groups 1 and 2 are disproportionately represented among clustered cases of tuberculosis. The trivial explanation that Group 3 organisms are not found in these populations at a large enough frequency to be included among the clusters was ruled out. Among the strains included by Musser et al. in Group 1 are the W superfamily, common throughout Asia, including China, South Korea, Thailand, and the Philippines (51–53). These organisms are also causes of disease in New York and Houston and are responsible for relatively large (30 patients) case clusters (7,8,54,55). It is reasonable to speculate that the Beijing isolates identified in the United States were introduced by human population migration and should be found in regions with a relatively high percentage of people with Chinese ethnicity. These strains are rarely found in west Texas, Mexico, Guatemala, Honduras, Peru, Trinidad-Tobago, Israel, Romania, Kenya, the Netherlands, elsewhere in Europe, Tunisia, Pakistan, and Tanzania (48,56–59). On the other hand, group 1 genotypes were found in 16 of 49 (33%) isolates from Singapore, a city with approximately 40% ethnic Chinese. Scrutiny of the New York and Houston epidemiological databases reveals that the majority of the isolates belonging to group 1 are of Chinese and Vietnamese ethnicity, respectively. The group 1 strains (W-SUS, W-MDR, Beijing family, and N family) were further studied at the molecular level by identifying the precise chromosomal insertion sites of 5 of the 18 copies of IS6110 (40). Such analyses are aided by the recent availability of the entire DNA sequence of two M. tuberculosis genomes (26,60,61). None of the five insertion sites was in an open reading frame, suggesting that the insertion element does not interrupt gene expression in these five instances. However, one site was located in the origin of replication. A total of 722 strains was evaluated for precise sequence of insertion of the five IS6110 copies. The insertion-site mapping in this study identified the 537-base-pair region between the genes encoding dnaA and dnaN as a hot spot for IS6110 insertion. Ten different insertions in this region were identified, and the transposon was found in both orientations. Comparison of the specific sequences suggests further that there are small hairpin motif structures flanking the IS6110 insertion sites (46,62). A recent computer-based analysis also indicates that the M. tuberculosis genome contains hot spots for IS6110 insertion (63). V. Implications for Basic Research Taken together, the restricted nucleotide sequence variation and extensive IS6110 polymorphism provide strong evidence that transposition of IS6110 occurs at a greater frequency than unselected nucleotide changes. This has led to the proposition that transposition of IS6110 and other repetitive elements might be an im-
270
Connell and Kreiswirth
portant mechanism to alter gene expression (21). The hypothesis remains largely unexplored in M. tuberculosis pathogenesis. Variance in pathogenic behavior has been attributed to insertion sequence-based alterations in gene expression in Yersinia pestis (64) and in Neisseria meningitidis (65). Among the few studies of the chromosomal context of IS6110 insertion in clinical strains of M. tuberculosis (46,62), only one describes a copy of IS6110 interrupting an open reading frame (66). The site, mtp40, was originally identified as a region found in strains of M. tuberculosis but not in BCG (67). mtp40 was eventually shown to be a portion of an operon with two open reading frames (mpcA and mpcB) encoding proteins homologous to hemolytic phospholipases (20). Remarkable polymorphism was found among the mtp40 regions of 100 clinical strains of M. tuberculosis, including insertion of a copy of IS6110 in one strain in the 3 end of the mtp40 region (66). The effect of this insertion on phospholipase expression or on any other parameter, such as virulence, has not been examined (66). VI. Clinical Applications of Molecular Fingerprinting The new molecular tools and the kinds of analyses they provide are changing the face of tuberculosis epidemiology on an international scale (68,69). A comprehensive epidemiology of the disease will lead to better identification of index cases and efficient treatment methodologies. These techniques will enable the study of the interaction between M. tuberculosis and the human immunodeficiency virus (10,70–72). Population-based studies of transmission will help define the risk factors for transmission within communities and within and among countries. Finally, the behavior of drug-resistant strains can be monitored and analyzed. In a recent report issued by the World Health Organization–International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance, drug-resistant tuberculosis was identified in all 35 countries surveyed (73). Acknowledgment Publication No. 66 from the Tuberculosis Center, Public Health Research Institute. References 1. Gruft H, Johnson R, Claflin R, Loder A. Phage-typing and drug-resistance patterns as tools in mycobacterial epidemiology. Am Rev Respir Dis 1984; 130:96–97. 2. Hermans PW, van Soolingen D, Dale JW, et al. Insertion element IS986 from Mycobacterium tuberculosis: a useful tool for diagnosis and epidemiology of tuberculosis. J Clin Microbiol 1990; 28:2051–2058.
Mycobacterial Strain Genotyping
271
3. McAdam RA, Hermans PW, van Soolingen D, et al. Characterization of a Mycobacterium tuberculosis insertion sequence belonging to the IS3 family. Mol Microbiol 1990; 4:1607–1613. 4. Thierry D, Cave MD, Eisenach KD, et al. IS6110, an IS-like element of Mycobacterium tuberculosis complex. Nucleic Acids Res 1990; 18:188. 5. Thierry D, Brisson-Noel A, Vincent-Levy-Frebault V, Nguyen S, Guesdon JL, Gicquel B. Characterization of a Mycobacterium tuberculosis insertion sequence, IS6110, and its application in diagnosis. J Clin Microbiol 1990; 28:2668–2673. 6. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods [see comments]. N Engl J Med 1994; 330:1710–1716. 7. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276:1229–1235. 8. Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family [see comments]. JAMA 1996; 275:452–457. 9. Lemaitre N, Sougakoff W, Truffot-Pernot C, et al. Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers. Int J Tuberc Lung Dis 1998; 2:390–396. 10. Cohn DL, O’Brien RJ. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 1998; 2:16–26. 11. Nivin B, Nicholas P, Gayer M, Frieden TR, Fujiwara PI. A continuing outbreak of multidrug-resistant tuberculosis, with transmission in a hospital nursery. Clin Infect Dis 1998; 26:303–307. 12. Mangura BT, Napolitano EC, Passannante MR, McDonald RJ, Reichman LB. Mycobacterium tuberculosis miniepidemic in a church gospel choir. Chest 1998; 113:234–237. 13. Braden CR. Infectiousness of a university student with laryngeal and cavitary tuberculosis. Investigative team. Clin Infect Dis 1995; 21:565–570. 14. Cummings KC, Mohle-Boetani J, Royce SE, Chin DP. Movement of tuberculosis patients and the failure to complete antituberculosis treatment. Am J Respir Crit Care Med 1998; 157:1249–1252. 15. Angarano G, Carbonara S, Costa D, Gori A. Drug-resistant tuberculosis in human immunodeficiency virus infected persons in Italy. The Italian Drug-Resistant Tuberculosis Study Group. Int J Tuberc Lung Dis 1998; 2:303–311. 16. Segal SP, Gomory T, Silverman CJ. Health status of homeless and marginally housed users of mental health self-help agencies. Health Soc Work 1998; 23:45–52. 17. Dwyer B, Jackson K, Raios K, Sievers A, Wilshire E, Ross B. DNA restriction fragment analysis to define an extended cluster of tuberculosis in homeless men and their associates. J Infect Dis 1993; 167:490–494. 18. Segal-Maurer S, Kreiswirth BN, Burns JM, et al. Mycobacterium tuberculosis specimen contamination revisited: the role of laboratory environmental control in a pseudo-outbreak. Infect Control Hosp Epidemiol 1998; 19:101–105.
272
Connell and Kreiswirth
19. Van Duin JM, Pijnenburg JE, van Rijswoud CM, de Haas PE, Hendriks WD, van Soolingen D. Investigation of cross contamination in a Mycobacterium tuberculosis laboratory using IS6110 DNA fingerprinting. Int J Tuberc Lung Dis 1998; 2:425–429. 20. Johansen KA, Gill RE, Vasin ML. Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria. Infect Immun 1996; 64:3259– 3266. 21. Sreevatsan S, Pan X, Stockbauer KE, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997; 94:9869–9874. 22. Fang Z, Morrison N, Watt B, Doig C, Forbes KJ. IS6110 transposition and evolutionary scenario of the direct repeat locus in a group of closely related Mycobacterium tuberculosis strains. J Bacteriol 1998; 180:2102–2109. 23. Collins DM, De Lisle GW. DNA restriction endonuclease analysis of Mycobacterium bovis and other members of the tuberculosis complex. J Clin Microbiol 1985; 21:562–564. 24. Palittapongarnpim P, Chomyc S, Fanning A, Kunimoto D. DNA fingerprinting of Mycobacterium tuberculosis isolates by ligation-mediated polymerase chain reaction. Nucleic Acids Res 1993; 21:761–762. 25. Agasino CB, Ponce de Leon A, Jasmer RM, Small PM. Epidemiology of Mycobacterium tuberculosis strains in San Francisco that do not contain IS6110. Int J Tuberc Lung Dis 1998; 2:518–520. 26. Philipp WJ, Poulet S, Eiglmeier K, et al. An integrated map of the genome of the tubercle bacillus, Mycobacterium tuberculosis H37Rv, and comparison with Mycobacterium leprae. Proc Natl Acad Sci USA 1996; 93:3132–3137. 27. Zhang Y, Mazurek GH, Cave MD, et al. DNA polymorphisms in strains of Mycobacterium tuberculosis analyzed by pulsed-field gel electrophoresis: a tool for epidemiology. J Clin Microbiol 1992; 30:1551–1556. 28. Collins DM, Stephens DM. Identification of an insertion sequence, IS1081, in Mycobacterium bovis. FEMS Microbiol Lett 1991; 67:11–15. 29. Hermans PW, van Soolingen D, Bik EM, de Haas PE, Dale JW, van Embden JD. Insertion element IS987 from Mycobacterium bovis BCG is located in a hot-spot integration region for insertion elements in Mycobacterium tuberculosis complex strains. Infect Immun 1991; 59:2695–2705. 30. Hermans PW, van Soolingen D, van Embden JD. Characterization of a major polymorphic tandem repeat in Mycobacterium tuberculosis and its potential use in the epidemiology of Mycobacterium kansasii and Mycobacterium gordonae. J Bacteriol 1992; 174:4157–4165. 31. Ross BC, Raios K, Jackson K, Dwyer B. Molecular cloning of a highly repeated DNA element from Mycobacterium tuberculosis and its use as an epidemiological tool. J Clin Microbiol 1992; 30:942–946. 32. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993; 37:2054–2058. 33. Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38:773–780.
Mycobacterial Strain Genotyping
273
34. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35:907–914. 35. Cousins D, Williams S, Liebana E, et al. Evaluation of four DNA typing techniques in epidemiological investigations of bovine tuberculosis. J Clin Microbiol 1998; 36:168–178. 36. Sola C, Horgen L, Maisetti J, Devallois A, Goh KS, Rastogi N. Spoligotyping followed by double-repetitive-element PCR as rapid alternative to IS6110 fingerprinting for epidemiological studies of tuberculosis. J Clin Microbiol 1998; 36:1122–1124. 37. Goyal M, Shaw RJ, Banerjee DK, Coker RJ, Robertson BD, Young DB. Rapid detection of multidrug-resistant tuberculosis. Eur Respir J 1997; 10:1120–1124. 38. Goguet de la Salmoniere YO, Li HM, Torrea G, Bunschoten A, van Embden J, Gicquel B. Evaluation of spoligotyping in a study of the transmission of Mycobacterium tuberculosis. J Clin Microbiol 1997; 35:2210–2214. 39. Frothingham R, Meeker-O’Connell WA. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats. Microbiology 1998; 144:1189–1196. 40. Kapur V, Li LL, Iordanescu S, et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32:1095–1098. 41. Braden CR, Templeton GL, Cave MD, et al. Interpretation of restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from a state with a large rural population. J Infect Dis 1997; 175:1446–1452. 42. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997; 41:636–640. 43. Sreevatsan S, Stockbauer KE, Pan X, et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 1997; 41:1677–1681. 44. Alangaden GJ, Kreiswirth BN, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:1295–1297. 45. Goyal M, Saunders NA, van Embden JD, Young DB, Shaw RJ. Differentiation of Mycobacterium tuberculosis isolates by spoligotyping and IS6110 restriction fragment length polymorphism. J Clin Microbiol 1997; 35:647–651. 46. Kurepina NE, Sreevatsan S, Plikaytis BB, et al. Characterization of the phyogenetic distribution and chromosomal insertion sites of five IS6110 elements of Mycobacterium tuberculosis: non-random integration in the dnaA-dnaN region. Tubercle Lung Dis 1998; 79:31–42. 47. Borgdorff MW, Nagelkerke N, van Soolingen D, de Haas PE, Veen J, van Embden JD. Analysis of tuberculosis transmission between nationalities in the Netherlands in the period 1993–1995 using DNA fingerprinting. Am J Epidemiol 1998; 147:187–195. 48. Hermans PW, Messadi F, Guebrexabher H, et al. Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia, and The Netherlands: usefulness of DNA typing for global tuberculosis epidemiology [see comments]. J Infect Dis 1995; 171:1504–1513.
274
Connell and Kreiswirth
49. van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991; 29: 2578–2586. 50. van Soolingen D, Qian L, de Haas PE, et al. Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol 1995; 33:3234–3238. 51. Huh YJ, Ahn DI, Kim SJ. Limited variation of DNA fingerprints (IS6110 and IS1081) in Korean strains of Mycobacterium tuberculosis. Tuberc Lung Dis 1995; 76:324–329. 52. Lim EM, Rauzier J, Timm J, et al. Identification of Mycobacterium tuberculosis DNA sequences encoding exported proteins by using phoA gene fusions. J Bacteriol 1995; 177:50–65. 53. Torrea G, Levee G, Grimont P, Martin C, Chanteau S, Gicquel B. Chromosomal DNA fingerprinting analysis using the insertion sequence IS6110 and the repetitive element DR as strain-specific markers for epidemiological study of tuberculosis in French Polynesia. J Clin Microbiol 1995; 33:1899–1904. 54. Moss AR, Alland D, Telzak E, et al. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis 1997; 1:115–121. 55. Edlin BR, Valway SE, Onorato IM. Clusters of multidrug-resistant tuberculosis [letter]. Ann Intern Med 1993; 118:77. 56. Yang ZH, de Haas PE, van Soolingen D, van Embden JD, Andersen AB. Restriction fragment length polymorphism Mycobacterium tuberculosis strains isolated from Greenland during 1992: evidence of tuberculosis transmission between Greenland and Denmark. J Clin Microbiol 1994; 32:3018–3025. 57. Yang ZH, Mtoni I, Chonde M, et al. DNA fingerprinting and phenotyping of Mycobacterium tuberculosis isolates from human immunodeficiency virus (HIV)seropositive and HIV-seronegative patients in Tanzania. J Clin Microbiol 1995; 33:1064–1069. 58. Sechi LA, Zanetti S, Delogu G, Montinaro B, Sanna A, Fadda G. Molecular epidemiology of Mycobacterium tuberculosis strains isolated from different regions of Italy and Pakistan. J Clin Microbiol 1996; 34:1825–1828. 59. Sola C , Horgen L, Goh KS, Rastogi N. Molecular fingerprinting of Mycobacterium tuberculosis on a Caribbean island with IS6110 and DRr probes. J Clin Microbiol 1997; 35:843–846. 60. TIGR. TIGR releases EST data publicly [news]. Nat Biotechnol 1997; 15:397. 61. TIGR. HGS-TIGR splits, opportunity knocks [editorial]. Nat Biotechnol 1997; 15:693. 62. Mendiola MV, Martin C, Otal I, Gicquel B. Analysis of the regions responsible for IS6110 RFLP in a single Mycobacterium tuberculosis strain. Res Microbiol 1992; 143:767–772. 63. McHugh TD, Gillespie SH. Nonrandom association of IS6110 and Mycobacterium tuberculosis: implications for molecular epidemiological studies. J Clin Microbiol 1998; 36:1410–1413.
Mycobacterial Strain Genotyping
275
64. Simonet M, Riot B, Fortineau N, Berche P. Invasin production by Yersinia pestis is abolished by insertion of an IS200-like element within the inv gene. Infect Immun 1996; 64:375–379. 65. Hammerschmidt S, Hilse R, van Putten JP, Gerardy-Schahn R, Unkmeir A, Frosch M. Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. Embo J 1996; 15:192–198. 66. Vera-Cabrera L, Howard ST, Laszlo A, Johnson WM. Analysis of genetic polymorphism in the phospholipase region of Mycobacterium tuberculosis. J Clin Microbiol 1997; 35:1190–1195. 67. Del Portillo P, Murillo LA, Patarroyo ME. Amplification of a species-specific DNA fragment of Mycobacterium tuberculosis and its possible use in diagnosis [see comments]. J Clin Microbiol 1991; 29:2163–2168. 68. Roth A, Schaberg T, Mauch H. Molecular diagnosis of tuberculosis: current clinical validity and future perspectives. Eur Respir J 1997; 10:1877–1891. 69. Staneck JL. Impact of technological developments and organizational strategies on clinical laboratory cost reduction. Diagn Microbiol Infect Dis 1995; 23:61–73. 70. Gampper SN, George JA, Carter EJ, et al. Co-infection with Mycobacterium tuberculosis and HIV in high risk clinical care setting in Rhode Island. AIDS Care 1998; 10:221–229. 71. Johnson JL, Vjecha MJ, Okwera A, et al. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 1998; 2:397–404. 72. Jansa JM, Serrano J, Cayla JA, Vidal R, Ocana I, Espanol T. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis. Int J Tuberc Lung Dis 1998; 2:140–146. 73. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance [see comments]. N Engl J Med 1998; 338:1641–1649.
Part Three CLINICAL ASPECTS
277
page 278 is blank
12 Tuberculin Skin Testing
RICHARD I. MENZIES Montreal Chest Institute McGill University Montreal, Canada
I. Introduction Among tests presently used in clinical medicine, the tuberculin skin test is one of the few that was developed in the last century. Given such a long history of use it may seem surprising that the interpretation of this test remains controversial. However, this reflects the changing epidemiology, clinical features, investigation, and management of tuberculosis. In industrialized countries new problems have arisen in the interpretation of the tuberculin skin test in certain high-risk populations because of aging, HIV infection, intravenous (IV) drug use, and other phenomena. The first tuberculin test material was prepared by Robert Koch, who filtered heat-sterilized cultures of Mycobacterium tuberculosis grown on veal broth and then evaporated the filtrate to 10% of the original volume (1). This became known as old tuberculin (OT). Koch tried this unsuccessfully as a therapeutic agent, but in 1907 von Pirquet recognized its potential value for detection of persons infected with tuberculosis (2). The next year, Mantoux introduced the intradermal technique, which still bears his name (3). Old tuberculin proved unreliable and nonspecific because the filtrate was very heterogeneous. In 1934, Dr. Florence Seibert working at the Phipps Institute 279
280
Menzies
in Philadelphia developed a technique of extraction of protein from autoclaved tuberculosis bacteria grown on artificial media. Results with this purified protein derivative (PPD) proved much more reproducible and specific (4). After considerable work to standardize this material, a large quantity was carefully prepared by Dr. Siebert in 1939, termed PPD Standard, or PPD-S (5). By international agreement, since that time all tuberculin skin testing material produced must be bioequivalent to this standard lot. North American manufactured tuberculin test material, which is bioequivalent to PPD-S, will be referred to as PPD-T in this review. The final refinement of the tuberculin test, was the addition of Tween, a detergent that minimized the absorption of tuberculin protein by glass or plastic. This allowed prolonged storage and further improved the reproducibility of test results (6–9). Injection of tuberculin material intradermally into a person previously infected with M. tuberculosis will result in infiltration of previously sensitized lymphocytes circulating in peripheral blood. At the site of injection, CD4 and CD8 T lymphocytes will accumulate, as well as monocytes and macrophages. These release inflammatory mediators, which produce edema and erythema. Although there is increased blood flow, the locally increased metabolic activity of these inflammatory cells results in relative hypoxia and acidosis, which may be severe enough to lead to ulceration and necrosis (10). Although tuberculin reactions have often been equated with immune status, it has been well established that tuberculin skin test reactions and immunity are, in fact, independent phenomena (11–13), although both result from exposure and acquisition of infection. New molecular biology techniques (14) could prove useful to better understand these two phenomena and how they affect the tuberculin skin test. It would be of enormous benefit if we could learn how to distinguish tuberculin reactions that indicate immunity from reactions that indicate increased future risk of tuberculosis. II. Technical Aspects A. Administration of the Test
Tuberculin material, manufacturer, and technique of administration may affect tuberculin skin tests results. At the present time, the only accepted material for use in tuberculin testing is PPD. Manufacturers must ensure that each batch of tuberculin material is standardized using experimental animals infected with H-37RV strain against the original batch lot of PPD-S. There are two North American manufacturers: Connaught Laboratories (manufacturing Tubersol) and Parke-Davis (Aplisol). Earlier studies demonstrated that the Connaught product had significantly higher sensitivity when compared to the Parke-Davis product (8,15). Since that time, there have been a number of reports of high rates of apparent false-positive results using the Parke-Davis product (16–18). As a result, the Connaught
Tuberculin Skin Testing
281
product has been strongly recommended elsewhere (19), although in more recent studies, results with the two products have been closely comparable (20). In Europe, the Serum Statens Institute of Copenhagen, Denmark, developed a tuberculin test material termed RT-23. After considerable effort at standardization (21), this product is now accepted as a standard tuberculin by the World Health Organization (21,22) and is widely used outside of North America. In one comparative study, two tuberculin units (TU) of RT-23 had nearly identical sensitivity as 5 TU of PPD-S, although specificity was lower (23). The results of these two test materials are similar enough that results from studies using 2 TU of RT23 can be considered reasonably comparable to results of studies using 5 TU of PPD-T. Tuberculin test materials are commercially available in strengths ranging from 1 to 250 TU per test dose. Administration of 1 TU is not recommended because this preparation has a sensitivity of only 50% in children (24) and 80% in adults (25) with confirmed active tuberculosis, yet there is no evidence of reduced occurrence of adverse events (26). Higher strength formulations such as 100 or 250 TU are not recommended because virtually all subjects with sensitivity to nontuberculous mycobacteria will be positive (27), these reactions are more likely to revert later (28) and, as shown in Figure 1, there is no relationship of reactions to these higher dose tests and the likelihood of true tuberculosis infection (29).
Figure 1
Reactions to 250 and 5 TU of PPD-S and degree of contact with tuberculosis.
282
Menzies
Commonly used methods of tuberculin skin test administration are the Mantoux method of intradermal injection and multipuncture techniques such as the Tine test. Results of studies comparing the Mantoux with other techniques are summarized in Table 1. In general, multipuncture techniques have lower sensitivity: in young healthy volunteers, false-negative rates of up to 15% have been reported (30). Sensitivity can be improved by lowering the cut-point, but this will reduce specificity (31). Results of dual testing in the same subjects or dual readings of the same test are much less reproducible with multipuncture compared to Mantoux techniques (32,33). In a British study, clinically important differences were noted in 42 of 180 (23%) subjects who had repeat tine tests (32). Problems of the multipuncture devices include uneven coating of the tuberculin material on the tines (34) and difficulty of standardizing the technique of administration (30). Jet injectors have been used, particularly in surveys of young children, but the depth and amount injected is much less reliable so results are more variable (35). Based on this evidence, it can be strongly recommended that for all tuberculin testing a dose bioequivalent to 5 TU of PPD-S be administered using the Mantoux technique of intradermal injection. If by error injections are given subcutaneously, larger, more diffuse reactions will result (36), which are more diffi-
Table 1
Comparison of Mantoux with Other Tuberculin Skin Testing Techniques Population Comparison technique
Author (Ref.)
Year
Age (mean or range)
Badgder (31)
1962
All ages
1001
5 TU
Furcolow (33)
1966
36
5 TU
Fine (165) Wijsmuller (35)
1972 1975
54 Adults
670 100 589 915
5 TU 5 TU
Donaldson (166) Lunn (167)
1976
15–69
135
5 TU
1980
18–21
250
5 TU
Ackerman (168) Hansen (169) Rudd (170) Biggs (171)
1981
14
10 IU
1982 1982 1987
Adults Adults Adults
6239 2574 829 100 105
a
Mantoux taken as gold standard.
No.
Mantoux dose
5 TU 10 IU 10 TU
Type Tine (OT) 3mm 6mm Tine-OT Tine-OT J T injector—more variable than Mantoux amount injected both Tine-OT Tine-PPD Imotest-PPD (Merieux) Tine-PPD Imotest-PPD Tine-OT Imotest-PPD Imotest-PPD 4mm 2mm
Sensitivitya (%)
Specificitya (%)
96 78 98 95 98 73
73 84 92 83 82 —
84 90 67
— — 65
76 75 69 72 33 60
— — 98 94 90 85
Tuberculin Skin Testing
283
cult to read (37). Use of smaller needles will result in less pain, bruising, and bleeding (38) but may result in more leakage and therefore less reliable results (38). Although a wheal should be produced following intradermal injection, the size of this wheal is a poor estimate of the amount injected because it is affected by age and gender (22,39). Failure to inject the correct dose (e.g., from leakage) will result in smaller reactions (37) and so may lead to false-negative results. The site of injection is not important (37), although the inner or volar aspect of the forearm is generally used for convenience. The site of testing should be varied, especially with the two-step protocol, because repeated tests at exactly the same site may result in increased reaction size (40). B. Reading the Test
Timing and method of reading as well as experience of readers may affect results. Reading after 6 hours was suggested as indicative of active disease because 72% of 109 patients with smear-positive active tuberculosis had reactions of 5 mm after 6 hours compared to only 3.5% of 143 healthy volunteers (41). However, in a subsequent study, reactions after 6 hours were equally common in patients with inactive tuberculosis and other respiratory diseases and health-care workers with heavy exposure (42), i.e., this was a nonspecific phenomenon. Readings at 24 hours were compared to readings at 48 hours in another study. Using the 48-hour readings as the gold standard, readings at 24 hours had only 71% sensitivity and 9% false-positive rate (43). In another study of 308 adults with active tuberculosis (mean age 51 years), readings were made every day for 7 days following tuberculin testing. In total, 296 (97%) had positive reactions 48–72 hours following testing. Reading at 96 hours was almost as sensitive, but by day 7, 21% had reverted to negative (25). Among 380 elderly nursing home residents (mean age 75), 23 (19%) of those with positive reactions (10 mm) after 48 hours had reverted to negative after 7 days (44). On the other hand, 20 other residents with negative reactions at 48 hours had positive reactions after 7 days (44). When two-step testing is performed, reading the first tuberculin test after 7 days is suggested because a second test can be administered immediately for those with negative reactions. Although this approach is more practical, the clinical significance of reactions that are positive after one week but negative after 48 hours is unknown because all information regarding risk of tuberculosis is based on tuberculin reactions measured between 48 and 72 hours after testing. In summary, readings should be made 2–3 days following administration given the reduced sensitivity and uncertain interpretation of readings made later (22). Originally induration was defined by palpation. The ballpoint method was introduced by Sokal as a faster, more reliable technique (45). Correlation between these two reading techniques is very high (R 0.94) (46), and differences between readings are small (46–49), irregardless of reader experience (47,49). Over-
284
Menzies
all, the ballpoint technique appears to be slightly faster (48), more sensitive (48), and less variable (49). Self-reading by patients has resulted in clinically significant misclassification in 8.5% of Heaf tests (50) and 11% misclassification following Mantoux testing (43). In the latter study, of 525 patients with no tuberculin reaction, only 5 patients believed there was significant induration (specificity 99%). On the other hand, of 212 patients with reactions of 10 mm measured by a trained observer, only 79 believed there was any reaction (sensitivity 37%) (43). Underreading by patients was also reported by a New York hospital where only 1 of 18 patients with a positive tuberculin reaction correctly interpreted their reaction as positive (51). Table 2 summarizes the variability of tuberculin tests using the Mantoux technique. Standard deviation of readings and misclassification errors are considerably less within than between readers, although differences between readers should average less than 2 mm (22). In two studies (52,53) systematic differences between one reader and the others contributed the majority of variance and misclassification
Table 2
Variability of Tuberculin Test Results (Mantoux Test Only) Population
Author (Ref.)
Year
No.
Type
A. Variability of reaction: 2 tests in same subject Furcolow 1966 212 Mental hospital (33) patients Chaparas (172)
1985
1036 46
Reading Age (yr)
Misclassification (Pos. vs. Neg.)
Standard Deviation
36
—
Adults Adults
—
General
16–17
4
1.3–1.9 mm
Mental hospital patients
11–90
2
—
1.2%
20–60
7
—
9%
54 18–25
4 4
— 2.5 mm
770
6
2.3 mm
Adults
2a
—
11%
adults
2
2.7–3.5
12–23%
General TB patients
0–4 mm 5–9 mm 10 mm
92% 7% 1% 4.6% 0
B. Variability of reading: within readers Bearman (53) Furcolow (33)
1964
36
1966
670
C. Variability of readings: between readers Loudon 1963 53 Workers (173) Fine (174) 1972 189 General Erdtmann 1974 121 General (52) Perez Stable 1985 537 Nursing home (175) residents Howard 1988 806 General (43) Pouchot 1997 96 Health workers (176) a
Patient self-reading compared to trained health professional.
12% — 4.3%
Tuberculin Skin Testing
285
errors—a potentially correctable problem through further training and/or elimination of such readers. Another potential cause of reader error is terminal digit preference or rounding. This problem can result in substantial misclassification, particularly if there is conscious or unconscious bias on the part of the reader. This can be eliminated by use of simple measuring calipers, such as are used by mechanics or for sewing, which are available in most hardware stores for less than $2. Biological variation estimated from two simultaneous tuberculin tests is remarkably small given the inherent variability resulting from administration and reading. C. Adverse Reactions
Adverse reactions to tuberculin skin tests are rare. Vaso-vagal reactions can occur as with any injection. Immediate wheal and flare with a local rash was seen in 2.3% of allergy clinic patients (54). These reactions were associated with atopic history but not with positive tuberculin reactions at 48–72 hours. Lymphangitis has been reported following testing using Mantoux or Heaf techniques (55), usually associated with strongly positive tuberculin tests with severe blistering and/or ulceration at the site of injection. Severe anaphylaxis has been reported on one occasion following Mantoux testing. A patient with active tuberculous lymphadenitis developed shock with renal and hepatic dysfunction within hours of receiving a 1-TU dose of PPD-T (26). There have been two cases of anaphylaxis, one of them fatal (56,57), associated with tine testing. In the nonfatal case, serum IgE to PPD was undetectable and the authors believed that the gum used as an adherent to coat the tuberculin material on the tines was responsible (56). Anaphylaxis reactions are not related to true tuberculin reactions. In approximately 1–2% of patients with positive reactions, there may be severe blistering and even ulceration. Hydrocortisone cream is often given but was of no benefit in the only randomized controlled trial to assess its use (58). An undocumented history of a prior positive tuberculin test is not a contraindication to tuberculin testing because patient recall is often inaccurate, and severe reactions are not more frequent (59). There is no evidence whatsoever that tuberculin testing poses any risk in pregnancy (60) or that tuberculin reactions are influenced by pregnancy (61), although the manufacturers’ product monograph mentioned this as a potential precaution in past years (62). III. Simple Cognitive Aspects: False-Negative and FalsePositive Reactions Interpretation of any test in clinical medicine requires understanding of the causes and likelihood of false-negative and false-positive results in the population being tested.
286
Menzies A. False-Negative Tests
As summarized in Table 3, tests may give false-negative results because of technical problems in the preparation or storage of material as well as administration or reading of the test. Most of these problems can be avoided by meticulous technique in tuberculin testing and reading. Proper storage is important because test material will deteriorate if exposed to light, heat, or if frozen. However, some misclassification is inevitable because of the variability related to differences in administration, biological response, and reading. Biological cause of false-negative results are more difficult to avoid. Falsenegative tests may occur in patients with active tuberculosis disease: estimates range from 5–8% in cross-sectional studies of patients already on treatment (63) to 17% (7) at the time of diagnosis and up to 30% among elderly patients (64). False-negative tests in TB patients are associated with more advanced forms of tuberculosis (65), malnutrition (66), and elevated serum creatinine levels (67). Malnutrition and associated immunological changes have also been implicated in the temporary anergy seen in refugees from Southeast Asia (68). An important cause of false-negative reactions is HIV infection. The proportion of false-negative reactions in dually infected (HIV and TB) patients ranges Table 3 Causes of False-Negative TST Technical Material
Administration
Reading
• Poor-quality production • Inadequate dose (e.g., 1 TU) • Improper storage (exposure to light/heat) • Material not injected • Too long in syringe • Inexperienced or biased reader • Error in recording • Too early, too late
Biological Viral infection
• HIV • Other infections, measles, mumps, chickenpox • Live virus vaccination
Bacterial or fungal infection Tuberculosis
• Extensive disease
Malignancies Therapy Age Other
• Miliary or pleural forms • Lymphoma, leukemia • Corticosteroids, chemotherapy • Newborn, elderly • Malnutrition, renal failure, sarcoidosis, stress, surgery
Tuberculin Skin Testing
Figure 2
287
Effect of HIV infection on prevalence of TST reactions.
from 15–28% in those with CD4 counts greater than 400–500 up to 100% in patients with CD4 counts less than 200 (69–72). An important observation is that while the proportion of HIV-seropositive patients with a positive TST diminishes, the pattern of reactions in the populations have not changed appreciably (Fig. 2), even as the CD4 count falls progressively (71,73–75) lower (Fig. 3). It appears that rather than progressive diminution in size, there is simply a greater proportion of individuals with negative tests as the CD4 count falls. This suggests that the tuberculin skin test response may be an all-or-nothing phenomenon in HIV-infected individuals and that once immunity falls below a certain threshold the tuberculin response is lost. Another important cause of false-negative tests is older age (76). In North American populations, the proportion with a positive tuberculin reaction increases up to the age of 65, after which it declines. As seen in Figure 4, although the number with reactions diminishes with older age, the size of reaction does not change—a finding confirmed elsewhere (77). These cross-sectional findings have been confirmed in longitudinal studies, which have demonstrated reversion of positive tuberculin reactions in elderly nursing home residents (44,78,79). As with HIV-infected patients, it seems that tuberculin reactions in the elderly do not di-
288
Figure 3
Menzies
Effect of HIV infection and CD4 counts on tuberculin reaction.
minish gradually but “turn off,” suggesting that there is some threshold reached during aging. The trigger or threshold for reversion (and presumably conversion) has not been explored. Anergy testing, reviewed extensively elsewhere (80), has been suggested for the assessment of individuals with negative tests (81). Reactions to antigens such as mumps, Candida, diphtheria, or tetanus are seen in almost all healthy adults (82). Therefore, an individual who does not react to any of these antigens may have a false-negative tuberculin test. On the other hand, a tuberculin test can be considered true negative if an individual reacts to one or more of these common antigens. As shown in Figure 5, among HIV-infected patients with negative tuberculin tests, the incidence of tuberculosis was significantly higher in those who were anergic compared to those who were not (83–85). In another study, negative tuberculin tests were strongly associated with anergy (69). However, in individual patients results of anergy testing can be very misleading, because anergy status may change over time independent of changes in tuberculin status (72,86,87). Anergy testing may be useful for epidemiological studies in populations with high HIV sero-prevalence but is not useful in populations with low HIV sero-prevalence (88) and is no longer recommended for management of individual patients (89).
Figure 4 dents.
Effect of age on initial tuberculin reactions in Arkansas nursing home resi-
Figure 5 results.
Incidence of active tuberculosis in HIV-infected, by tuberculin and anergy test
289
290
Menzies B. False-Positive Tests: BCG Vaccination
Of the 1.2 million infants born each year worldwide, approximately 88% receive BCG (bacille Calmette-Guérin) vaccination (see Chap. 19). BCG vaccination of tuberculin negative individuals will almost invariably result in tuberculin conversion within 4–8 weeks. The size of reactions following BCG vaccination may be affected by the vaccine manufacturer (90), dose (91), as well as method of administration (91,92). On occasion, individual strains produced by different manufacturers have been associated with significantly fewer tuberculin conversions (11,90). Generally, such strains are discarded because regulatory agencies in most countries require that BCG strains induce tuberculin conversion in over 90% of recipients. This requirement is based on the belief that a positive tuberculin reaction correlates with immunity, a belief based on observations in the preantibiotic era that incidence and mortality from tuberculosis was considerably higher in nursing students who were initially tuberculin negative (93–95). However, this phenomenon was actually the result of the protective effect of prior tuberculosis infection (96). There is convincing evidence from many studies that postvaccinal tuberculin reactions have no relationship to protective efficacy (11,97–99). The continuing insistence on the part of regulatory agencies on demonstration of tuberculin reactivity following BCG vaccination is primarily because there is no alternative practical way to measure immunity. From a tuberculosis-control program point of view, it would be much more practical if BCG vaccination conferred immunity yet had no effect on tuberculin reactions. Although virtually all recipients will have positive tuberculin reactions within 2 months of BCG vaccination, these reactions will wane over time. There have been numerous studies of the effect of BCG vaccination on tuberculin reactions, but many of these relied on the presence of BCG scars, which may not form in 20–25% of recipients (100,101). Also, the effect of BCG vaccination on tuberculin reactions will be overestimated in populations with a high prevalence of infection with tuberculosis or nontuberculous mycobacteria (101–104). As summarized in Table 4, virtually all subjects who received BCG vaccination in infancy will have reverted to negative within 5 years. This may reflect the relative immaturity of the immune system in infancy (105), although protective efficacy is, if anything, higher (102,106). Of those vaccinated at an older age, tuberculin reactions are larger and wane more slowly, although after an interval of more than 10 years, further waning does not appear to occur and tuberculin reactions persist in a subgroup of 15–25%. The size of tuberculin reactions in this subgroup is similar to the size of reactions in tuberculosis-infected persons, suggesting that in this group, as well, tuberculin reactions represent an all-or-nothing phenomenon and may be genetically determined (107,108). In the great majority of countries with intermediate or high incidence of tuberculosis, BCG vaccination is given routinely at birth and often repeated in primary school. As shown in Figure 6, among foreign-born schoolchildren and young
Tuberculin Skin Testing Table 4 Author (Ref.) Lifschitz (177) Margus (178) Joncas (179) Karalliede (180) Sepulveda (181) Friedland (182) Menzies (183) Comstock (184) Bahr (102) Horowitz (90) Joncas (179) Menzies (183) Margus (178)
291
Effect of BCG Vaccination on TST in General Population Samples Year of study
Setting
No. of subjects
Age vaccinated (yr)
Age tested (yr)
TST 10mm (% pos.)
1965
Arizona
250
0–1
1–6
0
1965
Israel
758
0–1
1–2
7
1975
Montreal
68
0–1
1
5
1985
Sri Lanka
106
0–1
1
18
1988
Chile
40
0–1
6
10
1990
Southern Africa
85
0–1
1
/2–5
13
1992
Montreal
162
0–1
11–17
1.7a
1971
129
1–18
18–21b
16
1987
Southern United States Lebanon
1200
5
10–14
35
1972
Denmark
955
6
11
60–80
1975
Montreal
165
6
7
1992
Montreal
469
6–8
1965
Israel
241
13
73
15–25
23
14
14
a
No significant differences compared to 1064 nonvaccinated schoolchildren of same age an socioeconomic status. b Minimum interval between BCG and TST was 8 years.
adults in Montreal, history of BCG vaccination appeared to be an important cause of reaction in subjects from low-incidence countries but was less and less important with greater incidence of tuberculosis in their country of origin (109). C. False-Positive Tests: Nontuberculous Mycobacteria
Nontuberculous mycobacteria (NTM) exist in soil and water in the environment, particularly where the climate is warm and moist (110–113). The mechanism of
292
Figure 6
Menzies
Effect of BCG vaccination on initial tuberculin skin test reactions.
acquisition of infection or sensitization to NTM antigens is unclear. However, as summarized in Table 5, in many parts of the world, a high proportion of individuals will have sensitivity to at least one NTM antigen by the age of 20. Although much less pathogenic than M. tuberculosis (114), these NTM are important because they may result in disease in humans, particularly lymphadenitis in young children, pulmonary disease in adults, and disseminated disease in patients with advanced immune suppression (115,116). Antigens purified from the nontuberculous mycobacteria (NTM antigens) have been used for the diagnosis of patients with disease due to these mycobacteria. Sensitivity and specificity vary considerably between studies and NTM antigen cannot, as yet, be recommended for routine clinical use in the differentiation of nontuberculous mycobacterial disease (117–120). The NTM are also important because of the similarity of NTM antigens to tuberculous antigens resulting in cross-reactivity when tuberculin testing. In experimental studies, animals infected with different mycobacteria developed the largest reactions to antigens prepared from that specific mycobacteria (121,122). They also manifested reactions to antigens from other mycobacteria, although these were smaller. As shown in Figure 7, the distribution of reactions to RT-23, PPD-S, or PPD-T in different parts of the world (63) could be reproduced by test-
Tuberculin Skin Testing
293
ing with these antigens in groups of guinea pigs with varying proportions of uninfected, infected with M. tuberculosis, or infected with nontuberculous mycobacteria (122). As shown in Table 6, the relative importance of NTM as a cause of falsepositive tuberculin tests depends upon the frequency of sensitization to nontuberculous mycobacteria, which is determined primarily by climate and geography, and the occurrence of tuberculosis infection, which is low and declining rapidly in many countries. If sensitivity to NTM remains stable and prevalence of tubercu-
Table 5 Prevalence of Positive Reactions to Nontuberculous Mycobacterial Antigens (Non–BCG-Vaccinated Only) Positive reactions (5 mm)
Population Author, year (Ref.) Edwards, 1958–65 (147) Bleiker, 1965–70 1980–85 (185) Jeanes, 1967 (186) Grzy, 1967 (27) Paul, 1975 (187) Karditjo, 1985 (188) Lind, 1986 (189) Menzies, 1987 (109) Ly, 1989 (190) a
Country
Type
Age (yr)
No.
Antigen
No.
(%)
90,935
33
712 2,152 21
5
817 1782
15 7
PPD-Be PPD-Ge PPD-Aviumc
426 538 86 213
11 19 18 62
PPD-Scrof d
30
88
PPD-Bb
United States
Military recruits
17–22
275,558
Netherlands, Delft
Students students
7–14 7–14
13,546 10,312
PPD-Scrof a PPD-Scrof a
Canada
Students
15–17
5,552 24,763
PPD-Be PPD-Ge
Canada, British Columbia Kenya
Students
14–19
Students
6–10 11–17
3,917 2,884 477 344
Indonesia
Healthy adults
21
34
Sweden
Students
8–9
1,368 1,451
RS10a RS15a
442 554
32 38
Canada, Montreal
Students foreign-born
11–17 11–25
3,710 875
PPD-Be PPD-Be
122 57
3 7
Vietnam
Students
7–19
153 155
56 36
37 23
PPD-Aviumd PPD-Scrofd
Serum Statens Institute, Copenhagen — RS10 from M. Avium, RS15 from M. scrofulaceum. U.S. Public Health Service Laboratories — PPD-B, PPD-G. c Prepared in London from organisms isolated from soil/water in Uganda. d Prepared in London from respective organisms. e Connaught Laboratories — PPD-B from M. intracellulare and PPD-G from M. scrofulaceum. b
294
Menzies
Figure 7 Reactions to PPD-S among populations of guinea pigs with varying proportions of mycobacterial infections (top and bottom left), and in schoolchildren in Pakistan (top right), and North Carolina (bottom right). (From Ref. 122.)
losis infection declines, the relative importance of NTM will increase. Reactions to PPD-T in persons infected with NTM are less severe than in persons infected with M. tuberculosis. Therefore, increasing the cut-point for a positive test will improve the specificity. This is the rationale for the recommendation of a 15-mm cut-point in United States (123) where the expected prevalence of NTM sensitivity is high (at least in the southern United States) and true tuberculosis infection low. It should be remembered that the 15-mm cut-point for a positive test is close to the mode of tuberculin reactions in those with true infection (63), so adoption of this cut-point will improve specificity, but the sensitivity of the tuberculin test will be reduced to approximately 50%. In experimental animals infected with NTM, the proportion demonstrating cross-reactivity to tuberculin antigens was reasonably constant (122). One would predict that this should also be true in human populations, although the ratio of NTM reactions to false-positive tuberculin reactions varies considerably (Table 6). However, the age and ethnic origins of populations studied varied consider-
295
3710
875
8–9
11–25
Sweden
Montreal (Can.-born)
Montreal 11–25 (Foreign-born)
1,368 1,451
542
15–19
Quebec
5,552 24,763
No.
15–17
Age
Canada
Setting
Population
PPD-B
PPD-B
RS10 RS95
Battey
PPD-B PPD-G
Antigenb
93
103
442 554
30
817 1782
57
34
140 192
9
N/A N/A
127
80
81 80
9
52 246
5 mm 10 mm Total (N) (N) N
Reactions to NTMa
54
15
58 61
2
19 128
42%
19%
72% 76%
22%
37% 52%
NTM PPD-T (N) (%)c
5–9 mm
393
90
11 6
12
93 299
0
9% 21%
16
2
4%
2%
9 82% 6 100%
0
8 64
Total NTM PPD-T N (N) (%)c
10 mm
Reactions to PPD-T (for MTB)
Effect of Nontuberculous Mycobacteria on Tuberculin Reactions (Non–BCG-Vaccinated Populations)
b
If reaction to NTM was smaller than simultaneous reaction to PPD-T, then it was assumed to represent a cross-reaction and considered negative (0MM). Antigens: PPD-B, prepared from M. intracellulare (Connaught Labs, Toronto, Canada); PPD-G, from M. scrofulaceum (Connaught Labs, Toronto, Canada); RS10, prepared from M. avium (Statens Serum Institute, Coppenhagen, Denmark); RS95, prepared from M. scrofulaceum (Statens Serum Institute, Coppenhagen, Denmark); Battey, prepared from M. intracellulare (Statens Serum Institute, Coppenhagen, Denmark). c Percent of subjects with reactions to PPD-T of 5–9 mm or 10 mm which may have been due to cross-reactivity to NTM antigens because they had larger simultaneous reactions to the NTM antigens.
a
Jeanes, 1967 (186) Frappier, 1975 (191) Lind, 1986 (189) Menzies, 1987 (192) Menzies, 1987 (109)
Author, year (Ref.)
Table 6
296
Menzies
ably, and the nontuberculous mycobacterial antigens used have never been standardized (124). IV. Complicated Cognitive Aspects: Interpreting Tuberculin Tests A. Expected Prevalence of True Positive Tests (Tuberculosis Infection)
As shown in Table 7, the prevalence of positive tuberculin tests in non–BCG-vaccinated populations in North America varies widely. Prevalence is very low in schoolchildren and young adults, although it is substantially higher in certain ethnic minorities (125–127). Particularly high rates of infection are found among the urban poor such as intravenous drug users (IVDU), persons receiving social assistance (128,129), and homeless persons (130,131). The elderly also have high rates of positive tests attributable to the much higher risk of tuberculous infection during their youth. Among the foreign-born, prevalence of infection is correlated with incidence of tuberculosis in their country of origin and age of immigration (Fig. 8). Another group with high prevalence of infection is contacts of active cases as summarized in Table 8. In these studies risk of infection was consistently higher if the index case was smear positive or if the contact was close. However, absoTable 7 Prevalence of Positive Tuberculin Reactions (Results of Mantoux Testing with PPD5TU or RT23-2TU) Author, year (Ref.)
Country (city)
Population
Ethnic group
Age, mean (SD) or range (yr)
No. tested (N)
TST positive (10 mm) No.
%
A. Native-Born, Non–BCG-Vaccinated General Population Comstock, 1958–69 (125) Reichman, 1973–74 (193) Cross, 1980–86 (194) Menzies, 1987 (192) Barry, 1987 (126) Trump, 1990 (127) Menzies, 1990 (146)
United States
Military recruits
Whites, blacks
17–22 17–22
1,125,193 70,550
42,757 8,749
3.8 12.4
United States (New York)
Workers, Board of Education Military recruits
White, black, Hispanic All
20–68 20–68 20–68 17–22
37,224 10,364 2,744 618,074
3,094 2,384 706 8,962
8.3 23 26 1.5
Canada (Montreal)
Schoolchildren
95% white
11 (1) 16 (2)
1351 628
17 18
1.3 2.9
United States (Boston)
Schoolchildren
United States
Military recruits
Canada (Montreal)
University students
White, black, Hispanic White, black, Hispanic 95% white
16 (2) 17 (2) 17 (2) 17–24 17–24 17–24 21 (2)
661 1235 457 1,588 386 167 837
9 60 29 12 20 9 15
1.4 4.9 6.4 0.8 5.2 5.4 1.8
United States
Tuberculin Skin Testing
297
Table 7 Continued Author, year (Ref.)
Country (city)
Population
Ethnic group
TST positive (10 mm)
Age, mean (SD) or range (yr)
No. tested (N)
No.
%
3,788
853
23
B. Prevalence in Special Populations Reichman, 1973 (129) Several, 1982–89 (44,144,195) Friedman, 1984 (128) Gzrybowski, 1985 (196) Paul, 1993 (131) Zolopa, 1994 (130)
United States (New York)
Methadone clinic
All
N/A
United States Canada Holland United States (New York)
Nursing home residents ETOH/Drug users, welfare Urban poor
All
White, black, Hispanic White males
50–74 75–84 85 36 (9) 36 (9) 36 (9) 15–34 35–54
340 559 643 97 477 311 170 254
155 156 112 17 158 95 28 113
46 28 17 18 33 31 16 44
Canada (Vancouver) United States (New York)
Homeless
All
35 (9)
104
72
69
United States (San Francisco)
Homeless
All
36
843
270
32
United States
Southeast Asia
Refugees
All ages
9328
3300
35
United States
Southeast Asia
Refugees
21
954
424
44
Netherlands
Southeast Asia
Refugees
18
221
86
39
United States
Southeast Asia
Refugees
11–19
77
40
52
Britain
India/ Pakistan
New immigrants
0–14
231
30
13
Pakistan
Afghanistan
Male refugees
8 (1)
1358
187
14
Canada
All countries
Refugees
21
865
329
38
Canada
TB endemic
Schoolchildren, 21 (3) workers
780
288
37
United States
90% from Mexico
Immigrant applicants
All ages
4,840
2039
42
Canada
All countries
Schoolchildren 13 (5)
720
162
23
C. Foreign-Born Populations Nolan, 1980–81 (149) Morse, 1980 (197) Veen, 1981 (68) Fitzpatrick, 1981–85 (198) Omerod, 1983–88 (199) Spinaci, 1985 (200) Godue, 1987 (201) Menzies, 1987–88 (109) Blum, 1988 (202) Yuan, 1992 (203)
Figure 8 Prevalence of positive tuberculin reactions in foreign-born according to age at which immigrated. Immigrants in Montreal grouped into those from regions with intermediate (TB inter) or high (TB endemic) rates of TB.
Table 8 Prevalence of Positive Tuberculin Reactions in Contacts of Active Cases (All Cases Culture-Confirmed Active Pulmonary TB) Contacts Author, year (Ref.)
TST positive
General population TST (%)
Country (population)
Age range
Tested (yr)
(N)
(%)
England (general)
0–14
225
164
73
38
All Ages
3,330
1732
52
13a
0–19 0–19 0–14
2,501 854 115
1209 466 80
48 55 70
21 41 1
0–16
155
37
24
1
A. Smear-Positive Cases Close/Household Contact Zwanenburg, 1949–53 (204) Zaki, 1965–72 (205) Grzybowski, 1966–71 (206) Van Geuns, 1967–69 (207) Karalus, 1980/84 (208)
New York City (general) Canada (white) (aboriginal) Holland (general) New Zealand (general)
Tuberculin Skin Testing
Table 8
299
Continued Contacts
Author, year (Ref.) Casual Contact Grzybowski, 1966–71 (206) Van Geuns, 1967–69 (207) Karalus, 1980–84 (208)
TST positive
General population TST (%)
Country (population)
Age range
Tested (yr)
(N)
(%)
Canada (white) (aboriginal) Holland (general)
0–19 0–19 0–14
5,364 654 1,733
1630 327 519
30 50 30
21 41 1
0–16
898
10
1.1
1
0–14
96
44
46
38
All ages
1096
437
40
13a
0–19 0–19 0–14
1340 527 128
399 237 45
30 45 35
21 41 1
0–16
146
2
1.4
1
0–19 0–19 0–14
2270 413 602
442 161 141
20 39 23
21 41 1
0–16
307
0
0
1
New Zealand (general)
B: Smear-Negative, Culture-Positive Cases Close/Household Contact Zwanenburg, 1949–53 (204) Zaki, 1965–72 (205) Grzybowski, 1966–71 (206) Van Geuns, 1967–69 (207) Karalus, 1980–84 (208) Casual Contact Grzybowski, 1966–71 (206) Van Geuns, 1967–69 (207) Karalus, 1980–84 (208) a
England (general) New York City (general) Canada (white) (aboriginal) Holland (general) New Zealand (general) Canada (white) (aboriginal) Holland (general) New Zealand (general)
General population estimate for this study from Ref. 193.
lute levels of risk have been estimated in relatively few studies that measured the prevalence of infection in noncontacts from the general population. B. Predictive Value of a Positive Initial Tuberculin Test
As shown in Table 9, BCG vaccination and nontuberculous mycobacteria have important effects on the predictive value when the expected prevalence of true in-
None
Age of 6
Age of 6
Southern United States
Western Europe
Southeast Asia (newly arrived)
Screening Casual contact Close contact Screening Casual contact Close contact Screening Casual contact Close contact Screening Casual contact Close contact
Clinical situationa 2 40 2 10 2 2 40 2 10 2 2 40 2 10 2 50 70 (40 50) 55 (10 50)
True positive 2 2 2 6 6 6 4 4 4 6 6 6
NTM — — — — — — 15 15 15 15 15 15
BCG
False positive
Expected prevalence of reactions (%)b
50 95 86 25 88 67 10 69 39 83 92 85
Predictive value of a positive test (%)
b
Clinical situation: screening means test done in absence of exposure/risk factor; contacts are of smear-positive, culture-positive case of TB. Expected prevalence is prevalence of TB infection in 20-year-olds from general population plus additional prevalence infected depending on clinical situation (see Table 7 for prevalence in population and Table 8 for prevalence according to the clinical situation).
a
None
Northern United States or Canada
History of BCG vaccination
Predictive Value for TB Infection of a Positive Initial TST (10 mm) in a 20-Year-Old Adult
Subject born in
Table 9
300 Menzies
Tuberculin Skin Testing
301
fection is low, such as in screening situations. On the other hand, when the expected prevalence of tuberculous infection is high, such as in close contacts of smear-positive cases or immigrants from tuberculous-endemic areas, then the predictive value of a positive tuberculin test is high even in those with BCG vaccination and possibly sensitized to nontuberculous mycobacteria. In these situations, the effects of BCG vaccination and sensitivity to NTM can be ignored. C. Risk of Tuberculosis for a Given TST
Interpretation of the tuberculin skin test (TST) as true positive is only part of the evaluation. The second step is the assessment of risk of development of disease. As shown in Table 10, the likelihood of developing tuberculosis disease varies by several orders of magnitude in different populations with positive TST. Interestingly, the incidence of tuberculosis was lower among reactors in the Danish study (132,133) than the incidence in some tuberculin-negative groups in other studies (125,134,135). Use of this Danish data would substantially bias cost-benefit or risk-benefit analyses because these results likely represent an underestimate of the likelihood of disease in most tuberculin reactors. D. Serial Tuberculin Testing: Boosting, Conversion, and Reversion
Repeated tuberculin testing can result in larger reaction sizes because of nonspecific variation or as a result of boosting conversion. Nonspecific increases occur because of differences in administration, reading, and minor variation in response. The combined effect of these factors result in standard deviation of results of 2–3 mm (Table 2). Therefore, random variation should result in increased reactions of less than 6 mm (two standard deviations) in 95% of all those tested (136). Increases of 6 mm or more, therefore, should represent a true biological phenomenon but could be conversion or boosting. Both terms refer to a newly positive tuberculin test after an initially negative test. Boosting is defined as recall of immunity in the absence of new infection, whereas conversion is defined as development of new hypersensitivity to mycobacteria following new infection either with tuberculous or nontuberculous mycobacteria, including BCG vaccination. This distinction is not merely academic—boosting is associated with a substantially lower risk of tuberculosis of as little as 0.05% annually, whereas conversion has been associated with annual incidence of tuberculosis of 4% in adolescents (137) or 6% in contacts of smear-positive cases of active TB (138). The boosting phenomenon, first noted among BCG vaccine recipients in 1955 (139), is seen when there has been mycobacterial sensitization many years earlier. It is believed to occur when there are too few sensitized lymphocytes in circulation to produce a significant local response following the initial intradermal injection of tuberculin material. However, this injection results in a rapid increase
302
Menzies
Table 10 Risk of TB According to TST Reactions and Other Factors Risk group author, year (Ref.) HIV-infected Selywn, 1989 (209) Moreno, 1993 (85) Guelar, 1993 (83) Antonucci, 1995 (84) Abnormal chest x-ray Hong Kong Chest Service, 1992 (210) Nolan, 1980 (149) IUAT, 1982 (211)
Population
Country
Group
Follow-up period (yr)
TST (criterion)
Annual incidence of TB (per 100,000)
49 168 108 268
5 5 5 5b
7,900 300 10,400 8,290
87 733
5a 5b
11,100 2,350
197 2,498
5 5b
5,420 2,130
2–5
116
10c
5,400
5
185
10
650
5
6,990 4,701 2,094
6
286 232
12
286,000
6
United States
IVDU
2–5
Spain
IVDU
2–6
Spain
IVDU
1.3 (1)
Italy
IVDU
2
Hong Kong
Elderly men With silicosis
United States
Vietnam refugees
Eastern Europe
Inactive TB Overall Lesions 2cm Lesions 2cm
Horwitz, Denmark 1969 (132) Contacts and abnormal chest x-ray Veening Netherlands (138) Recent conversion Sutherland Britain (137) Normal chest x-ray, no other risk factor Comstock, Alaska 1967 (212) Nolan, United States 1980 (149) Palmer, United States 1968 (134) Comstock, United States 1974 (125)
Young adults Suspicious Calcified
Contacts of S 128 cases First year Next 3 years Adolescence
Inuit
2
5.8
Vietnam refugees
5
Military recruits
4
Military recruits White Black Asian
4
Number
426 710 48
≥5 7,031 2,521 2,170
5 20
2600 4250
570 275
5 5
972 378
3,115 6,028
10 10
133 10
12 1–11 0
377 110 36
10 10 10
79 93 196
1,082,336 62,027 8,238
Tuberculin Skin Testing
303
Table 10 Continued Risk group author, year (Ref.)
Population
Country
Group
Follow-up period (yr)
Ferebee, 1959 (135)
United States
Mental institution patients
Comstock, 1974 (213) Horwitz, 1969 (132)
Puerto Rico
Children
Denmark
Young adults
Number
10
18–20
82,269
12
286,000
TST (criterion) T1 10 T1 5–9 T2 10 T2 5 6d
6e
Annual incidence of TB (per 100,000) 122 82 66 19 90
23
a
Excludes those still on INH therapy. Anergic and nonanergic combined. c 94% had reactions of 10 mm to 1 TU of RT23. d Tested with 1 or 10 Tu RT–20/2 22. e Tested with 10 Tu. b
in the population of sensitized lymphocytes in circulation, so that a second test as little as a week later will produce a much larger reaction. Boosting is maximal if the interval between the first and second test is between 1 and 5 weeks (135,140,141) and is significantly less frequent if the interval is only 48 hours (142) or more than 60 days (141), although it can be seen up to 2 years after a first tuberculin test (139,142,143). As shown in Table 11, the boosting phenomenon has been demonstrated in almost all populations. The prevalence is usually less but is roughly proportional to the prevalence of initial tuberculin reactions in the same populations. In elderly patients, boosting may occur after a third (78) or even a fourth (144) sequential test. This has also been described in a group of malnourished Southeast Asian refugees (68). As shown in Table 12, boosting is strongly associated with BCG vaccination at all ages. As shown in Figure 9, among foreign-born subjects history of BCG vaccination was a more important cause of boosting than country of origin (109). In a study of persons sensitized to NTM antigens, only 1–4% had significant reactions to a first test with 5 TU of PPD-T, compared to 12–13% who demonstrated boosting after a second test with the same antigen (Table 13) (145,146). Based on this, it could be predicted that of young adults in the southern United States, 70% of whom will be sensitive to NTM antigens (147), only 1–3% will have positive initial reactions to PPD-T but 7–9% will demonstrate
304
Menzies
Table 11 Prevalence of Positive Initial and Second TST from Two-Step Testing Author (Ref.)
Population Health-care workers
Nursing home residents
Hospital patients HIV-infected IVDU Foreign-born
No. subjects undergoing T1
Setting
Percent with positive Initial testa
Second testb
Thompson (142)
United States
750
N/A
5.91
Bass (143) Valenti (214) Menzies (146) Gross (215) Richards (145) Slutkin (44)
Alabama Rochester, NY Montreal Maryland Chicago San Francisco
N/A 416 951 2558 267 411
8.2 3.1 2.2 3.8 2.6 35
8.31 01 2.51 0.33 6.61 61
Gordin (78)
San Francisco Washington W. Virginia Tennessee Holland
1726
28
141
510 223
30 29
190 141
Boston Boston United States Uganda United States
323 162 709 345c HIV 900 HIV 95 211 2469 323 524 221
26 12 N/A 71 13 13 44 36 32 46 39
61 61 2.72 292 83 122 311 31 161 43 183
Alvarez (216) Van den Brande (144) Barry (217) Burstin (218) Webster (219) Hecker (220) Lifson (221) Morse (222) Cauthen (141) Menzies (109) Morse (197) Veen (68)
New York State United States Montreal New York State Netherlands
Initial test—% based on number undergoing T1, considered positive if 10mm. Second test—% based on number undergoing T2, considered positive if: 0—no definition; 1—▲ 6 10; 2—T1 5, T2 5; —T1 10, T2 10. c Number extrapolated from figures given in paper. a
b 3
Table 12
Effect of BCG Vaccination on the Booster Effect in Two-Step Tuberculin Testing
Author (Ref.)
Year
Sepulveda (181) Friedland (223) Sepulveda (224) Menzies (146)
1988 1990 1990 1994
a
Setting Chile Southeast Africa Chile Montreal
No. of subjects 36 102 73 380 210
Age vaccinated (yr) 0–1 0–5 0–14 0–1 2–8
Definitions of Booster: T1 10mm; T2 10mm and increased by at least 6mm.
Age tested (yr)
% with Boostera
6 1–14 19–22 17–25 17–25
31 16 26 8 15
Tuberculin Skin Testing
Figure 9
305
History of BCG vaccination on reactions to second tuberculin test (boosting).
boosting—remarkably close to observed results in health-care workers in Alabama (143). There has been considerable debate regarding the definition of boosting. This debate seems pointless as there is no evidence that the size of the boosting reaction determines prognosis (except if one is using size to distinguish boosting
Table 13 Effect of Non Tuberculous Mycobacteria on the Booster Phenomenon in 2-Step Tuberculin Testing Author (Ref.) Richards (145) Menzies (146) a
Year
Place
No. tested
1979
Chicago
1994
Montreal
No. response to NTM a
Sensitive to NTM
N
% Boosting
N
% Boostinga
213
110
1
103
13
277
252
1.6
25
12
Initial PPD-T (for MTB) 10mm. Second PPD-T 10mm and increased by at least 6mm.
306
Menzies
from conversion—see below). A simple and practical definition is that the second test is positive if induration is 10 mm or greater. Subjects with such a result should be referred for medical evaluation including a chest x-ray and not undergo further tuberculin testing. If the chest x-ray is normal and there are no associated factors that increase the risk of tuberculosis reactivation, then preventive therapy is probably not warranted. This is because a positive second TST is much less likely to represent true infection (141,146) and because in two longitudinal surveys, the risk of tuberculosis was lower in subjects with a positive second TST compared to subjects with a positive initial TST from the same population (135,148). It must also be remembered that in several large-scale longitudinal surveys, the risk of tuberculosis was very low among those whose initial TST was less than 10 mm (125,149). Boosting is best distinguished from conversion on clinical grounds. One can confidently attribute an increase in reaction size to boosting when the increase in reaction is seen after an interval of 1–5 weeks and there has been no possibility of exposure, such as a health-care worker undergoing preemployment testing. On the other hand, conversion can be confidently stated to have occurred following BCG vaccination in a previously tuberculin-negative individual or in a situation of high risk of exposure, such as in an outbreak investigation or a close contact of a highly contagious index case. One can also be more confident that an increased reaction is due to true conversion if several prior tuberculin tests were negative, particularly if two-step tuberculin testing was performed (143). But in many situations, it is difficult to distinguish conversion from boosting on clinical grounds alone. In these situations, the size of the second reaction and/or the increase in size can be used, although many conflicting size criteria have been recommended, i.e., increases of 10 mm (150,151), 12 mm (152), 15 mm (123), and 18 mm (153). The last three criteria are based on cross-sectional studies in elderly subjects (152) populations with high prevalence of BCG vaccination and/or NTM (153,154). These studies did not fully account for the possibility of boosting, which may have influenced the findings (see Tables 11–13). At the present time it is difficult to recommend any one cut-point to define conversion. The criterion should be lowered for young children or adolescents, close contacts, and immunocompromised hosts, because they have increased risk of disease. The cut-point should also be lowered if there have been two or more negative tuberculin tests in the past—particularly if prior two-step testing has been negative. As with initial tuberculin testing, tuberculin conversions should be interpreted in light of the likelihood of true conversion as opposed to boosting and the likelihood of disease, if truly infected, as well as risks of preventive therapy in a particular patient. Another important issue is the interval between acquisition of infection and tuberculin conversion, which determines the interval between the first and second
Tuberculin Skin Testing
307
test in contact investigations—the so-called window period. Traditionally, this has been considered to be 12 weeks (116), but all available evidence from BCG vaccination and natural infection points to a shorter interval. Following BCG vaccination, all but one of 120 recipients had TST reactions of 11 mm within 6 weeks (155). In a separate group of 163 BCG recipients, all had TST 5 mm in less than 4 weeks (155). In animals experimentally infected with M. tuberculosis, all developed a positive TST within 2–3 weeks if the bacillary load was small (156), as it usually is in natural infection. Following inadvertent vaccination with M. tuberculosis (the Lübeck disaster), tuberculin reactions were positive in all children within 3–7 weeks (157). As shown in Figure 10, the interval from exposure to development of clinical illness accompanied by a positive tuberculin test averaged 37 days and ranged from 19 to 57 days in 127 well-documented cases (158–160). If the interval from infection to conversion is never more than 8 weeks, then the window period for contact investigation could be shortened to 8 weeks. This would mean that new conversions among high-risk contacts would be detected one month sooner. A more important advantage is that this could simplify the contact investigation of low-risk casual contacts and substantially reduce the
Figure 10 Interval from infection to tuberculin conversion in 127 cases with documented time of exposure. (From Refs. 158–160.)
308
Menzies
occurrence of false-positive conversions. As shown in Table 14, when two sequential tuberculin tests are done, boosting is much more likely to account for apparent conversion in casual contacts in populations where BCG or NTM sensitivity are common. This results in unnecessary medical and radiological evaluation as well as potentially unnecessary therapy for these individuals. Also, the resultant overestimate of conversion may result in further extension of contact investigation. In most situations, 4–6 weeks are needed to confirm M. tuberculosis in the index case, evaluate the close or high-risk contacts, and identify lower-risk casual contacts. This means that the first tuberculin test is usually given 6–8 weeks after the contact is broken. Following current recommendations, tuberculin testing is then repeated 12 weeks after the contact was broken. If all tuberculin conversions have occurred by 8 weeks, then a single tuberculin test at 8 weeks would be sufficient to detect all low-risk casual contacts with infection. Performing only one test would avoid the difficulties of distinguishing boosting from conversion in this group. Waiting for 8 weeks to perform a single test would not be appropriate for contacts who are young children and/or are immunocompromised, such as HIV-infected populations, where false-positive results from boosting are of less concern and risks resulting from new infection are much greater. Serial tuberculin testing has also revealed that tuberculin reversion may occur (28). Among 179 sailors treated with INH following tuberculin conversion, the majority later demonstrated reversion (161), although some of the initial tuberculin conversions may have actually resulted from the booster phenomenon in this study. Among South African schoolchildren with reactions of 14 mm who were retested three times over the next 2 years, average reaction size was slightly smaller (perhaps because of regression to the mean), but more than 95% of reactions remained 10 mm on all occasions (162). Of 346 children with TST 10 mm who were treated for primary tuberculosis in Houston between 1953 and 1960 and were retested 3–10 years later, only 29 (8.4%) reverted (163). Reversion is most common for those who react only to 250 TU dose (28), have initial reactions in the 5- to 9-mm range (163) or in the 10- to 14-mm range (28,161,164), or demonstrate the booster phenomenon (79,164). Reversion is also more likely if only a third sequential tuberculin test is positive (164). The phenomenon of reversion emphasizes that once a tuberculin reaction reaches 10 mm or greater, results of further testing become uninterpretable. If the tuberculin reaction reverts to negative and then becomes positive again, no clinical or epidemiological information is available to allow interpretation of such a phenomenon.
None
Age of 6
Age of 6
Southern United States
Western Europe
Southeast Asia (newly arrived)
Screening Close contact Casual contact Screening Close contact Casual contact Screening Close contact Casual contact Screening Close contact Casual contact
Clinical situationa 1 10 1 2.5 1 1 10 1 2.5 1 1 10 1 2.5 1 15 15 10 15 2.5
True positive 2 2 2 8 8 8 5 20 5 8 8 8
NTM — — — — — — 20 20 20 20 20 20
BCG
False positive
Expected Prevalence of Reactions (%)b
33 85 64 11 58 30 4 33 13 39 54 43
Predictive value of a positive test (%)
b
Clinical situation: screening means test done in absence of exposure/risk factor; contacts are of smear-positive, culture-positive case of TB. Expected prevalence is prevalence in general population plus added prevalence infected from clinical situation (screening—no additional; contacts—from Table 11).
a
None
Northern United States or Canada
Subject born in
History of BCG vaccination
Table 14 Predictive Value of a Positive Second TST in a 20-Year-Old Adult (Second Test Performed 1–3 Months After Initial Negative TST)
Tuberculin Skin Testing 309
310
Menzies V. Conclusions
The following can be concluded about tuberculin skin testing: 1. The tuberculin skin test is a test—not a condition. 2. As with all tests in clinical medicine, the tuberculin test is most useful when used selectively, i.e., when there is a good indication to perform the test. 3. Tuberculin testing can not be recommended for the diagnosis of active disease—specificity is very low and sensitivity is only 70–85%. 4. Although the dictum “once positive always positive” may not be true, the corollary “once documented positive no further utility” is correct. All tuberculin reactions that are 10 mm (or 5 mm in certain situations) should be considered positive. Individuals with positive tests should be referred for medical and radiological evaluation, and tuberculin testing should not be repeated if proper documentation is available. 5. Rather than rely simply on cut-points, more emphasis should be placed on understanding the predictive value of a positive test based on the likelihood of true and false, positive and negative reactions in the population being tested. 6. There is no association between tuberculin reactions and immunity subsequent to BCG vaccination. Therefore the ideal BCG vaccine would stimulate immunity while having no effect on tuberculin reactions. 7. The boosting phenomenon is common and in many populations is almost as frequent as initial tuberculin reactions. However, it is much less specific because it is strongly affected by sensitivity to NTM antigens as well as prior BCG vaccination. Therefore, the likelihood of future development of tuberculosis is lower than for positive initial reactions in the same population. 8. In populations with high prevalence of sensitivity to NTM antigens and/or BCG vaccination who undergo two sequential tuberculin tests, a significant proportion will manifest the boosting phenomenon. 9. Tuberculin skin test conversion occurs within 8 weeks of mycobacterial infection. 10. The best definition of tuberculin conversion remains unclear, because there are few data from cohort studies. Examination of tuberculin reactions from cross-sectional studies in different populations suggests that 10 mm remains a useful criterion and that larger increases will be more specific but will reduce sensitivity substantially. 11. Among casual contacts, even of smear-positive cases, undergoing a second tuberculin test at the end of the “window period,” the majority of new reactions detected will result from the boosting phenomenon
Tuberculin Skin Testing
311
rather than new infection. Therefore, investigations of casual low-risk contacts should be restricted to a single tuberculin test performed 8 weeks following the end of exposure. 12. Anergy testing, while useful in population studies, is of limited clinical value in the management of individual patients. 13. After close to 100 years of use, there is an enormous amount of clinical and epidemiological information available to assist in interpretation of the tuberculin test, but we still cannot identify with certainty those who will develop the disease. New molecular biology techniques may improve our understanding of the tuberculin reaction and thereby our ability to predict this. Acknowledgments The author acknowledges with thanks additional information, suggestions and comments on an earlier draft of this paper provided by Drs. George Comstock, Cindy Driver, Anne Fanning, the late Stephan Grzybowski, Sonal Munsiff, William Stead, and Jaap Veen. The author also thanks Mme Sylvie Ouimet for, seemingly endless, secretarial support. References 1. Koch R. An address on bacteriological research. Br Med J 1890; 2:380–383. 2. von Pirquet C. Frequency of tuberculosis in childhood. JAMA 1907; 52:675–678. 3. Mantoux MC. La voie intradermique en tubercalinothérapie. Presse Med 1912; 20:146–148. 4. Landi S, Held HR, Gupta KC. The multi-facets of tuberculin standardization. International WHO IABS Symposium on Standardization and Control of Allergens Administered to Man, Geneva, 1974. Dis Biol Stand 1975; 29:393–411. 5. Seibert FB, Glenn JT. Tuberculin purified protein derivative: preparation and analyses of a large quantity for standard. Am Rev Tuberc 1941; 44:49. 6. Landi S, Held HR, Tseng MC. Disparity of potency between stabilized and nonstabilized dilute tuberculin solutions. Am Rev Respir Dis 1971; 101:385–393. 7. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med 1971; 285:1506–1509. 8. Grzybowski S, Dorken E, Bates C. Disparities of tuberculins. Am Rev Respir Dis 1969; 100:86–87. 9. Guld J, Magnus K, Magnuson M. Instability of the potency of tuberculin dilutions. Am Rev Tuberc 1955; 72:126–128. 10. Swanson Beck J. Skin Changes in the tuberculin test. Am Rev Respir Dis 1979; 120:59–65. 11. Hart P, Sutherland I, Thomas J. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations induced tuberculin sensitivity and technical variations in the vaccines. Tubercle 1967; 48:201–210.
312
Menzies
12. Youmans GP. Relation between delayed hypersensitivity and immunity in tuberculosis. Am Rev Respir Dis 1975; 111:109–118. 13. Rich AR. The Pathogenesis of Tuberculosis. Springfield, IL: Charles C Thomas, 1944. 14. Toews GB. Cell-mediated immunity. In: Pratter MR, Nelson S, eds. Cytokines and Pulmonary Infection. Part 1: Host-Pathogen Interactions in Pulmonary Infections. New York: American Thoracic Society, 1997:39–50. 15. Rowe JF. A comparison between two commercial tuberculin products, Connaught and Parke Davis, Vancouver Island, 1972. Can J Public Health 1975; 66:241–246. 16. Lifson AR, Watters JK, Thompson S, Crane CM, Wise F. Discrepancies in tuberculin skin test results with two commercial products in a population of intravenous drug users. J Infect Dis 1993; 168:1048–1051. 17. Rupp ME, Schultz AW, Davis JC. Discordance between tuberculin skin test results with two commercial puriried protein derivative preparations. J Infect Dis 1994; 169:1174–1175. 18. Lanphear BP, Linnemann CC, Cannon CG. A high false-positive rate of tuberculosis associated with Aplisol: an investigation among health care workers. J Infect Dis 1994; 169:703–704. 19. Stead WW. Annual tuberculosis screening of hospital employees: an idea whose time has not passed. Am Rev Respir Dis 1987; 136:803–804. 20. Muder RR, Brennen C, Yu KT. Choosing appropriate criteria for tuberculin positivity and conversion in a long-term care facility. Infect Control Hosp Epidemiol 1993; 14:523–526. 21. Guld J, Bentzon MW, Bleiker MA, Griep WA, Magnuson M, Waaler H. Standardization of a new batch of purified tuberculin (PPD) intended for international use. Bull WHO 1958; 19:845–951. 22. The WHO Standard Tuberculin Test. Geneva: World Health Organization, 1963. 23. Comstock GW, Edwards LB, Philip RN, Winn WA. A comparison in the United States of America of two tuberculins, PPD-S and PPD-RT 23. Bull WHO 1964; 31:161–170. 24. Murtagh K. Unreliability of the Mantoux test using 1 TU PPD in excluding childhood tuberculosis in Papua New Guinea. Arch Dis Child 1980; 55:795–799. 25. Duboczy BO, Brown BT. Multiple readings and determination of maximal intensity of tuberculin reaction. Am Rev Respir Dis 1960; 82:60–67. 26. Spiteri MA, Bowman A, Assefi AR, Clarke SW. Life threatening reaction to tuberculin testing. Br Med J 1986; 293:243–244. 27. Gryzbowski Stefan, Brown MT, Stothard D. Infections with atypical mycobacteria in British Columbia. CMAJ 1969; 100:896–900. 28. Dahlstrom AW. The instability of the tuberculin reaction. Observations on dispensary patients, with special reference to the existence of demonstrable tuberculous lesions and the degree of exposure to tubercle bacilli. Am Rev Tuberc 1940; 42:471–487. 29. Palmer CE. Tuberculin sensitivity and contact with tuberculosis. Am Rev Tuberc 1953; 68:678–694. 30. Chaparas SD. Multiple puncture tuberculin tests. Pediatr Infect Dis J 1987; 6:496–497.
Tuberculin Skin Testing
313
31. Badger TL, Breitwieser ER, Muench H. Tuberculin tine test: multiple-puncture intradermal technique compared with PPD-S, intermediate strength. Am Rev Respir Dis 1963; 87:338–351. 32. Research Committee of the British Thoracic Association. Reproducibility of the tine tuberculin test. Br J Dis Chest 1982; 76:75–78. 33. Furcolow ML, Watson KA, Charron T, Lowe J. A. comparison of the tine and mono-vacc tests with the intradermal tuberculin test. Am Rev Respir Dis 1967; 96:1009–1027. 34. Herzog C. Reason for variable response to tuberculin tine test. Lancet 1981; 417–418. 35. Wijsmuller G, Snider DE, jr. Skin testing: a comparison of the jet injector with the Mantoux method. Am Rev Respir Dis 1975; 112:789–798. 36. Rhoades EV, Bryant RE. The influence of local factors on the reaction to tuberculin. 1. The effect of injection. Chest 1980; 77:190–193. 37. Guld J. Quantitative aspects of the intradermal tuberculin test in humans. Acta Tuberc Scand 1954; 30:26–36. 38. Flynn P, Shenep J, Mao L, Crawford R, Williams B, Williams BG. Influence of needle gauge in Mantoux skin testing. Chest 1994; 106:1463–1465. 39. Comstock GW. False tuberculin test results. Chest 1975; 68:465–469. 40. Duboczy BO. Repeated tuberculin tests at the same site in tuberculin-positive patients. Am Rev Respir Dis 1964; 90:77–86. 41. Glenchur H, Fossieck BE, Silverman M. An immdediate skin test for the diagnosis of active pulmonary tuberculosis. Am Rev Respir Dis 1965; 92:741–748. 42. Kardjito T, Grange JM. A clinical evaluation of the diagnostic usefulness of an early dermal reaction to tuberculin: a failure to distinguish between tuberculosis and other respiratory disease. Tubercle 1985; 66:129–132. 43. Howard TP, Solomon DA. Reading the tuberculin skin test: who, when, and how? Arch Intern Med 1988; 148:2457–2459. 44. Slutkin G, Perez-Stable EJ, Hopewell PC. Time course and boosting of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1986; 134:1048–1051. 45. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975; 293:501–502. 46. Bouros D, Zeros G, Panaretos C, Vassilatos C, Siafakas N. Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test). Chest 1991; 99:416–419. 47. Bouros D, Maltezakis G, Tzanakis N, Tzortzaki E, Siafakas N. The role of inexperience in measuring tuberculin skin reaction (Mantoux test) by the pen or palpation technique. Respir Med 1992; 86:219–223. 48. Jordan T, Sunderam G, Thomas L, Reichman LB. Tuberculin reaction size measurement by the pen method compared to traditional palpation. Chest 1987; 92:234–236. 49. Longfield JN, Marsileth AM, Golden SM, Lazoritz S, Bohan S, Cruess DF. Interobserver and method variability in tuberculin skin testing. Pediatr Infect Dis 1984; 3:323–326. 50. Selby CD, Allen MB, Leitch AG. How well do the general public read Heaf skin tests? Engl J Med 1975; 293:501–502.
314
Menzies
51. Colp C, Goldfarb A, Wei I, Graney J. Patient’s self-interpretation of tuberculin skin tests. Chest 1996; 110:1275–1277. 52. Erdtmann FJ, Dixon KE, Liewellyn CH. Skin testing for tuberculosis. Antigen and observer variability. JAMA 1974; 228:479–481. 53. Bearman JE, Kleinman H, Glyer VV, LaCroix OM. A study of variability in tuberculin test reading. Am Rev Respir Dis 1964; 90:913–918. 54. Tarlo SM, Day JH, Mann P, Day MP. Immediate hypersensitivity to tuberculin in in vivo and in vitro studies. Chest 1977; 71:33–37. 55. Morrison JB. Lymphangitis after tuberculin tests. Br Med J 1984; 289:413 56. Wright DN, Ledford DK, Lockey RF. Systemic and local allergic reactions to the tine test purified protein derivative. JAMA 1989; 262:2999–3000. 57. DiMaio VJM, Froede CRC. Allergic reactions to the tine test. JAMA 1975; 233:769. 58. Hanson ML, Comstock GW. Efficacy of hydrocortisone ointment in the treatment of local reactions to tuberculin skin tests. Am Rev Respir Dis 1968; 97:472–473. 59. Reichman LB, O’Day R. The influence of a history of a previous test on the prevalence and size of reactions to tuberculin. Am Rev Respir Dis 1977; 115:737–741. 60. Snider DE. The tuberculin skin test. Am Rev Respir Dis 1982; 125:108–112. 61. Present PA, Comstock GW. Tuberculin sensitivity in pregnancy. Am Rev Respir Dis 1975; 112:413–416. 62. Snider DE, Farer LS. Package inserts for antituberculosis drugs and tuberculins. Am Rev Respir Dis 1985; 131:809–810. 63. WHO Tuberculosis Research Office. Further studies of geographic variation in naturally acquired tuberculin sensitivity. Bull WHO 1955; 22:63–83. 64. Stead WW, To T. The significance of the tuberculin skin test in elderly persons. Ann Int Med 1987; 107:837–842. 65. Howard L, Klopfenstein MD, Steininger WJ, Woodruff CE. The loss of tuberculin sensitivity in certain patients with active pulmonary tuberculosis. Chest 1970; 57:530–534. 66. Kardjito T, Donosepoetro M. The Mantoux test in tuberculosis: correlations between the diameters of the dermal responses and the serum protein levels. Tubercle 1981; 62:31–35. 67. Selroos O, Pasternack A, Virolainen M. Skin test sensitivity and antigen induced lymphocyte transformation in Uraemis. Clin Exp Immunol 1973; 14:365–370. 68. Veen J. Aspects of Temporary Specific Anergy to Tuberculin in Vietnamese Refugees. Amsterdam: K.N.C.V., 1992:1–119. 69. Graham NMH, Nelson KE, Solomon L, Bonds M, Rizzo RT, Scavotto J, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and seronegative intravenous drug users. JAMA 1992; 267:369–373. 70. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. Clin Infect Dis 1994; 19:26–32. 71. Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119:185–193. 72. Caiaffa WT, Graham NMH, Galai N, Rizzo RT, Nelson KE, Vlahov D. Instability of delayed-type hypesensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med 1995; 155:2111–2117.
Tuberculin Skin Testing
315
73. Gourevitch MN, Hartel D, Schoenbaum EE, Klein RS. Lack of association of induration size with HIV infection among drug users reacting to tuberculin. Am J Respir Crit Care Med 1996; 154:1029–1033. 74. Johnson MP, Coberly JS, Clermont HC, Chaisson RE, Davis HL, Losikoff P, et al. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 1992; 166:194–198. 75. Okwera A, Eriki PP, Guay LL, Ball P, Daniel TM. Tuberculin reactions in apparently healthy HIV-seropositive and HIV-seronegative women—Uganda. MMWR 1990; 39:638–646. 76. Woodruff CE, Chapman TP. Tuberculin sensitivity in elderly patients. Am Rev Respir Dis 1971; 104:261–263. 77. Battershill JH. Cutaneous testing in the elderly patient with tuberculosis. Chest 1980; 77:188–189. 78. Gordin F, Perez-Stable E, Flaherty D, Reid M, Schecter G, Joe L, et al. Evaluation of a third sequential tuberculin skin test in a chronic care population. Am Rev Respir Dis 1988; 137:153–157. 79. Perez-Stable EJ, Flaherty D, Schecter G, Slutkin G, Hopewell PC. Conversion and reversion of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1988; 137:801–804. 80. Pesanti EL. The negative tuberculin test. Tuberculin, HIV, and anergy panels. Am J Respir Crit Care Med 1994; 149:1699–1709. 81. Centers for Disease Control (CDC). Purified protein derivative (PPD)–tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at high risk of tuberculosis. MMWR 1991; 40 RR-5:27–33. 82. Kniker WT, Anderson CT, McBryde JL, Roumiantzeff M, Lesourd B. Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cellmediated immunity. Normal values and proposed scoring system for healthy adults in the U.S.A. Ann Aller 1984; 52:75–82. 83. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993; 7:1345–1349. 84. Antonucci G, Girardi E, Raviglione MC, Ippolito G, for the GISTA. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. JAMA 1995; 274:143–148. 85. Moreno S, Baraia-Etxaburu J, Bouza E, Parras F, Perez-Tascon M, Miralles P, et al. Risk of developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119:194–198. 86. Yanai H, Uthaivoravit W, Mastro TD, Limpakarnjanarat K, Sawanpanyalert P, Morrow RHJ, et al. Utility of tuberculin and anergy skin testing in predicting tuberculosis infection in human immunodeficiency virus-infected persons in Thailand. Int J Tuberc Lung Dis 1997; 1:427–434. 87. Chin DP, Osmond D, Page-Shafer K, Glassroth J, Rosen MJ, Reichman LB, et al. Reliability of anergy skin testing in persons with HIV infection. Am J Respir Crit Care Med 1996; 153:1982–1984. 88. Villarino ME, Geiter LJ, Schulte JM, Castro KG. Purified protein derivative tuberculin and delayed-type hypersensitivity skin testing in migrant farm workers at risk for tuberculosis and HIV coinfection. AIDS 1994; 8:477–481.
316
Menzies
89. Center for Disease Control. Anergy skin testing and preventive therapy for HIV-infected persons. MMWR 1997; 46. 90. Horwitz O, Bunch-Christensen K. Correlation between tuberculin sensitivity after 2 months and 5 years among BCG vaccinated subjects. Bull WHO 1972; 47:49–58. 91. Ashley MJ, Siebenmann CO. Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts. Can Med Assoc J 1967; 97:1335–1339. 92. Landi S, Ashley M, Grzybowski S. Tuberculin sensitivity following the intradermal and multiple puncture methods of BCG vaccination. Can Med Assoc J 1967; 97:222–225. 93. Badger TL, Ayvazian LF. Tuberculosis in nurses: Clinical observations on its pathogenesis as seen in a fifteen year follow-up of 745 nurses. Am Rev Tuberc 1949; 60:305–331. 94. Heimbeck J. Incidence of tuberculosis in young adult women, with special reference to employment. Br J Tubercle 1938; 32:154–166. 95. Daniels M. Primary tuberculosis infection in nurses: manifestations and prognosis. Lancet 1944; 165–170. 96. Stead WW. Management of health care workers after inadertent exposure to tuberculosis: a guide for use of preventive therapy. Ann Intern Med 1995; 122:906–912. 97. Al-Kassimi FA, Al-Hajjaj MS. Al-Orainey IO, Bamgboye EA. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Respir Crit Care Med 1995; 152:1575–1578. 98. Fine P, Sterne J, Ponnighaus J, Rees R. Delayed type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 1994; 344:1245–1249. 99. Comstock GW. Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 1988; 138:479–480. 100. Grindulis H, Baynham M, Scott P, Thompson R, Wharton B. Tuberculin response two years after BCG vaccination at birth. Arch Dis Child 1984; 59:614–619. 101. Young TK, Mirdad S. Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination. Tuberc Lung Dis 1992; 73:94–100. 102. Bahr GM, Chugh TD, Behbehani K, Shaaban MA, et al. Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Tuberculosis 1968; 68:105–112. 103. Osman AA, Hakim JG, Luneborg-Nielsen M, Benzton MW, Magnusson M, Ageel AM, et al. Comparative skin testing with PPD tuberculin, Mycobacterium avium and M. scrofulaceum sensitin in schoolchildren in Saudi Arabia. Tuberc Lung Dis 1994; 75:38–43. 104. Larsson LO, Magnusson M, Skoogh E-E, Lind A. Sensitivity to sensitins and tuberculin in Swedish children. IV. The influence of BCG-vaccination. Eur Respir J 1992; 5:584–586. 105. Pabst HF, Kreth HW. Ontegeny of the immune response as a basis of childhood disease. J Pediatr 1980; 97:519–534. 106. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154.
Tuberculin Skin Testing
317
107. Schier DJ, Sternick JL, Allen EM, Moore VL. Genetic basis of BCG-induced suppression of delayed hypersensitivity. Nature 1981; 289:405–407. 108. Sepulveda RL, Heiba IM, King A, Gonzalez B, Elston RC, Sorensen RU. Evaluation of tuberculin reactivity in BCG-immunized siblings. Am J Respir Crit Care Med 1994; 149:620–624. 109. Menzies RI, Vissandjee B, Amyot D. Factors associated with tuberculin reactivity among the foreign-born in Montreal. Am Rev Respir Dis 1992; 146:752–756. 110. Kirschner RA, Parker BC, Falkinham JO. Epidemiology of Infection by nontuberculous mycobacteria. Am Rev Respir Dis 1992; 145:271–275. 111. George KL, Parker BC, Gruft H, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. II. Growth and survival in natural waters. Am Rev Respir Dis 1980; 122:89–94. 112. Parker BC, Ford MA, Gruft H, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. IV. Preferential aerosolization of Mycobacterium intracellulare from natural waters. Am Rev Respir Dis 1983; 128:652–656. 113. Fry KL, Meissner PS, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. VI. Identification and use of epidemiologic markers for studies of Mycobacterium avium, M. intracellulare, and M. scrofulaceum. Am Rev Respir Dis 1986; 134:39–43. 114. Robakiewicz M, Grzybowski S. Epidemiologic aspects of nontuberculous mycobacterial disease and of tuberculosis in British Columbia. Am Rev Respir Dis 1974; 109:613–620. 115. Margileth AM. Nontuberculous (atypical) mycobacterial disease. Sem Pediatr Infect Dis 1993; 4:307–315. 116. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990; 142:940–953. 117. Huebner RE, Schein MF, Cauthen GM, Geiter LJ, O’Brien RJ. Usefulness of skin testing with mycobacterial antigens in children with cervical lymphadenopathy. Pediatr Infect Dis 1992; 11:450–456. 118. Huebner RE, Schein MF, Cauthen GM, Geiter LJ, Selin MJ, Good RC, et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am Rev Respir Dis 1992; 145:1160–1166. 119. Fordham von Reyn C, Green PA, McCormick D, Huitt GA, Marsh BJ, Magnusson M, et al. Dual skin testing with mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis. Clin Infect Dis 1994; 19:15–20. 120. Marks J, Palfreyman JM, Yates MD, Schaefer WB. A differential tuberculin test for mycobacterial infection in children. Tubercle 1977; 58:19–23. 121. Smith DT, Johnston WW. Single and multiple infections with typical and atypical mycobacteria. Am Rev Respir Dis 1964; 90:899–912. 122. Palmer CE, Edwards LB, Hopwood L, Edwards PQ. Experimental and epidemiologic basis for the interpretation of tuberculin sensitivity. J Pediatr 1959; 55:413–428. 123. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990; 142:725–735. 124. Magnusson M. Tuberculins, other mycobacterial sensitins and “new tuberculins.” Eur J Respir Dis 1986; 69:129–134.
318
Menzies
125. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the US Navy: its distribution and decline. Am Rev Respir Dis 1974; 110:572–580. 126. Barry MA, Shirley L, Grady MT, Etkind SW, Almeida C, Bernardo J, et al. Tuberculosis infection in urban adolescents: results of a school-based testing program. Am J Public Health 1990; 80:439–441. 127. Trump DH, Hyams KC, Cross ER, Struewing JP. Tuberculosis infection among young adults entering the US navy in 1990. Arch Intern Med 1993; 153:211–216. 128. Friedman LN, Sullivan GM, Bevilaqua RP, Loscos R. Tuberculosis screening in alcoholics and drug addicts. Am Rev Respir Dis 1987; 136:1188–1192. 129. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979; 139:337–339. 130. Zolopa AR, Hahn JA, Gorter R, Miranda J, Wlodarczyk D, Peterson J, et al. HIV and tuberculosis infection in San Francisco’s homeless adults. JAMA 1994; 272:455–461. 131. Paul EA, Lebowitz SM, Moore RE, Hoven CW, Bennett BA, Chen A. Nemesis revisited: tuberculosis infection in a New York City men’s shelter. Am J Public Health 1993; 83:1743–1745. 132. Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull WHO 1969; 41:95–113. 133. Groth-Peterson E, Knudsen J, Wilbeck E. Epidemiological basis of tuberculous eradication in Denmark. Bull WHO 1959; 21:5–49. 134. Edwards L, Acquaviva F, Livesay V. Identification of tuberculous infected: dual tests and density of reaction. Am Rev Respir Dis 1973; 108:1334–1339. 135. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969; 17:28–106. 136. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Englewood Cliffs, NJ: Prentice Hall, 1990. 137. Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle 1966; 47:308. 138. Veening GJJ. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Against Tuberc 1968; 41:169–171. 139. Magnus K, Edwards L. The effect of repeated tuberculin testing on post-vaccination allergy. Lancet 1995; 24:643–644. 140. Narain RO. Interpretation of the repeat tuberculin test. Tubercle 1968; 49:92. 141. Cauthen GM, Snider DE, Onorato IM. Boosting of tuberculin sensitivity among Southeast Asian refugees. Am J Respir Crit Care Med 1994; 149:1597–1600. 142. Thompson NJ, Glassroth JL, Snider DE, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119:587–597. 143. Bass JB, Serio RA. The use of repeated skin tests to eliminate the booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1981; 123:394–396. 144. Van den Brande P, Demedts M. Four-stage tuberculin testing in elderly subjects induces age-dependent progressive boosting. Chest 1992; 101:447–450. 145. Richards N, Nelson K, Batt M, Hackbarth D, Heidenreich J. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis 1979; 120:59–65.
Tuberculin Skin Testing
319
146. Menzies RI, Vissandjee B, Rocher I, St. Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994; 120:190–198. 147. Edwards L, Acquiviva F, Livesay V, Palmer C. An atlas of sensitivity to tuberculin and PPD-B in the United States. Am Rev Respir Dis 1969; 99:1–132. 148. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985; 23:1483–1487. 149. Nolan CM, Elarth AM. Tuberculosis in a Cohort of Southeast Asian Refugees. Am Rev Respir Dis 1988; 137:805–809. 150. Canadian Thoracic Society. FitzGerald JM, ed. Canadian Tuberculosis Standards. Ottawa: Canadian Lung Association, 1996. 151. American Thoracic Society. The tuberculin skin test. Am Rev Respir Dis 1981; 124:356–363. 152. Stead WW, To T, Harrison RW, Abraham JH. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987; 107:843–845. 153. March-Ayuela Pd. Choosing an appropriate criterion for true or false conversion in serial tuberculin testing. Am Rev Respir Dis 1990; 141:815–820. 154. Bass JB, Sanders RV, Kirkpatrick MB. Choosing an appropriate cutting point for conversion in annual tuberculin skin testing. Am Rev Respir Dis 1985; 132:379–381. 155. Guld J. Response to BCG Vaccination. In: Edwards LB, Palmer CE, Magnus K., eds. Studies at the WHO Tuberculosis Research Office, World Health Organization: Geneva, 1953, pp. 51–56. 156. Youmans GP. Tuberculosis. Philadelphia: W.B. Saunders Company, 1979. 157. Triep WA. De tuberculinereactie (in Dutch). The Hague, Netherlands: Royal Netherlands Tuberculosis Association (KNCV), 1957. 158. Wasz-Hockert O. On the period of incubation in tuberculosis. Ann Med Fenn 1947; 96:764–772. 159. Wallgren A. The time-table of tuberculosis. Tubercle 1948; 29:245–251. 160. Poulsen A. Some clinical features of tuberculosis. I. Incubation period. Acta Tuberc Scand 1954; 24:311–346. 161. Houk VN, Kent DC, Sorenson K, Baker JH. The eradication of tuberculosis infection by isoniazid chemoprophylaxis. Arch Environ Health 1968; 16:46–50. 162. Felten MK, Van Der Merwe CA. Random variation in tuberculin sensitivity in schoolchildren. Am Rev Respir Dis 1989; 140:1001–1006. 163. Hsu KHK. Tuberculin reaction in children treated with Isoniazid. Am J Dis Child 1983; 137:1090–1092. 164. Gordon FM, Perez-Stable EJ, Reid M, Schecter G, Cosgriff L, Flaherty D, et al. Stability of positive tuberculin tests: Are boosted reactions valid? Am Rev Respir Dis 1991; 144:560–563. 165. Fine MH, Furcolow ML, Chick EW, Bauman DS, Arik M. Tuberculin skin test reactions. Am Rev Respir Dis 1972; 106:752–758. 166. Donaldson JC, Elliot RC. A study of co-positivity of three multipuncture techniques with intradermal PPD tuberculin. Am Rev Respir Dis 1978; 118:843–846. 167. Lunn JA, Johnson AJ, Fry JS. Comparison of multiple puncture liquid tuberculin test with Mantoux test. Lancet 1981; i:695–698.
320
Menzies
168. Ackerman-Liebrich U. (Letter.) Lancet 1982; ii:934. 169. Hansen JP, Falconer JA, Gallis HA, Hamilton JD. Inadequate sensitivity of tuberculin tine test for screening employee populations. J Occup Med 1982; 24:602–604. 170. Rudd RB, Gellert AR, Venning M. Comparison of Mantoux, tine, and ‘Imotest’ tuberculin tests. Lancet 1982; 515–518. 171. Biggs B, Connor H, Dwyer BW, Speed BR. Comparison of a multiple puncture tuberculin test, “Imotest,” and the Mantoux test in an Australian population. Tubercle 1987; 68:285–290. 172. Chaparas SD, Mac Vandiviere H, Melvin I, Koch G, Becker C. Tuberculin test: variability with the Mantoux procedure. Am Rev Respir Dis 1985; 132:175–177. 173. Loudon RG, Lawson JR, Brown J. Variation in tuberculin test reading. Am Rev Respir Dis 1963; 87:852–861. 174. Fine MH, Furculow ML, Chick EW, Bauman DS, Arik M. Tuberculin skin test reactions. Am Rev Respir Dis 1972; 106:752–758. 175. Perez-Stable EJ, Slutkin G. A demonstration of lack of variability among six tuberculin skin test readers. Am J Public Health 1985; 75:1341–1343. 176. Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997; 126:210–214. 177. Lifschitz M. The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. Pediatrics 1965; 36:624–627. 178. Margus J, Khassis Y. The tuberculin sensitivity in BCG vaccinated infants and children in Israel. Acta Tuberc Pneumonol Scand 1965; 46:113–122. 179. Joncas J, Robitaille R, Gauthier T. Interpretation of the PPD skin test in BCG-vaccinated children. Can Med Assoc J 1975; 113:127–128. 180. Karalliede S, Katugha L, Uragoda C. The tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle 1987; 68:33–38. 181. Sepulveda R, Burr C, Ferrer X, Sorensen R. Booster effect of tuberculin testing in health 6-year-old school children vaccinated with Bacillus Calmette-Guerin at birth in Santiago, Chile. Pediatr Infect Dis J 1988; 7:581. 182. American Conference of Governmental Industrial Hygenists. Guidelines for assessment and sampling of saprophytic bioaerosols in the indoor environment. Appl Indus Hyg 1987; 2:R10–R16. 183. Menzies RI, Vissandjee B. Effect of bacille Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992; 145:621–625. 184. Comstock GW, Edwards LB, Nabangwang H. Tuberculin sensitivity eight to fifteen years after BCG vaccination. Am Rev Respir Dis 1971; 103:572–575. 185. Bleiker MA, Misljenovic O, Styblo K. Study into the risk of tuberculous infection in schoolchildren in the city of Delft in the period 1966–1985. In: Anonymous Selected Papers. The Hague: Royal Netherlands Tuberculosis Association, 1997:19– 24. 186. Jeanes CWL, Davies JW, McKinnon NE. Sensitivity to “atypical” acid-fast mycobacteria in Canada. CMAJ 1969; 100:1–8. 187. Paul RC, Standord JL, Misljenovic O, Lefering J. Multiple skin testing of Kenyan schoolchildren with a series of new tuberculins. J Hyg Camb 1975; 75:303–313. 188. Kardjito T, Swanson Beck J, Grange JM, Stanford JL. A comparison of the responsiveness to four new tuberculins among Indonesion patients with pulmonary tuberculosis and healthy subjects. Eur J Respir Dis 1986; 69:142–145.
Tuberculin Skin Testing
321
189. Lind A, Larsson O, Bentzon MW, Magnusson M, Olofson J, Sjogren I, et al. Sensitivity to sensitins and tuberculin in Swedish children. Tubercle 1991; 72:29–36. 190. Ly HM, Trach DD, Long HT, Thuy NK, Tuan NA, Thi Ninh T, et al. Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. Tubercle 1989; 70:27–36. 191. Frappier-Davignon Lise, Fortin Robert, Desy M. Sensitivity to “atypical” mycobacteria in high school children in two community health departments. Can J Public Health 1989; 80:335–338. 192. Menzies RI. The determinants of the prevalence of tuberculous infection among Montreal schoolchildren. M.Sc. thesis Montreal: McGill University, 1989. 193. Reichman LB, O’Day R. Tuberculous infection in a large urban population. Am Rev Respir Dis 1978; 117:705–712. 194. Cross ER, Hyams KC. Tuberculin skin testing in US Navy and Marine Corps personnel and recruits, 1980–1986. Am J Public Health 1990; 80:435–438. 195. Dorken E, Grzybowski S, Allen EA. Significance of the tuberculin skin test in the elderly. Chest 1992; 2:237–240. 196. Grzybowksi S, Allen EA, Black WA, Chao CW, Enarson DA, Isaac-Renton JL, et al. Inner-city survey for tuberculosis: evaluation of diagnostic methods. Am Rev Respir Dis 1987; 135:1311–1315. 197. Morse DL, Hansen RE, Swalbach G, Redmond SR, Grabau JC. High rate of tuberculin conversion in Indochinese refugees. JAMA 1982; 248:2983–2986. 198. Fitzpatrick S, Johnson J, Shragg P, Felice ME. Health care needs of Indochinese refugee teenagers. Pediatrics 1987; 79:118–124. 199. Ormerod LP. Tuberculosis screening and prevention in new immigrants 1983–88. Respir Med 1990; 84:269–271. 200. Spinaci S, De Virgilio G, Bugiani M, Linari D, Bertolaso G. Tuberculin survey among afghan refugee children. Tuberculosis control programme among Afghan refugees in North West frontier province (NWFP) Pakistan. Tubercle 1989; 70:83–92. 201. Godue CB, Goggin P, Gyorkos TW. L’allergie tuberculinique chez les revendicateurs du statut de réfugié nouvellement arrivés au Canada. CMAJ 1988; 139:41–44. 202. Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest 1993; 103:1670–1674. 203. Yuan L, Richardson E, Kendall PRW. Evaluation of a tuberculosis screening program for high-risk students in Toronto schools. Can Med Assoc J 1995; 153:925–932. 204. van Zwanenberg D. Tuberculous infection in the home. Tubercle 1955; 36:238–244. 205. Zaki MH, Lyons HA, Robins AB, Brown EP. Tuberculin sensitivity. NY State J Med 1976; 2138:2143. 206. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull IUAT 1975; 50:90–106. 207. Van Geuns HA, Meijer J, Styblo K. Results of contact examination in Rotterdam, 1967–1969. Bull Int Union Tuberc 1975; 50:107–121. 208. Karalus NC. Contact screening procedures for tuberculosis in Auckland. NZ Med J 1988; 101:45–49.
322
Menzies
209. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545–550. 210. Hong Kong Chest Service/Tuberculosis Research Centre MM. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36–41. 211. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982; 60:555–564. 212. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95:935–943. 213. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99:131–137. 214. Valenti WM, Andrews BA, Presley BA, Reifler CB. Absence of the booster phenomenon in serial tuberculin skin testing. Am Rev Respir Dis 1982; 125:323–325. 215. Gross TP, Israel E, Powers P, Cauthen G, Rose J. Low prevalence of the booster phenomenon in nursing-home employees in Maryland. Maryland Med J 1984; 35:107–109. 216. Alvarez S, Karprzyk DR, Freundl M. Two-stage skin testing for tuberculosis in a domiciliarly population. Am Rev Respir Dis 1987; 136:1193–1196. 217. Barry MA, Regan AM, Kunches LM, Harris ME, et al. Two-stage tuberculin testing with control antigens in patients residing in two chronic disease hospitals. JAGS 1987; 35:147–153. 218. Burstin SJ, Muspratt JA, Rossing TH, et al. Studies of the dynamics of reactivity to tuberculin and Candida antigen in institutionalized patients. Am Rev Respir Dis 1986; 134:1072–1074. 219. Webster CT, Gordin FM, Matts JP, Korvick JA, Miller C, et al. Two-stage tuberculin skin testing in individuals with human immunodificiency virus infection. Am J Respir Crit Care Med 1995; 151:805–808. 220. Hecker MT, Johnson JL, Whalen C